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ABSTRACT 
The transcription factor p53 plays an important role in suppression of tumor development, 
as it is involved in several important regulation of cell process, such as activation of DNA repair, 
cell cycle arrest, apoptosis and senescence. About 50% of human cancers carry mutated or 
deleted TP53, the gene coding p53 protein, which renders p53 nonfunctional as a tumor 
suppressor. Even in cancer cells with wild-type TP53, the p53 functions are inhibited by several 
mechanisms. Human MDM2 protein is a primary, endogenous cellular inhibitor of the tumor 
suppressor p53 through a direct protein-protein interaction, which makes it an attractive target 
for cancer treatment. In the past 15 years, a number of potent, selective and efficacious MDM2 
inhibitors have been developed and advanced into clinical trials for cancer treatment. Recently, 
targeting protein degradation using small molecules emerged as a novel strategy for drug 
development. Herein, we present our design, synthesis and evaluation of MDM2 degraders 
based on a proteolysis targeting chimera (PROTAC) strategy. One of our most promising 
compounds (LE-102) could effectively induce MDM2 degradation at a concentration as low as 1 
nM within 0.5 hour in RS4;11 leukemia cells. LE-102 achieves an IC50 value of 2.3 nM in cell growth 
inhibition of RS4;11 with wild-type p53. It can also induce complete and durable tumor regression 
in vivo against RS4;11 xenograft tumors in mice and can significantly extend the survival time in 
the RS4;11 survival model. Mechanism studies have shown that LE-102 is a highly potent and 
xxiv 
 
efficacious MDM2 degrader. The development of MDM2 degraders is a novel efficient strategy 
targeting MDM2 for cancer therapy. 
Inducing MDM2 protein degradation by PROTACs has shown its promising potential in 
cancer treatment. While during our study, a class of compounds based on the core structure of 
our MDM2 inhibitor MI-1061, failed to induce degradation of their consensus target, they 
displayed pronounced cell proliferation inhibition effects in several cancer cell lines. The cell 
growth inhibition activity of LD-277, a compound in this class, is not related to MDM2 
degradation and activation of p53 pathway but mediated through the cereblon-dependent 
ubiquitination and degradation of the translation termination factor GSPT1. These findings 
demonstrated that a small modification could convert a PROTAC to molecular glue with 
unexpected mechanisms and effects. Careful target validation and activity evaluation are 
required in the development of PROTACs and molecular glue.  
MLL1 is a histone H3 Lysine 4 methyltransferase, an important regulator of transcription 
and mediator of normal development and disease. Translocation of MLL1 has been found widely 
in infant ALL and AML. Persistent activation of HoxA9 and MEIS1 caused by MLL1 fusions is 
important for sustaining the leukemic phenotype. Although MLL1 fusion proteins are oncogenic, 
they require the maintenance of a wild-type allele for leukemogenesis. WDR5 is important for 
the HMT activity of the wild-type MLL1 complex. Therefore, inhibition of WDR5-MLL1 protein-
protein interaction could be a valid approach for the treatment of MLL-rearranged leukemias. 
xxv 
 
Herein, we report the design, synthesis and evaluation of macrocyclic peptidomimetics that bind 
to WDR5 and block the WDR5-MLL protein-protein interaction. LC-337 binds to WDR5 with a Ki 
value << 1 nM, inhibits cell growth in MOLM13 with IC50 value of 33 nM and is >800 times better 
than the previously reported compound MM-401. 
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Chapter 1 
Development of Small-Molecule PROTAC Degraders of the MDM2 Oncoprotein 
Introduction 
The tumor suppressor p53 plays a critical role in protection against tumor development.1-
3 Although p53 is inactivated by mutation or deletion in about 50% of human cancers, it retains 
its wild-type status in the remaining cases.4 The function of wild-type p53 is impaired by other 
mechanisms. One important mechanism is the overproduction of MDM2 protein, which could 
disable p53 function by direct protein-protein interactions.5 MDM2, as an E3 ubiquitin ligase, 
regulates p53 protein level through an autoregulatory feedback loop.6-7 It has also been shown 
that MDM2 blocks the transactivation domain of p53 and transports p53 from nucleus to 
cytoplasm by direct binding.8 Stabilization and activation of wild-type p53 by inhibition of the 
MDM2 p53 protein-protein interaction has been explored as a novel approach for cancer therapy 
with several small molecule inhibitors that have been developed and advanced to clinical trials.9-
14 Among them, Idasanutlin (RG-7388) is currently in a clinical phase III trial for the treatment of 
AML. 
In addition to small-molecule inhibitors, a new approach has recently been developed for 
target protein degradation based upon the small molecular PROTAC concept.15-17 In this strategy, 
a heterobifunctional molecule is designed to contain a target protein inhibitor, another small-
molecule ligand, which binds to an E3 ubiquitin ligase complex, and a linker to tether these two 
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ligands together. Several target protein degraders have been developed based on this strategy, 
with targets including the Bromodomain and Extra-Terminal (BET) BRD418-20, Androgen 
Receptor21, Bcr-Abl22-23, Estrogen related Receptor α (ERRα)24 and other proteins. The protein 
degraders are conjugated with the ligands of E3 ubiquitin ligases, and include  cereblon, von 
Hippel-Lindau (VHL-1) ligase, and cellular inhibitors of apoptosis protein 1 (cIAP1) and MDM2. 
PROTACs have been shown to induce target protein degradation efficiently and to be more 
potent in inhibition of cancer cell growth. 
Herein, we report the design, synthesis, and evaluation of a series of MDM2 degraders 
based on the PROTAC strategy. The MDM2 inhibitor MI-1061, with its high binding affinity to 
MDM2 (Ki = 0.16 nM) and good stability in solution25 was used as a binding ligand to recruit 
MDM2 to the E3 ubiquitin ligase. Our studies have led to the discovery of LE-102, which 
significantly, can cause MDM2 degradation in vitro and in vivo and achieves complete and 
durable tumor regression in RS4;11 xenograft models in mice.  
Literature Review 
Development of Small Molecular MDM2 Inhibitors 
The transcription factor p53 controls the expression of a number of genes, which play 
important roles in cell cycle progression, apoptosis, senescence, DNA repair and metabolism1-2, 
26-27 and it is also a well-known and powerful tumor suppressor. Previous research has shown 
that about 50% humor cancers carry mutated or deleted TP53, the gene encoding p53.28 The 
level and activity of p53 is tightly controlled in cells because of its critical functions. Oncoprotein 
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MDM2 is a primary negative endogenous regulator of p53 and it can regulate the function of p53 
through three major mechanisms: MDM2, as an E3 ubiquitin ligase can directly ubiquitinate p53 
and induce its proteasomal degradation; MDM2 can also directly block functions of the p53 
transcription factor by blocking the binding of p53 to its target DNA through protein-protein 
interactions between MDM2 and p53; it could make p53 inaccessible to its target genes by 
promoting the exporting of p53 out of the cell nucleus.6, 8 Through these inhibitory mechanisms, 
MDM2 functions as an effective p53 antagonist in cancer cells with wild  type p53. This makes 
MDM2 an oncoprotein target and a therapeutic target in human cancers with wild type p53. 
Overexpression of MDM2 protein has been found widely in human cancers. One of the critical 
mechanisms of MDM2 overexpression is the amplification of the MDM2 gene. Based on an 
analysis of 4000 tumor samples in 28 different types of cancers,29-30 the MDM2 gene has been 
found to be amplified in about 7% of human cancers   
As MDM2 functions as a critical inhibitor of p53 tumor suppressor functions through 
direct binding to p53, inhibitors targeting the MDM2-p53 protein-protein interaction can 
reactivate p53 functions for cancer treatment. In the past 20 years, peptides and nonpeptide 
small molecule inhibitors have been designed to block the protein-protein interactions between 
MDM2 and p53. These MDM2 inhibitors can cause significant p53 accumulation and can activate 
p53 transcription functions, and this may have therapeutic potential for the treatment of human 
cancers with wild-type p53. 1, 31 
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Figure 1-1. Co-crystal structure of MDM2 (Green) in complex with p53 peptide (Cyan) PDB 
ID:1YCR 
From the early biochemical study, the first 120 amino-terminal amino acid residues of 
MDM2 and the first 30 N-terminal residues of p53 have been shown to be critical for the MDM2 
p53 protein-protein interaction.32 A high-resolution x-ray co-crystal structure of MDM2 in a 
complex with the p53 peptide (Figure 1-1) provided more details about their interaction.33 It has 
been shown that three hydrophobic residues in p53 F19, W23, and L26 bind into a well-defined 
hydrophobic pocket in MDM2, which suggesting the feasibility of nonpeptide small-molecule 
inhibitors to block the MDM2-p53 interaction. This hydrophobic pocket in MDM2 can be used for 
the design of small molecule inhibitors.  
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Figure 1-2. (A) Co-crystal structure of Nutlin-3a complexed with MDM2 (PDB ID:4HG7); (B) 
Structure of Nutlin-3a (C) Structure of RG-7112. 
Nutlins, discovered by Hoffmann-La Roche were first published in 2004 as highly potent, 
specific, nonpeptide small-molecule inhibitors of the MDM2–p53 interaction.34 Nutlin-3a can 
bind to MDM2 protein with an IC50 of 90 nM and effectively activate wild-type p53 in cancer cells, 
which is consistent with its targeting the MDM2–p53 interaction. It activates the p53 target genes 
MDM2 and p21, which are critical for cell-cycle arrest. Nutlin-3a potently inhibits cancer cell 
growth with wild-type p53 in a dose-dependent manner and has more than 10-fold selectivity 
over cancer cell lines harboring p53 mutation or p53 deletion. It can also effectively inhibit tumor 
growth in the xenograft mice model of the human osteosarcoma SJSA-1 cell line with no signs of 
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toxicity to mice at oral doses up to 200 mg/kg. From co-crystal structure of nutlin-3a in a complex 
with MDM2, nutlin-3a mimics the three key binding residues (F19, W23, and L26) of p53 and 
occupies the important hydrophobic binding pocket of MDM2. (Figure 1-2) Preclinical studies of 
nutlin-3a have revealed its therapeutic potential for the treatment of human cancers retaining 
wild-type p53.  
Following the pioneering study of nutlin3a, further studies were done by scientists at 
Hoffmann-La Roche to improve its binding affinity to MDM2, and its cellular potency and 
pharmacokinetics. Subsequently, RG7112 (RO5045337), an analog of nutlin3a, was advanced 
into human clinical trials.13 RG7112 has a binding affinity to MDM2 (IC50 = 18 nM), and is 5-times 
more potent than nutlin-3a. It can effectively inhibit cell growth in cancer cell lines with wild-
type p53 (IC50 = 0.18-2.2 µM) and exhibits good selectivity over cancer cell lines with a p53 
mutation (IC50 = 5.7-20.3 µM). Pharmacodynamic studies have shown that RG7112 can activate 
wild-type p53 dose-dependently in xenograft mice model of SJSA-1 and can achieve partial tumor 
regression upon oral administration, without  any  signs of toxicity in mice. 
 
Figure 1-3. Structures of MDM2 inhibitors with a spiro-oxindole core structure. 
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Using the co-crystal structure of p53 peptide in a complex with MDM2, our laboratory 
completed a computational structure-based drug design for a new class of small-molecule 
inhibitors with a spiro-oxindole core structure.35 MI-77301 was the first compound in this series 
of compounds that was developed and ultimately advanced to clinical trials.14 MI-77301 binds to 
MDM2 with a Ki value of 0.88 nM and is 50 times more potent than nutlin-3a in the same binding 
assay. MI-77301 can also selectively bind to MDM2 more than 10,000 times effectively than to 
MDMX, a protein homologous with MDM2. The co-crystal structure of MI-77301 in a complex 
with the MDM2 protein has shown that MI-77301 occupies the key hydrophobic pocket on 
MDM2, mimicking the three key p53-binding residues and has additional hydrophobic and 
hydrogen-bonding interactions. It was also shown that MI-77301 has a π-π stacking interaction 
with the H96 residue of MDM2. It can also cause the refolding of the unstructured residues at 
the N-terminal region of MDM2, forming a new pocket with which to further enhance its binding 
affinity to MDM2. 
 
Figure 1-4. Co-crystal structure of MI-77301 in a complex with MDM2. (PDB ID: 5TRF) 
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Another MDM2 inhibitor based on this spiro-oxindole core structure that has been 
advanced to clinical trials is RG-7388 (RO5503781) from Hoffmann-La Roche, which was 
published in 2013.9 RG-7388  is currently in phase III clinical trials for acute myeloid leukemia and 
phase II clinical trials for polycythemia vera.  RG-7388 binds to MDM2 with an IC50 value of 6 nM, 
potently inhibits cell growth in cancer cell lines containing wild-type p53 at about 30 nM and 
is >100-fold more potent against cancer cell lines with mutated p53. Efficacy studies have shown 
that RG-7388 can achieve complete tumor regression in the SJSA-1 xenograft model when orally 
administered to mice.  
Based on the spiro-oxindole core structure for MDM2 inhibitors, our group discovered 
APG-115 following an extensive structure–activity relationship study.11 APG-115 has a very high 
affinity to MDM2 with an IC50 value of 3.8 nM and a Ki  < 1 nM. It has potent cellular activity on 
SJSA-1 with an IC50 value of 60 nM, and an excellent oral pharmacokinetic profile. APG-115 can 
achieve complete and long-lasting tumor regression upon oral administration in tumor xenograft 
models and it is currently in phase I clinical trials for cancer treatment. 
DS-3032 is another MDM2 inhibitor based on the spiro-oxindole core structure and 
currently in phase I clinical trials. DS-3032 was developed by scientists from Daiichi-Sankyo.36 It 
can stabilize TP53 and selectively induce CDKNA1, BAX and MDM2 expression in neuroblastoma 
cells with wild-type TP53. It can delay tumor growth and significantly improve the survival time 
in mice xenografted with wild-type TP53 neuroblastoma cells. 
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Figure 1-5. Structures of AMG-232 and NVP-CGM097 
AMG-232 is a member of new class of potent MDM2 inhibitors which has been advanced 
to clinical trials.12 It was discovered by scientists at Amgen through structure-based design and 
extensive optimization and its structure contains a 1,3,5,6-tetrasubstituted piperidinone scaffold. 
AMG-232 has a Kd value of 0.045 nM in an MDM2 binding assay and a cell growth inhibition 
activity with IC50 values of 9.1 nM and 10 nM in SJSA-1 and HCT-116 cell lines with wild-type p53, 
respectively. An efficacy study has shown that AMG-232 effectively inhibits tumor growth in the 
SJSA-1 osteosarcoma model and achieves complete tumor regression with a 60 mg/kg daily dose. 
AMG-232 can also achieve complete tumor growth inhibition without tumor regression in the 
HCT-116 xenograft model. The co-crystal structures of AMG-232 analogs complexed with MDM2 
shows that it also targets all of the three key p53-binding residues in its interactions with MDM2. 
In addition, AMG-232 also interacts with G58 of MDM2 through its sulfonyl isopropyl group and 
forms a salt bridge with H96 and the carboxylic acid group of AMG-232. 
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Figure 1-6 Co-crystal structure of NVP-CGM097 in a complex with MDM2. (PDB ID:4ZYF) 
NVP-CGM097 was reported as a new class of MDM2 inhibitor with a 
dihydroisoquinolinone scaffold and was advanced into clinical development.10 The co-crystal 
structure of NVP-CGM097 in a complex with MDM2 showed that the dihydroisoquinolinone 
scaffold can reach the critical binding pockets by interacting with the three key p53 residues in 
MDM2. Additional interactions were also achieved through water-mediated H-bond interactions 
of its isopropyl ether group with the hydroxyl group of Y100 and with the carbonyl oxygen of F55. 
NVP-CGM097 binds to MDM2 with an IC50 value of 1.7 nM and has cell growth inhibition activity 
with a GI50 value of 350 nM in SJSA-1 cells. Pharmacodynamic studies have shown that NVP-
CGM097 can inhibit the interaction between p53 and MDM2 and reactivate the p53 pathway in 
vivo in a SJSA-1 human tumor model. Daily treatment for 3 weeks with NVP-CGM097 can 
significantly induce >85% tumor regression in SJSA-1 tumor xenografts in rats with no negative 
histopathology findings.  
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MK-8242 (SCH 900242) was developed by the scientists from Merck as a potent MDM2 
inhibitor and currently advanced into phase I clinical trials. The Structure of MK-8242 and its 
characterization have not been disclosed.  
In summary, several classes of highly potent and specific small-molecular MDM2 
inhibitors designed to block the MDM2-p53 protein-protein interaction have been designed, 
synthesized and advanced into clinical trials for cancer treatment. These MDM2 inhibitors can 
efficient activate wild-type p53 in vitro and in vivo. It was also noted that they can also upregulate 
the MDM2 expression level through an autoregulatory feedback loop, as the MDM2 gene is also 
the transcription target of p53.6 Consequently, high concentrations of MDM2 inhibitors are 
needed to block the newly formed MDM2. Moreover, high expression levels of MDM2 may also 
lead to unknown side effects. Therefore, development of new strategies to activate wild-type 
p53 without upregulation of MDM2 can be more effective than the traditional method of 
inhibiting the MDM2-p53 protein-protein interaction. 
Development of PROTACs Targeting Protein Degradation 
In recent years, the PROTAC has become one of the most exciting strategies for 
therapeutic intervention.17 PROTACs are heterobifunctional molecules containing an E3 binding 
ligand, a target protein binding ligand and a linker between them. Both the E3 binding ligand and 
target protein binding ligand can specifically and simultaneously bind to the E3 ubiquitin ligase 
and the target protein to form a ternary complex. By linking the target protein to the E3 ubiquitin 
ligase, PROTACs are capable of promoting the ubiquitination and subsequent proteasomal 
degradation of target proteins to achieve their therapeutic effect. There are two reasons why 
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this is a more efficient strategy than is offered by traditional protein inhibitors. If reversible 
binding ligands are involved in the PROTACs, they can function as catalysts to induce protein 
degradation. This suggests the use of lower drug concentrations of PROTACs than inhibitors with 
the same therapeutic efficacy. Lower drug concentrations can also help to lower the off-target 
side effects and toxicity.15 A second reason is that PROTACs can be used with “undruggable” 
targets. Sometimes the nature of the functional domain or binding site makes it difficult to 
develop small molecule inhibitors. By targeting other druggable domains or binding sites on the 
same protein, PROTACs could induce the degradation of a whole protein to inhibit the protein 
functions which are “undruggable” for inhibitors.37-38 In this thesis, we will assess the 
development of PROTACs during the past 20 years. 
Peptide Based PROTACs 
 
Figure 1-7. Structure of peptide-based PROTACs 
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In 2001, the Sakamoto group developed the first PROTACs targeting degradation of the 
methionine aminopeptidase-2 protein (MetAP-2).39 Ovalicin, a covalent inhibitor was used as the 
target protein ligand and a phosphopeptide (DRHDpSGLDpSM) derived from the NF-ĸB inhibitor-
α (IĸBα) was used to recruit SCFβ-TrCP E3 ubiquitin ligase. It was shown that MetAP-2 is recruited 
to the SCFβ-TrCP E3 ubiquitin ligase by this chimeric molecule 1 (Protac-1) and is ubiquitinated and 
degraded in a Protac-1-dependent manner. As Ovalicin is a covalent inhibitor, only MetAP-2-
PROTAC, but not the free MetAP-2 was degraded. Introduction of proteasome inhibitors LLnL or 
epoxomicin could block the degradation of MetAP-2. 
In 2003, several new PROTACs targeting androgen receptor (AR) and estrogen receptor 
(ER) degradation were published by the Sakamoto group.40 Both of these contained the 
phosphopeptide used in Protac-1 to recruit SCFβ-TrCP E3 ubiquitin ligase. Dihydrotestosterone 
(DHT) was used as the target protein ligand in AR PROTACs and estradiol in the ER PROTACs. It 
demonstrated that the ER PROTAC was capable of causing the ubiquitination and degradation of 
ERα in vitro, and AR PROTAC could promote the rapid disappearance of AR in a proteasome-
dependent manner. Although all PROTACs designed with phosphopeptide can cause target 
protein degradation, these PROTACs are introduced to cells by microinjection. Development of 
cell permeable PROTACs is important for the application of the technique in drug development. 
In 2004, the first cell permeable PROTAC was developed by the Crews group.41 A 7-mer 
peptide (ALAPYIP) derived from hypoxia inducible factor 1α (HIF1α) was used to recruit VHL 
protein, which is the substrate acceptor of CRL2VHL E3 ubiquitin ligase. AP21998 was used as 
target protein ligand to recruit FKBP12(F36V) protein and DHT was used to recruit the AR protein. 
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An eight-poly-D-arginine tag was attached to the PROTAC to improve its cell permeability and 
prevent nonspecific proteolysis. Protein degradation of FKBP12(F36V) and AR induced by the two 
PROTACs were clearly shown by western blot and fluorometric analyses.  
PhosphoPROTACs 
 
Figure 1-8. Structures of phosphoPROTACs 
PhosphoPROTACs are composed of a receptor tyrosine kinase (RTK) phosphorylation 
sequence to recruit target protein, a VHL-binding sequence to recruit CRL2VHL E3 ubiquitin ligase, 
a poly-D-arginine tag to improve cell permeability and a linker. Phosphorylation of tyrosine in the 
RTK phosphorylation sequence can recruit target proteins with a phosphotyrosine-binding (PTB) 
or an Src homology 2 (SH2) domain.42 In 2013, the Crews group published two phosphoPROTACs 
with tyrosine phosphorylation sequences derived from the nerve growth factor receptor, TrkA to 
recruit fibroblast growth factor receptor substrate 2α (FRS2α) or a sequence from neuregulin 
receptor ErbB3 to recruit p85 with an SH2 domain. It was demonstrated that these 
phosphoPROTACs could decrease target proteins both in vitro and in vivo. Treatment with p85 
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phosphoPROTAC significantly reduced tumor size in mouse xenograft tumor model, and this 
indicates the promising therapeutic effects of PROTACs. 
Small-Molecule PROTACs 
Both peptide-based PROTACs and phosphoPROTACs are not useful for drug development 
due to their poor cell permeability, high molecular weight and metabolic instability in cells. These 
disadvantages stem mainly from the peptide structure used in these PROTACs. Developing non-
peptidic PROTACs with small molecules replacing the peptide ligands should achieve much better 
cell permeability and stability. Recent studies on PROTACs have shown the small molecule ligands 
known to bind to MDM2, cIAP1, CRBN and VHL could be used in the design of stable and cell 
permeable PROTACs.43 
 
Figure 1-9. Structure of an MDM2-based small molecule PROTAC. 
In 2008, the Crews group reported the first non-peptide PROTACs targeting AR 
degradation.44 They used nutlin-3a in the PROTACs to recruit the E3 ubiquitin ligase protein 
MDM2 and a non-steroidal, selective androgen receptor modulator ligand (SARM) was linked to 
the nutlin through a PEG linker. Nutlins were designed to bind to MDM2 at the pocket used for 
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binding of p53, which is the primary target protein for MDM2. A SARM-nutlin PROTAC could 
hijack MDM2 to the target protein and lead the ubiquitination and subsequent proteasomal 
degradation of AR by treatment of HeLa cells with 10 μM PROTAC for 7 h. Pretreatment of the 
proteasome inhibitor epoxomicin blocks the degradation of AR, which shows that the decrease 
of AR is through PROTAC induced proteasome degradation.  
 
Figure 1-10. Structures of cIAP-1 based small molecule PROTACs. 
Another important E3 ubiquitin ligase is involved in the design of the PROTACs cIAP1. 
These PROTACs, which hijack cIAP-1 have also been called specific and non-genetic inhibitors of 
apoptosis protein dependent protein erasers (SNIPER).45 In 2010, the Hashimoto group 
developed a PROTAC targeting cellular retinoic acid-binding proteins (CRABP-I and CRABP-II) for 
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degradation.46 These PROTACs contain methyl bestain (MeBS), which can directly and selectively 
bind to the BIR3 domain of cIAP1, and to all-trans retinoic acid (ATRA), involving retinoic acid 
receptors (RARs). RARs could be used to further recruit CRABP-I and CRABP-II. The designed 
PROTACs induce proteasome protein degradation of CRABP-I and CRABP-II, and this could also 
inhibit the migration of neuroblastoma IMR-32 cells. Later, the Hashimoto group replaced MeBS 
with MV1, a pan-ligand for cIAP1, cIAP2 and the X-linked inhibitor of apoptosis (XIAP), as cIAP2 
and XIAP also possess ubiquitin ligase activity.47 These PROTACs can achieve double degradation 
of cIAP1 and CRABP-II and efficiently inhibit proliferation of IMR32 cells. 
In 2013, cIAP-1-dependent PROTACs targeting ERα protein degradation by conjugating 
ERα ligand, 4-hydroxy tamoxifen (4-OHT), to MeBS were developed by the Naito group.48 The 
PROTAC SNIPER(ER)-3 can induce the proteasome degradation of ERα and inhibit estrogen- 
dependent expression of the pS2 gene in MCF-7 cells in 24 h with 10 µM treatment, causing 
necrotic cell death accompanied by a release of HMGB1, a marker of necrosis in MCF-7 cells. 
In 2016, the Kurihara group developed a PROTAC, SNIPER(ABL)-2 which targets BCR-ABL 
degradation. 23 An imatinib derivative that binds to BCL-ABL was linked to MeBS in the PROTAC 
to recruit BCR-ABL to cIAP1 thus inducing ubiquitination and subsequent proteasomal 
degradation. SNIPER(ABL)-2 can cause BCR-ABL protein degradation and subsequent cell growth 
inhibition following treatment at 30-100 µM. 
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Figure 1-11. Structures of CRBN based PROTACs 
In 2010, the Ito group showed that CRBN, which is the substrate acceptor of the CRL4CRBN 
E3 ubiquitin ligase, is the protein target for thalidomide.49 This suggests that thalidomide and its 
derivatives could be used to hijack the ubiquitin ligase CRL4CRBN ligase in the design of PROTACs. 
Later in 2015, the Crews and Brander Groups both published new PROTACs designed to target 
the transcriptional co-activator BRD4 with thalidomide analogues.18-19 ARV-825, published by the 
Arvinas and Crews group, recruits BRD4 using pomalidomide to recruit CRBN and OTX015 to 
recruit a BRD4 bromodomain inhibitor. While dBET1, published by the Brander group, recruits  
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BRD4 and is composed of thalidomide to recruit CRBN and JQ1. Both ARV-825 and dBET1 can 
efficiently and rapidly cause proteasomal degradation of BRD4. ARV-825 can completely degrade 
BRD4 in 6 h with a 10 nM treatment and efficiently inhibit cell proliferation and cause apoptosis. 
dBET1 can cause complete BRD4 degradation in 2 h with a 100 nM treatment. It significantly 
inhibits tumor growth in mouse xenograft models and disseminated leukemia mouse models. To 
extend the application of this strategy, another two PROTACs causing degradation of cytosolic 
signaling protein FKBP12, were developed with FKBP12-directed ligand steel factor (SLF) and the 
same thalidomide moiety as was used in dBET1.19 Both can cause complete FKBP12 degradation 
in 18 h with a 1 µM treatment. Later in 2017, BETd-260, developed by our group, was found to 
effectively degrade BRD4 protein at concentrations as low as 30 pM in the RS4;11 cell line and to 
induce rapid tumor regression in vivo against RS4;11 xenograft tumors.50 With the previous 
success of PROTACs hijacking the target protein in CRBN, the Crews group developed BCR-ABL 
targeting PROTACs by linking dasatinib or bosutinib to CRBN. 22 Both PROTACs can cause the 
proteasomal degradation of ABL and BCR-ABL. 
In 2017, PROTAC targeting of bromodomain-containing protein BRD9 degradation was 
developed by the Brander group.51 BRD9 is a subunit of the SWI/SNF nucleosome remodeling 
complex. The BRD9 PROTAC (dBRD9) consists of BI7273, a potent BRD9 bromodomain inhibitor 
(Kd = 15.4 nM; IC50 = 19 nM)52 which recruits BRD9 and pomalidomide to hijack CRBN. In this case, 
complete BRD9 degradation was achieved in 1 h with a 10 nM treatment of dBRD9 in MOLM-13 
cells.  
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In 2017 the Natarajan and Rana groups developed a PROTAC targeting cyclin-dependent 
kinase 9 (CDK9).53 An aminopyrazole CDK9 inhibitor and thalidomide were linked with methylene 
linker in this PROTAC. In HCT116 cells, this CDK9 PROTAC can selectively cause CDK9 degradation 
without affecting other CDK family members, such as CDK2 or CDK5. 
 
Figure 1-12. Structures of VHL-based BROTACs 
Another important E3 ubiquitin ligase involved in small molecule PROTACs is CRL2VHL. The 
strategy, which involves hijacking VHL to recruit CRL2VHL E3 ubiquitin ligase in PROTACs for 
protein degradation has been confirmed with a 7-mer peptide derived from HIF1α.41 With the 
development of small molecule inhibitors targeting the HIF1α binding site of VHL, 54-56 
development of small molecule PROTACs with a VHL binding ligand becomes attractive and 
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accessible. In 2015 and 2016, PROTACs with a VHL ligand targeting BRD4 degradation MZ1, MZ2 
and ARV-771 with JQ1 to recruit BRD4 were developed by the Cuilin group and Arvinas groups.20, 
57 ARV-771 can cause almost complete degradation of BRD4 in 16 h with a 1 nM treatment in 
22Rv1, VCap and LnCaP95 cells. It is much more potent than the BRD4 inhibitor OTX015 for cell 
proliferation inhibition in vitro and tumor growth regression with a mouse xenograft model in 
vivo.  
In 2015, two PROTACs, PROTAC-ERRα, targeting the estrogen-related receptor alpha 
(ERRα), and PROTAC-RIPK2 targeting the serine/threonine kinase RIPK2, were published by the 
Crews group.24 Both hijacked CRL2VHL E3 ubiquitin ligase, causing target protein degradation. 
PROTAC_ERRα causes almost complete degradation of ERRα in 8 h by the treatment with 1 µM 
in MCF7 cells and PROTAC_RIPK2 can induce more than 90% degradation of RIPK2 in 16 h with a 
10 nM treatment in THP-1 cells.   
Another PROTAC (ARV-330) targeting AR degradation with a VHL binding ligand was 
developed by Arvinas et al.21 The Structure of ARV-330 has not been revealed, but data have 
shown that DC50 of ARV-330 for AR degradation is lower than 1 nM, and it can cause cell 
proliferation and apoptosis in VCap cells following treatment with 20 nM. It can also robustly 
block tumor growth in the xenograft VCap mouse model.  
In summary, PROTAC strategy shows great potential in field of drug discovery, especially 
the recently published small molecule PROTACs which have good cell permeability, stability, 
solubility and appropriate pharmacokinetic properties. PROTACs eliminate the target proteins by 
inducing ubiquitination and degradation, which is more efficient than traditional small molecule 
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inhibitors, which simply bind to the protein. This also provides a promising method with which 
to target undruggable disease-related proteins. To extend the application of PROTAC strategy, 
more druggable proteome and better binding ligands for E3 ubiquitin ligase should be explored. 
As most of PROTACs generally have larger molecular weights and more hydrogen bonding donors 
and acceptors than small molecule inhibitors, improvement of pharmacokinetic properties is also 
important for the application of this strategy in the future. 
Results and Discussion 
Judging from published reviews, the PROTAC strategy targeting MDM2 degradation can 
be more efficient than the traditional MDM2 inhibitors. MI-1061, a potent MDM2 inhibitor, 
which can bind to MDM2 with Ki value of 0.16 nM, was employed in our design of MDM2 PROTAC 
degraders. 
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Figure 1-13. (A) Co-crystal structure of MDM2 complexed with MI-77301 (Cyan, PDB ID: 5TRF); 
(B) Modeled structure of MDM2 complexed with MI-1061 (Yellow, PDB ID: 5TRF); (C) Modeled 
structure of MDM2 complexed with MI-1061 (Yellow, PDB ID: 4LWU).  
Upon the basis of the co-crystal structure of MDM2 complexed with MI-77301 (PDB ID: 
5TRF)14, we modeled the structure of MDM2 (PDB ID: 4LWU)58 complexed with MI-1061. In the 
crystal structure of MDM2-MI-77301, the hydroxy-cyclohexyl group of MI-77301 forms at least 
one hydrogen bond with K94. When the same MDM2 structure was used to model MI-1061, we 
failed to obtain a docking pose of MI-1061 similar to MI-77301 (Figure 1-13B.) possibly due to 
the restricted conformation of K94 that was observed in the MDM2-MI-77307 crystal structure. 
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Another MDM2 crystal structure (PDB ID: 4LWU) in which K94 adopts a different conformation 
for docking simulation led to a pose of MI-1061 similar to that of MI-73301. In this model, MI-
1061 is involved in a salt-bridge interaction with K94 (3.4 Å) and H73 (2.5 Å) The benzoic acid 
group in this model is exposed to solvent, making it a suitable site for tethering to E3 ubiquitin 
ligase ligand for the design of potential PROTAC degraders of MDM2 proteins. 
 
Figure 1-14. Western blotting analysis of MDM2 and p53 proteins in RS4;11 cells treated with 
MDM2 inhibitor MI-1061 and MDM2 degraders LD-074, LD-075. RS4;11 cells were treated for 2 
h with each individual compound at indicated concentrations, and proteins were probed by 
specific antibodies. GAPDH was used as the loading control. 
Thalidomide analogues, which can recruit CRBN, the substrate accepter of the CUL4ACRBN 
E3 ubiquitin ligase, was used in the design of MDM2 degrader. We designed and synthesized LD-
074 and LD-075 (Table 1-1) as potential MDM2 degraders using MI-1061 for the MDM2 inhibitor 
portion, thalidomide as the cereblon ligand, and in the beginning, the hydrophobic carbon and 
hydrophilic PEG linker were used. WST-8 cell viability assay showed that LD-074 and LD-075 can 
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efficiently inhibit cell growth in the RS4;11 acute leukemia cell line with IC50 values of 10 nM or 7 
nM respectively, and are 14-20 times more potent than MI-1061. Western blotting analysis 
showed that both LD-074 and LD-075, at concentrations as low as 10 nM, are effective in 
decreasing the level of the MDM2 protein and increasing the level of p53 protein in the RS4;11 
cells when compared with the MDM2 inhibitor MI-1061 (Figure 1-14). It was concluded that LD-
074 and LD-075 are promising MDM2 degraders for further optimization. 
Table 1-1. MDM2 degraders designed with thalidomide and linkers with various lengths. 
 
Compound 
No. 
Linker IC50/µM RS4;11 
MI-1061  0.141±0.012 
LD-117 
 
0.015±0.002 
LD-270 
 
0.009±0.002 
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LD-074 
 
0.010±0.001 
LD-252 
 
0.012±0.002 
LD-091 
 
0.022±0.007 
LD-251 
 
0.100±0.027 
LD-111 
 
0.008±0.002 
LD-075 
 
0.007±0.002 
LD-112 
 
0.0045±0.0001 
LD-086 
- - 
0.005±0.001 
LD-085 
 
0.024±0.006 
LD-076 
 
0.009±0.002 
 
Then we next explored the linker length optimal for cellular potency for both hydrophobic 
and hydrophilic linkers in MDM2 degraders and results are shown in Table 1-1. For the 
hydrophobic carbon linker, the linker length was increased progressively by one methylene group. 
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Similar IC50 values from 9 nM to 12 nM in inhibition of RS4;11 cell growth were obtained with 
linkers composed of 3 to 5 methylene groups. But compound LD-117 with one methylene group 
less than LD-270 is about half as potent as LD-270. Further elongation of carbon linkers to 6 or 7 
methylenes resulted in a 2-fold or 10-fold decrease in the cellular potency compared with LD-
074. Hence the optimal length of a hydrophobic carbon linker is 3-5 methylene groups. With the 
hydrophilic PEG linkers, no significant change in cell growth inhibition activity was obtained from 
single ethylene glycol unit up to seven units. Among these, LD-112, with two such units shows 
best cell growth inhibitory activity with an IC50 value of 4.5 nM. Thus, modifications of the linker 
compositions identified compounds LD-074 and LD-112 as two potent MDM2 degraders with low 
nanomolar IC50 values in inhibition of RS4;11 cell growth. These two compounds were used for 
further modification. 
Table 1-2. MDM2 degraders designed with different cereblon ligands. 
 
 
Compound 
No. 
Linker X IC50/µM RS4;11 
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MI-1061   0.141±0.012 
LD-110 
 
CO 0.026±0.011 
LD-210 
 
CO 0.053±0.015 
LD-131 
 
CH2 0.006±0.001 
LD-243 
 
CH2 0.0038±0.0006 
LD-188 
 
CH2 0.022±0.005 
LD-214 
 
CO 0.029±0.008 
LE-021 
 
CH2 0.005±0.005 
LD-186 
 
CH2 0.012±0.001 
LD-222 
 
CH2 0.0028±0.0011 
 
Having determined the optimal linker length, we next sought to focus on the 
modifications of the linker composition and the cereblon ligand. Replacing NH in LD-112 by 
oxygen or methylene resulted in LD-110 and LD-210, which were 5 and 10 times less potent than 
LD-112, respectively. A similar result was obtained when LD-214 was compared with LD-074, as 
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LD-214 is 3-fold less potent than LD-074.  In all these synthetic compounds, we employed 
thalidomide as the ligand for cereblon. Lenalidomide, a second-generation thalidomide analogue 
used for the treatment of multiple myeloma and myelodysplastic syndromes, was also employed 
for the design of MDM2 degraders. Similar cellular potency was obtained by changing 
thalidomide in LD-112, to lenalidomide, which yielded LD-131 with IC50 = 6 nM. LD-243, 
containing lenalidomide is 14 times more potent than LD-210 which contains thalidomide. 
Introducing an amide attachment to lenalidomide in LD-131 yielded LD-188 and decreased the 
cellular potency. With a hydrophobic methylene linker, changing thalidomide to lenalidomide 
significantly improved the cellular potency in the RS4;11 cell line, LD-222 being about 10 times 
more potent than LD-074 and a similar loss of potency was obtained for LD-186 with amide in 
the linker. The two most potent MDM2 degraders, LD-222 and LD-243 therefore were obtained 
by deleting one carbonyl group in thalidomide. 
Table 1-3. MDM2 degraders designed with more rigid linkers. 
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Compound 
No. 
Linker IC50/μM RS4;11 
MI-1061  0.141±0.012 
LE-013 
 
0.0039±0.0004 
LE-004 
 
0.0015±0.0005 
LE-081 
 
0.013±0.004 
LE-082 
 
0.014±0.005 
LE-083 
 
0.014±0.003 
LE-084 
 
0.012±0.003 
LE-254 
 
0.0012±0.0003 
LE-093 
 
0.0041±0.0003 
LE-094 
 
0.014±0.005 
LE-095 
 
0.0039±0.0010 
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LE-096 
 
0.009±0.004 
LE-102 
 
0.0023±0.0005 
LE-103 
 
0.015±0.007 
LE-194 
 
0.824±0.687 
LE-200 
 
0.052±0.031 
LD-254 
 
0.0029±0.0012 
LE-243 
 
0.008±0.004 
LE-244 
 
0.0047±0.0015 
LE-224 
 
0.0030±0.0012 
 
From the SAR study of linker length, composition and cereblon ligands, the two best 
compounds with hydrophobic linkers that were obtained were LE-021 and LD-222. No co-crystal 
structures of MDM2 degraders in a complex with MDM2 and cereblon protein were obtained, 
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but several modifications to increase the linker rigidity were applied as increasing the rigidity of 
MDM2 degraders is thought to increase the potency, selectivity, stability and pharmacokinetic 
properties.59 Several MDM2 degraders with rigid linkers were synthesized and tested and the 
results are summarized in Table 1-3. At first, based on the structure of LE-021, several piperidine 
or azetidine rings were introduced. Both LE-081 and LE-083 with piperidine or LE-082 and LE-084 
with azetidine in the linker are about half as potent as LE-021, which indicates a poor 
conformation of the linkers. Introduction of a shorter flexible methylene linker to LE-081 or LE-
083 yields LE-254, LE-093 and LE-095 all of which show better cell growth inhibitory activity. 
Among these, LE-254 shows best cell growth inhibition activity with IC50=1.2 nM in the RS4;11 
cell line. Introduction of a triple bond into the hydrophobic methylene linkers, should decrease 
the flexibility of the linker and accordingly, LE-013 and LE-004 were synthesized. Both show good 
cellar potency with IC50 = 3.9 and 1.5 nM in the RS4;11 cell line. In a combination of these two 
strategies, a more rigid linker was used to yield LE-102, which shows good cell growth inhibitory 
activity with IC50 = 2.3 nM in the RS4;11 cell line, but increasing the flexibility by reducing the 
triple bond or using cyclohexylamine to replace piperidine in LE-102 was found to decrease its 
inhibitory activity, indicating that LE-102 reaches an appropriate confirmation to form the protein 
complex for MDM2 degradation. Imidazole and pyrazole rings were also introduced to the linker, 
and among these, LD-254 shows good cellar potency with IC50 = 2.9 nM in the RS4;11 cell line. 
Introduction of a triple bond into the polyethylene glycol linker led to less potent compounds 
than introduction of the corresponding methylene linker. Thus, according to the study of MDM2 
degrader with rigid linkers, LE-102 was chosen for further preclinical evaluation. 
Table 1-4. MDM2 degraders linked to different positions of the cereblon ligand. 
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Compound 
No. 
Linker with cereblon ligand IC50/μM RS4;11 
MI-1061  0.141±0.012 
LE-178 
 
0.0048±0.0018 
LE-179 
 
0..005±0.003 
LE-180 
 
0.0030±0.0011 
LE-181 
 
0.012±0.003 
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Figure 1-15. Co-crystal structure of DDB1-CRBN E3 ubiquitin ligase complexed with Lenalidomide 
(Yellow, PDB ID 4CI2).  
Another important question is whether other parts of thalidomide analogues could be 
used to link to MDM2 inhibitors. To answer this question, different linking sites of lenalidomide 
analogues were explored with hydrophobic methylene linkers in LD-222 and LE-004. Based on 
the co-crystal structures of lenalidomide with cereblon (PDB ID: 4CI2)60, other positions on the 
phenyl ring facing outside the pocket could be useful for PROTAC design (Figure 1-15). 
Accordingly LE-178, LE-179, LE-180 and LE-181 were synthesized and tested (Table 1-4). These 
MDM2 degraders show good cellar potency in the RS4;11 cell line and the results indicate that 5- 
and 6-positions on the 1-oxoisoindolinyl group of lenalidomide ananlogue are promising linking 
sites for the design of PROTACs. 
Further Evaluation of Two Potent PROTAC MDM2 Degraders LE-004 and LE-102 
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Next, extensive evaluations to investigate the mechanism of action and therapeutic 
potentials of LE-004 and LE-102, were performed with MI-1061 as the MDM2 inhibitor control. 
 
Figure 1-16. Western blotting analysis of MDM2 and p53 proteins in RS4;11 cells treated with 
MDM2 inhibitor MI-1061 and MDM2 degraders LE-102. RS4;11 cells were treated for 0.5 and 2 h 
with each individual compound at indicated concentrations, and proteins were probed by specific 
antibodies. GAPDH was used as the loading control. 
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Figure 1-17. qPCR analysis of MDM2, p21, Puma and BAX mRNA levels in RS4;11 cells treated 
with MI-1061 or LE-102 degrader at the indicated concentrations for 6 h. 
The results of the MDM2 degradation and p53 activation by LE-102 were examined and 
compared with data from the MDM2 inhibitor MI-1061 in the RS4;11 cell line giving the results 
shown in Figure 1-16. LE-102 can effectively and potently induce degradation of MDM2 protein 
in a dose-dependent manner after 30 min treatment. Clear MDM2 degradation was observed at 
concentrations as low as 3 nM. After 2 h treatment, significant and more efficient p53 activation 
was obtained with LE-102 than with MI-1061. No MDM2 protein accumulation was observed 
following MDM2 degrader treatment when compared with the MDM2 inhibitor treatment. qPCR 
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analysis also confirmed that LE-102 is more effective than MI-1061 in activation of p53 
downstream genes (Figure 1-17). 
 
Figure 1-18. (A) & (B) Excess lenalidomide reduces cell growth inhibition, MDM2 degradation and 
p53 activation activity of LE-004. (C) Proteasome inhibitors and neddylation inhibitors reduce 
MDM2 degradation and p53 activation activity of LE-004. 
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As the design of MDM2 PROTACs requires their binding to the Cul4CRBN 4 E3 ubiquitin 
ligase complex through CRBN for MDM2 degradation and p53 activation, we predicted that 
excess lenalidomide should effectively block the MDM2 degradation and p53 activation induced 
by LE-004. Lenalidomide should not affect the upregulation of MDM2 and p53 proteins induced 
by MI-1061. Western blotting analysis showed that lenalidomide indeed effectively blocks MDM2 
degradation and accumulation of p53 protein by LE-004 and has no effect on MDM2 and p53 
accumulation induced by the MDM2 inhibitor MI-1061 (Figure 1-18A).  Co-treatment of LE-004 
with 30 µM of lenalidomide also greatly reduces its cell growth inhibitory activity and has 
essentially the same effect as the MDM2 inhibitor MI-1061, used alone. (Figure 1-18B) These 
data indicate that the binding of LE-004 to cereblon is effectively blocked by lenalidomide, and 
the degradation of MDM2 induced by LE-004 is dependent upon CRBN. We also found that 
proteasome inhibitors MG-132 and PR-171 and the neddylation inhibitor MLN4924 can 
effectively block the MDM2 degradation caused by LE-004 in RS4;11 cells. (Figure 1-18c) 
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Figure 1-19. Activity of the negative control compounds LE-154 and LE-157 with weaker binding 
affinity to MDM2 or CRBN compared with LE-004. 
To further investigate the mechanism of MDM2 degradation induced by LE-004, two 
control compounds LE-154 and LE-157 were synthesized (Figure 1-19A). LE-154, an enantiomer 
of LE-004 is more than 100-times less potent than LE-004 in inducing MDM2 degradation in 
RS4;11 cells (Figure 1-19B). Consistently, it is more than 100-times less potent when compared 
to LE-004 in growth inhibition assay in RS4;11 cells (Figure 1-19C). In the other negative control 
compound LE-157, the amino group of the piperidine-2,6-dione was methylated. The previous 
study showed that the amino group of the piperidine-2,6-dione in lenalidomide forms a strong 
hydrogen bond with CRBN60-61  and methylation on this amino group can completely block its 
binding to CRBN18, 60. Indeed, LE-157 was found to be completely inactive in inducing MDM2 
degradation (Figure 1-19B) and is more than 100-times less potent than LE-004 in inhibition of 
cell growth in RS4;11 cells (Figure 1-19C). These data confirm that the degradation of MDM2 
induced by LE-004 requires its strong binding to MDM2 and cereblon, which is consistent with 
our original PROTAC design. 
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Figure 1-20. MDM2 degrader LE-102 induces complete tumor regression in the xenograft model 
of human RS4;11 tumor cells with minimal body weight change with variety dose of LE-102. 
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Figure 1-21. MDM2 degrader LE-102 extended the survival time in RS4;11 disseminated model. 
Based on this SAR study of MDM2 degraders, LE-102 was chosen for further in-vivo study. 
The antitumor activity of LE-102 was tested in the RS4;11 xenograft model in mice and the results 
are shown in Figure 1-20. Mice bearing RS4;11 xenograft tumors were administered 25, 40 and 
50 mg/kg of LE-102 intravenously every other day, three times a week for 3 weeks and achieved 
rapid and complete tumor regression. There was no weight loss or other signs of toxicity in mice 
treated with LE-102, and the animal weight gained in the vehicle control group of mice was 
attributed largely to rapid tumor growth. Although no complete tumor regression was obtained 
by doses of 25 or 40 mg/kg of LE-102 once per week, such doses can significantly inhibit the 
tumor growth (Figure 1-20). In the RS4;11 mice disseminated model, dosing of the mice with 50 
mg/kg of LE-102 intravenously every other day, three times a week for 3 weeks achieved 
significant extension of the survival time. No significant weight loss was observed in the 
treatment groups (Figure 1-21). Therefore, the in vivo data firmly establish that LE-102 has highly 
efficacious antitumor activity at a well-tolerated dose-schedule in mice.  
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Figure 1-22. Pharmacodynamic analysis of LE-102 in RS4;11 xenograft tumor tissue. SCID mice 
bearing RS4;11 tumors were treated with a single intravenous dose of LE-102 of 40 mg/kg. Mice 
were sacrificed at 1, 2, 4, 6, 8, 24, 48 and 72 h time-points after administration of compound LE-
102 or at 6 h with vehicle control, and tumors were harvested from the mice for Western blotting 
analysis of MDM2, p53, p21, PARP and cleaved PARP (Cl PARP). GAPDH was used as the loading 
control and three mice were used for each time-point with each mouse bearing one tumor. 
To gain a better understanding of the strong antitumor activity of LE-102 and its 
mechanism of action in vivo, pharmacodynamics (PD) analysis in SCID mice bearing the RS4;11 
xenograft tumors was performed. In this experiment, mice bearing RS4;11 xenograft tumor were 
administered a single dose of LE-102 at 50 mg/kg intravenously and were sacrificed at 1, 2, 4, 6, 
8, 24, 48 and 72 h time-points after the treatment. Mice treated with vehicle control were 
sacrificed at the 6 h time point. Western blotting analysis was performed to probe the level of 
MDM2 proteins, as well as p53, p21 and PARP proteins in the tumor tissue. The PD data in Figure 
1-22 clearly show that a single dose of LE-102 is highly effective, dramatically reducing the level 
of MDM2 proteins with p53 protein accumulation in the RS4;11 tumor tissue. The effects persist 
longer than 24 h.  The level of p21 is strongly up-regulated, with the effect persisting for as long 
as 72 h. PD analysis clearly demonstrates that a single dose of LE-102 is sufficient to induce 
significant degradation of MDM2 protein with p53 accumulation for more than 24 h in mice. 
Table 1-5. Analysis of concentration of LE-102 in Plasma and RS4;11 Tumor Tissue. 
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Pharmacokinetic (PK) analysis was performed to study the concentrations of LE-102 in 
plasma and RS4;11 xenograft tumors in the same mice used in the PD experiment. PK data have 
shown that despite its relatively large size, LE-102 can effectively penetrate the RS4;11 xenograft 
tumor tissue and stay in the tumor for a long time. It produces a concentration of  LE-102 of 2064 
to 4636 ng/mL in the tumor from 1 h to 72 h, thus exceeding the drug concentrations shown in 
our in vitro experiments to be necessary for effective MDM2 degradation. Our PK data indicates 
that a single dose of LE-102 at 40 mg/kg achieves sufficient exposure in the tumor tissue for 
effective induction of MDM2 protein degradation for over 72 h. 
Table 1-6. MDM2 inhibitors conjugated with VHL-1 ligands. 
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Compound 
No. 
Linker IC50/μM RS4;11 
MI-1061  0.141±0.012 
LE-175 
 
1.23±0.77 
LE-176 
 
0.497±0.137 
LE-177 
 
0.343±0.023 
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Figure 1-23. Western blotting analysis of MDM2 and p53 proteins in RS4;11 cells treated with 
MDM2 inhibitor MI-1061 and MDM2 degraders LE-177. RS4;11 cells were treated for 12 h with 
each individual compound at indicated concentrations, and proteins were probed by specific 
antibodies. GAPDH was used as the loading control. 
With the successful design of MDM2 PROTACs containing a cereblon binding ligand, we 
sought to explore other E3 ubiquitin ligases for MDM2 degradation. Specific small peptide 
mimetic VHL ligands were developed and successfully applied in the design of PROTACs targeting 
BET and AR protein degradation with Cul2VHL E3 ubiquitin ligase.21, 57 Accordingly, LE-175 with a 
hydrophobic linker and LE-176 and LE-177 with hydrophilic linkers were synthesized and tested. 
They were found to be 4-9 times weaker than MI-1061 in a cell growth inhibition assay. No MDM2 
degradation by treatment with these bivalent compounds was observed in a Western Blotting 
assay. The result indicates that PROTACs recruiting Cul2VHL E3 ubiquitin ligase could not induce 
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MDM2 degradation. (Figure 1-23) Similar results have been reported for the design of PROTACs 
targeting BCR-ABL protein.22 
 
Table 1-7. MDM2 degraders and inhibitors with different binding affinity to MDM2. 
 
Compound No.  R1 R2 R3, R4 Kd (nM) RS4;11 IC50/μM 
HXA-110 Inhibitor Cl F Cyclohexyl 11.2±0.9 0.025±0.006 
AA-231 Degrader Cl F Cyclohexyl  0.0008±0.0001 
LE-211 Inhibitor Cl H Cyclohexyl 18.3±4.1 0.058±0.015 
LE-297 Degrader Cl H Cyclohexyl  0.0007±0.0002 
HXA-119 Inhibitor H F Cyclohexyl 101±8 0.135±0.022 
LE-295 Degrader H F Cyclohexyl  0.203±0.106 
LE-217 Inhibitor F H Cyclohexyl 230±25 0.535±0.166 
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LE-298 Degrader F H Cyclohexyl  2.71±0.57 
HXA-120 Inhibitor H H Dimethyl 5578±1670 1.75±0.09 
LE-296 Degrader H H Dimethyl  21.5±8.6 
 
 
Figure 1-24. Western blotting analysis of MDM2 and p53 proteins in RS4;11 cells treated by 
MDM2 inhibitors and degraders with different binding affinities to MDM2. RS4;11 cells were 
treated for 2 h with each compound at indicated concentrations, and proteins were probed by 
specific antibodies. GAPDH was used as the loading control. 
PROTAC strategy in which protein inhibitors are linked with an E3 ubiquitin ligase has 
become a promising method in drug discovery. The binding affinity requirement of the protein 
binding ligand has however not been clearly explored. To address this problem, several MDM2 
inhibitors with different MDM2 binding affinities were synthesized. The linker and cereblon 
binding ligand used in LE-004 were linked to these MDM2 inhibitors. The cell growth inhibition 
activities and MDM2 protein degradation effects of these MDM2 inhibitors and the 
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corresponding degraders have been tested and the results are summarized in Table 1-7 and 
Figure 1-24. The binding affinity of MDM2 inhibitors was tested in an OctetRED assay. The most 
potent MDM2 degrader, HXA-110 binds to MDM2 with Kd = 11 nM, and can efficiently inhibit the 
RS4;11 cell line with IC50 = 25 nM. The corresponding degrader, AA-231 is 30 times more potent 
than HXA-110 with IC50 = 0.8 nM in the RS4;11 cell line. Similar results were obtained with LE-211 
and LE-297. HXA-119, which binds to MDM2 with Kd= 101 nM has a cell growth inhibition activity 
similar to that of its corresponding degraders LE-295, with IC50 = 135 nM and 203 nM. The less 
potent inhibitor LE-217 with Kd= 230 nM is 5 times more potent than the degrader LE-298. Similar 
results were obtained with the weakest inhibitor HXA-120 with Kd = 5.6 µM and the degrader LE-
296. Western Blotting has shown that AA-231, LE-297 and LE-295 could cause significant MDM2 
degradation compared with their inhibitors, while little MDM2 degradation was observed in the 
treatment with LE-298 and LE-296. This result indicates that MDM2 inhibitors with protein 
binding affinity < 200 nM can be applied with a cereblon ligand for MDM2 degradation only with 
difficulty. The weak binding affinity may fail to recruit the target proteins to the E3 ubiquitin 
ligases and subsequently induce protein degradation. 
Synthesis 
The synthesis of MDM2 inhibitors HXA-110, LE-211, HXA-119, LE-217, HXA-120 and 
corresponding MDM2 degraders AA-231, LE-297, LE-295, LE-298, LE-296 is shown in Scheme 1. 
Various substituted (E)-3-benzylidene-6-chloroindolin-2-one and ketones were used to 
synthesize compounds 108a-108e. Then these intermediates were methylated with methanol 
and concentrated sulfuric acid and the chiral auxiliary group was removed with ammonium 
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cerium(IV) nitrate in acetonitrile/water to form 110a-110e. Compounds 112a-112e were 
obtained by hydrolysis with lithium hydroxide in water, MeOH and THF and subsequently, an 
amide condensation reaction with trans-methyl 4-aminocyclohexanecarboxylate. The esters 
were hydrolyzed and reacted with methylamine or with compound 105d to form the MDM2 
inhibitors and degraders. 
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Scheme 1-1. Synthesis of AA-231, LE-297, LE-295, LE-298,  LE-296, HXA-110, LE-211, HXA-119, 
LE-217 and HXA-120. Reaction conditions: (a) toluene, reflux; (b) conc. H2SO4, MeOH rt; (c) 
ammonium cerium(IV) nitrate, acetonitrile, water; (d) LiOH, MeOH, H2O, THF; (e) HATU, DIEA, 
DMF. 
The synthesis of MDM2 degraders with thalidomide is shown in Scheme 2. The 
intermediates 101a-101j were synthesized by a nucleophilic substitution reaction with 2-(2,6-
dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione and the Boc protecting groups were removed 
under acidic conditions. MDM2 degraders LD-117, LD-270, LD-074, LD-252, LD-091, LD-251, LD-
111, LD-075, LD-112 and LD-076 were then obtained by an amide condensation reaction with MI-
1061. LD-110 was synthesized from 2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindoline-1,3-dione 
and 2,2-dimethyl-4-oxo-3,8,11,14-tetraoxa-5-azahexadecan-16-yl 4-methylbenzene- sulfonate 
under weak basic conditions. The Boc protecting group was removed with trifluoroacetic acid to 
yield LD-114. LD-110 was obtained by an amide condensation reaction with MI-1061.  
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Scheme 1-2. Synthesis of LD-117, LD-270, LD-074, LD-252, LD-091, LD-251, LD-111, LD-075, LD-
112, LD-076 and LD-110. Reaction conditions: (a) DIPEA, DMF, 80 °C; (b) trifluoroacetic acid, DCM, 
rt; (c) HATU, DIPEA, DMF, rt; (d) KHCO3, DMF, 50 oC. 
The synthesis of MDM2 degraders containing lenalidomide is shown in Schemes 3 and 4. 
The intermediates 102a-102d and 103a-103e were synthesized by a reductive amination reaction 
with lenalidomide and the Boc groups were then removed under acidic conditions. Intermediates 
104a-104e were then synthesized by another reductive amination reaction with 103a-103d and 
subsequent deprotection reactions. The MDM2 degraders LD-131, LE-021, LD-188, LD-186, LE-
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081, LE-082, LE-083, LE-084, LD-254, LE-254, LE-093, LE-094, LE-095 and LE-096 were then 
obtained by an amide condensation reaction with MI-1061. 
 
 
Scheme 1-3. Synthesis of LD-131, LE-021, LD-188 and LD-186. Reaction conditions: (a) 
NaBH(OAc)3, HOAc, DCE; (b) HATU, DIEA, DMF, rt; (c) trifluoroacetic acid, DCM, rt; (d) HATU, 
DIPEA, DMF, rt. 
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Scheme 1-4. Synthesis of LE-081, LE-082, LE-083, LE-084, LD-254, LE-254, LE-093, LE-094, LE-095 
and LE-096. Reaction conditions: NaBH(OAc)3, HOAc, DCE; (b) trifluoroacetic acid, DCM, rt; (c) 
HATU, DIPEA, DMF, rt. 
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The synthesis of MDM2 degraders with direct C-C bond linking to 3-(1-oxoisoindolin-2-
yl)piperidine-2,6-dione is shown in Schemes 5 and 6. Linkers with a Boc protected amino group 
and an ethynyl group were linked to the cereblon binding ligand by Sonogashira coupling 
reactions with corresponding bromo-substituted thalidomide or the bromo-substituted 3-(1-
oxoisoindolin-2-yl)piperidine-2,6-dione. The Boc protecting groups were removed with 
trifluoroacetic acid to obtain intermediates 105a-105g and 113a-113b. The triple bonds were 
then reduced by H2 with Pd/C to form intermediates 106a-106g and 114a-114b. MDM2 
degraders LE-224, LE-04, LE-102, LE-194, LE-243, LD-210, LD-214, LD-243, LD-222, LE-103, LE-200, 
LE-244, LE-178, LE-179, LE-180, LE-181 were then obtained by an amide condensation reaction 
with MI-1061. 
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Scheme 1-5. Synthesis of LE-224, LE-004, LE-102, LE-194, LE-243, LD-210, LD-214, LD-243, LD-222, 
LE-103, LE-200 and LE-244. Reaction conditions: (a) Pd(PPh3)2Cl2, CuI, triethylamine, DMF, 80 oC; 
(b) trifluoroacetic acid, DCM, rt; (c) H2 (1 atm), Pd/C, EtOH, rt; (d) HATU, DIPEA, DMF, rt. 
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Scheme 1-6. Synthesis of LE-178, LE-179, LE-180 and LE-181. Reaction conditions: (a) Pd(PPh3)2Cl2, 
CuI, triethylamine, DMF, 80 oC; (b) trifluoroacetic acid, DCM, rt; (c) H2 (1 atm), Pd/C, EtOH, rt; (d) 
HATU, DIPEA, DMF, rt. 
The synthesis of MDM2 degraders with a VHL ligand are shown in Scheme 7. The VHL 
binding ligands 107a-107d with different linkers were synthesized according to previous reports 
published by Crews et al.18 The bivalent molecules LE-175, LE-176, LE-177 and LE-334 were then 
obtained by an amide condensation reaction with MI-1061. 
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Scheme 1-7. Synthesis of LE-175, LE-176, LE-177 and LE-334. Reaction conditions: (a) HATU, 
DIPEA, DMF, rt; (b) trifluoroacetic acid, DCM, rt; (c) HATU, DIPEA, DMF, rt. 
Summary 
A new class of PROTAC small-molecule degraders of MDM2 proteins has been developed 
based on our potent and selective MDM2 inhibitors and thalidomide derivatives. Several highly 
potent MDM2 protein degraders, exemplified by LE-102, were obtained by extensive 
optimization of the linker length and composition. LE-102 effectively induces degradation of 
MDM2 protein and activates p53 pathway within 0.5 h at concentrations as low as 1 nM in the 
RS4;11 acute leukemia cell line. It achieves an IC50 value of 2.3 nM in cell growth inhibition in the 
RS4;11 cell line. Significantly, LE-102 achieves complete tumor regression with an every second 
day dosing schedule and tumor growth inhibition with a weekly dosing schedule in RS4;11 
xenograft model in mice. Collectively, our data demonstrate that LE-102 is a highly potent, 
efficacious, and promising MDM2 degrader which warrants further evaluation as a potential new 
therapy for the treatment of human acute leukemia. Development of PROTACs targeting MDM2 
protein degradation is a new strategy with which to target acute leukemia harboring wild-type 
58 
 
p53 and the designed PROTACs are much more potent and efficacious than simple MDM2 
inhibitors. 
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Chapter 2 
Development of Molecular Glues from PROTACs 
Introduction 
PROTAC as an emerging method targeting protein degradation has been widely used for 
target validation and development of novel therapeutics15, 39, 62. PROTACs are designed by linking 
the target protein ligand to an E3 ubiquitin ligase ligand. These bifunctional molecules can recruit 
a target protein into proximity with an E3 ubiquitin ligase to induce target protein ubiquitination 
and subsequent proteasomal degradation. Recent development of PROTACs with more ‘drug-
like’ molecular properties has led to remarkable improvement of in vitro and in vivo activities 
compared with the traditional target protein inhibitors. CRBN has been identified as a substrate 
acceptor for Cul4CRBN E3 ubiquitin ligase. Its ligands, thalidomide and various corresponding 
derivatives have been widely used in PROTACs design, leading to BET, MDM2, and BCR-Abl 
proteins PROTAC degraders23. 
Thalidomide and its derivative molecules, which are named immunomodulatory drugs 
(IMiDs) are widely used in the treatment of multiple myeloma with excellent efficacy.63-64 Recent 
research has shown that IMiDs can bind to cereblon, a critical substrate acceptor of Cul4CRBN E3 
ubiquitin ligase and as “molecular glue” or molecular switches, promote recruitment and 
ubiquitination of substrate proteins.49, 60, 65-66 Lenalidomide can induce proteasomal degradation 
of essential transcription factors of the Ikaros family zinc finger proteins 1 and 3 (IKZF1/3) in 
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multiple myeloma.63, 67 CC-885, derived from lenalidomide, has been developed with potent 
antitumor activity through the cereblon-dependent ubiquitination and degradation of the 
translation termination factor GSPT168. The cereblon modulators are molecular glue which can 
recruit GSPT1 to cereblon through interaction with the modulators and a 'hotspot' on the 
cereblon surface.  Structural degradation underlying cereblon substrate selectivity could be 
redefined by cereblon modulation.  
During our study of MDM2 PROTAC degraders, a new cereblon modulator, LD-277 was 
discovered with potent antitumor activity. The original design of LD-277 was based on the 
PROTACs strategy for MDM2 degradation, but its antitumor activity is mediated through 
molecular glue mechanism, which could modulate the cereblon substrate selectivity. GSPT1 was 
identified as the primary target protein of LD-277 and GSPT1 degradation dominantly drives the 
effect of LD-277 in cancer cell lines and these findings identify a new class of cereblon modulators 
targeting GSPT1 degradation. The study also suggested the importance of careful evaluation of 
function and mechanism in the development of PROTACs.  
Literature Review 
Development of Molecular Glue Inducing Protein-Protein Interactions 
In the past 20 years, development of compounds that perturb protein-protein 
interactions has been become a popular field in drug discovery and compounds that can enhance 
the novel protein-protein interactions provide another opportunity for drug discovery. 
Compounds which can induce protein-protein interactions are known as molecular glues, and 
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they can promote the new protein-protein interactions through direct binding at the protein-
protein interaction surface or allosteric modification of protein structures.69 
 
Figure 2-1. Structures of macrocyclic immunosuppressant molecular glues 
Several macrocyclic immunosuppressants have been reported to function as molecular 
glues. Rapamycin70 could attach to the FK506 binding protein (FKBP12) and the FKBP-rapamycin 
associated protein (FRAP) to inhibit IL-2 signaling. FK50671 could also form a ternary complex with 
FKBP12 and calcineurin and so inhibit the phosphatase activity of calcineurin.  With their large 
contact surfaces, these macrocyclic compounds could contribute more than 25% of the protein-
protein interaction surface area. 
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Figure 2-2. (A) Structures of RO-5963; (B) Structure of RO-2443; (C) Co-crystal structure of RO-
2443 in a complex with MDMX (PDB ID: 3U15); (D) Co-crystal structure of RO-2443 in a complex 
with MDM2. (PDB ID: 3VBG) 
In 2012, RO-596349 was discovered by scientists at Hoffmann-La Roche to activate the 
tumor suppressor gene p53. Unlike normal MDM2-p53 inhibitors or MDMX-p53 inhibitors, RO-
5963 can potently block p53 binding with both MDM2 and MDMX by inducing homo- and/or 
heterodimerization of MDM2 and MDMX proteins as molecular glue. Structural studies of an 
analogue compound, RO-2443 have shown that these inhibitors might bind to and occupy the 
p53 pockets of MDM2 and MDMX by inducing the formation of dimeric protein complexes. The 
protein complexes were kept together by a dimeric small-molecule and then activated the tumor 
suppressor p53. Treatment with 10 µM of RO-5963 could significantly inhibit the cell proliferation 
and promote apoptosis in cells with wild-type p53.  
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Figure 2-3. Structures of IMiDs 
Immunomodulatory drugs (IMiD) and anticancer sulfonamides have also been reported 
as molecular glues. But distinct from the macrocyclic immunosuppressants and RO-5963, IMiDs 
and anticancer sulfonamides can cause target protein degradation. Recent studies have shown 
that the anticancer activity of IMiDs is related to their direct binding to cereblon, which is a 
substrate acceptor for CRL4CRBN E3 ubiquitin ligase, and blocking its autoubiquitination and native 
substrate ubiquitination.49 By binding directly to cereblon, IMiDs can change the substrate 
specificity of the E3 ubiquitin ligase and cause abnormal target protein ubiquitination and 
degradation. As there is no interaction between cereblon and the target protein without IMiDs, 
this suggests that IMiDs function as molecular glues to fill in the binding surface between 
cereblon and target proteins.68 It has been shown that thalidomide, lenalidomide and 
pomalidomide can all induce the cereblon-CK1α interaction, but only lenalidomide can promote 
the degradation of CK1α. This might be so because the extra carbonyl group in thalidomide and 
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pomalidomide could clash with the cereblon backbone. More recently developed IMiDs, CC-
12272 and CC-22073, have been shown to promote the degradation of IKZF1/3. Another analogue, 
CC-885 can cause cell growth proliferation in a large range of different cancer cells. Later studies 
have shown that CC-885 can cause degradation of IKZF1/3 and GSPT1, which are cereblon-
dependent.74 Brander et al. and Winter et al. also reported a PROTAC, MI-389 which targets RTKs 
degradation can induce the degradation of GSPT-1 as a converging off-target.75 MI-389 can 
significantly cause GSPT-1 degradation with 100 nM treatment in 4 h in MOLT4 cells. MI-389 
might function as CC-885, as a knockout of CRBN can fully block the degradation of GSPT-1 in 
MOLT cells. 
 
Figure 2-4. Structures of anti-cancer sulfonamide molecular glues. 
Sulfonamides such as chloroquinoxaline sulfonamide (CQS), E7820, indisulam and 
tasisulam can inhibit the proliferation of certain human cancer cell lines. But the mechanism of 
action of these compounds has not been clear until recently. Two studies have shown that these 
anticancer sulfonamides are molecular glues which can induce the degradation of RNA splicing 
factor RBM39 (CAPERα), which is a coactivator for several transcription factors. Co-treatment 
with the neddylation inhibitor MLN4924 or the proteasomal inhibitor bortezomib could block the 
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activity of E7820 and indisulam.76-77 The E3 ubiquitin ligase DCAF15 was found in 
immunoprecipitation experiments to be responsible for the degradation of RBM39.  
 
Figure 2-5. Structures of plant hormone molecular glues 
Plant hormones are well-known molecular glues which can cause protein degradation. 
The hormone auxin can bind to the Cullin-RING ubiquitin ligase TIR1 and activate the 
ubiquitination and degradation of transcriptional repressors AUX/IAAs.78  The plant hormone JA-
Ile can bind to the Cullin-RING ubiquitin ligase COI1 and catalyze the ubiquitination and 
degradation of transcriptional repressor JAZ proteins.79  
In summary, molecular glues promote the association of proteins to form unnatural 
protein complexes, which could be widely used to alter cellular physiology for disease treatment. 
Although rational design of molecular glues is difficult because it involves multiprotein 
interactions, the recent structural studies on multiprotein and advanced technologies to identify 
protein interactions inside cells have encouraged the development of novel molecular glues for 
drug design in an effort to modulate the diverse processes implicated in diseases.80 
Results and Discussion 
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In Chapter 1, we showed that MDM2 PROTACs formed by linking the MDM2 inhibitor MI-
1061 and a cereblon binding ligand such as pomalidomide, lenalidomide or thalidomide could 
successfully induce MDM2 degradation and activate the p53 pathway in p53 wild-type cancer 
cell lines. Based on our previous studies of the MDM2 inhibitor MI-106125, the core structure LD-
103 can also efficiently bind to MDM2 protein with Kd value of 80 nM and thus activate the p53 
pathway. Linking LD-103 to a cereblon binding ligand might yield a new class of MDM2 PROTACs 
with smaller molecular weights, which would be beneficial for the PK properties. LD-222 is one 
of our best MDM2 degraders with a hydrophobic methylene linker. This linker and the cereblon 
binding ligand in LD-222 was used in the design of our new bifunctional molecule LD-277, which 
was synthesized accordingly.  
 
 
Figure 2-6. (A) Modeled structure of MDM2 complexed with MI-1061 (yellow, PDB ID: 4LWU); (B) 
Design of LD-277 based on LD-103 and MDM2 degrader LD-222. 
The anti-proliferative activities of LD-277 were tested in RS4;11, MV-4-11, MOLM13 cells 
with wild-type p53 or RS4;11/IRMI-1 and RS4;11/IRMI-2, MDA-MB-231, and MDA-MB-468 cells 
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with mutated p53 and HL-60 cells without p53 to enable comparison with LD-222 (Table 2-1). 
Both RS4;11/IRMI-1 and RS4;11/IRMI-2 cell lines were developed by our group. They all harbor 
mutated p53 and are resistant to the MDM2 inhibitor MI-1061. LD-222 and LD-277 can efficiently 
inhibit RS4;11 cell growth and are more potent than the corresponding MDM2 inhibitors MI-1061 
and LD-103. But LD-277 also demonstrates good anti-proliferative activity in RS4;11/IRMI-1 and 
RS4;11/IRMI-2 cell lines with IC50 values of 1.5 nM and 1.4 nM, while no growth inhibition was 
observed upon treatment with the MDM2 degrader LD-222 or the inhibitors MI-1061 and LD-
103 at concentrations up to 3 µM. Similar results were obtained for MV-4-11, MOLM-13, MDA-
MB-231, MDA-MB-468, HL-60 and RS4;11 with p53 knock-out cell lines (Table 2-1). LD-277 
potently inhibits cell proliferation in cancer cells with p53 wild-type, p53 mutation or p53 null, 
which indicates an inhibition mechanism for LD-277 distinct from that of the bona fide MDM2 
degrader LD-222. Protein expression levels of MDM2, p53 and p21 in RS4;11 and RS4;11/IRMI-1 
cell lines treated with LD-222 and LD-277 were tested by Western Blotting and it was found that 
LD-222 significantly causes MDM2 degradation in 2 h in both RS4;11 and RS4;11/IRMI-2 cell lines, 
which is consistent with our previous MDM2 PROTACs. Significant p53 accumulation was 
observed after 2 h treatment of LD-222 in the RS4;11 cell line, while no significant upregulation 
of p53 was observed in the RS4;11/IRMI-2 cell line. The RS4;11/IRMI-2 cell line with p53 mutation 
is resistant to either MDM2 inhibitors or MDM2 degraders, as mutated p53 fails to activate its 
downstream gene and causes subsequent inhibition of cell proliferation. Comparing with LD-222, 
no clear MDM2 degradation was observed in a 2 h treatment with LD-277 in RS4;11 and 
RS4;11/IRMI-2 cell lines. Results obtained with RT-qPCR results have shown that MDM2, p21, 
PUMA and BAX genes are all up-regulated by treatment with LD-222 in the RS4;11 cell line. There 
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is no significant change of gene expression in RS4;11 of MDM2, p53, p21 and BAX following a 12 
h treatment with LD-277, indicating that LD-277 functions differently as a MDM2 degrader. 
Table 2-1. Binding affinities of MDM2 and cell growth inhibitory activities of MDM2 inhibitors 
and corresponding degraders in RS4;11 parental cell lines and RS4;11/p53 mutated cell lines. 
IC50/ µM p53 MI-1061 LD-222 LD-103 LD-277 
RS4;11 Wild-type 0.12 0.005 0.9 0.001 
MV-4-11 Wild-type 0.11 0.011 0.89 0.008 
MOLM-13 Wild-type 0.10 0.015 1.2 0.025 
HL60 Null >3 >3 >3 0.0083 
RS4;11/ IRMI-1 Mutation >3 >3 >3 0.0015 
RS4;11/ IRMI-2 Mutation >3 >3 >3 0.0014 
MDA-MB-231 Mutation >3 >3 >3 0.039 
MDA-MB-468 Mutation >3 >3 >3 0.026 
RS4;11 sh p53 Knock out 0.4 >3 >3 0.0028 
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Figure 2-7. (A)  MDM2, p53 and p21 protein expression levels in RS4;11 cell line after treatment 
for the indicated time with 10 nM LD-222 or 3 nM LD-277; (B) MDM2, p53 and p21 protein 
expression levels in RS4;11/IRMI-1 cell line after treatment for the indicated time with 10 nM LD-
222 or 3 nM LD-277; (C)-(G) MDM2, p53, p21, PUMA, BAX mRNA levels in RS4;11 cell after 
treatment for the indicated time with 10 nM LD-222 or 3 nM LD-277.  
Linker-Activity relationship study of LD-277 
To explore the linker-activity relationship of LD-277, a series of compounds with hydrophobic 
methylene linkers and hydrophilic polyethylene glycol linkers were synthesized and tested in 
RS4;11 cells. The observed cell growth inhibition activities are summarized in Table 2-2. 
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Compounds LE-016 and LD-277 with 4 and 5 methylene linkers had similar potencies. Further 
shortening  the linker to 3 methylene groups gave compound LE-010 which is 59 times less 
potent than LE-016 and LE-008 with no linker is 570 times less potent than LE-006, whose 
potency is similar to that of the MDM2 inhibitor LD-103. Compounds LE-344, LD-257, LD-256 
with 1-3 ethylene glycol units in the linkers were similarly potent , but all were slightly less 
potent than LD-277 and LE-016. This result suggests that to retain the potent anti-proliferative 
activity, a linker at least 4-atoms long is needed between the inhibitor and cereblon ligand. 
Table 2-2. Linker-activity relationship results for cell growth inhibitory activities of degraders with 
different linker in RS4;11 cell line. 
 
 Linker  
RS4;11 
IC50/ µM 
LD-103  0.89 
LE-008              No linker 0.56 
LE-010  0.055 
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LE-016 
 
0.00083 
LD-277  0.0012 
LE-344 
 
0.0011 
LD-257 
 
0.0033 
LD-256 
 
0.01 
 
LD-277 is a cereblon-dependent and MDM2- or p53-independent antitumor agent 
Although good activities were obtained by LD-277 and its analogues, the mechanism was 
not fully understood. LD-277 has two components, an MDM2 inhibitor and a cereblon binding 
ligand. The importance of both these moieties was further explored.  
To check the importance of cereblon binding in the anti-proliferative activity, one methyl 
group was introduced to LD-277 to block the lenalidomide site at which cereblon binds (Figure 
2-8A). LE-024 was synthesized accordingly and showed weak cell growth inhibition activity with 
IC50 = 1.5 µM in RS4;11 cell line and no inhibition in RS4;11-IRMI-1 at LE-024 concentrations up 
to 3 µM (Figure 2-8B). The significant decrease in cell growth inhibition activity of LE-024 
compared with LD-277 indicated that cereblon binding was critical for the anti-proliferative effect 
of LD-277. Further, the MDA-MB-231 cell line was treated with LD-277 in presence of an excess 
of the cereblon ligand lenalidomide and as expected, the excess lenalidomide was able to block 
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cell growth inhibition by LD-277, confirming the existence of a cereblon-mediated mechanism. 
Lenalidomide treatment in the same experiment had little impact on cell growth (Figure 2-8C). 
 
Figure 2-8. (A) Structure of LE-024; (B) Dose-dependent response of LD-277 and LE-024 in RS4;11 
and RS4;11/IRMI-1 cell lines with indicated concentrations of LD-277 or LE-024; (C)  Dose-
dependent response of LD-103 or LE-024 in the MDA-MB-231 cell line with excess lenalidomide; 
(D) cereblon, MDM2 and p53 and p21 protein expression levels in MDA-MB-231 cell lines 
pretreated with siControl, siCRBN #2 or siCRBN#3 after time treatment for the indicated time 
with 100 nM LD-277; (E) Dose-dependent response of LD-277 and LD-103 in RS4;11 cell line 
pretreated with siControl, siCRBN #2 or siCRBN#3, with the indicated concentrations of LD-277 
or LD-103. 
To further confirm this result, two siRNAs targeting different cereblon sequences were 
used to genetically inhibit cereblon gene expression in the breast cancer cell line MDA-MB-231. 
The knockdown efficiency and cell growth inhibition results in Figure 2-8D show that LD-277 
could efficiently inhibit MDA-MB-231 cell line treated with control siRNA with IC50 = 50 nM, while 
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no cell growth inhibition activities were obtained in cereblon knockdown cell lines at 
concentrations up to 3 µM. Taken together, these data demonstrate that the anti-proliferation 
phenotype induced by LD-277 is cereblon-mediated. 
Another important component in LD-277 is the MDM2 inhibitor LD-103. To further 
explore the relationship between the activity of LD-103 and MDM2 binding, the core structures 
of two weaker MDM2 inhibitors AA-211 and AA-214 were linked to the cereblon binding ligand. 
Although AA-211 and AA-214 are more than 600 times less potent to MI-1061, the corresponding 
degraders, AA-215 and AA-216 are only 20 and 50 times less potent than LD-277. Knockdown of 
MDM2 in breast cancer cell lines MDA-MB-231 and MDA-MB-468 and knockdown of p53 in 
RS4;11 failed to affect the cell growth inhibition activities of LD-277. Similar results were also 
obtained in MEF p53 -/- and MEF p53 -/- MDM2 -/- cells, when compared with wild-type MEF cell 
lines (Figure 2-9). Taken together, the anti-proliferation effect of LD-277 is independent  of both 
MDM2 and p53.  
Table 2-3. Results for binding affinities to MDM2 and cell growth inhibitory activities of degraders 
with weaker binding affinities to MDM2 in RS4;11 and RS4;11/IRMI-1 cell lines. 
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IC50/µM 
Binding Affinity 
to MDM2 
Kd /µM 
RS4;11 RS4;11/IRMI-1 
AA-MI211 6.5 >3 >3 
AA-MI-215  0.020 0.022 
AA-MI-214 > 30 >3 >3 
AA-MI-216  0.054 0.061 
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Figure 2-9. (A) Dose-dependent responses of LD-277 and LD-103 in the MDA-MB-231 cell line 
pretreated with siControl, siMDM2, with indicated concentrations of LD-277 or LD-103. Data are 
mean ± s.d; n = 3 independent experiments; (B) MDM2 protein expression level in MDA-MB-231 
cell lines treated with siControl and siMDM2; (C) Dose-dependent response of LD-277 and LD-
103 in the MDA-MB-468 cell line pretreated with siControl, siMDM2, with indicated 
concentrations of LD-277 or LD-103; (D) MDM2 protein expression level in MDA-MB-468 cell lines 
treated with siControl, siMDM2; (E) Dose-dependent response of LD-277 and LD-103 in HL-60 
cell line with indicated concentrations of LD-277 or LD-103; (F) Dose-dependent response of LD-
277 and LD-103 in RS4;11 cell line pretreated with sh control or sh p53 , with indicated 
concentrations of LD-277 or LD-103; (G) Dose-dependent response of LD-277 and LD-103 in MEF 
WT, MEF p53-/-, MEF p53-/- MDM2-/- cell lines, with indicated concentrations of LD-277 or LD-
103.  
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LD-277 promotes cereblon-dependent GSPT1 degradation 
As the substrate acceptor of CRL4CRBN(CUL4-DDB1-RBX1-cereblon) E3 ubiquitin ligase, 
CRBN is critical for the substrate protein recruitment. Previous experiments have demonstrated 
that the anti-proliferation effect of LD-277 is cereblon- and proteasome-dependent. Upon 
treatment with LD-277, CRBN might recruit other proteins to the E3 ubiquitin ligase and promote 
their ubiquitination and degradation. To identify potential substrates of CRL4CRBN regulated by 
LD-277, quantitative proteomic profiling by tandem mass spectrometry was used to compare the 
protein expression level with treatment of LD-277. GSPT1(eRF3a) was identified as a key protein 
down-regulated by LD-277. The results are summarized in Figures 2-10, A and B. The statistical 
p-value was calculated by permutation-based statistical testing of peptide ratios81-82. The 
translation termination factor GSPT1 in RS4;11 was significantly down-regulated compared to 
other identified proteins after 3 h treatment with LD-277. Similar results were obtained in the 
RS4;11/IRMI-1 cell line (Figure 2-10, C and D). Western blotting assay of GSPT1 in RS4;11 cell 
treated by LD-103 and LD-277 analogues also confirmed the degradation of GSPT1 induced by 
these compounds (Figure 2-10, E and F). In presence of excess lenalidomide, GSPT1 degradation 
induced by LD-277 was blocked due to competition from cereblon binding in the MDA-MB-231 
cell line. (Figure 2-10, G) Consistently, the presence of excessive lenalidomide rescues the 
proliferation suppression effect of LD-277 in previous experiments (Figure 2-8E). 
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Figure 2-10. (A) & (C) Protein expression levels in RS4;11 cell line or RS4;11 IMRI-1 are ranked in 
a scatter plot according to absolute value of the relative abundance ratio (log2 fold change) 
between a 3 h LD-277 treatment and untreated groups (y-axis). Green points represent proteins 
with absolute value of the relative abundance ratio (log2 fold change) higher than 2. (B) & (D) 
Volcano plot according to negative log P-value (y-axis) and relative abundance ratio (log2 fold 
change) of each protein between 3 h LD-277 treatment and untreated groups (x-axis). Red points 
represent proteins with statistical P-value lower than 0.05. Green points with statistical P-value 
lower than 0.05 and absolute value of the relative abundance ratio (log2 fold change) higher than 
2. (E) & (F) MDM2, p53 , GSPT-1 protein expression level in RS4;11 cell lines treated with LD-103, 
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LE-008, LE-016, LD-277, LE-344, LD-257, LD-256. (G) GSPT-1 protein expression level in RS4;11 
cell lines treated with LD-103, LD-277 and LD-222 with and without co-treatment with 
lenalidomide. 
Synthesis 
The synthesis of MDM2 inhibitors AA-MI-211 and AA-MI-214 and the corresponding 
molecular glues AA-MI-215 and AA-MI216 is shown in Scheme 1.25 Various (E)-3-benzylidene-6-
chloroindolin-2-ones and (E)-3-benzylideneindolin-2-ones were used as starting materials. 
Cyclohexanone and the chiral auxiliary (5S,6R)-5,6-diphenylmorpholin-2-one were used to 
synthesize 201a and 201b. These intermediates were methylated with methanol with 
concentrated sulfuric acid and the chiral auxiliary group was removed with ammonium cerium(IV) 
nitrate in acetonitrile/water to form 203a and 203b. 204a and 204b were obtained by hydrolysis 
with lithium hydroxide in water, MeOH and THF. AA-MI-211 and AA-MI-214 were obtained by 
an amide condensation reaction with methyl 4-aminobenzoate and subsequent hydrolysis with 
sodium hydroxide in water and methanol. AA-MI-215 and AA-MI-216 were synthesized from 
204a and 204b by an amide condensation reaction with 3-(4-(5-aminopentyl)-1-oxoisoindolin-2-
yl)piperidine-2,6-dione. 
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Scheme 2-1. Synthesis of AA-MI-211, AA-MI-214, AA-MI-215 and AA-MI-216. Reaction 
conditions: (a) toluene, reflux; (b) conc. H2SO4, MeOH. rt; (c) ammonium cerium(IV) nitrate, 
acetonitrile, water; (d) LiOH, MeOH, water, THF; (e) diphenylphosphinic chloride, DIEA, DCM, 
methyl 4-aminobenzoate, DMAP; (f) Sodium hydroxide, MeOH, water (g) HATU, DIEA, DMF. 
The synthesis of the molecular glues in Table 2-2 and LE-024 is shown in Scheme 2-2. The 
intermediate 206a-206g was synthesized by Sonogashira coupling reaction from 3-(4-bromo-1-
oxoisoindolin-2-yl)piperidine-2,6-dione or 3-(4-bromo-1-oxoisoindolin-2-yl)-1-methyl-
piperidine-2,6-dione and the Boc protecting groups were then removed under acidic conditions. 
The carbon-carbon triple bonds were reduced by palladium-catalyzed hydrogenation.  Target 
molecules were then obtained by an amide condensation reaction with (3'R,4'S,5'R)-6''-chloro-
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4'-(3-chloro-2-fluorophenyl)-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-
carboxylic acid.  
 
Scheme 2-2. Synthesis og LE-010, LE-016, LD-277, LE-344, LD-257, LD-256 and LE-024. Reaction 
conditions: (a) Pd(PPh3 )Cl2, CuCl, DIPEA, DMF, 80 °C; (b) trifluoroacetic acid, DCM, rt; (c) H2, Pd/C, 
MeOH, rt. (d) HATU, DIPEA, DMF, rt. 
LD-103 and LE-008 were synthesized with the same method as was used for LD-277, and 
is shown in Scheme 2-3. 207c, which was used for LD-277 was replaced by methylamine and 
lenalidomide for the synthesis of LD-103 and LE-008. 
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Scheme 2-3. Synthesis of LD-103 and LE-008. Reaction conditions: (a) HATU, DIPEA, DMF, rt. 
Summary 
In this chapter, a new class of cereblon modulators with potent anti-proliferative activity 
in cancer cell lines based on the structures of MDM2 PROTACs was developed. Among them, LD-
277 was achieved by linking LD-103, the core structure of MDM2 inhibitor MI-1061 with slightly 
weaker binding affinity to MDM2, to a cereblon binding ligand with a hydrophobic linker. 
Compared with the bona fide MDM2 degrader LD-222, which can cause MDM2 degradation and 
is activated in the p53 pathway, no significant MDM2 degradation or p53 activation was observed 
with LD-277. Further study has shown that the anti-proliferation activity of LD-277 in cancer cell 
lines is independent of MDM2 and p53 but is related to the cereblon and proteasome activity. 
This result suggests that a new mechanism, distinct from the original MDM2-related p53 pathway 
is involved in the anti-proliferative activity of LD-277. 
 
Figure 2-11. (A) Mechanisms for PROTACs; (B) Mechanisms for Molecular glue.  
Further proteomics studies have shown that significant degradation of GSPT1 is induced 
by LD-277, which is similar to the behavior of the previously reported cereblon modulator CC-
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885.74 CC-885 could direct cereblon to target GSPT1 by creating an interaction hotspot on the 
cereblon surface for direct protein–protein interactions with the substrate, which in this case 
works as molecular glue between cereblon and GSPT1. A similar mechanism for LD-277 is 
proposed here. 
PROTAC strategy has emerged as an efficient technology with which to target protein 
degradation, and it has attracted great interest in the pharmaceutical industry and drug discovery 
fields. It could efficiently induce protein degradation by dragging the target protein to a E3 
ubiquitin ligase with a linker based on bifunctional molecules. Compared with PROTAC, molecular 
glue could modify the protein surface and create an interaction hotspot for direct protein–
protein interactions with the substrate, underlying the gain-of-function ‘chemo-neomorphic’ 
activity (Figure 2-11). Discovery of LD-277 has indicated that minor modification of PROTAC could 
convert it to molecular glue with unexpected functions. Even though these unexpected functions 
are still dependent on binding to E3 ubiquitin ligase and proteasome activity, they can be totally 
unrelated to the original targets. These functions could also dominate the phenotype of 
compounds in vitro and in vivo, which complicates their evaluation.75 It may also be possible 
however to rationally design compounds with both PROTAC and molecular glue functions 
targeting degradation of various proteins in different signaling pathways, and this will be more 
efficient than targeting a single protein with either technology. 
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Chapter 3 
Development of Macrocyclic Peptidomimetic Targeting WDR5-MLL1 Protein-Protein 
Interaction 
Introduction 
MLL1 is a Histone 3 Lysine 4 (H3K4) methyltransferase which plays an important role in 
hematopoiesis and neurogenesis in normal cells. It’s also found to be mis-regulated in a number 
of human acute leukemia.83-84 More than 70 MLL fusion proteins have found with chromosomal 
translocations at 11q2385, which leads to aggressive leukemia with very poor prognosis and 
treatment.83 MLL1 fusions occur in more than 70% of acute lymphoid leukemia (ALL), 35% of 
acute myeloid leukemia (AML) in infant and 5% ALL and 5-10% AML in adults. 86-88  
Interestingly, MLL translocations always occurs on only one MLL allele and result in the 
loss of the H3K4 methyltransferase activity. But the remaining wild-type MLL1 with H3K4 
methyltransferase activity, is required by MLL-AF9 fusion protein to induce leukemogenesis and 
maintenance of MLL-AF9-transformed cells.89-90 Therefore, inhibition of the wild-type MLL1 H3K4 
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methyltransferase activity could be developed as a novel therapeutic method  for the treatment 
of aggressive leukemia harboring MLL fusion proteins91-92. 
Although the catalytic SET domain in MLL1 is responsible for its H3K4 methyltransferase 
(HMT) effect, the isolated MLL1 protein has very low enzymatic activity. While, the HMT activity 
of MLL1 is dramatically enhanced when it formed a protein complex with WDR5 (WD repeat 
domain 5 protein), ASH2L and RbBP5 (Retinoblastoma Binding Protein 5).93 Research has shown 
that WDR5 is essential for MLL1 complex formation and its enzymatic activity.93 Hence, targeting 
protein-protein interactions (PPIs) in the MLL core complex, especially WDR5-MLL1 protein-
protein interaction could be an effective strategy to inhibit the H3K4 HMT activity of MLL1, and 
further for the treatment of leukemia with MLL1 fusion proteins. 
Herein, we reported the design, modification and evaluation of macrocyclic 
peptidomimetics based on our previous inhibitors MM-401. These new WDR5 inhibitors have 
high binding affinities to WDR5 and achieve potent cell growth inhibitory activity in acute 
leukemia cells harboring MLL translocation. Of which, LC-337 binds to WDR5 with an IC50 value 
of 1.9 nM (Ki value << 1 nM), and potently inhibits cell growth of MOLM13 cell line harboring 
MLL-AF9 fusion protein with IC50 value of 33 nM. LC-337 is more than 800 times better than our 
previously reported compound MM-401. Further optimization of LC-337 may ultimately yield a 
new therapy for acute leukemia. 
Literature Review 
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MLL1 is a H3K4 methyltransferase, which has been shown to be associate with the process 
of leukemogenesis.94-95 The methylated H3K4 markers regulated the expression of target 
clustered HOX genes, myeloid exotropic viral integration site 1 (MEIS1) gene96. Both are 
frequently overexpressed in leukemia with rearrangement of MLL1 and the overexpression of 
HOXA9 and MEIS1 were corelated with the inducement of leukemia.97 Translocation and 
rearrangement of MLL1 genes, which caused abnormal MLL1 fusion proteins, are mostly found 
in ALL or AML, especially in more than 70% of infant ALL and 35%-50% infant AML.98-99 Wild-type 
MLL1 is important for hematopoiesis and neurogenesis and regulation of stem cell functions.84, 
100 While MLL1 fusion proteins are responsible for the dysregulation of the hyperplasia, 
differentiation and death of hematopoietic cells.101-102 In cancer cells with MLL1 fusion proteins, 
the transcription function of wild-type MLL1 is hijacked for cancer growth and angiogenesis.103-
104 Wild-type MLL1 is required by MLL1 fusion proteins for the full transformation activity, which 
it an attractive target for cancer therapy. 
MLL1 has multiple domains including the catalytic C-terminal domain and the N-terminal 
domain.102 The N-terminal domain interacts with Menin105-106 and C-terminal domain interacts 
with WDR, ASH2L, RbBP5 and DPY30.107 The SET domain, located in C-terminal domain process 
the catalytic activity when assembled in a core structure with WDR5, ASH2L, RbBP5 and 
DPY30.107-108 Without WDR5, MLL1 shows very low histone methyltransferase activity.107 It’s 
because the SET domain has an open confirmation, and WDR5 could help to stabilize the whole 
complex to transfer the methyl group from S-adenosyl-L-methionine to H3K4. Developing 
antagonists targeting the protein-protein interactions between WDR5 and MLL1 is a promising 
therapeutic method for leukemia with MLL1 fusion proteins. 
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Figure 3-1. Co-crystal structure of WDR5-MLL1 Win motif peptide binary complex (PDB ID: 4ESG) 
WDR5 is a highly conserved WD40 repeat protein, which is critical for the H3K4 
methyltransferase activity of MLL1 and the following HOX genes expression in hematopoiesis.108 
It binds to the SET domain of MLL1, with RbBP5, ASH2L and DPY30 to form a core complex for 
methylation of H3K4. It has been shown that MLL1 binds to WDR5 with a conserved arginine 
motif (Win motif) and mutation on the Win motif on MLL1 could block the MLL1 H3K4 transferase 
activity.109-110 The co-crystal structure of Win motif in complex with WDR5 was obtained to give 
much detailed information for the protein-protein interactions. The side chain of the R3765 was 
deeply anchored in the binding pocket. The guanidinium group forms strong - stacking 
interaction with WDR5 which is sandwiched between two phenyl rings from F133 and F263. It 
also forms hydrogen bonds with C261, F133, and S91 of WDR5. 
Development of Peptidomimetic WDR5 Inhibitors 
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Based on the sequence of Win motif, our group did a detailed truncation study from 
12mer peptide and found out the minimal element of 3mervpeptide ARA was critical for Win 
motif binding to WDR5. The 3mer Ac-ARA-NH2 could bind to WDR5 with Ki value of 0.12 µM 
comparing with 12mer peptide Ki value of 0.16 µM. Changing one of the alanine to threonine 
yield another 3mer peptide Ac-ART-NH2 could bind to MLL1 with Ki value of 0.02 µM.111 Further 
detailed chemical modification of the side chains on the 3mer peptide was performed and a 
number of peptidomimetics with high binding affinity to WDR5, including MM-101 and MM-102 
were obtained with Ki value lower than 1 nM. It has been shown that MM-102 can suppress the 
expression of HOXA9 and MEIS1 genes in leukemia cells with MLL1-AF9 fusion.92 The crystal 
structure (PDB ID: 4GM8) of MM-102 in complex with WDR5 has shown that the side chain of 
unnatural amino acid on MM-102 significantly enhanced hydrophobic interactions with WDR5 
comparing with Win motif 12mer peptide. Study of the co-crystal structure also provided a 
further rational design and optimization to yield a cyclized peptidomimetic MM-401.112 MM-401 
is also extremely potent binding to WDR5 with Ki value lower than 1 nM and IC50 value of 0.9 nM 
to disrupt WDR5 MLL1 interactions. The co-crystal structure (PDB ID: 4GM9) of MM-401 in 
complex with WDR5 shows it has a similar binding mode comparing with previous linear peptide 
MM-102. Additionally, the phenyl group on Phg of MM-401 stacks with the phenyl group on Y260 
of WDR5 and the hydrophobic methylene linker interacts with the side chains of Y131 and F149 
of WDR5.  
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Figure 3-2. (A)  Co-crystal structure of MM-102 in complex with WDR5 (PDB ID: 4GM8); (B) Co-
crystal structure of MM-401 in complex with WDR5 (PDB ID: 4GM9). 
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Figure 3-3. Structures of Peptidomimetic WDR5 Inhibitor 
MM-401 specifically inhibit MLL1 without affecting other MLL or non-MLL family histone 
methyltransferases including MLL2, MLL3, MLL4, SET1, SET7/9 and EZH2.  It has shown that MM-
401 can inhibit MLL1 methyltransferase activity and block proliferation of MLL cells by inducing 
cell-cycle arrest, apoptosis, and myeloid differentiation. No general toxicity was found to normal 
bone marrow cells or non-MLL cells by the treatment of MM-401.  
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Further optimization based on the structure of MM-401 advanced MM-589 which is 40-
times more potent than MM-401 in inhibition of the MLL HMT activity and growth of MV4;11 
and MOLM-13 cell lines.113 The smaller ring size of MM-589 comparing with MM-401 makes the 
confirmation more compact and stable with additional intra-molecular hydrogen bond. 
Methylation on guanidium group can also improve the cell permeability of these cyclic 
peptidomimetic inhibitors. 
Development of Small Molecular WDR5 inhibitors 
Besides the peptidomimetic WDR5 inhibitor, several small molecular inhibitors were also 
developed from Al-awar group and You group. In 2013, WDR5-1010, WDR5-0102, WDR5-0103 
was discovered from a high-throughput screening study with a Kd value of 0.45-5.5 M. Crystal 
structure (PDB ID: 3SMR) of WDR5-0102 in complex with WDR5 has shown that it occupies the 
Arginine binding pocket with a methyl piperidine group and formed two hydrogen bonds with 
S91 and C261. WDR5-0103 occupies the binding pocket with a similar as WDR5-0102. The 
methoxy group on WDR5-0103 induces a shift of benzamide ring and flip of S91. This also 
increases the hydrophobic interaction with F149 and Y191, which contributes the improvement 
of binding affinity.114 
Further optimization of the benzamide moiety based on the structure of WDR5-0102 
yields compound WDR5-47 with Kd value of 0.38 M.115 The co-crystal structure (PDB ID: 4IA9) 
of WDR5-47 in complex with WDR5 has shown that the substituted benzamide group gains 
hydrophobic interactions with D107, A65, L321, A47 of WDR5.  
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Figure 3-4. (A)  Co-crystal structure of WDR5-0102 complex with WDR5 (PDB ID: 3SMR); (B) Co-
crystal structure of WDR5-0103 complex with WDR5 (PDB ID: 3UR4); (C) Co-crystal structure of 
WDR5-47 complex with WDR5 (PDB ID: 4IA9); (D) Co-crystal structure of OICR-9429 complex with 
WDR5 (PDB ID: 4QL1). 
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Figure 3-5. Structures of small molecular WDR5 inhibitors 
Further SAR study based on WDR5-47 led to the discovery of OICR-942991, 116, which could 
bind to WDR5 with Kd value of 0.03 µM. The co-crystal structure (PDB ID:4QL1) of OICR-9429 has 
shown that the additional phenyl ring could form - stacking interactions with F133 and Y191. 
The trifluoromethyl group on the benzamide also forms hydrophobic interactions with A47, L321 
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and I305 of WDR5. Significantly OICR-9429 selectively inhibited proliferation and induced 
differentiation in N-terminal C/EBP-mutated p30-expressing human AML cells.91 
In 2017, DDO-2117 was developed based on the structure of WDR5-47 with Kd value of 
13.6 nM and IC50 value of 7.6 nM, which is currently published most potent small molecular 
inhibitor for WDR5.117-119 Docking studies of DDO-2117 with WDR5 has shown the additional 
phenyl group could occupy the hydrophobic pocket of F133, F149 and Y191. 
In summary, both peptidomimetic and small molecular inhibitor targeting WDR5 MLL1 
protein-protein interaction have been developed for the treatment of leukemia with MLL-FPs. 
Most of the published studies were done in vitro. Further evaluation of these compounds should 
focus on the efficacy and pharmacodynamic studies in vivo. 
Results and Discussion 
From MM-102 to MM-401, great binding affinity improvement was achieved from the 
cyclization of the linear peptide to stabilize the bound confirmation of the peptidomimetics. Since 
the linker length or ring size of our peptidomimetics might play an important role for their 
confirmations, we did a model study on compounds with different linker lengths. Interestingly, 
modeling result suggested that cyclic peptidomimetics with a linker, as short as 2-carbon appear 
to be able to adopt low-energy conformations that closely resemble the bound conformation of 
compound MM-401. 
As MM-401 has a binding affinity exceeding the lower assay limit in the FP-based 
competitive binding assay, several less potent cyclic peptidomimetic with different linker length 
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were synthesized as template to better understand linker length effect on binding affinity to 
WDR5. From our previous study, the methyl group attached to the bridging carbon atom 
contributes significantly to their affinity to WDR592 Indeed, removal of this methyl group in MM-
401 yielded LC-058, which has a Ki value of 60.3 nM, > 50-times less potent than MM-401. Several 
compounds with variety linker length were synthesized based on the structure of LC-058 and the 
results were summarized in Table 3-1. Compound LC-043-1 with a 3-carbon linker has Ki value of 
32.9 nM to WDR5 and is 2-times more potent than LC-058. Compound LC-040 with a one-carbon 
linker, has Ki value of 242 nM to WDR5 and is thus 4-times less potent than LC-058 with a 4-
carbon linker. However, compound LC-042-1 with a 2-carbon linker has Ki value of 0.8 nM to 
WDR5 and is > 70-times more potent than LC-058, which suggested 2-carbon linker achieves the 
best confirmation bound to WDR5.   
MLL HMT functional assay developed by our group was used to test these compounds 
(LC-058-LC-040) for their inhibitory activity. The results showed that their potencies in inhibition 
of the MLL HMT activity correlate nicely with their binding affinities to WDR5. Accordingly, 
compound LC-042-1 has the best potency to inhibit the MLL HMT activity (IC50= 1.8 µM), while 
IC50 of the other compounds are higher than 10 µM (Table 3-1).  
Table 3-1. Structures, binding affinities to WDR5 and MLL HMT inhibition activities of 
demethylated analogues of compound MM-401 with different linker sizes. 
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Compound n 
Binding Affinity to WDR5 
Inhibition of MLL 
HMT Activity 
IC50 ± SD 
(nM) 
Ki ± SD 
(nM) 
IC50 ± SD 
(µM) 
LC-058 4 298 ± 58 60.3 ± 11.9 > 10 
LC-043-1 3 164 ± 26 32.9 ± 5.3 > 10 
LC-042-1 2 6.2 ± 0.5 0.8 ± 0.1 1.8 ± 0.4 
LC-040 1 1190 ± 160 242 ± 33 > 10 
 
According to the promising data for LC-042-1, a series of analogues of compound MM-
401 with different ring sizes were synthesized and tested with the FP-binding assay and MLL HMT 
assay. The results were summarized in Table 3-2. 
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Table 3-2. Structures, binding affinities and MLL HMT inhibition activities of Compound MM-401 
analogues with different linker length. 
 
  Binding Affinity to WDR5 
Inhibition of MLL 
HMT Activity 
Compound n 
IC50 ± SD 
(nM) 
Ki ± SD 
(nM) 
IC50 ± SD 
(nM) 
MM-401 4 0.9 ± 0.2 < 1 373 ± 44 
LC-081 (MM-
581) 
2 1.08 ± 0.12 < 1 12.6 ± 1.2 
LC-044 3 0.97 ± 0.13 < 1 84.8 ± 23.8 
HK-06-223C 5 2.6 ± 0.2 < 1 1527 ± 218 
HK-05-121C 6 1.0 ± 0.2 < 1 216 ± 88 
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HK-06-229C 8 1.3 ± 0.2 < 1 744 ± 79 
 
Compounds LC-081, LC-044, MM-401, HK-06-223C, HK-05-121C and HK-06-229C with 
linker lengths of 2, 3, 4, 5, 6 and 8 carbons, respectively, all bind to WDR5 with very high affinities 
(IC50 = 0.9-2.6 nM, Ki < 1 nM), which exceed the lower assay limit. The potential differences in 
their binding affinities to WDR5 cannot be determined from the FP binding assay. While, our MLL 
HMT functional assay could help to compare these compounds. The results showed that all of 
them can effectively inhibit MLL HMT activity, but their potencies are not the same. Among these 
analogues, compound LC-081 has the best inhibitory activity with IC50 value of 12.6 nM, which is 
about 30-times more potent than MM-401, similar to the difference between LC-042-1 and LC-
058 in binding assay. Compound LC-044 with a 3-carbon linker is the second most potent inhibitor 
of the MLL HMT activity with an IC50 value of 84.8 nM. 
Then these compounds were evaluated for their cell growth inhibitory activity in MOLM-
13, MV4;11 and HL-60 cell lines (Table 3-3). In the MV4;11 cell line harboring MLL-AF4 fusion 
protein and the MOLM-13 cell line harboring MLL-AF9 fusion protein, MM-401 has IC50 values of 
9.8 µM and 18.4 µM, similar to those values reported in the previous study.112 LC-042-1 displays 
modest cellular activities with IC50 values of 42.8 µM and 43.4 µM against MOLM-13 and MV4;11 
cell lines, respectively, and LC-058 and LC-043-1 have minimal activity at 100 µM in both cell lines. 
Compound LC-081 (MM-581) is the most potent compound in this series and has IC50 values of 
0.28 µM and 0.46 µM, respectively, in inhibition of cell growth in the MOLM-13 and MV4;11 cell 
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lines. Significantly, compounds LC-081 and LC-044 have much weaker activity in the HL-60 cell 
line lacking MLL translocation and display more than 30-fold cellular selectivity. 
Table 3-3. Inhibition of cell growth with representative cyclic peptidomimetics. 
 IC50 (µM) in cell growth inhibition 
Compound MOLM-13 MV-4-11 HL-60 
MM-401 18.4 ± 6.6 9.8 ± 8.0 > 100 
LC-042-1 42.8 43.4 > 100 
LC-043-1 > 100 > 100 > 100 
LC-058 > 100 > 100 > 100 
LC-081 0.28 ± 0.02 0.46 ± 0.02 17.4 
LC-044 1.28 ± 0.01 1.29 46.8 
HK-06-223C 37.6 ± 12.1 15.1 ± 11.8 > 100 
HK-05-121C 5.6 ± 0.7 3.2 ± 0.4 29.7 ± 11.5 
HK-06-229C 21.6 ± 4.8 7.5 ± 3.0 > 100 
LC-089 0.21 ± 0.02 0.25 ± 0.01 8.56 ± 1.14 
LC-088 14.3 ± 0.9 35.0 ± 4.4 2.95 
 
According to our previous study, mono-methylation of the guanidine group in MM-401, 
which yielded MM-408, improves cellular potency against MV4;11 and MOLM-13 cell lines.113 LC-
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089 was synthesized with mono-methylated the guanidine group in compound LC-081 and tested. 
LC-088, with the chiral center in the phenylglycine residue changed from D- to L-configuration in 
LC-089, was used as a negative control compound (Table 3-4). Similar to compound LC-081, 
compound LC-089 binds to WDR5 with high affinity (IC50= 0.90 nM, Ki value of < 1 nM), which is 
also lower than assay limit and potently inhibits the MLL HMT activity with IC50 value of 12.7 nM. 
Table 3-4. Structures, binding affinities to WDR5 and MLL HMT inhibition activities of compounds 
LC-081, LC-089 and LC-088. 
 
 Binding Affinity to WDR5 
Inhibition of MLL 
HMT Activity 
Compound 
IC50 ± SD 
(nM) 
Ki ± SD 
(nM) 
IC50 ± SD 
(nM) 
LC-081 1.08 ± 0.12 < 1 12.6 ± 1.2 
100 
 
LC-089 0.90 ± 0.20 < 1 12.7 ± 1.5 
LC-088 2.0 ± 0.1 < 1 477 ± 51 
 
Compound LC-089 was next evaluated for its cell growth inhibition activity on acute 
leukemia cancer cell lines (Table 3-3.). LC-089 can well inhibit the cell proliferation of both the 
MV4;11 and MOLM-13 cell lines with IC50 values of 0.25 µM and 0.21 µM. It has much weaker 
activity in the inhibition of cell growth of the HL-60 cell line the IC50 value is 8.6 µM. LC-089 
displayed more than 30-times selectivity for the MV4;11 and MOLM-13 cell lines harboring MLL 
translocations over the HL-60 cell line without MLL translocation. Compound LC-088 is 40-times 
less potent (IC50 = 477 nM) than LC-089 (IC50 = 12.7 nM) in inhibition of the MLL HMT activity, 
although it can still bind to WDR5 with a high affinity (IC50 = 2.0 nM, Ki < 1 nM), LC-088 shows 70-
150 times weaker activity than LC-089 in inhibition of cell growth of both MV4;11 and MOLM-13 
cell lines (Table 3-3). 
Several previous publications have reported that small molecule inhibitors targeting HMT 
activity, such as inhibitors of the EZH2 H3K27 activity20 and the DOT1L H3K79 activity21, had slow 
kinetics in inhibition of cell growth. Extra treatment time was needed for the cell growth 
inhibition assay. We therefore evaluated compound LC-089 for its inhibitory activity of cell 
growth in MV4;11 and MOLM-13 leukemia cell lines with either 4- or 7-day treatment. Although 
2-3 times IC50 value improvement from 4-day treatment to 7-day treatment in both cell lines 
were achieved, the maximum inhibition has changed from partial inhibition to essentially 
complete inhibition (Figure 3-6). With 4-day treatment. approximately 75% cell proliferation 
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inhibition was obtained with LC-089 in MV4;11 and MOLM-13 cell lines. While with 7-day 
treatment, more than 95% inhibition was achieved in both cell lines.  
 
Figure 3-6. Cell growth inhibition of compound LC-089 upon 4-day or 7-day treatment in MV4;11 
and MOLM-13 acute leukemia cell lines. 
To gain further structural insights into the high-affinity interactions of cyclic 
peptidomimetics with WDR5, we have successfully determined a co-crystal structure for LC-089 
in complex with WDR5 at a resolution of 1.64 Å (Figure 3-7, PDB code: 5VFC). In the co-crystal 
structures of LC-089 in complex with WDR5, WDR5 adopts an almost identical β-propeller 
configuration as the apo-WDR5 structure (PDB ID: 2H14). The electron density map shows clear 
extra density in the central channel of  the WD40 propeller where MLL peptide binds120, enabling 
us to unambiguously dock LC-089 into the structure (Figure 3-7A). LC-089 adopts a compact 
bound conformation with three intramolecular hydrogen bonds, which is similar to that in MM-
401.112 LC-089 binds to the central channel of WD40 propeller in WDR5 through the conserved 
interaction network as observed in WDR5/MLL and WDR5/MM-401 complex structures.112 
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Comparing with MM-401, the methyl on the guanidinium moiety in LC-089 gained hydrophobic 
interactions with C134 and F263, but lost a direct hydrogen bond with S175 (Figure 3-7B). The 
aliphatic carbon linker and side chains of LC-089 gains strong hydrophobic interactions with the 
hydrophobic surfaces formed by the side chains of Y131, F149, F133, Y191, Y260, L321, I305, A47 
and A65 from WDR5 (Figure 3-7C). The different linker length of MM-401, HK-05-121C and LC-
089 causes different orientations of the phenyl group on Phg. The phenyl groups in LC-089 and 
MM-401 stack almost parallel to the phenyl group of WDR5 Y260 (Figure 3-7D, magentas and 
yellow, respectively). In contrast, the phenyl group in HK-05-121C (cyan) is oriented near 
perpendicular to the phenyl group of WDR5 Y260, comprising an incomplete aromatic cage. But 
it can form cation- interaction with K259, which is surrounded by the aromatic cage. Comparing 
with MM-401 and HK-05-121C, LC-089 with shorter linker length and small ring size can form a 
more compact structure, which forms several optimal intramolecular hydrogen bonds and 
reduces the conformational flexibility. This optimal confirmation helps to achieve a very high 
affinity to WDR5 and consequently strong MLL HMT inhibition activity. 
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Figure 3-7. (A-C) Co-crystal structure of cyclic peptidomimetic LC-089 in complex with WDR5 (PDB 
ID: 5VFC) and (D) in comparison with co-crystal structures of MM-401 in complex with WDR5 
(PDB ID: 4GM9) and HK-05-121C in complex with WDR5 (PDB ID: 4GMB). Carbon atoms for 
compound LC-089, HK-05-121C and compound MM-401 are shown in magentas, cyan and 
yellow, respectively. Nitrogen atoms are shown in blue and oxygen atoms are shown in red. 
From our study, the linear peptidomimetic MM-101 has very poor stability in human 
microsomes (T1/2 = 4 min) and moderate stability in mouse and rat microsomes (T1/2 = 44 min and 
T1/2 = 34 min, respectively). This limits its further application in drug discovery. While cyclized 
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peptidomimetics with more compact and stably confirmation can improve their stability. The 
microsomal stability result of the cyclized peptidomimetics MM-401, LC-089 and others have 
shown excellent stability in human, mouse and rat microsomes with half-life greater than 60 
minutes. (Table 3-5) This makes feel more confident about application of the cyclized 
peptidomimetics in drug discovery. 
Table 3-5. Microsomal stabilities of linear peptidomimetic MM-101 and selected cyclic 
peptidomimetics. 
 T1/2 (min) 
Compound Human Rat Mouse 
MM-101 4 34 44 
MM-401 > 60 > 60 > 60 
LC-081 > 60 > 60 > 60 
LC-044 > 60 > 60 > 60 
LC-089 > 60 > 60 > 60 
 
Based on the promising data of the cyclized peptidomimetic inhibitors targeting WDR5, 
further modifications on the side chains of LC-081 were performed. As the current cyclized 
peptidomimetic inhibitors have reached the assay limit of both FP binding assay and MLL1 HMT 
functional assay, cell growth inhibition assay was used to compare the different inhibitors. 
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Table 3-6. Modification on the side chain of Abu (L-2-aminobutyric acid) 
 
 R 
MOLM-13 
IC50 ± SD (µM) 
LC-081 
 
 
LC-313 
 
1.05 
LC-300 
 
6.332 
LC-314 
 
>10 
LC-322  > 10 
 
At first, modification on the side chain of L-2-aminobutyric acid was performed. From the 
co-crystal structure of LC-081 in complex with WDR5, the ethyl group could form hydrophobic 
interaction with the hydrophobic surface formed with A47 and L321. And according to the 
previous study on the linear peptide92, several modifications could be tolerated and cycloleucine 
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(CycLeu) was preferred at this position. Then several amino acids with variety hydrophobic side 
chains were tested and result is summarized in Table 3-6. To our surprise, all the modification 
could not be well tolerated. Changing ethyl group to isopropyl group reduced the cell growth 
inhibition activity by 3 folds, while with larger substitution groups such as n-propyl, sec-butyl 
group or using CylLeu instead of Abu cause more than 20-fold cell growth inhibition loss. So, ethyl 
group will be kept in this position and further modification can performed on other sites. 
Table 3-7. Modification on the side chain of Phg (L-Phenyl glycine) with non-aromatic groups. 
 
ID R 
MOLM-13 
IC50 ± SD (µM) 
LC-081 
 
0.28 
AK-012 
 
1.72 
AK-010 
 
1.88 
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AK-020 
 
1.19 
AK-011 
 
0.64 
LC-261 
 
1.49 
AK-005 
 
1.57 
AK-021 
 
3.59 
AK-022 
 
1.29 
AK-036 
 
6.51 
AK-033 
 
2.37 
LC-294  1.01 
 
Next, we focused on the modification of the phenyl group on Phg in LC-081. From the co-
crystal structure of LC-081 in complex with WDR5, the phenyl group in LC-081 could form a - 
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stacking interaction. Well in the co-crystal structure of HK-05-121C, the orientation of phenyl ring 
could form hydrophobic interaction with K259. According to these different interactions between 
the inhibitors and WDR5, both aromatic and non-aromatic substitution groups were used to 
explore this binding site. In Table 3-7, different aromatic or non-aromatic substitution group 
were used to replace the phenyl group in LC-081. Replacing the phenyl group with methyl group 
yields AK-012, which is about 8 times less potent than LC-081, which means the - stacking 
interaction is important for the WDR5 binding and subsequent cell preliberation inhibition. While 
replacing the phenyl group with other non-aromatic aliphatic groups yields AK-010-LC-261 are 
similar as AK-012, except for AK-011. Although AK-011 is still less potent than LC-081, but results 
indicate that cyclohexyl group could form hydrophobic interaction with WDR5. 
Next, some phenylaniline or substituted phenylaniline were used to replace the 
phenylglycine in the peptidomimetics. Using phenylaniline can help us to overcome the 
racemization problem of phenylglycine during the synthesis. And it might keep the - stacking 
interaction with WDR5. AK-005 – AK-033 were synthesized accordingly. But unfortunately, none 
of them is as potent as LC-081 in cell growth inhibition assay. To overcome the racemization 
problem, a methyl group was introduced to the -carbon of phenylglycine, which yields LC-294. 
But it’s 3-fold less potent than LC-081, which indicates the methyl group can affect the 
orientation of the phenyl group and block the - stacking interaction. 
Table 3-8. Modification on the side chain of Phg (L-Phenyl glycine) with aromatic groups. 
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ID R 
MOLM-13 
IC50 ± SD (µM) 
LC-334 
 
0.35 
LC-321 
 
0.42 
AK-035-2 
 
0.38 
AK-057 
 
2.6 
AK-058 
 
0.51 
AK-059 
 
2.2 
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AK-042 
 
1.6 
LC-345 
 
0.56 
LC-339 
 
0.083 
LC-324 
 
1.285 
LC-326 
 
0.054 
 
The results in Table 3-7 indicate that the original phenylglycine structure is critical for the 
WDR5 binding and could not be replaced by non-aromatic substitution or substituted benzyl 
groups in the inhibitor design. So further modifications are directly on the structure of 
phenylglycine. Substitution at different positions on the phenyl ring with fluoro, chloro and 
methoxy groups were explored and the results are summarized in table 3-8. Fluoro substitutions 
on phenyl group can barely affect the cell growth inhibition activity, as IC50 of LC-334 -AK-035-2 
are 0.35-0.42 M. While AK-057 with 2-chloro and AK-042 with 2-methoxyl substitutions are 
much less potent than LC-081, which suggests that the large substitution group at 2-position can 
affect the confirmation of the phenyl group. Similar results were obtained when Naphthalen-1-
yl group was used to replace the phenyl group in LC-081 to yield LC-324. Replacing the phenyl 
111 
 
group with naphthalen-2-yl group yields LC-326, which is 5-times more potent LC-081. It might 
be because the naphthalenyl group form stronger - stacking interaction with Y260 in WDR5. 
Similar result was found by introducing methoxy group at 4-position of the phenyl ring, which 
yields LC-339 is about 3-fold more potent than LC-081.  
Table 3-9. Modification on the side chain of Arg (L-Arginine) 
 
ID R 
MOLM-13 
IC50 ± SD (µM) 
LC-081 
 
0.28 
LC-186-2 
 
> 10 
LC-183-2 
 
> 10 
LC-187-2  
>10 
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LC-169  
> 10 
LC-174  
> 10 
LC-164  
> 10 
LC-210 
 
> 10 
LC-182 
 
1.55 
LC-227 
 
> 10 
LC-202  
0.088 
LC-337  
0.033 
LC-315  
0.47 
 
 Comparing with the small molecule inhibitors, our peptidomimetic inhibitors have much 
better binding affinity to WDR5, but weaker or similar cell growth inhibition activities. This might 
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be because of low cell permeability caused by the polar guanidino group on arginine. The 
guanidino group is critical for the binding to WDR5 as it forms several important interactions with 
the protein. According to the co-crystal structures of LC-089 and MM-401 in complex with WDR5,  
guanidino group can form strong sandwiched - stacking interaction with F133 and F263, 
hydrogen bonds with C261, F133, S91, S218 and salt bridge with D92. Replacing the guanidino 
groups with variety groups targeting different interactions were explored and the results were 
summarized in Table 3-9. To keep the - stacking interaction, aromatic groups including phenyl, 
pyridinyl, pyrimidinyl, imidazolyl groups were used to replace the guanidino groups yields LC-
186-2, LC-183-2, LC-210, LC-182, LC-227. Linkers with different length were used to offer variety 
orientation for these aromatic groups. But unfortunately, all these peptidomimetics are much 
weaker than LC-081 in cell growth inhibition assay. (1-methylpiperidin-4-yl)amino group, which 
is used in OICR-9429 and occupies the similar pocket as guanidino group in MM-401, was 
introduced to the peptidomimetic yields LC-174 and LC-164, but no cell growth inhibition 
activities were obtained up to 10 M treatment with such modification. So further modifications 
were done with the original guanidino group structure. Cyclization of the two nitrogen atoms 
with 5- and 6-member rings yields LC-202 and LC-337 with IC50 values of 88 nM and 33 nM in cell 
growth inhibition assay, which are 3-8 times more potent than LC-081. 4,5-dihydro-1H-imidazol-
2-yl group in LC-202 and 1-methylpiperidin-4-yl group in LC-337 can interact with the 
hydrophobic surface composed with F219 and A176. It might also reduce the basicity of the 
guanidino group and improve the cell permeability of the peptidomimetics. Introducing electron 
withdrawing groups acetyl groups yields LC-315, which is 2 times less potent as LC-081.  
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Combining the SAR results above on different sites of LC-081, LC-395 was synthesized 
accordingly. But the improvement of the different substitution groups could not be well 
combined. LC-395 has similar cell growth inhibition activity as LC-337, with IC50 value of 38 nM.  
Table 3-10.  Binding affinity to WDR5 of selected peptidomimetic inhibitors. 
 
IC50/ nM Ki/ nM 
AK-035-2 0.8783 < 1 
AK-058 1.478 < 1 
LC-089 2.129 < 1 
LC-182 3.253 < 1 
LC-202 2.397 < 1 
LC-300 2.378 < 1 
LC-313 1.833 < 1 
LC-315 3.649 < 1 
LC-321 2.874 < 1 
LC-326 2.302 < 1 
LC-334 0.3195 < 1 
LC-337 1.865 < 1 
LC-339 1.794 < 1 
LC-345 3.997 < 1 
LC-395 2.542 < 1 
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To further confirm our new cyclic peptidomimetic inhibitor could still bind to WDR5, the 
binding affinity to WDR5 of selected compounds were tested and the results were summarized 
in Table 3-10. All these potent WDR5 inhibitors can potently bind to WDR5 with IC50 values of 
0.32-3.6 nM and Ki values << 1 nM, which are lower than the assay limit. 
Synthesis 
Intermediates 301 was prepared on the 2-chlorotrityl chloride resin using solid phase 
peptide synthesis with Fmoc chemistry and cleaved from the resin to yield carboxylic acids 302, 
respectively (Scheme 3-1). 
 
Scheme 3-1. Synthesis of 302. Reaction conditions: (a) Solid phase peptide synthesis; (b) 1% 
CF3COOH in CH2Cl2, rt, 30 min. 
Synthesis of the designed cyclic peptidomimetics (MM-401, HK-06-223C-HK-06-229C) is 
shown in Scheme 3-2. Alkeneamines were first attached to an Fmoc-phenylglycine yielding 303a-
303d. Fmoc deprotection of 303a-303d followed by amide coupling with intermediate 26 
afforded 304a-304d. RCM cyclization followed by catalytic hydrogenation and removal of the Pbf 
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protecting group from arginine side chain yielded the cyclic peptidomimetics MM-401 and HK-
06-223C-HK-06-229C as trifluoroacetic acid salt.  
 
Scheme 3-2. Synthesis of MM-401, HK-06-223c, HK-05-121c and HK-06-229c. Reaction 
conditions: (a) EDCI, HOAt, DIPEA, CH2Cl2, rt, 2-3 h; (b) DEA, Acetonitrile, 2h; (c) 302, EDCI, HOAt, 
DIPEA, CH2Cl2, rt, 4h; (d) Hoveyda-Grubb's 2nd generation catalyst, CH2Cl2, rt, overnight; (e) 
H2/Pd.C, MeOH, rt, 2h; (f) CH2Cl2:CF3COOH:H2O (20:10:0.5), reflux, 2h; 
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Synthesis of cyclic peptidomimetics (LC-040-LC-044, LC-089-LC-088) is shown in Scheme 
3-3 and Scheme 3-4. Intermediates 305a-305e and 309a-309b were prepared on the 2 -
chlorotrityl chloride resin using solid phase peptide synthesis with Fmoc chemistry. The 
intermediate peptides were cleaved from the resin followed by Boc or Benzyl protecting group 
removal with 10% trifluoroacetic acid in dichloromethane or hydrogenation with Pd/C in ethanol, 
respectively, to yield peptides 306a-306e (Scheme 3-3) and 310a-310c (Scheme 3-4). 
Intramolecular amide coupling of 306a-306e, 310a-310c and followed by removal of Pbf 
protecting group from arginine side chain yielded cyclic peptidomimetics LC-058-LC-044 and LC-
089-LC-088 as trifluoroacetic acid salt. 
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Scheme 3-3. Synthesis of LC-040, LC-042-1, LC-043-1, LC-058 and LC-044. Reaction conditions: (a) 
Solid phase peptide synthesis; (b) 1% CF3COOH in CH2Cl2, rt, 30 min then 10% CF3COOH in CH2Cl2 
1h; (c) HATU, DIPEA, DMF, rt, 1h; (d) 95% CF3COOH in water, rt ,2h 
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Scheme 3-4. Synthesis of LC-081, LC-089 and LC-088. Reaction conditions: (a) OsO4, NaIO4, H2O, 
THF, rt, 4h; (b) Dibenzylamine, NaBH(OAc)3, ClCH2CH2Cl, rt, 10h; (c) Solid phase peptide synthesis; 
(d) 1% CF3COOH in CH2Cl2, rt, 30 min then H2, Pd/C, ethanol, 50 oC, 12h; (e) HATU, DIPEA, DMF, 
rt, 1h; (f) 95% CF3COOH in water, rt, 2h 
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Scheme 3-5. Synthesis of LC-172, LC-162 and LC-167. Reaction conditions: (a) Solid phase peptide 
synthesis; (b) 1% CF3COOH in CH2Cl2, rt, 30 min then H2, Pd/C, ethanol, 50 oC, 12h; (c) HATU, 
DIPEA, DMF, rt, 1h; (d) 20% CF3COOH in in CH2Cl2, rt, 2h 
Synthesis of the intermediates (LC-172, LC-162, LC-167) is shown in Scheme 3-5. 
Intermediates 312a-312d were prepared on the 2 -chlorotrityl chloride resin using solid phase 
peptide synthesis with Fmoc chemistry. The intermediate peptides were cleaved from the resin 
followed by Benzyl protecting group removal with hydrogenation with Pd/C in ethanol, 
respectively, to yield peptides 313a-313d. Intramolecular amide coupling and following removal 
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of Boc protecting group from L-ornithine side chain yielded cyclic peptide intermediates LC-172, 
LC-162 and LC-167. 
 
Scheme 3-6. Synthesis of LC-313, LC-300, LC-314, AK-012, AK-010, AK-020, AK-011, LC-261, AK-
005, AK-021, AK-022, AK-036, AK-033, LC-334, LC-321, AK-035-2, AK-057, AK-058, AK-059, AK-
042, LC-345, LC-339, LC-324, LC-326, LC-322 and LC-294. Reaction conditions: (a) Solid phase 
peptide synthesis; (b) 1% CF3COOH in CH2Cl2, rt, 30 min then H2, Pd/C, ethanol, 50 oC, 12h; (c) 
HATU, DIPEA, DMF, rt, 1h; (d) 95% CF3COOH in water, rt, 2h. 
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Scheme 3-7. Synthesis of LC-186-2, LC-187-2 and LC-183-2. Reaction conditions: (a) Solid phase 
peptide synthesis; (b) 1% CF3COOH in CH2Cl2, rt, 30 min then H2, Pd/C, ethanol, 50 oC, 12h; (c) 
HATU, DIPEA, DMF, rt, 1h; 
The synthesis of AK-012 – LC-187-2 were shown in Scheme 3-6 and Scheme 3-7. Different 
unnatural amino acids to replace Fmoc-D-Phg-OH, Fmoc-L-Abu-OH, Fmoc-L-Arg(Pbf)-OH in the 
original synthesis of LC-081 were involved for the synthesis of intermediates 314a-314z and 317a-
317d, which were prepared on the 2-chlorotrityl chloride resin using solid phase peptide 
synthesis with Fmoc chemistry. The intermediate peptides were cleaved from the resin followed 
by Benzyl protecting group removal with hydrogenation with Pd/C in ethanol, respectively, to 
yield peptides 315a-315z (Scheme 3-6) and 318a-318d (Scheme 3-7). Intramolecular amide 
coupling of 315a-315z, 318a-318d and followed by removal of Pbf protecting group from arginine 
side chain yielded cyclic peptidomimetics AK-012-LC-326 and LC-186-2–LC-187-2. 
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Scheme 3-8. Synthesis of LC-174, LC-164 and LC-169. Reaction conditions: (a) Sodium 
triacetoxyborohydride, acetic acid, dichloroethane, overnight, rt. 
The synthesis of LC-169-LC-164 were shown in Scheme 3-8 from LC-172, LC-162 and LC-
167, which were synthesized according to Scheme 3-5. LC-169-LC-164 were synthesized with 
reduction amination reaction with Formaldehyde or 1-methylpiperidin-4-one. 
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Scheme 3-9. Synthesis of LC-210, LC-182, LC-227, LC-202, LC-337 and LC-315. Reaction 
conditions: (a) DIEA, Ethanol, 120 oC, microwave, 2h. 
The synthesis of LC-210 – LC-315 were shown in Scheme 3-9. The products were 
synthesized with a direct nucleophilic attack reaction with variety reagents under basic 
condition with microwave. 
Summary 
In this study, we describe the design, synthesis and evaluation of macrocyclic 
peptidomimetic inhibitors binding to WDR5 and blocking WDR5 MLL1 protein-protein 
interactions. Optimization of linker length and detailed SAR studies on the side chain of different 
amino acids were performed for these macrocyclic peptidomimetics. A number of potent and 
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promising macrocyclic peptidomimetics were discovered. LC-089 potently binds to WDR5 with Ki 
value smaller than 1 nM and inhibits the MLL HMT activity with IC50 value of 12.7 nM. In cell 
growth inhibition assay in the MV4;11 and MOLM-13 human AML cell lines harboring MLL 
translocation, LC-089 achieves IC50 values of 0.25 and 0.21 µM. It also displays more than 30-fold 
selectivity for the MV4;11 and MOLM-13 cell lines with MLL translocation over the HL-60 
leukemia cell line without MLL translocation. LC-089 also displays excellent metabolic stability in 
human, mouse and rat microsomes (T1/2 > 60 min). With further SAR study, more potent 
compounds LC-337 and LC-395 were discovered with IC50 values of 33 nM and 38 nM in cell 
growth inhibition in MOLM13 cell line. In direct comparison, LC-337 is more than 800-times more 
potent than MM-401 in cell growth of MOLM-13 cell line. Collectively, our developed macrocyclic 
peptidomimetics are excellent agents to investigate the role of the MLL activity and the MLL-
WDR5 protein-protein interaction in different biological and pathological processes. It may 
ultimately yield a new therapy for the treatment of human acute leukemia carrying MLL 
translocation. Future study on these cyclo peptidomimetic inhibitors will focus their in-vivo 
effects including PK/PD, efficacy and toxicity studies. 
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Chapter 4 
Population Pharmacokinetics(PK) of Mycophenolic Acid(MPA) and its Metabolites in Liver 
Transplant Recipients 
Introduction 
Mycophenolate mofetil (MMF, CellCept, Hoffman-La Roche) is an immunosuppressant 
prodrug of mycophenolic acid (MPA), which is commonly used for the prophylaxis of acute 
allograft rejection in solid organ (kidney, liver, renal and lung) transplantation and autoimmune 
diseases.121-124 MPA is a reversible inosine monophosphate dehydrogenase (IMPDH) inhibitor, 
which could selectively reduce guanine nucleotide synthesis. As T-cells and B-cells are more 
dependent on de novo synthesis of purines for their proliferation than regular cells. MPA could 
selectively inhibit the proliferation of lymphocytes resulting the immunosuppressing effect. MPA 
also could prevents antibody formation by B-lymphocytes and suppresses the glycosylation of 
lymphocyte and monocyte glycoproteins which is important for the intercellular adhesion to 
endothelial cell.125-126 
MMF was first approval by the United States Food and Drug Administration (FDA) in 1995 
for renal transplantation127. Currently, MMF is commonly used as maintenance 
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immunosuppressant for solid organ transplantation patients in combination with additional 
immunosuppressants, such as cyclosporine, sirolimus and tacrolimus.124  
MMF could be rapidly and nearly completely absorbed following oral administration and 
hydrolyzed to the active metabolite MPA with undetectable MMF level in plasma after about 5 
min. MPA is metabolized principally by UDP-glucuronosyl transferase (UGT) enzymes to form the 
phenolic glucuronide of MPA (MPAG) after oral dosing.122 (Figure 4-1)  MPAG is a stable 
metabolite and is not pharmacologically active. MPAG are excreted unchanged in the urine, but 
may undergo enterohepatic recirculation (EHR), and convert back to MPA via multidrug-resistant 
protein-2 (MRP-2). The EHR process of MPAG could contribute about 40% of MPA area under the 
concentration-time curve (AUC), which might result in multiple peaks in the plasma drug 
concentration-time curves of MPA.123 MPA-acyl-glucuronide (AcMPAG) is a relative minor, but 
active metabolite. AcMPAG has been demonstrated that some independent mechanism from 
major MPA action, which is associated with inosine monophosphate dehydrogenase inhibition.128 
It has been speculated that AcMPAG could exert an antiproliferative effect and inhibit 
proliferation of human mononuclear leukocytes via a mechanism independent of guanosine 
triphosphate (GTP) depletion. Either MAPG or AcMPAG might be linked to side effects of MMF. 
In addition, unlike population PK models of MPA with renal transplantation patients, the 
population PK models with liver transplantation patients are quite limited, especially for the 
model with metabolites.124, 129-130   And Therefore, a better understanding of the PK of MPA, 
MPAG and AcMPAG is needed considering its contributions to the systemic exposure and 
gastrointestinal toxicity of MPA. 
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Figure 4-1. Hydrolyzation of MMF to MPA and metabolized to MAPG and AcMPAG. 
The purpose of this work was to characterize the population PK of MPA and its 
metabolites MPAG and AcMPAG in adult Chinese liver transplant recipients following repeated 
oral administration of the prodrug MMF. And a good description of the metabolites of MPA may 
provide a useful tool future dose selection and in predicting some MPA-related side effects.  
Method 
Sixty-four adult patients (52 males, 12 females) received liver transplantation at Organ 
Transplantation Center in Ruijin Hospital were recruited. The study protocol was approved by the 
regional ethics committee (Ruijin Hospital, Shanghai Jiao Tong University School of Medicine) and 
performed in accordance with the Declaration of Helsinki and Chinese guidelines for good clinical 
practice. All the patients gave informed consent before inclusion. The demographic and 
pathophysiological data were collected retrospectively.  
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All patients received immunosuppressive therapy consisting of MMF, tacrolimus, and 
corticosteroids. 1g of MMF was given within 6h before liver transplantation. After transplantation, 
dosage of MMF was adjusted according to the occurrence of side effects. 1g Bid, 0.75g Bid and 
0.5g Bid were given to 54, 8 and 2 patients, respectively. Tacrolimus was given as an oral dose of 
0.1 mg/kg per day initially, and then adjusted to achieve a steady-state trough concentration of 
10-15 ng/ml in the first week after the start of therapy and 5-10 ng/ml thereafter. Five hundred 
milligram of methylprednisolone was injected during a hepatic period and tapered after 
operation. After 7 days therapy, prednisone was used at a dosage of 20 mg daily, and then further 
tapered according to the protocol. All concomitant medications were recorded for each patient. 
Blood samples were collected at 0- 12 h after MMF administration after 7-30 days MMF oral 
administration. The plasma concentration of MPA and its metabolites was determined by HPLC 
assay we established. 
Table 4-1. Clinical data summary of liver transplantation recipients 
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Characters (Unit) Means  SD (Range) 
Age (yrs) 48.812.4 (14~76)  
Gender Male: 52; Famale: 12 
weight (kg) 66.118.0 (37~87)  
height (cm) 169.55.0 (158~182)  
Time interval (days) 8.22.1 (7~15) 
Total bilirubin (TBIL) (mol/L) 72.762.7 (21.1~282.1)  
Direct bilirubin (DBIL) (mol/L) 38.838.4 (3.9~144.5)  
Albumin (g/L) 35.15.2 (23~46)  
Creatinine (mol/L) 70.724.8 (37~181)  
Creatinine clearance (ClCr) (ml/min) 108.443.4 (32.4~244.9)  
White Blood Cells count (WBC) (109/L) 7.983.71 (2.6~19.9)  
Red Blood Cells count (RBC) (1012/L) 3.440.60 (2.4~5.0)  
Platelet (PLT) (109/L) 102.561.0 (10~249)  
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Figure 4-2. Population pharmacokinetic model of MPA, MPAG and AcMPAG. CL/F, CLm1/F and 
CLm2/F are the apparent clearance of MPA, MPAG and AcMPAG; V2/F and V5/F are apparent 
volume of distribution of MPA in central and peripheral compartments; V3/F and V4/F are the 
apparent volume of distribution of MPAG and AcMPAG; Q/F is apparent compartmental 
clearance between the MPA central and peripheral compartments; Ka is the absorption rate 
constant of MPA; Fm1 and Fm2 are the fraction of MPA metabolized to MPAG and AcMPAG; K31 
and K41 are the rate constant for biliary excretion and enterohepatic recycling of MPAG and 
AcMPAG. 
The population PK model with simultaneous modelling of MPA, MPAG and AcMPAG was 
developed with nonlinear mixed effects modeling (NONMEM) using the iterative two-stage (ITS) 
method, followed by the stochastic approximation expectation maximization (SAEM) method, 
followed by Monte Carlo importance sampling (IMP) method. Model development was guided 
by the likelihood ratio test using objective function values (OFV), graphical goodness-of-fit, and 
visual predictive check. 
MPA, MPAG and AcMPAG plasma concentration-time data, after MMF oral 
administration, were adequately described by a 5-compartment model. The absorption of MPA 
from the gastrointestinal tract (GIT), central and peripheral compartments for MPA disposition, 
and the formation, EHR and elimination of MPA, MPAG and AcMPAG was assumed to follow first-
order kinetic. The conversion from MMF to MPA was assumed to be rapid and complete prior to 
reaching the systemic circulation. The fractions of MPA metabolized to MPAG and AcMPAG were 
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assumed to be fixed 90% and 10% based on literature information131-133, which indicates that 
clearance of MPA through MPAG and AcMPAG. 
Inter-individual variability (IIV) of the PK parameters was assumed to follow a log-normal 
distribution and described by an exponential error model (1)with following equations 
Pi = θ * exp (ηi) (1) 
where Pi is the parameter estimate for ith individual, θ is the typical individual and ηi is the IIV. 
Additive (2), proportional (3) and mixed (4) error models were evaluated for the residual 
unexplained variability using the following equations: 
Y= IPRED + ε (2) 
Y = IPRED × (1 + ε) (3) 
Y = IPRED × (1+ ε1) + ε2 (4) 
where Y is the observed concentration, F is the individual prediction and ε is the residual 
variability. IIVs, residual errors were included in the model only if they were associated with a 
decrease in OFV by at least 3.84. 
The final PK model was evaluated with visual predictive checks. Posterior prediction was 
obtained with 1000 simulation cooperating with the parameters’ uncertainties from the final 
model. The 95% prediction intervals for the simulated median, 5th and 95th percentiles were 
calculated and compared with the observed data points of MPA, MPAG and AcMPAG, 
respectively.   
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Results and Discussion 
Plasma MPA, MPAG and AcMPAG concentration-time profiles were described by the 
compartmental model shown in Figure 4-2. Proportional error model was selected as the final 
model for the residual unexplained variability.  
The model estimated population means of the absorption rate constant Ka (0.93 h-1), 
apparent clearance CL/F (18.1 L/hr), volumes of distribution (central compartment: V2/F = 71.7 
L, peripheral compartment: M5/F = 2111 L), and intercompartmental clearance (Q = 28.4 L/hr) 
are shown in Table 4-2. Comparing with a previously published two compartment-model of 
MPA129, the apparent clearance CL/F and intercompartmental clearance are higher than the two-
compartment model (CL/F = 17.4 L/hr, Q= 21.7 L/hr). It could be explained by the following 
equation: 
CL/F = 
𝐷𝑜𝑠𝑒
𝐹∗𝐴𝑈𝐶
 (5) 
With the same AUC value, EHR of MPAG is equivalent to add extra dose to the system which can 
increase CL/F and Q. 
The apparent elimination clearance and volumes of distribution of the metabolites MPAG 
and AcMPAG are quantified (CLm1/F = 1.2 L/hr, CLm2/F = 4.8 L/hr, V3/F = 19.9 L and V4/F = 90.9 L 
respectively).  The estimated rate constant describing the EHR of MPAG (K31) and AcMPAG (K41) 
are 2.3 * 10-5 and 0.024 h-1. (Table 4-2.) The relative small K31 value probably is caused by the 
liver or renal functions in patients, which could not be evaluated in current model. The IIVs of 
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these parameter estimates are large which is consistent with literature.134 The values of 
percentiles of RSE are acceptable except for CLm1/F, which is close to 40%. 
Table 4-2. Population PK parameter estimates for MPA, MPAG and AcMPAG. 
 
For model diagnosis, the population and individual predictions well follow the trend of 
the data, as it’s shown in Figure 4-3A. No significant trend was observed in the conditional 
weighted residuals vs population predictions and time after last dose plots. (Figure 4-3B). As 
shown in the visual predicted check plots (Figure 4-3C), the trend is consistent to the observed 
data of MPA, MPAG and AcMPAG, but the coverage between 5th and 95th percentile of the 1000 
simulated data suggests slightly over prediction of data variation, especially for the two 
metabolites MPAG and AcMPAG. 
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Figure 4-3. (A) & (B) Basic goodness-of-fit plots of population PK parameters. (C) Visual predictive 
check of final model. 
Summary 
The population PK model developed from our study successfully characterized the 
absorption, distribution, and elimination of MPA and its major metabolites in liver transplant 
recipients. A good description of the metabolites of MPA may provide a useful tool in predicting 
some MPA-related side effects. In the futures, covariate analysis with patient’s gender, body 
weights, age, renal and liver functions could be done with current model. 
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Chapter 5 
General Discussion 
Design of PROTACs 
A set of PROTACs were developed from the previously reports with different E3 ubiquitin 
ligase ligands. The PTORACs could simultaneously bind to the target proteins and E3 ubiquitin 
ligases causing target protein ubiquitination and degradation. The ubiquitination pathway 
includes three enzymes: an E1-activating enzyme, an E2-conjugating enzyme, and an E3 ligase, 
which needs to be activated sequentially.135 E2-conjugating enzyme prepares ubiquitin for 
conjugation, while the E3 ligase recognizes the substrate protein and catalyzes the transfer of 
activated ubiquitin to it. Cullin E3 ubiquitin ligases are responsible for about 20% of the protein 
ubiquitination in cells. It contains a Cullin protein as a scaffold, a RING finger protein to recruit E2 
enzyme with ubiquitin and a substrate receptor to recruit substrate protein. Substrate protein 
with ubiquitin tag is then recognized by the 26S proteasome, a very large multi-catalytic protease 
complex, then degraded to small peptides pieces.  
Although PROTACs could successfully cause target protein degradation and some of them 
are much more efficient than the corresponding inhibitors, how to choose E3 ligase ligand is still 
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unclear for the design of efficient PROTACs. Currently the most efficient PROTACs were designed 
to recruit the Cul4A/B-DDB1-Cereblon E3 ubiquitin ligase complex and Cul2-Rbx1-EloBC-VHL 
ubiquitin ligase complex. In these PROTACs, the E3 ligase ligand could bind to cereblon or VHL-1 
which are both the substrate receptors in the E3 ligase complex. Comparing them with PROTACs 
recruiting IAPs or MDM2, PROTACs recruiting Cullin E3 ligase can cause target protein 
degradation with much lower concentration treatment in cells. MDM2 PROTAC LE-004 and BRD4 
PROTAC BETd-260 recruiting cereblon could cause MDM2 or BRD4 protein degradation with 
lower than 1 nM.50 While AR PROTAC recruiting MDM2 could cause AR protein degradation with 
10 µM treatments.44 These results suggested that small molecule ligand targeting the substrate 
receptor of Cullin E3 ligase can be good choice for the design of successful PROTACs. Other 
important properties of PROTACs are the cell permeability, solubility, stability and PK properties. 
As both target protein and E3 ligase ligands are difficult to modify, more effort to improve these 
properties will focus on the modification of linkers. From our study, rigid and hydrophobic linker 
can improve the in-vivo PK properties. But these linkers may cause solubility problems. 
Development of novel hydrophilic rigid linker might further improve effects of PROTACs. 
Evaluation of PROTACs 
From our study of MDM2 PROTACs and the molecular glue causing GSPT-1 degradation, 
detailed evaluation of these bifunctional molecules is important for the development of 
PROTACs. The evaluation of PROTACs needs to two questions: confirmation of the biological 
effect; comparing the potencies for further modification. To solve these questions, the following 
assay is important for the evaluation of PROTACs. 
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1. Western Blot and qPCR for the target protein: 
To confirm the biological effect of the designed PROTACs, western blot and qPCR assay 
are most important and direct evidence to confirm the degradation of target proteins. If the 
western blot indicates that target protein expression level is decreased and at the same time 
qPCR assay has confirmed the mRNA expression level of target protein does not change or 
increases, the PROTACs probably can cause the target protein degradation.  
2. Proteomics Study 
From our study of molecular glue LD-277 and the study from Bradner Group, bifunction 
molecules designed with lenalidomide and its derivatives can cause GSPT-1 degradation. It results 
un expected cell growth inhibition activities comparing with bona fide MDM2 degraders and 
inhibitors. Carefully evaluation of degradation events with proteomic study is important to figure 
out unpredictable effects. It is also significant to figure out off-target side effects for the future 
application. 
3. Competition Study 
Competition study is very useful to confirm the supposed mechanisms for the target 
protein degradation. If pretreatment of excess of target protein or E3 ligase ligands can block the 
protein degradation caused by the PROTACs, it indicates both interactions between target 
protein-PROTACs and E3 ligase-PROTACs are important for protein degradation. Besides the 
competition study with protein degradation, it could also be used for in-vitro efficiency assay, for 
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example, cell growth inhibition assay. Competition of excess target protein or E3 ligase ligands 
should also block the cell activities of PROTACs.  
4. Cotreatment of Proteasome inhibitors 
PROTACs can promote the ubiquitination of target proteins and increase its proteasome 
degradation. Cotreatment of proteasome inhibitors, such as MG-132 should significantly block 
the target protein degradation. But it might not be useful in certain cases. In p53 wildtype cell 
lines, MDM2 protein, as an E3 ligase, can ubiquitinate p53 protein and cause p53 protein 
degradation. Treatment of MDM2 PROTACs can cause MDM2 protein degradation and 
accumulation of p53.  With feedback loop, activation of p53 can also increase the MDM2 protein 
expression level. While treatment of proteasome inhibitor MG-132 can efficiently block the 
degradation of p53, which can activate p53 and increase expression of MDM2. So cotreatment 
of proteasome inhibitor with MDM2 PROTACs could not give direct evidence about the blockage 
of protein degradation.  
5. Cell growth inhibition evaluation 
Currently, most of PROTACs developments are in the field of oncology. And then cell 
growth inhibition assay is an important method for the evaluation of PROTAC modification. Two 
important factors might affect the cell growth inhibition activities of PROTACs. The binding 
affinity to the target protein and E3 ligase of PROTACs is critical for the design of PROTACs. From 
our study of MDM2 PROTACs, the binding affinity of MDM2 inhibitor moiety is important for the 
cell anti-proliferation activity of PROTACs. PROTACs synthesized with MDM2 inhibitor with Kd 
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value higher than 200 nM to MDM2 failed to cause significant MDM2 degradation up to 3 M. 
And the cell growth inhibition activity is also weaker than the corresponding MDM2 inhibitors. 
But PROTACs synthesized with MDM2 inhibitor with Kd value lower than 100 nM to MDM2 are 
much more potent their MDM2 inhibitors. So the binding affinity to target protein can 
significantly affect the cellular potency of PROTACs. Another important factor for cell growth 
inhibition activity is the cell permeability. Even currently most of the PROTACs are designed with 
small molecule ligands, the molecular weight is still around 1000 Da. Cell permeability might be 
poor for PROTACs with such high molecular weight. So cell permeability assay on PROTACs could 
bring us better understanding on the modification and mechanism of PROTACs. 
6 In-vivo PK/PD, toxicity and efficacy studies 
In-vitro assay on PROTACs can bring us clear mechanism of it in cell and also guide us for 
the chemical modification. But the significance of these results might be limited as the 
environment in body is quite different from in-vitro. In-vivo assay is important for the further 
application of PROTACs in drug development field. PK/PD and toxicity studies on our MDM2 
PROTACs helped us to decide the efficient administration method and doses. Although PK data 
has shown the concentration of MDM2 PROTACs in tumor is lower than plasma, it’s still much 
higher than the concentration required for MDM@ degradation in-vitro. Efficient MDM2 
degradation was also obtained from the PD study. Efficacy studies then helped us to confirm the 
antitumor activities of our MDM2 PROTACs comparing with their MDM2 inhibitors. MDM2 
PROTACs is much more potent than their inhibitors in xenograft tumor mice models.  
Future Perspectives 
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Recently, PROTACs have become an important and popular area in drug discovery. While 
the development of PROTACs are still focused on preclinical stage. Further advanced evaluation 
in clinical studies are the main next stage for PROTACs. Another important future direction for 
PROTACs is to further explore its application for other protein targets. Although enormous effort 
has been spent in the field of drug discovery, only 2% of human proteins are the targets for 
current approved drugs. It’s also estimated that only 1-2 % of disease modified proteins are likely 
to be druggable with inhibitors, which means most of the disease related protein could not be 
targeted by direct interaction with proteins.136 While PROTACs offers the potential of reaching 
beyond the limitations of the current pharmaceutical and expand the druggable targets by 
inducing target protein degradation. 
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Experimental Section 
General  
Unless otherwise noted, all purchased reagents were used as received without further 
purification. 1H NMR and 13C NMR spectra were recorded on a Bruker Advance 400 MHz 
spectrometer. 1H NMR spectra were reported in parts per million (ppm) downfield from 
tetramethylsilane (TMS). All 13C NMR spectra were reported in ppm and obtained with 1H 
decoupling. In reported spectral data, the format (δ) chemical shift (multiplicity, J values in Hz, 
integration) was used with the following abbreviations: s = singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet. MS analyses were carried out with a Waters UPLC–mass spectrometer. 
The final compounds were all purified by C18 reverse phase preparative HPLC column with 
solvent A (0.1% TFA in H2O) and solvent B (0.1% TFA in MeCN) as eluents. The purity of all the 
final compounds was confirmed to be >95% purity by UPLC–MS or UPLC. 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3-
dioxoisoindolin-4-yl)amino)ethyl)carbamoyl)phenyl)-2''-oxodispiro[cyclohexane-1,2'-
pyrrolidine-3',3''-indoline]-5'-carboxamide (LD-117) 
LD-117 (10.9 mg, Yield: 43% from MI-1061) was obtained as yellow powder using the same 
synthetic strategy described for LD-074.  
LC-MS(ESI) m/z (M +H)+: 880.21; calcd for C45H41Cl2FN7O7 (M +H)+ : 880.24; >98% purity. 
144 
 
1H NMR (400 MHz, Methanol-d4) δ 7.85 – 7.75 (m, 2H), 7.74 – 7.61 (m, 3H), 7.53 (dd, J = 8.6, 7.1 
Hz, 1H), 7.45 (dd, J = 8.2, 2.4 Hz, 1H), 7.25 (t, J = 7.4 Hz, 1H), 7.19 (d, J = 8.5 Hz, 1H), 7.13 – 6.98 
(m, 3H), 6.74 (d, J = 2.0 Hz, 1H), 5.05 (dd, J = 12.4, 5.5 Hz, 1H), 4.83 – 4.63 (m, 2H), 3.69 – 3.52 (m, 
4H), 2.93 – 2.59 (m, 4H), 2.25 – 1.90 (m, 5H), 1.79 – 1.71 (m, 2H), 1.62 – 1.59 (m, 1H), 1.15 – 0.99 
(m, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((3-((2-(2,6-dioxopiperidin-3-yl)-1,3-
dioxoisoindolin-4-yl)amino)propyl)carbamoyl)phenyl)-2''-oxodispiro[cyclohexane-1,2'-
pyrrolidine-3',3''-indoline]-5'-carboxamide (LD-270) 
LD-270 (10.9 mg, Yield: 69% from MI-1061) was obtained as yellow powder using the same 
synthetic strategy described for LD-074. 
LC-MS(ESI) m/z (M +H)+: 894.24; calcd for C46H43Cl2FN7O7 (M +H)+ : 894.26; >98% purity. 
1H NMR (400 MHz, Methanol-d4) δ 7.87 – 7.74 (m, 2H), 7.72 (t, J = 7.4 Hz, 1H), 7.67 – 7.57 (m, 2H), 
7.58 – 7.44 (m, 2H), 7.37 (t, J = 7.6 Hz, 1H), 7.18 (t, J = 8.0 Hz, 1H), 7.12 (dd, J = 8.2, 2.0 Hz, 1H), 
7.08 – 6.94 (m, 2H), 6.79 (d, J = 2.0 Hz, 1H), 5.31 (d, J = 10.8 Hz, 2H), 5.07 – 4.93 (m, 2H), 3.55 – 
3.37 (m, 5H), 2.93 – 2.77 (m, 3H), 2.78 – 2.60 (m, 1H), 2.24 – 2.13 (m, 1H), 2.12 – 2.01 (m, 1H), 
2.03 – 1.90 (m, 5H), 1.84 – 1.71 (m, 3H), 1.54 (d, J = 14.0 Hz, 1H), 1.26 (d, J = 21.4 Hz, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((4-((2-(2,6-dioxopiperidin-3-yl)-1,3-
dioxoisoindolin-4-yl)amino)butyl)carbamoyl)phenyl)-2''-oxodispiro[cyclohexane-1,2'-
pyrrolidine-3',3''-indoline]-5'-carboxamide (LD-074) 
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Reaction 1: 
2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (200 mg, 0.73 mmol) was added to a 
solution of tert-butyl (4-aminobutyl)carbamate (207mg, 1.1 mmol) and DIEA (0.6 mL, 4 mmol) in 
DMF (2 mL). The reaction was heated to 90 oC for 12h. Then the mixture was cooled to room 
temperature and load on the celite. The crude residue was purified by reverse phase C18 column 
to afford tert-butyl (4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-
yl)amino)butyl)carbamate without further purification. The product was then dissolved in 5 mL 
DCM and 1 mL trifluoroacetic acid was added to the reaction. The reaction was stirred for 2 h at 
room temperature until there is no starting material detected by HPLC. The solvent was removed 
to yield 101c (107mg, Yield: 43%) as yellow solid. 
Reaction 2:  
HATU (13.3 mg, 1.2 eq.) and N,N-Diisopropylethylamine (0.026 mL, 0.15 mmol) were added to a 
solution of MI-1061 (20 mg, 0.029 mmol) in 0.5 mL DMF and stirred. After 10 minutes, 101c (0.35 
mL, 0.1 M in DMSO) was added to the reaction. After 30 minutes, the solvent was removed and 
the crude was dissolved in 3:1 methanol/water, acidified with trifluoroacetic acid and purified by 
reverse-phase preparative HPLC. The purified fractions were combined, concentrated in vacuo, 
re-dissolved in H2O, frozen and lyophilized to give LD-074 (18.5 mg, Yield: 71%) as a yellow 
powder. 
LD-074 was obtained using the same synthetic strategy described for LD-072.  
LC-MS(ESI) m/z (M +H)+: 908.32; calcd for C47H45Cl2FN7O7 (M +H)+ : 908.27; >98% purity. 
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1H NMR (400 MHz, MeOD) δ 7.79 – 7.68 (m, 3H), 7.63 – 7.58 (m, 2H), 7.53 (dd, J = 8.3, 2.4 Hz, 1H), 
7.49 (ddd, J = 8.5, 7.1, 1.4 Hz, 1H), 7.39 – 7.32 (m, 1H), 7.17 (t, J = 8.1 Hz, 1H), 7.11 (dd, J = 8.2, 
2.0 Hz, 1H), 7.02 (d, J = 8.6 Hz, 1H), 6.98 (dd, J = 6.8, 2.8 Hz, 1H), 6.79 (d, J = 1.9 Hz, 1H), 5.30 (d, J 
= 10.7 Hz, 1H), 5.03 (dd, J = 12.6, 5.5 Hz, 1H), 4.96 (d, J = 10.8 Hz, 1H), 3.44 – 3.34 (m, 4H), 2.92 – 
2.79 (m, 2H), 2.78 – 2.65 (m, 2H), 2.17 (d, J = 14.1 Hz, 1H), 2.13 – 2.05 (m, 1H), 2.02 – 1.87 (m, 
3H), 1.81 – 1.69 (m, 6H), 1.62 – 1.48 (m, 1H), 1.27 – 1.16 (m, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((5-((2-(2,6-dioxopiperidin-3-yl)-1,3-
dioxoisoindolin-4-yl)amino)pentyl)carbamoyl)phenyl)-2''-oxodispiro[cyclohexane-1,2'-
pyrrolidine-3',3''-indoline]-5'-carboxamide (LD-252) 
LD-252 (8.6 mg, Yield: 33% from MI-1061) was obtained as yellow powder using the same 
synthetic strategy described for LD-074.  
LC-MS(ESI) m/z (M +H)+: 922.30; calcd for C48H47Cl2FN7O7 (M +H)+ : 922.29; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.79 – 7.67 (m, 3H), 7.63 – 7.57 (m, 2H), 7.57 – 7.46 (m, 2H), 7.37 – 
7.30 (m, 1H), 7.16 (t, J = 7.9 Hz, 1H), 7.10 (dd, J = 8.2, 1.9 Hz, 1H), 7.02 (d, J = 8.6 Hz, 1H), 6.98 (dd, 
J = 6.7, 4.1 Hz, 1H), 6.78 (d, J = 1.9 Hz, 1H), 5.22 (d, J = 9.8 Hz, 1H), 5.04 – 4.98 (m, 1H), 4.95 (dd, 
J = 10.6, 2.9 Hz, 1H), 3.41 – 3.33 (m, 4H), 2.90 – 2.61 (m, 4H), 2.17 – 2.04 (m, 2H), 1.97 – 1.82 (m, 
3H), 1.78 – 1.49 (m, 9H), 1.24 – 1.13 (m, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((6-((2-(2,6-dioxopiperidin-3-yl)-1,3-
dioxoisoindolin-4-yl)amino)hexyl)carbamoyl)phenyl)-2''-oxodispiro[cyclohexane-1,2'-
pyrrolidine-3',3''-indoline]-5'-carboxamide (LD-091) 
147 
 
LD-091 (14.3 mg, Yield: 53% from MI-1061) was obtained as yellow powder using the same 
synthetic strategy described for LD-074.  
LC-MS(ESI) m/z (M +H)+: 936.27; calcd for C49H49Cl2FN7O7 (M +H)+ : 936.31; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.76 (d, J = 8.7 Hz, 2H), 7.71 (t, J = 6.7 Hz, 1H), 7.60 (d, J = 8.7 Hz, 
2H), 7.56 – 7.47 (m, 2H), 7.36 (t, J = 7.0 Hz, 1H), 7.18 (t, J = 8.0 Hz, 1H), 7.11 (dd, J = 8.2, 1.9 Hz, 
1H), 7.02 – 6.97 (m, 2H), 6.79 (d, J = 1.9 Hz, 1H), 5.33 (d, J = 10.9 Hz, 1H), 5.03 (dd, J = 12.4, 5.3 
Hz, 1H), 4.97 (d, J = 10.9 Hz, 1H), 3.40 – 3.27 (m, 4H), 2.93 – 2.65 (m, 4H), 2.19 (d, J = 11.6 Hz, 1H), 
2.15 – 2.06 (m, 1H), 2.04 – 1.89 (m, 3H), 1.78 (d, J = 11.8 Hz, 2H), 1.71 – 1.59 (m, 4H), 1.55 – 1.38 
(m, 5H), 1.27 – 1.18 (m, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((7-((2-(2,6-dioxopiperidin-3-yl)-1,3-
dioxoisoindolin-4-yl)amino)heptyl)carbamoyl)phenyl)-2''-oxodispiro[cyclohexane-1,2'-
pyrrolidine-3',3''-indoline]-5'-carboxamide (LD-251) 
LD-251 (16.3 mg, Yield: 60% from MI-1061) was obtained as yellow powder using the same 
synthetic strategy described for LD-074.  
LC-MS(ESI) m/z (M +H)+: 950.29; calcd for C50H51Cl2FN7O7 (M +H)+ : 950.32; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.80 – 7.74 (m, 2H), 7.74 – 7.68 (m, 1H), 7.64 – 7.59 (m, 2H), 7.55 – 
7.47 (m, 2H), 7.37 – 7.30 (m, 1H), 7.16 (t, J = 8.1 Hz, 1H), 7.10 (dd, J = 8.2, 1.9 Hz, 1H), 7.01 (s, 1H), 
6.99 (d, J = 2.2 Hz, 1H), 6.79 (d, J = 1.9 Hz, 1H), 5.27 (d, J = 10.6 Hz, 1H), 5.03 (dd, J = 12.6, 5.4 Hz, 
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1H), 4.95 (d, J = 10.7 Hz, 1H), 3.38 – 3.27 (m, 4H), 2.90 – 2.64 (m, 4H), 2.20 – 2.05 (m, 2H), 2.00 – 
1.84 (m, 3H), 1.83 – 1.71 (m, 2H), 1.67 – 1.53 (m, 5H), 1.46 – 1.35 (m, 6H), 1.25 – 1.13 (m, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((2-(2-((2-(2,6-dioxopiperidin-3-yl)-
1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethyl)carbamoyl)phenyl)-2''-oxodispiro[cyclohexane-
1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide (LD-111) 
LD-111 (15.9 mg, Yield: 60% from MI-1061) was obtained as yellow powder using the same 
synthetic strategy described for LD-074.  
LC-MS(ESI) m/z (M +H)+: 924.20; calcd for C47H45Cl2FN7O8 (M +H)+ : 924.27; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.76 – 7.68 (m, 3H), 7.61 – 7.51 (m, 3H), 7.47 – 7.39 (m, 1H), 7.35 (t, 
J = 7.6 Hz, 1H), 7.19 (t, J = 8.1 Hz, 1H), 7.11 (dd, J = 8.2, 0.9 Hz, 1H), 7.01 (d, J = 8.6 Hz, 1H), 6.91 
(t, J = 7.2 Hz, 1H), 6.79 (d, J = 1.9 Hz, 1H), 5.39 (d, J = 10.9 Hz, 1H), 5.03 – 4.92 (m, 3H), 3.69 (dt, J 
= 10.5, 5.0 Hz, 4H), 3.58 – 3.50 (m, 2H), 3.45 (t, J = 4.9 Hz, 2H), 3.03 – 2.53 (m, 4H), 2.22 (d, J = 
13.4 Hz, 1H), 2.09 – 1.86 (m, 4H), 1.78 (d, J = 12.1 Hz, 2H), 1.54 (dd, J = 27.2, 13.5 Hz, 1H), 1.29 – 
1.12 (m, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-
1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl)carbamoyl)phenyl)-2''-
oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide (LD-075) 
LD-075 (20.8 mg, Yield: 75% from MI-1061) was obtained as yellow powder using the same 
synthetic strategy described for LD-074.  
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LC-MS(ESI) m/z (M +H)+: 968.35; calcd for C49H49Cl2FN7O9 (M +H)+ : 968.30; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.79 – 7.66 (m, 3H), 7.59 – 7.47 (m, 3H), 7.40 – 7.27 (m, 2H), 7.19 (t, 
J = 8.1 Hz, 1H), 7.10 (dd, J = 8.2, 1.8 Hz, 1H), 6.95 – 6.83 (m, 2H), 6.79 (d, J = 1.9 Hz, 1H), 5.40 (d, 
J = 10.9 Hz, 1H), 5.03 – 4.96 (m, 3H), 3.73 – 3.62 (m, 8H), 3.57 – 3.50 (m, 2H), 3.42 – 3.35 (m, 2H), 
2.94 (d, J = 8.0 Hz, 1H), 2.85 – 2.57 (m, 3H), 2.21 (d, J = 13.6 Hz, 1H), 2.07 – 1.87 (m, 4H), 1.76 (d, 
J = 11.6 Hz, 2H), 1.53 (dd, J = 26.9, 13.3 Hz, 1H), 1.31 – 1.10 (m, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-
yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)ethyl)carbamoyl)phenyl)-2''-
oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide (LD-112) 
LD-112 was (11.8 mg, Yield: 41% from MI-1061) obtained as yellow powder using the same 
synthetic strategy described for LD-074.  
LC-MS(ESI) m/z (M +H)+: 1012.30; calcd for C51H53Cl2FN7O10 (M +H)+ : 1012.32; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.76 (d, J = 8.7 Hz, 2H), 7.72 (t, J = 6.6 Hz, 1H), 7.58 (d, J = 8.7 Hz, 
2H), 7.53 (dd, J = 8.2, 2.3 Hz, 1H), 7.49 – 7.43 (m, 1H), 7.36 (t, J = 7.0 Hz, 1H), 7.19 (t, J = 8.1 Hz, 
1H), 7.11 (dd, J = 8.2, 1.8 Hz, 1H), 6.99 (d, J = 8.0 Hz, 2H), 6.79 (d, J = 1.9 Hz, 1H), 5.37 (d, J = 10.9 
Hz, 1H), 5.02 (ddd, J = 12.3, 5.4, 1.3 Hz, 1H), 4.97 (d, J = 11.0 Hz, 1H), 3.68 – 3.60 (m, 12H), 3.52 
(t, J = 5.3 Hz, 2H), 3.42 (t, J = 5.2 Hz, 2H), 2.95 – 2.87 (m, 1H), 2.86 – 2.79 (m, 1H), 2.76 – 2.61 (m, 
2H), 2.21 (d, J = 13.4 Hz, 1H), 2.13 – 2.05 (m, 1H), 2.00 – 1.88 (m, 3H), 1.77 (d, J = 11.7 Hz, 2H), 
1.53 (dd, J = 27.1, 13.2 Hz, 1H), 1.29 – 1.19 (m, 2H). 
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(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((3-(2-(2-(3-((2-(2,6-dioxopiperidin-3-
yl)-1,3-dioxoisoindolin-4-yl)amino)propoxy)ethoxy)ethoxy)propyl)carbamoyl)phenyl)-2''-
oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide (LD-076) 
LD-076 (17.6 mg, Yield: 59% from MI-1061) was obtained as yellow powder using the same 
synthetic strategy described for LD-074.  
LC-MS(ESI) m/z (M +H)+: 1040.40; calcd for C53H57Cl2FN7O10 (M +H)+ : 1040.35; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.80 – 7.74 (m, 2H), 7.70 (t, J = 7.1 Hz, 1H), 7.61 (d, J = 8.6 Hz, 2H), 
7.55 – 7.46 (m, 2H), 7.39 – 7.31 (m, 1H), 7.17 (t, J = 8.1 Hz, 1H), 7.10 (dd, J = 8.2, 1.6 Hz, 1H), 7.04 
– 6.96 (m, 2H), 6.79 (d, J = 1.9 Hz, 1H), 5.26 (d, J = 10.4 Hz, 1H), 5.03 (dd, J = 12.4, 5.5 Hz, 1H), 4.94 
(d, J = 10.7 Hz, 1H), 3.68 – 3.62 (m, 4H), 3.62 – 3.54 (m, 8H), 3.45 (t, J = 6.6 Hz, 2H), 3.38 (t, J = 6.5 
Hz, 2H), 2.90 – 2.67 (m, 4H), 2.20 – 2.05 (m, 2H), 1.96 – 1.73 (m, 9H), 1.55 (dd, J = 27.1, 13.6 Hz, 
1H), 1.27 – 1.13 (m, 2H) 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-
yl)-1,3-dioxoisoindolin-4-yl)oxy)ethoxy)ethoxy)ethoxy)ethyl)carbamoyl)phenyl)-2''-
oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide (LD-110) 
Reaction 1: 
Potassium bicarbonate (150mg, 1.5 mmol) was added to a solution of 2-(2,6-dioxopiperidin-3-yl)-
4-hydroxyisoindoline-1,3-dione (274 mg, 1.0 mmol) in DMF (5mL) and stirred for 30 min. Then 
2,2-dimethyl-4-oxo-3,8,11,14-tetraoxa-5-azahexadecan-16-yl 4-methylbenzenesulfonate (492 
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mg, 1.1 mmol) was added to the reaction and stirred at 50oC overnight. Then the product was 
purified by reverse phase chromatography over C18 column to yield product. Then the product 
was dissolved in DCM (5 mL) and trifluoroacetic acid (1 mL) and stirred for 30 min until the 
reaction is complete. Solvent was removed under vacuum to yield 114 
Reaction 2: 
HATU (13.3 mg, 0.035 mmol) and N,N-Diisopropylethylamine (0.026 mL, 0.15 mmol) were added 
to a solution of MI-1061 (20 mg, 0.029 mmol) in 0.5 mL DMF and stirred. After 10 minutes, 114 
(0.35 mL, 0.1 M in DMSO) was added to the reaction. After 30 minutes, the solvent was removed 
and the crude was dissolved in 3:1 methanol/water, acidified with trifluoroacetic acid and 
purified by reverse-phase preparative HPLC. The purified fractions were combined, concentrated 
in vacuo, re-dissolved in H2O, frozen and lyophilized to yield LD-110 (8.5 mg, Yield: 29%) as a 
white powder. 
LC-MS(ESI) m/z (M +H)+: 1013.33; calcd for C51H52Cl2FN6O11 (M +H)+ : 1013.31; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.77 (d, J = 8.8 Hz, 2H), 7.74 – 7.65 (m, 2H), 7.60 (d, J = 8.7 Hz, 2H), 
7.52 (dd, J = 8.2, 2.4 Hz, 1H), 7.42 – 7.30 (m, 3H), 7.17 (t, J = 8.0 Hz, 1H), 7.10 (dd, J = 8.2, 1.5 Hz, 
1H), 6.79 (d, J = 1.8 Hz, 1H), 5.29 (d, J = 10.7 Hz, 1H), 5.08 (dd, J = 12.4, 5.5 Hz, 1H), 4.95 (d, J = 
10.8 Hz, 1H), 4.33 – 4.25 (m, 2H), 3.90 – 3.82 (m, 2H), 3.75 – 3.69 (m, 2H), 3.65 – 3.58 (m, 8H), 
3.52 (t, J = 5.3 Hz, 2H), 2.89 – 2.66 (m, 4H), 2.19 – 2.05 (m, 2H), 1.98 – 1.84 (m, 3H), 1.77 (d, J = 
10.9 Hz, 2H), 1.55 (dd, J = 27.2, 13.7 Hz, 1H), 1.26 – 1.14 (m, 2H). 
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(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((2-(2-(2-(3-(2-(2,6-dioxopiperidin-3-
yl)-1,3-dioxoisoindolin-4-yl)propoxy)ethoxy)ethoxy)ethyl)carbamoyl)phenyl)-2''-
oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide (LD-210) 
LD-210 (8.8 mg, Yield: 30% from MI-1061) was obtained as white powder using the same 
synthetic strategy described for LD-222. 
LC-MS(ESI) m/z (M +H)+:1011.31; calcd for C52H54Cl2FN6O10 (M +H)+ : 1011.33; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.77 (d, J = 8.1 Hz, 2H), 7.74 – 7.64 (m, 3H), 7.64 – 7.56 (m, 3H), 7.53 
(dd, J = 8.2, 2.4 Hz, 1H), 7.36 (t, J = 7.2 Hz, 1H), 7.19 (t, J = 8.1 Hz, 1H), 7.14 – 7.10 (m, 1H), 6.80 
(d, J = 1.8 Hz, 1H), 5.37 (dd, J = 11.0, 1.6 Hz, 1H), 5.11 (dd, J = 12.9, 5.0 Hz, 1H), 4.97 (d, J = 10.9 
Hz, 1H), 3.68 – 3.57 (m, 8H), 3.57 – 3.49 (m, 4H), 3.44 (t, J = 6.3 Hz, 2H), 3.17 – 3.06 (m, 2H), 2.98 
– 2.91 (m, 1H), 2.89 – 2.79 (m, 1H), 2.79 – 2.65 (m, 2H), 2.22 (d, J = 15.2 Hz, 1H), 2.17 – 2.09 (m, 
1H), 2.02 – 1.84 (m, 5H), 1.84 – 1.74 (m, 2H), 1.52 (dd, J = 27.2, 13.3 Hz, 1H), 1.30 – 1.19 (m, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-
yl)-1-oxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)ethyl)carbamoyl)phenyl)-2''-
oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide (LD-131) 
Reaction 1: 
Lenalidomide (73 mg, 0.28 mmol) was added to a solution of tert-butyl (2-(2-(2-(2-
oxoethoxy)ethoxy)ethoxy)ethyl)carbamate (100 mg, 0.34 mmol)  in 3 mL DCE and stirred for 30 
min. Then sodium triacetoxyborohydride (120 mg, 0.56 mmol) was added to the mixture and 
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reaction was stirred at room temperature overnight. Then the reaction was quenched by adding 
saturated sodium bicarbonate solution (30 mL). The product was extracted out by DCM (30 mL*3) 
and the combined organic solution was washed by brine. Crude product was obtained by 
removing the solvent by vacuum. The crude product was then dissolved in 10 mL DCM and 2 mL 
trifluoroacetic acid. The reaction was stirred for 30 min and the solvent was removed by vacuo. 
The residue was purified by reverse phase chromatography over C18 column to yield 102a as 
colorless oil. 
Reaction 2: 
HATU (13.3 mg, 1.2 eq.) and N,N-Diisopropylethylamine (0.026 mL, 0.15 mmol) were added to a 
solution of MI-1061 (20 mg, 0.029 mmol) in 0.5 mL DMF and stirred. After 10 minutes, 102a (0.35 
mL, 0.1 M in DMSO) was added to the reaction. After 30 minutes, the solvent was removed and 
the crude was dissolved in 3:1 methanol/water, acidified with trifluoroacetic acid and purified by 
reverse-phase preparative HPLC. The purified fractions were combined, concentrated in vacuo, 
re-dissolved in H2O, frozen and lyophilized to yield LD-186 17.6 mg, Yield: 43%) as a white powder. 
LC-MS(ESI) m/z (M +H)+: 998.29; calcd for C51H55Cl2FN7O9 (M +H)+ : 998.34; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.76 (dd, J = 8.8, 2.8 Hz, 2H), 7.71 (t, J = 7.0 Hz, 1H), 7.57 (t, J = 8.3 
Hz, 2H), 7.51 (dt, J = 8.2, 2.7 Hz, 1H), 7.36 (t, J = 7.6 Hz, 1H), 7.30 – 7.23 (m, 1H), 7.18 (t, J = 8.1 
Hz, 1H), 7.11 (d, J = 8.2 Hz, 1H), 7.07 (dd, J = 7.3, 2.2 Hz, 1H), 6.84 – 6.77 (m, 2H), 5.32 (d, J = 10.9 
Hz, 1H), 5.16 – 5.10 (m, 1H), 4.95 (dd, J = 10.8, 2.7 Hz, 1H), 4.32 – 4.19 (m, 2H), 3.68 – 3.60 (m, 
12H), 3.52 (t, J = 5.3 Hz, 2H), 3.36 (t, J = 4.6 Hz, 2H), 2.97 – 2.86 (m, 2H), 2.80 – 2.71 (m, 1H), 2.50 
154 
 
– 2.37 (m, 1H), 2.22 – 2.12 (m, 2H), 1.94 (dd, J = 19.7, 10.4 Hz, 3H), 1.78 (d, J = 12.3 Hz, 2H), 1.54 
(dd, J = 25.6, 13.6 Hz, 1H), 1.28 – 1.17 (m, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((2-(2-(2-(3-(2-(2,6-dioxopiperidin-3-
yl)-1-oxoisoindolin-4-yl)propoxy)ethoxy)ethoxy)ethyl)carbamoyl)phenyl)-2''-
oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide (LD-243) 
LD-243 (17.6 mg, Yield: 61% from MI-1061) was obtained as white powder using the same 
synthetic strategy described for LD-222. 
LC-MS(ESI) m/z (M +H)+:997.32; calcd for C52H56Cl2FN6O9 (M +H)+ : 997.35; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.80 – 7.74 (m, 2H), 7.71 (t, J = 7.2 Hz, 1H), 7.63 – 7.54 (m, 3H), 7.54 
– 7.48 (m, 1H), 7.47 – 7.29 (m, 3H), 7.18 (t, J = 8.1 Hz, 1H), 7.11 (ddd, J = 8.3, 1.9, 0.7 Hz, 1H), 6.79 
(d, J = 1.9 Hz, 1H), 5.34 (d, J = 10.9 Hz, 1H), 5.16 (ddd, J = 13.4, 9.3, 5.2 Hz, 1H), 4.96 (dd, J = 10.9, 
3.8 Hz, 1H), 4.43 (t, J = 4.9 Hz, 2H), 3.67 – 3.58 (m, 8H), 3.58 – 3.47 (m, 4H), 3.47 – 3.37 (m, 2H), 
2.98 – 2.82 (m, 2H), 2.82 – 2.63 (m, 3H), 2.50 (qdd, J = 13.4, 8.8, 4.7 Hz, 1H), 2.27 – 2.10 (m, 2H), 
2.03 – 1.81 (m, 5H), 1.77 (d, J = 11.9 Hz, 2H), 1.54 (dd, J = 26.4, 13.3 Hz, 1H), 1.34 – 1.12 (m, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((2-(2-(2-(3-((2-(2,6-dioxopiperidin-3-
yl)-1-oxoisoindolin-4-yl)amino)-3-oxopropoxy)ethoxy)ethoxy)ethyl)carbamoyl)phenyl)-2''-
oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide (LD-188) 
LD-188 (27.6 mg, Yield: 62% from MI-1061) was obtained as white powder using the same 
synthetic strategy described for LD-186. 
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LC-MS(ESI) m/z (M +H)+:1026.30; calcd for C52H55Cl2FN7O10 (M +H)+ : 1026.34; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.80 – 7.74 (m, 2H), 7.74 – 7.68 (m, 2H), 7.63 – 7.56 (m, 3H), 7.53 
(dd, J = 8.2, 2.5 Hz, 1H), 7.46 (t, J = 7.8 Hz, 1H), 7.39 – 7.31 (m, 1H), 7.17 (t, J = 8.1 Hz, 1H), 7.13 – 
7.03 (m, 1H), 6.79 (d, J = 1.9 Hz, 1H), 5.35 (d, J = 10.9 Hz, 1H), 5.15 (dt, J = 13.3, 5.4 Hz, 1H), 4.97 
(d, J = 10.9 Hz, 1H), 4.45 (t, J = 2.6 Hz, 2H), 3.79 (t, J = 5.9 Hz, 2H), 3.64 – 3.51 (m, 10H), 3.48 (t, J 
= 5.2 Hz, 2H), 2.99 – 2.82 (m, 2H), 2.76 (ddd, J = 17.6, 4.5, 2.3 Hz, 1H), 2.65 (dd, J = 7.2, 4.7 Hz, 
2H), 2.43 (qdd, J = 13.2, 4.6, 2.3 Hz, 1H), 2.25 – 2.10 (m, 2H), 2.04 – 1.85 (m, 3H), 1.76 (d, J = 11.7 
Hz, 2H), 1.60 – 1.44 (m, 1H), 1.23 (td, J = 13.7, 3.8 Hz, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((5-(2-(2,6-dioxopiperidin-3-yl)-1,3-
dioxoisoindolin-4-yl)pentyl)carbamoyl)phenyl)-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-
3',3''-indoline]-5'-carboxamide (LD-214) 
LD-214 (18.2 mg, Yield: 58% from MI-1061) was obtained as white powder using the same 
synthetic strategy described for LD-222. 
LC-MS(ESI) m/z (M +H)+: 907.27; calcd for C48H46Cl2FN6O7 (M +H)+ : 907.28; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.75 – 7.68 (m, 3H), 7.66 – 7.63 (m, 2H), 7.63 – 7.57 (m, 3H), 7.54 
(dd, J = 8.2, 2.2 Hz, 1H), 7.37 (t, J = 7.4 Hz, 1H), 7.19 (t, J = 8.0 Hz, 1H), 7.11 (dd, J = 8.2, 1.4 Hz, 
1H), 6.80 (d, J = 1.5 Hz, 1H), 5.38 (d, J = 10.9 Hz, 1H), 5.09 (dd, J = 12.6, 5.4 Hz, 1H), 4.99 (d, J = 
11.0 Hz, 1H), 3.34 (t, J = 7.0 Hz, 2H), 3.11 (dd, J = 17.7, 10.1 Hz, 2H), 2.98 – 2.79 (m, 2H), 2.79 – 
2.62 (m, 2H), 2.22 (d, J = 13.9 Hz, 1H), 2.10 (dd, J = 8.6, 3.5 Hz, 1H), 2.04 – 1.91 (m, 3H), 1.80 – 
1.51 (m, 7H), 1.44 (dd, J = 15.0, 8.0 Hz, 2H), 1.31 – 1.19 (m, 2H). 
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(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((5-((2-(2,6-dioxopiperidin-3-yl)-1-
oxoisoindolin-4-yl)amino)-5-oxopentyl)carbamoyl)phenyl)-2''-oxodispiro[cyclohexane-1,2'-
pyrrolidine-3',3''-indoline]-5'-carboxamide (LD-186) 
Reaction 1: 
HATU (380 mg, 1 mmol) and N,N-Diisopropylethylamine (0.44 mL, 2.5 mmol) were added to a 
solution of Boc-5-aminopentanoic acid (110 mg, 0.5 mmol) in 3 mL DMF and stirred. After 10 
minutes, lenalidomide (200 mg, 0.75 mmol) was added to the reaction. After 30 minutes, the 
solvent was removed and the crude was dissolved in 10 mL DCM and 2 mL trifluoroacetic acid. 
The reaction was stirred for 30min and then the solvent was removed by vacuo. The residue was 
purified by reverse phase chromatography over C18 column to yield 102d as colorless oil. 
Reaction 2: 
HATU (13.3 mg, 1.2 eq.) and N,N-Diisopropylethylamine (0.026 mL, 0.15 mmol) were added to a 
solution of MI-1061 (20 mg, 0.029 mmol) in 0.5 mL DMF and stirred. After 10 minutes, 102d (0.35 
mL, 0.1 M in DMSO) was added to the reaction. After 30 minutes, the solvent was removed and 
the crude was dissolved in 3:1 methanol/water, acidified with trifluoroacetic acid and purified by 
reverse-phase preparative HPLC. The purified fractions were combined, concentrated in vacuo, 
re-dissolved in H2O, frozen and lyophilized to yield LD-186 (24.2 mg, Yield: 91%) as a white 
powder. 
LC-MS(ESI) m/z (M +H)+:922.26; calcd for C48H47Cl2FN7O7 (M +H)+ : 922.29; >98% purity. 
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1H NMR (400 MHz, MeOD) δ 7.77 (d, J = 8.2 Hz, 2H), 7.74 – 7.67 (m, 2H), 7.63 – 7.57 (m, 3H), 7.54 
(dd, J = 8.2, 2.4 Hz, 1H), 7.47 (t, J = 7.7 Hz, 1H), 7.39 – 7.31 (m, 1H), 7.17 (t, J = 8.1 Hz, 1H), 7.11 
(dd, J = 8.2, 1.9 Hz, 1H), 6.79 (d, J = 1.9 Hz, 1H), 5.38 (d, J = 10.9 Hz, 1H), 5.12 (dd, J = 13.3, 5.1 Hz, 
1H), 4.98 (d, J = 10.9 Hz, 1H), 4.45 (d, J = 2.1 Hz, 2H), 3.40 (t, J = 6.7 Hz, 2H), 3.02 – 2.79 (m, 2H), 
2.78 – 2.66 (m, 1H), 2.57 – 2.30 (m, 3H), 2.21 (d, J = 14.0 Hz, 1H), 2.17 – 2.07 (m, 1H), 2.06 – 1.88 
(m, 3H), 1.81 – 1.63 (m, 6H), 1.60 – 1.46 (m, 1H), 1.24 (td, J = 13.8, 3.9 Hz, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((5-(2-(2,6-dioxopiperidin-3-yl)-1-
oxoisoindolin-4-yl)pentyl)carbamoyl)phenyl)-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-
3',3''-indoline]-5'-carboxamide (LD-222) 
Reaction 1: 
To a solution of tert-butyl pent-4-yn-1-ylcarbamate (236 mg, 1.29 mmol) and 3-(4-bromo-1-
oxoisoindolin-2-yl)piperidine-2,6-dione (400mg, 1.29 mmol) in Triethylamine (3mL) and DMF (3 
mL), CuI (50mg, 0.25 mmol) and the Pd(Ph3P)2Cl2 (90 mg, 0.13 mmol) were added. The mixture 
was stirred at 80oC under N2-atmosphere overnight. The reaction mixture was poured into a 
saturated aqueous solution of NH4Cl and after separation of the organic layer the aqueous layer 
was extracted with Ethyl Acetate. The combined organic layers were washed with brine, dried 
over Na2SO4 and concentrated in vacuo. The crude product was purified by flash 
chromatography to afford 105d as white solid. 
Reaction 2: 
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To a solution of 105d (210 mg, 0.5 mmol) in EtOH (5 mL) was added Pd/C (20mg). The reaction 
was stirred under H2-atmosphere for 2 hr. Then the mixture was filtered by celite and the solvent 
was removed by vacuo. The residue was dissolved in 10 mL DCM and 2 mL trifluoroacetic acid. 
The reaction was stirred for 30min and then the solvent was removed by vacuo. The residue was 
purified by reverse phase chromatography over C18 column to 106d as colorless oil. 
Reaction 3: 
HATU (13.3 mg, 1.2 eq.) and N,N-Diisopropylethylamine (0.026 mL, 0.15 mmol) were added to a 
solution of MI-1061 (20 mg, 0.029 mmol) in 0.5 mL DMF and stirred. After 10 minutes, 106d (0.35 
mL, 0.1 M in DMSO) was added to the reaction. After 30 minutes, the solvent was removed and 
the crude was dissolved in 3:1 methanol/water, acidified with trifluoroacetic acid and purified by 
reverse-phase preparative HPLC. The purified fractions were combined, concentrated in vacuo, 
re-dissolved in H2O, frozen and lyophilized to give LD-222 (17.5 mg, Yield: 68%) as a white powder. 
LC-MS(ESI) m/z (M +H)+: 893.19; calcd for C48H48Cl2FN6O6 (M +H)+ : 893.30; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.78 – 7.66 (m, 3H), 7.66 – 7.56 (m, 3H), 7.53 (dd, J = 8.2, 2.5 Hz, 1H), 
7.47 – 7.38 (m, 2H), 7.38 – 7.32 (m, 1H), 7.17 (t, J = 8.1 Hz, 1H), 7.11 (dd, J = 8.2, 2.0 Hz, 1H), 6.79 
(d, J = 1.9 Hz, 1H), 5.29 (d, J = 10.7 Hz, 1H), 5.14 (dd, J = 13.3, 5.2 Hz, 1H), 4.97 (d, J = 10.8 Hz, 1H), 
4.46 (dd, J = 5.7, 2.5 Hz, 2H), 3.41 – 3.33 (m, 2H), 2.96 – 2.64 (m, 5H), 2.50 (qdd, J = 13.3, 4.6, 2.5 
Hz, 1H), 2.22 – 2.09 (m, 2H), 2.02 – 1.84 (m, 3H), 1.79 – 1.48 (m, 7H), 1.48 – 1.35 (m, 2H), 1.22 
(td, J = 13.7, 4.0 Hz, 2H). 
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(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((5-(2-(2,6-dioxopiperidin-3-yl)-1,3-
dioxoisoindolin-4-yl)pent-4-yn-1-yl)carbamoyl)phenyl)-2''-oxodispiro[cyclohexane-1,2'-
pyrrolidine-3',3''-indoline]-5'-carboxamide (LE-004) 
HATU (13.3 mg, 1.2 eq.) and N,N-Diisopropylethylamine (0.026 mL, 0.15 mmol) were added to a 
solution of MI-1061 (20 mg, 0.029 mmol) in 0.5 mL DMF and stirred. After 10 minutes, 105d (0.35 
mL, 0.1 M in DMSO) was added to the reaction. After 30 minutes, the solvent was removed and 
the crude was dissolved in 3:1 methanol/water, acidified with trifluoroacetic acid and purified by 
reverse-phase preparative HPLC. The purified fractions were combined, concentrated in vacuo, 
re-dissolved in H2O, frozen and lyophilized to give LE-004 (8.7 mg, Yield: 34%) as a white powder. 
LC-MS(ESI) m/z (M +2H)2+: 445.30; calcd for C48H45Cl2FN6O6 (M +2H)2+ : 445.14; >98% purity. 
1H NMR (400 MHz, Methanol-d4) δ 7.83 – 7.62 (m, 4H), 7.56 (dd, J = 8.3, 2.5 Hz, 1H), 7.54 – 7.47 
(m, 2H), 7.47 – 7.32 (m, 3H), 7.19 (ddd, J = 8.9, 7.6, 3.3 Hz, 1H), 7.12 (dd, J = 8.2, 2.0 Hz, 1H), 6.80 
(d, J = 1.9 Hz, 1H), 5.30 (d, J = 10.8 Hz, 1H), 5.13 (ddd, J = 13.0, 7.4, 5.2 Hz, 1H), 4.98 (d, J = 10.9 
Hz, 1H), 4.49 – 4.25 (m, 2H), 3.57 (t, J = 6.6 Hz, 2H), 2.97 – 2.83 (m, 2H), 2.83 – 2.73 (m, 1H), 2.68 
– 2.42 (m, 3H), 2.28 – 2.13 (m, 2H), 2.13 – 1.84 (m, 5H), 1.84 – 1.68 (m, 2H), 1.57 (ddd, J = 16.3, 
6.2, 3.0 Hz, 1H), 1.34 – 1.19 (m, 3H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-
dioxoisoindolin-4-yl)amino)piperidine-1-carbonyl)phenyl)-2''-oxodispiro[cyclohexane-1,2'-
pyrrolidine-3',3''-indoline]-5'-carboxamide (LE-081) 
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LE-081 (24.2 mg, Yield: 93% from MI-1061) was obtained as white powder using the same 
synthetic strategy described for LD-131. 
LC-MS(ESI) m/z (M +H)+: 906.48; calcd for CC48H47Cl2FN7O6 (M +H)+ : 906.29; >98% purity. 
1H NMR (400 MHz, MeOD/ DMSO) δ 7.78 (t, J = 7.2 Hz, 1H), 7.71 (d, J = 8.6 Hz, 2H), 7.63 (dd, J = 
8.2, 2.3 Hz, 1H), 7.51 – 7.43 (m, 3H), 7.39 (t, J = 7.8 Hz, 1H), 7.29 (t, J = 8.1 Hz, 1H), 7.19 (dd, J = 
8.2, 1.9 Hz, 1H), 7.12 (d, J = 7.5 Hz, 1H), 6.99 (d, J = 8.2 Hz, 1H), 6.89 (d, J = 1.9 Hz, 1H), 5.44 (d, J 
= 10.9 Hz, 1H), 5.21 (dd, J = 13.3, 5.1 Hz, 1H), 5.01 (d, J = 11.0 Hz, 1H), 4.32 (q, J = 17.1 Hz, 2H), 
3.93 – 3.59 (m, 2H), 3.20 – 2.86 (m, 4H), 2.84 – 2.74 (m, 1H), 2.49 (qd, J = 13.2, 4.5 Hz, 1H), 2.24 
– 1.91 (m, 7H), 1.78 (d, J = 11.6 Hz, 2H), 1.56 (m,, 4H), 1.31 – 1.12 (m, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-
dioxoisoindolin-4-yl)amino)azetidine-1-carbonyl)phenyl)-2''-oxodispiro[cyclohexane-1,2'-
pyrrolidine-3',3''-indoline]-5'-carboxamide (LE-082) 
LE-082 (24.4 mg, Yield: 97% from MI-1061) was obtained as white powder using the same 
synthetic strategy described for LD-131. 
LC-MS(ESI) m/z (M +H)+: 878.42; calcd for C46H43Cl2FN7O6 (M +H)+ : 878.26; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.71 (t, J = 6.6 Hz, 1H), 7.63 (s, 4H), 7.53 (dd, J = 8.3, 2.4 Hz, 1H), 7.41 
– 7.26 (m, 2H), 7.23 – 7.13 (m, 2H), 7.11 (dd, J = 8.2, 1.9 Hz, 1H), 6.79 (d, J = 1.9 Hz, 1H), 6.64 (d, 
J = 8.0 Hz, 1H), 5.37 (d, J = 10.9 Hz, 1H), 5.15 (dd, J = 12.8, 5.7 Hz, 1H), 4.96 (d, J = 11.0 Hz, 1H), 
4.73 (t, J = 8.0 Hz, 1H), 4.63 – 4.48 (m, 1H), 4.44 (dt, J = 12.0, 5.9 Hz, 1H), 4.38 – 4.25 (m, 2H), 4.20 
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(dd, J = 8.8, 4.5 Hz, 1H), 4.12 – 3.94 (m, 1H), 2.95 – 2.81 (m, 2H), 2.81 – 2.70 (m, 1H), 2.43 (dd, J = 
26.0, 13.0 Hz, 1H), 2.26 – 2.10 (m, 2H), 2.03 – 1.87 (m, 3H), 1.77 (d, J = 11.9 Hz, 2H), 1.61 – 1.43 
(m, 1H), 1.30 – 1.15 (m, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1,3-
dioxoisoindolin-4-yl)amino)methyl)piperidine-1-carbonyl)phenyl)-2''-oxodispiro[cyclohexane-
1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide (LE-083) 
LE-083 (15.9 mg, Yield: 54% from MI-1061) was obtained as white powder using the same 
synthetic strategy described for LD-131. 
LC-MS(ESI) m/z (M +H)+: 920.29 calcd for C49H49Cl2FN7O6 (M +H)+ : 920.31; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.72 (dd, J = 10.5, 3.9 Hz, 1H), 7.62 (d, J = 8.7 Hz, 2H), 7.53 (dd, J = 
8.3, 2.4 Hz, 1H), 7.42 – 7.34 (m, 3H), 7.31 (t, J = 7.8 Hz, 1H), 7.19 (t, J = 8.0 Hz, 1H), 7.11 (dd, J = 
8.2, 1.9 Hz, 1H), 7.06 (d, J = 7.5 Hz, 1H), 6.83 (d, J = 8.0 Hz, 1H), 6.80 (d, J = 1.9 Hz, 1H), 5.37 (d, J 
= 11.0 Hz, 1H), 5.14 (dd, J = 13.2, 5.0 Hz, 1H), 4.97 (d, J = 11.0 Hz, 1H), 4.69 – 4.48 (m, 1H), 4.27 
(dd, J = 16.0, 8.0 Hz, 2H), 3.82 – 3.62 (m, 1H), 3.18 – 2.67 (m, 7H), 2.45 (qd, J = 13.1, 4.6 Hz, 1H), 
2.25 – 2.10 (m, 2H), 2.04 – 1.84 (m, 5H), 1.78 (d, J = 11.6 Hz, 3H), 1.52 (dd, J = 27.0, 13.3 Hz, 1H), 
1.31 – 1.09 (m, 4H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-(3-(((2-(2,6-dioxopiperidin-3-yl)-1,3-
dioxoisoindolin-4-yl)amino)methyl)azetidine-1-carbonyl)phenyl)-2''-oxodispiro[cyclohexane-
1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide (LE-084) 
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LE-084 (13.5 mg, Yield: 53% from MI-1061) was obtained as white powder using the same 
synthetic strategy described for LD-131. 
LC-MS(ESI) m/z (M +H)+: 892.45; calcd for C47H45Cl2FN7O6 (M +H)+ : 892.28; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.72 (t, J = 6.9 Hz, 1H), 7.61 (s, 4H), 7.54 (d, J = 7.6 Hz, 1H), 7.37 (t, J 
= 7.2 Hz, 1H), 7.31 (t, J = 7.2 Hz, 1H), 7.19 (t, J = 7.9 Hz, 1H), 7.16 – 7.02 (m, 2H), 6.87 (d, J = 8.0 
Hz, 1H), 6.80 (s, 1H), 5.36 (d, J = 11.0 Hz, 1H), 5.15 (dd, J = 13.2, 5.1 Hz, 1H), 4.96 (d, J = 11.1 Hz, 
1H), 4.45 (t, J = 8.3 Hz, 1H), 4.37 – 4.17 (m, 3H), 4.16 – 4.02 (m, 1H), 3.93 (dd, J = 9.6, 5.0 Hz, 1H), 
3.48 (d, J = 6.6 Hz, 2H), 3.09 – 2.72 (m, 4H), 2.43 (dt, J = 13.3, 8.9 Hz, 1H), 2.31 – 2.11 (m, 2H), 
2.05 – 1.85 (m, 3H), 1.78 (d, J = 11.5 Hz, 2H), 1.52 (d, J = 13.7 Hz, 1H), 1.31 – 1.16 (m, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((3-(4-((2-(2,6-dioxopiperidin-3-yl)-1-
oxoisoindolin-4-yl)amino)piperidin-1-yl)propyl)carbamoyl)phenyl)-2''-
oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide (LE-254) 
103a (50 mg, 0.15 mmol) was added to a solution of tert-butyl (2-oxoethyl)carbamate (60 mg, 
0.3 mmol)  in 3 mL DCE and stirred for 30 min. Then sodium triacetoxyborohydride (127 mg, 0.6 
mmol) was added to the mixture and reaction was stirred at room temperature overnight. Then 
the reaction was quenched by adding saturated sodium bicarbonate solution (30 mL). The 
product was extracted out by DCM (30 mL*3) and the combined organic solution was washed by 
brine. Crude product was obtained by removing the solvent by vacuum. The crude product was 
then dissolved in 10 mL DCM and 2 mL trifluoroacetic acid. The reaction was stirred for 30 min 
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and the solvent was removed by vacuo. The residue was purified by reverse phase 
chromatography over C18 column to yield 104a as colorless oil. 
Reaction 2: 
HATU (13.3 mg, 1.2 eq.) and N,N-Diisopropylethylamine (0.026 mL, 0.15 mmol) were added to a 
solution of MI-1061 (20 mg, 0.029 mmol) in 0.5 mL DMF and stirred. After 10 minutes, 104a (0.35 
mL, 0.1 M in DMSO) was added to the reaction. After 30 minutes, the solvent was removed and 
the crude was dissolved in 3:1 methanol/water, acidified with trifluoroacetic acid and purified by 
reverse-phase preparative HPLC. The purified fractions were combined, concentrated in vacuo, 
re-dissolved in H2O, frozen and lyophilized to yield LE-254 (7.8 mg, Yield: 25%) as a white powder. 
LC-MS(ESI) m/z (M +H)+: 963.62; calcd for C51H54Cl2FN8O6 (M +H)+ 963.35; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.86 (d, J = 8.7 Hz, 2H), 7.74 (t, J = 6.7 Hz, 1H), 7.68 (d, J = 8.7 Hz, 
2H), 7.56 (dd, J = 8.2, 2.2 Hz, 1H), 7.44 – 7.32 (m, 2H), 7.25 – 7.09 (m, 3H), 7.01 – 6.89 (m, 1H), 
6.82 (d, J = 1.8 Hz, 1H), 5.41 (d, J = 10.9 Hz, 1H), 5.17 (dd, J = 13.2, 5.2 Hz, 1H), 5.00 (d, J = 11.0 Hz, 
1H), 4.43 – 4.22 (m, 2H), 3.78 – 3.64 (m, 2H), 3.57 – 3.36 (m, 3H), 3.30 – 3.01 (m, 4H), 3.01 – 2.85 
(m, 2H), 2.85 – 2.74 (m, 1H), 2.47 (qd, J = 13.1, 4.5 Hz, 1H), 2.38 – 1.91 (m, 10H), 1.80 (d, J = 11.0 
Hz, 3H), 1.55 (dd, J = 26.9, 13.6 Hz, 1H), 1.37 – 1.17 (m, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((2-(4-((2-(2,6-dioxopiperidin-3-yl)-1-
oxoisoindolin-4-yl)amino)piperidin-1-yl)ethyl)carbamoyl)phenyl)-2''-oxodispiro[cyclohexane-
1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide (LE-093) 
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LE-093 (24.4 mg, Yield: 89% from MI-1061) was obtained as white powder using the same 
synthetic strategy described for LE-254. 
LC-MS(ESI) m/z (M +H)+: 949.44; calcd for C50H52Cl2FN8O6 (M +H)+ 949.34; >98% purity. 
1H NMR (400 MHz, Methanol-d4) δ 7.92 – 7.79 (m, 2H), 7.72 (ddd, J = 8.0, 6.3, 1.6 Hz, 1H), 7.69 – 
7.62 (m, 2H), 7.53 (dd, J = 8.3, 2.5 Hz, 1H), 7.40 – 7.28 (m, 2H), 7.18 (td, J = 8.1, 1.2 Hz, 1H), 7.15 
– 7.05 (m, 2H), 6.93 (d, J = 8.0 Hz, 1H), 6.80 (d, J = 2.0 Hz, 1H), 5.38 (d, J = 11.0 Hz, 1H), 5.14 (dd, 
J = 13.2, 5.2 Hz, 1H), 4.97 (d, J = 11.0 Hz, 1H), 4.46 – 4.15 (m, 2H), 3.93 – 3.34 (m, 8H), 3.19 (t, J = 
12.8 Hz, 1H), 2.98 – 2.71 (m, 3H), 2.45 (qd, J = 13.2, 4.7 Hz, 1H), 2.38 – 2.02 (m, 5H), 2.02 – 1.87 
(m, 3H), 1.85 – 1.75 (m, 3H), 1.63 – 1.45 (m, 1H), 1.32 – 1.16 (m, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((2-(3-((2-(2,6-dioxopiperidin-3-yl)-1-
oxoisoindolin-4-yl)amino)azetidin-1-yl)ethyl)carbamoyl)phenyl)-2''-oxodispiro[cyclohexane-
1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide (LE-094) 
LE-094 (22.7 mg, Yield: 86% from MI-1061) was obtained as white powder using the same 
synthetic strategy described for LE-254. 
LC-MS(ESI) m/z (M +H)+: 921.56; calcd for C48H48Cl2FN8O6 (M +H)+ 921.31; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.86 (d, J = 8.1 Hz, 2H), 7.74 (t, J = 6.8 Hz, 1H), 7.67 (d, J = 8.3 Hz, 
2H), 7.56 (dd, J = 8.2, 1.9 Hz, 1H), 7.37 (dd, J = 14.4, 7.2 Hz, 2H), 7.21 (t, J = 8.4 Hz, 2H), 7.13 (dd, 
J = 8.2, 1.7 Hz, 1H), 6.82 (d, J = 1.7 Hz, 1H), 6.77 – 6.56 (m, 1H), 5.38 (d, J = 10.9 Hz, 1H), 5.17 (dt, 
J = 17.6, 8.8 Hz, 1H), 4.99 (d, J = 11.0 Hz, 1H), 4.85 – 4.50 (m, 3H), 4.50 – 4.15 (m, 3H), 4.15 – 3.90 
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(m, 1H), 3.68 (s, 1H), 3.54 (s, 1H), 3.04 – 2.65 (m, 3H), 2.46 (dt, J = 13.5, 8.9 Hz, 1H), 2.29 – 2.13 
(m, 2H), 2.06 – 1.87 (m, 3H), 1.80 (d, J = 11.8 Hz, 2H), 1.65 – 1.46 (m, 1H), 1.35 – 1.14 (m, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((2-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-
oxoisoindolin-4-yl)amino)methyl)piperidin-1-yl)ethyl)carbamoyl)phenyl)-2''-
oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide (LE-095) 
LE-095 (13.7 mg, Yield: 49% from MI-1061) was obtained as white powder using the same 
synthetic strategy described for LE-254. 
LC-MS(ESI) m/z (M +H)+: 962.94; calcd for C51H54Cl2FN8O6 (M +H)+ 963.35; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.84 (d, J = 8.8 Hz, 2H), 7.72 (dd, J = 10.5, 4.0 Hz, 1H), 7.67 (d, J = 8.8 
Hz, 2H), 7.52 (dd, J = 8.2, 2.4 Hz, 1H), 7.40 – 7.27 (m, 2H), 7.17 (t, J = 7.8 Hz, 1H), 7.14 – 7.05 (m, 
2H), 6.86 (d, J = 8.1 Hz, 1H), 6.79 (d, J = 1.9 Hz, 1H), 5.29 (d, J = 10.7 Hz, 1H), 5.15 (dd, J = 13.3, 5.1 
Hz, 1H), 4.95 (d, J = 10.8 Hz, 2H), 4.28 (q, J = 16.9 Hz, 2H), 3.85 – 3.64 (m, 4H), 3.53 – 3.33 (m, 2H), 
3.22 – 3.19 (m, 1H), 3.06 – 2.71 (m, 5H), 2.45 (qd, J = 13.2, 4.7 Hz, 1H), 2.25 – 2.07 (m, 4H), 2.02 
– 1.82 (m, 4H), 1.82 – 1.69 (m, 2H), 1.56 (dd, J = 24.8, 11.6 Hz, 3H), 1.41 – 1.05 (m, 3H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((2-(3-(((2-(2,6-dioxopiperidin-3-yl)-1-
oxoisoindolin-4-yl)amino)methyl)azetidin-1-yl)ethyl)carbamoyl)phenyl)-2''-
oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide (LE-096) 
LE-096 (16.4 mg, Yield: 61% from MI-1061) was obtained as white powder using the same 
synthetic strategy described for LE-254. 
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LC-MS(ESI) m/z (M +H)+: 934.92; calcd for C49H50Cl2FN8O6 (M +H)+ 935.32; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.69 (d, J = 8.0 Hz, 2H), 7.62 (t, J = 6.6 Hz, 1H), 7.58 – 7.50 (m, 2H), 
7.43 (dd, J = 8.2, 2.4 Hz, 1H), 7.31 – 7.14 (m, 2H), 7.08 (t, J = 8.1 Hz, 1H), 7.00 (dt, J = 7.7, 3.9 Hz, 
2H), 6.76 (dd, J = 29.7, 7.9 Hz, 1H), 6.69 (d, J = 1.9 Hz, 1H), 5.23 (d, J = 10.8 Hz, 1H), 5.04 (dd, J = 
13.3, 4.9 Hz, 1H), 4.87 (d, J = 10.9 Hz, 1H), 4.45 – 3.94 (m, 5H), 3.85 (t, J = 9.2 Hz, 1H), 3.63 – 3.41 
(m, 3H), 3.41 – 3.25 (m, 3H), 3.19 – 2.99 (m, 1H), 2.86 – 2.73 (m, 2H), 2.73 – 2.60 (m, 1H), 2.42 – 
2.24 (m, 1H), 2.08 (d, J = 12.7 Hz, 2H), 1.93 – 1.76 (m, 3H), 1.67 (d, J = 11.5 Hz, 2H), 1.45 (dd, J = 
27.2, 13.6 Hz, 1H), 1.21 – 1.04 (m, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1-
oxoisoindolin-4-yl)ethynyl)piperidine-1-carbonyl)phenyl)-2''-oxodispiro[cyclohexane-1,2'-
pyrrolidine-3',3''-indoline]-5'-carboxamide (LE-102) 
LE-102 (22.7 mg, Yield: 86% from MI-1061) was obtained as white powder using the same 
synthetic strategy described for LE-004. 
LC-MS(ESI) m/z (M +H)+: 915.39; calcd for C50H46Cl2FN6O6 (M +H)+ 915.28; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.77 (dd, J = 7.7, 0.8 Hz, 1H), 7.76 – 7.70 (m, 1H), 7.69 – 7.60 (m, 3H), 
7.56 (dd, J = 8.3, 2.5 Hz, 1H), 7.52 (t, J = 7.7 Hz, 1H), 7.46 – 7.34 (m, 3H), 7.21 (t, J = 8.1 Hz, 1H), 
7.13 (dd, J = 8.2, 1.9 Hz, 1H), 6.82 (d, J = 1.9 Hz, 1H), 5.38 (d, J = 11.0 Hz, 1H), 5.19 (dd, J = 13.3, 
5.2 Hz, 1H), 4.99 (d, J = 11.0 Hz, 1H), 4.51 (q, J = 17.5 Hz, 2H), 4.11 (br s, 1H), 3.81 – 3.61 (m, 1H), 
3.61 – 3.47 (m, 1H), 3.47 – 3.36 (m, 1H), 3.05 (dt, J = 12.2, 4.1 Hz, 1H), 3.01 – 2.85 (m, 2H), 2.80 
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(ddd, J = 17.5, 4.5, 2.4 Hz, 1H), 2.55 (qd, J = 13.2, 4.6 Hz, 1H), 2.29 – 2.14 (m, 2H), 2.10 – 1.88 (m, 
5H), 1.87 – 1.66 (m, 4H), 1.55 (dd, J = 27.0, 13.4 Hz, 1H), 1.27 (td, J = 13.7, 3.7 Hz, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-(4-(2-(2-(2,6-dioxopiperidin-3-yl)-1-
oxoisoindolin-4-yl)ethyl)piperidine-1-carbonyl)phenyl)-2''-oxodispiro[cyclohexane-1,2'-
pyrrolidine-3',3''-indoline]-5'-carboxamide (LE-103) 
LE-103 (16.7 mg, Yield: 63% from MI-1061) was obtained as white powder using the same 
synthetic strategy described for LD-222. 
LC-MS(ESI) m/z (M +H)+: 918.94; calcd for C50H50Cl2FN6O6 (M +H)+ 919.32; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.73 (dd, J = 10.5, 3.9 Hz, 1H), 7.67 – 7.58 (m, 3H), 7.54 (dd, J = 8.2, 
2.5 Hz, 1H), 7.49 – 7.42 (m, 2H), 7.41 – 7.32 (m, 3H), 7.19 (t, J = 8.1 Hz, 1H), 7.11 (dd, J = 8.2, 1.9 
Hz, 1H), 6.79 (d, J = 1.9 Hz, 1H), 5.35 (d, J = 10.9 Hz, 1H), 5.17 (dd, J = 13.3, 5.1 Hz, 1H), 4.96 (d, J 
= 11.0 Hz, 1H), 4.68 – 4.55 (m, 1H), 4.48 (q, J = 17.0 Hz, 2H), 3.71 (d, J = 10.9 Hz, 1H), 3.11 – 2.68 
(m, 7H), 2.53 (qd, J = 13.2, 4.6 Hz, 1H), 2.27 – 2.10 (m, 2H), 2.04 – 1.84 (m, 4H), 1.81 – 1.47 (m, 
7H), 1.31 – 1.08 (m, 4H). 
 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-(((1r,4R)-4-((2-(2,6-dioxopiperidin-3-
yl)-1-oxoisoindolin-4-yl)ethynyl)cyclohexyl)carbamoyl)phenyl)-2''-oxodispiro[cyclohexane-
1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide (LE-194) 
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LE-095 (18.1 mg, Yield: 68% from MI-1061) was obtained as white powder using the same 
synthetic strategy described for LE-004. 
LC-MS(ESI) m/z (M +H)+: 929.43; calcd for C51H48Cl2FN6O6 (M +H)+ 929.30; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.85 – 7.69 (m, 4H), 7.69 – 7.58 (m, 3H), 7.57 – 7.44 (m, 2H), 7.37 (t, 
J = 7.0 Hz, 1H), 7.18 (t, J = 8.1 Hz, 1H), 7.11 (dd, J = 8.2, 1.9 Hz, 1H), 6.79 (d, J = 1.9 Hz, 1H), 5.31 
(d, J = 10.7 Hz, 1H), 5.17 (dd, J = 13.3, 5.2 Hz, 1H), 4.96 (d, J = 10.9 Hz, 1H), 4.49 (q, J = 17.5 Hz, 
2H), 3.96 – 3.75 (m, 1H), 2.99 – 2.70 (m, 3H), 2.63 – 2.44 (m, 2H), 2.28 – 2.08 (m, 4H), 2.07 – 1.84 
(m, 5H), 1.78 (d, J = 11.4 Hz, 2H), 1.68 – 1.39 (m, 5H), 1.29 – 1.18 (m, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-(((1s,4R)-4-(2-(2-(2,6-dioxopiperidin-
3-yl)-1-oxoisoindolin-4-yl)ethyl)cyclohexyl)carbamoyl)phenyl)-2''-oxodispiro[cyclohexane-
1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide (LE-200) 
LE-095 (21.5 mg, Yield: 80% from MI-1061) was obtained as white powder using the same 
synthetic strategy described for LD-222. 
LC-MS(ESI) m/z (M +H)+: 933.36; calcd for C51H52Cl2FN6O6 (M +H)+ 933.33; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.82 – 7.75 (m, 2H), 7.74 – 7.68 (m, 1H), 7.68 – 7.60 (m, 3H), 7.51 
(dd, J = 8.2, 2.4 Hz, 1H), 7.49 – 7.43 (m, 2H), 7.35 (dd, J = 11.0, 4.1 Hz, 1H), 7.16 (t, J = 8.1 Hz, 1H), 
7.10 (dd, J = 8.2, 1.9 Hz, 1H), 6.78 (d, J = 1.9 Hz, 1H), 5.23 (d, J = 10.3 Hz, 1H), 5.17 (dd, J = 13.3, 
5.1 Hz, 1H), 4.94 (d, J = 10.7 Hz, 1H), 4.49 (q, J = 16.9 Hz, 2H), 3.82 (ddd, J = 11.6, 8.0, 3.9 Hz, 1H), 
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2.99 – 2.68 (m, 5H), 2.54 (qd, J = 13.2, 4.6 Hz, 1H), 2.25 – 2.07 (m, 2H), 2.01 – 1.87 (m, 6H), 1.76 
(t, J = 12.0 Hz, 2H), 1.66 – 1.49 (m, 3H), 1.42 – 1.25 (m, 4H), 1.25 – 1.08 (m, 4H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((3-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-
oxoisoindolin-4-yl)amino)methyl)-1H-imidazol-1-yl)propyl)carbamoyl)phenyl)-2''-
oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide (LD-254) 
LD-254 (30.6 mg, Yield: 90% from MI-1061) was obtained using the same synthetic strategy 
described for LD-131. 
LC-MS(ESI) m/z (M +H)+:960.28, 4.43 min; calcd for C50H49Cl2FN9O6 (M +H)+ : 960.32; >98% 
purity. 
1H NMR (400 MHz, MeOD) δ 8.90 (s, 1H), 7.86 – 7.75 (m, 2H), 7.72 (t, J = 7.2 Hz, 1H), 7.67 – 7.56 
(m, 3H), 7.52 (dd, J = 8.2, 2.4 Hz, 1H), 7.39 – 7.32 (m, 1H), 7.29 (t, J = 7.8 Hz, 1H), 7.21 – 7.12 (m, 
2H), 7.11 (dd, J = 8.2, 1.9 Hz, 1H), 6.89 – 6.72 (m, 2H), 5.35 (d, J = 10.8 Hz, 1H), 5.15 (dt, J = 9.2, 
4.9 Hz, 1H), 4.96 (dd, J = 10.9, 1.7 Hz, 1H), 4.53 (s, 2H), 4.41 – 4.29 (m, 2H), 4.25 (t, J = 6.7 Hz, 2H), 
3.39 (t, J = 6.1 Hz, 2H), 2.97 – 2.71 (m, 3H), 2.46 (qd, J = 13.2, 4.7 Hz, 1H), 2.25 – 2.09 (m, 4H), 
2.03 – 1.86 (m, 3H), 1.77 (d, J = 11.7 Hz, 2H), 1.66 – 1.47 (m, 1H), 1.27 – 1.12 (m, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((3-(4-((2-(2,6-dioxopiperidin-3-yl)-1-
oxoisoindolin-4-yl)ethynyl)-1H-pyrazol-1-yl)propyl)carbamoyl)phenyl)-2''-
oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide (LE-243) 
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LE-243 (12.3 mg, Yield: 45% from MI-1061) was obtained using the same synthetic strategy 
described for LE-004. 
LC-MS(ESI) m/z (M +H)+:955.52; calcd for C51H46Cl2FN8O6 (M +H)+ 955.29; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.99 (d, J = 1.4 Hz, 1H), 7.83 – 7.74 (m, 3H), 7.74 – 7.66 (m, 3H), 7.63 
(d, J = 8.6 Hz, 2H), 7.58 – 7.47 (m, 2H), 7.35 (t, J = 7.6 Hz, 1H), 7.17 (t, J = 8.0 Hz, 1H), 7.10 (dd, J = 
8.2, 1.9 Hz, 1H), 6.78 (d, J = 1.9 Hz, 1H), 5.32 – 5.14 (m, 2H), 4.93 (d, J = 11.2 Hz, 1H), 4.55 (q, J = 
17.6 Hz, 2H), 4.25 (t, J = 6.7 Hz, 2H), 3.39 (t, J = 6.6 Hz, 2H), 2.99 – 2.86 (m, 1H), 2.86 – 2.66 (m, 
2H), 2.53 (qd, J = 13.2, 3.0 Hz, 1H), 2.24 – 2.10 (m, 4H), 2.02 – 1.82 (m, 3H), 1.82 – 1.67 (m, 2H), 
1.55 (dd, J = 27.3, 13.7 Hz, 1H), 1.20 (t, J = 11.6 Hz, 2H). 
 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((3-(4-(2-(2-(2,6-dioxopiperidin-3-yl)-
1-oxoisoindolin-4-yl)ethyl)-1H-pyrazol-1-yl)propyl)carbamoyl)phenyl)-2''-
oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide (LE-244) 
LE-244 (8.5 mg, Yield: 31% from MI-1061) was obtained using the same synthetic strategy 
described for LD-222. 
LC-MS(ESI) m/z (M +2H)2+:479.55; calcd for C51H51Cl2FN8O6 (M +2H)2+ 479.16; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.77 (dd, J = 8.9, 0.9 Hz, 2H), 7.74 – 7.67 (m, 1H), 7.66 – 7.58 (m, 3H), 
7.54 (dd, J = 8.2, 2.5 Hz, 1H), 7.48 – 7.41 (m, 2H), 7.40 – 7.34 (m, 1H), 7.30 (s, 1H), 7.24 (s, 1H), 
7.19 (dd, J = 8.5, 7.7 Hz, 1H), 7.12 (dd, J = 8.2, 2.0 Hz, 1H), 6.80 (d, J = 1.9 Hz, 1H), 5.35 (d, J = 10.9 
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Hz, 1H), 5.12 (ddd, J = 13.3, 5.1, 1.9 Hz, 1H), 4.97 (d, J = 11.0 Hz, 1H), 4.27 (q, J = 16.9 Hz, 2H), 4.12 
(t, J = 6.7 Hz, 2H), 3.30 – 3.14 (m, 2H), 2.99 – 2.79 (m, 6H), 2.75 (ddd, J = 17.6, 4.5, 2.3 Hz, 1H), 
2.46 (qd, J = 12.8, 4.0 Hz, 1H), 2.21 (d, J = 13.1 Hz, 1H), 2.16 – 2.08 (m, 1H), 2.08 – 1.89 (m, 5H), 
1.78 (d, J = 11.9 Hz, 2H), 1.53 (q, J = 13.2 Hz, 1H), 1.24 (td, J = 14.2, 4.3 Hz, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((2-(2-(2-((3-(2-(2,6-dioxopiperidin-3-
yl)-1-oxoisoindolin-4-yl)prop-2-yn-1-yl)oxy)ethoxy)ethoxy)ethyl)carbamoyl)phenyl)-2''-
oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide (LE-224) 
LE-224 (17.2 mg, Yield: 60% from MI-1061) was obtained using the same synthetic strategy 
described for LE-004. 
LC-MS(ESI) m/z (M +2H)2+:496.68; calcd for C52H53Cl2FN6O9 (M +2H)2+ 496.15; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.88 – 7.74 (m, 3H), 7.71 (t, J = 6.6 Hz, 1H), 7.67 – 7.55 (m, 3H), 7.55 
– 7.43 (m, 2H), 7.40 – 7.30 (m, 1H), 7.18 (t, J = 8.1 Hz, 1H), 7.10 (dt, J = 8.2, 1.9 Hz, 1H), 6.79 (d, J 
= 1.9 Hz, 1H), 5.31 (d, J = 10.6 Hz, 1H), 5.16 (ddd, J = 13.2, 7.8, 5.2 Hz, 1H), 4.95 (dd, J = 10.9, 2.4 
Hz, 1H), 4.48 (dd, J = 6.4, 3.9 Hz, 1H), 4.42 (d, J = 0.9 Hz, 2H), 3.90 – 3.38 (m, 12H), 3.03 – 2.70 (m, 
3H), 2.57 – 2.38 (m, 1H), 2.17 (dd, J = 11.5, 6.5 Hz, 2H), 2.05 – 1.82 (m, 3H), 1.77 (d, J = 11.8 Hz, 
2H), 1.61 – 1.46 (m, 1H), 1.41 – 1.01 (m, 3H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((5-(2-(2,6-dioxopiperidin-3-yl)-1-
oxoisoindolin-5-yl)pent-4-yn-1-yl)carbamoyl)phenyl)-2''-oxodispiro[cyclohexane-1,2'-
pyrrolidine-3',3''-indoline]-5'-carboxamide (LE-178) 
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LE-178 (18.1 mg, Yield: 71% from MI-1061) was obtained using the same synthetic strategy 
described for LE-004. 
LC-MS(ESI) m/z (M +H)+:889.38; calcd for C48H44Cl2FN6O6 (M +H)+ 889.27; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.82 – 7.74 (m, 2H), 7.71 (ddd, J = 6.4, 4.0, 1.5 Hz, 1H), 7.66 (dd, J = 
7.9, 4.2 Hz, 1H), 7.61 – 7.46 (m, 4H), 7.38 (dt, J = 9.2, 8.4 Hz, 2H), 7.19 (t, J = 8.0 Hz, 1H), 7.15 – 
7.06 (m, 1H), 6.80 (d, J = 1.9 Hz, 1H), 5.35 (dd, J = 10.8, 8.6 Hz, 1H), 5.24 – 5.08 (m, 1H), 4.96 (dd, 
J = 11.0, 3.8 Hz, 1H), 4.55 – 4.28 (m, 2H), 3.66 – 3.44 (m, 2H), 2.97 – 2.84 (m, 2H), 2.84 – 2.72 (m, 
1H), 2.55 (t, J = 6.4 Hz, 2H), 2.53 – 2.40 (m, 1H), 2.27 – 2.10 (m, 2H), 2.04 – 1.87 (m, 5H), 1.78 (d, 
J = 12.3 Hz, 2H), 1.62 – 1.43 (m, 1H), 1.30 – 1.15 (m, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((5-(2-(2,6-dioxopiperidin-3-yl)-3-
oxoisoindolin-5-yl)pent-4-yn-1-yl)carbamoyl)phenyl)-2''-oxodispiro[cyclohexane-1,2'-
pyrrolidine-3',3''-indoline]-5'-carboxamide (LE-179) 
LE-179 (15.4 mg, Yield: 60% from MI-1061) was obtained using the same synthetic strategy 
described for LE-004. 
LC-MS(ESI) m/z (M +H)+:889.32; calcd for C48H44Cl2FN6O6 (M +H)+ 889.27; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.83 – 7.76 (m, 2H), 7.76 – 7.68 (m, 2H), 7.63 – 7.57 (m, 3H), 7.54 
(dd, J = 8.3, 2.5 Hz, 1H), 7.49 (dd, J = 7.9, 1.0 Hz, 1H), 7.41 – 7.34 (m, 1H), 7.19 (t, J = 8.0 Hz, 1H), 
7.12 (dd, J = 8.2, 1.9 Hz, 1H), 6.80 (d, J = 1.9 Hz, 1H), 5.36 (d, J = 10.9 Hz, 1H), 5.15 (ddd, J = 13.3, 
5.1, 1.5 Hz, 1H), 4.97 (d, J = 11.0 Hz, 1H), 4.57 – 4.34 (m, 2H), 3.53 (t, J = 6.9 Hz, 2H), 2.90 (ddd, J 
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= 15.3, 10.3, 3.6 Hz, 2H), 2.78 (ddd, J = 17.6, 4.5, 2.3 Hz, 1H), 2.59 – 2.43 (m, 3H), 2.26 – 2.12 (m, 
2H), 2.04 – 1.86 (m, 5H), 1.78 (d, J = 11.9 Hz, 2H), 1.53 (dd, J = 27.2, 13.4 Hz, 1H), 1.30 – 1.18 (m, 
2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((5-(2-(2,6-dioxopiperidin-3-yl)-1-
oxoisoindolin-5-yl)pentyl)carbamoyl)phenyl)-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-
3',3''-indoline]-5'-carboxamide (LE-180) 
LE-180 (21.5 mg, Yield: 84% from MI-1061) was obtained using the same synthetic strategy 
described for LD-222. 
LC-MS(ESI) m/z (M +H)+:893.28; calcd for C48H48Cl2FN6O6 (M +H)+ 893.29964; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.76 – 7.69 (m, 3H), 7.66 – 7.63 (m, 1H), 7.63 – 7.58 (m, 2H), 7.54 
(dd, J = 8.2, 2.5 Hz, 1H), 7.40 – 7.29 (m, 3H), 7.18 (t, J = 8.0 Hz, 1H), 7.11 (dd, J = 8.2, 1.9 Hz, 1H), 
6.80 (d, J = 1.9 Hz, 1H), 5.35 (d, J = 10.8 Hz, 1H), 5.12 (dt, J = 13.3, 5.4 Hz, 1H), 4.98 (d, J = 10.9 Hz, 
1H), 4.47 – 4.30 (m, 2H), 3.40 – 3.32 (m, 2H), 2.97 – 2.84 (m, 2H), 2.84 – 2.68 (m, 3H), 2.54 – 2.38 
(m, 1H), 2.24 – 2.08 (m, 2H), 2.03 – 1.88 (m, 3H), 1.80 – 1.47 (m, 7H), 1.44 – 1.33 (m, 2H), 1.29 – 
1.17 (m, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((5-(2-(2,6-dioxopiperidin-3-yl)-3-
oxoisoindolin-5-yl)pentyl)carbamoyl)phenyl)-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-
3',3''-indoline]-5'-carboxamide (LE-181) 
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LE-181 (22.4 mg, Yield: 87% from MI-1061) was obtained using the same synthetic strategy 
described for LD-222. 
LC-MS(ESI) m/z (M +H)+:893.27; calcd for C48H48Cl2FN6O6 (M +H)+ 893.29964; >98% purity. 
1H NMR (400 MHz, MeOD) δ 7.78 – 7.68 (m, 3H), 7.65 – 7.57 (m, 3H), 7.53 (dd, J = 8.2, 2.5 Hz, 1H), 
7.48 – 7.39 (m, 2H), 7.37 – 7.30 (m, 1H), 7.16 (t, J = 8.1 Hz, 1H), 7.10 (dd, J = 8.2, 1.9 Hz, 1H), 6.79 
(d, J = 1.9 Hz, 1H), 5.34 (d, J = 10.8 Hz, 1H), 5.14 (ddd, J = 13.3, 5.1, 3.0 Hz, 1H), 4.96 (d, J = 10.9 
Hz, 1H), 4.50 – 4.31 (m, 2H), 3.33 (t, J = 7.1 Hz, 2H), 2.97 – 2.65 (m, 5H), 2.48 (qd, J = 13.1, 4.5 Hz, 
1H), 2.25 – 2.09 (m, 2H), 2.02 – 1.85 (m, 3H), 1.76 (d, J = 11.6 Hz, 2H), 1.72 – 1.48 (m, 5H), 1.43 – 
1.32 (m, 2H), 1.27 – 1.14 (m, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((5-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-
1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-
2-yl)amino)-5-oxopentyl)carbamoyl)phenyl)-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-
indoline]-5'-carboxamide (LE-175) 
(2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-
yl)phenyl)ethyl)pyrrolidine-2-carboxamide (113) was synthesized according to the publication 
from Crews Group. And then LE-175 (21.3 mg, Yield: 67% from MI-1061) was synthesized with 
the same synthetic strategy described for LD-186 from compound 113 instead of lenalidomide. 
LC-MS(ESI) m/z (M +H)+:1107.41, 5.765 min; calcd for C58H66Cl2FN8O7S (M +H)+ : 1107.41; >95% 
purity. 
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1H NMR (400 MHz, MeOD) δ 9.01 (s, 1H), 7.88 – 7.74 (m, 2H), 7.72 (t, J = 6.5 Hz, 1H), 7.69 – 7.60 
(m, 2H), 7.53 (dd, J = 8.4, 2.6 Hz, 1H), 7.47 – 7.30 (m, 5H), 7.19 (t, J = 8.1 Hz, 1H), 7.14 – 7.05 (m, 
1H), 6.80 (d, J = 1.9 Hz, 1H), 5.38 (d, J = 11.0 Hz, 1H), 5.02 – 4.96 (m, 2H), 4.65 – 4.51 (m, 2H), 4.43 
(s, 1H), 3.88 (d, J = 11.2 Hz, 1H), 3.74 (dd, J = 11.0, 3.9 Hz, 1H), 3.37 (t, J = 6.5 Hz, 2H), 2.95 (d, J = 
8.1 Hz, 1H), 2.49 (s, 3H), 2.37 – 2.12 (m, 4H), 2.06 – 1.84 (m, 4H), 1.78 (d, J = 11.8 Hz, 2H), 1.72 – 
1.59 (m, 4H), 1.55 – 1.42 (m, 4H), 1.36 – 1.14 (m, 2H), 1.03 (s, 9H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((2-(2-(3-(((S)-1-((2S,4R)-4-hydroxy-2-
(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-
oxobutan-2-yl)amino)-3-oxopropoxy)ethoxy)ethyl)carbamoyl)phenyl)-2''-
oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide (LE-176) 
LE-176 (25.0 mg, Yield: 75% from MI-1061) was obtained using the same synthetic strategy 
described for LE-175. 
LC-MS(ESI) m/z (M +H)+:1167.64, 5.656 min; calcd for C60H70Cl2FN8O9S (M +H)+: 1167.44; >95% 
purity. 
1H NMR (400 MHz, MeOD) δ 8.97 (s, 1H), 7.86 – 7.76 (m, 2H), 7.71 (dd, J = 10.4, 3.9 Hz, 1H), 7.66 
– 7.58 (m, 2H), 7.53 (dd, J = 8.2, 2.5 Hz, 1H), 7.47 – 7.30 (m, 5H), 7.19 (t, J = 8.1 Hz, 1H), 7.10 (dd, 
J = 8.2, 1.9 Hz, 1H), 6.79 (d, J = 1.9 Hz, 1H), 5.38 (d, J = 10.9 Hz, 1H), 5.00 – 4.95 (m, 2H), 4.64 (s, 
1H), 4.57 (dd, J = 11.9, 4.6 Hz, 1H), 4.42 (s, 1H), 3.86 (d, J = 11.2 Hz, 1H), 3.76 – 3.53 (m, 11H), 
2.94 (d, J = 8.9 Hz, 1H), 2.62 – 2.40 (m, 5H), 2.26 – 2.09 (m, 2H), 2.04 – 1.86 (m, 4H), 1.78 (d, J = 
11.9 Hz, 2H), 1.63 – 1.38 (m, 4H), 1.32 – 1.17 (m, 2H), 1.01 (s, 9H). 
176 
 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-(((S)-14-((2S,4R)-4-hydroxy-2-(((S)-1-
(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carbonyl)-15,15-dimethyl-12-
oxo-3,6,9-trioxa-13-azahexadecyl)carbamoyl)phenyl)-2''-oxodispiro[cyclohexane-1,2'-
pyrrolidine-3',3''-indoline]-5'-carboxamide (LE-177) 
LE-177 (23.9 mg, Yield: 69% from MI-1061) was obtained using the same synthetic strategy 
described for LE-175. 
LC-MS(ESI) m/z (M +2H)2+:606.31, calcd for C62H75Cl2FN8O10S (M +2H)2+: 606.23; >95% purity. 
1H NMR (400 MHz, MeOD) δ 8.94 (s, 1H), 7.87 – 7.76 (m, 2H), 7.76 – 7.66 (m, 1H), 7.66 – 7.57 (m, 
2H), 7.54 (dd, J = 8.2, 2.5 Hz, 1H), 7.46 – 7.32 (m, 5H), 7.18 (t, J = 8.1 Hz, 1H), 7.11 (dd, J = 8.2, 2.0 
Hz, 1H), 6.79 (d, J = 1.9 Hz, 1H), 5.36 (d, J = 10.9 Hz, 1H), 5.04 – 4.95 (m, 2H), 4.64 (s, 1H), 4.57 
(dd, J = 9.9, 6.7 Hz, 1H), 4.43 (d, J = 1.8 Hz, 1H), 3.86 (d, J = 11.0 Hz, 1H), 3.76 – 3.53 (m, 15H), 2.94 
(d, J = 8.7 Hz, 1H), 2.62 – 2.36 (m, 5H), 2.28 – 2.07 (m, 2H), 2.03 – 1.83 (m, 4H), 1.78 (d, J = 12.1 
Hz, 2H), 1.61 – 1.44 (m, 4H), 1.29 – 1.18 (m, 2H), 1.02 (s, 9H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-(((S)-17-((2S,4R)-4-hydroxy-2-(((S)-1-
(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carbonyl)-18,18-dimethyl-15-
oxo-3,6,9,12-tetraoxa-16-azanonadecyl)carbamoyl)phenyl)-2''-oxodispiro[cyclohexane-1,2'-
pyrrolidine-3',3''-indoline]-5'-carboxamide (LE-334) 
LE-334 (19.5 mg, Yield: 54% from MI-1061) was obtained using the same synthetic strategy 
described for LE-175. 
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LC-MS(ESI) m/z (M +2H)2+:628.18, calcd for C64H79Cl2FN8O11S (M +2H)2+: 628.25; >95% purity. 
1H NMR (400 MHz, Methanol-d4) δ 9.13 (s, 1H), 7.85 – 7.76 (m, 2H), 7.72 (ddd, J = 7.9, 6.3, 1.5 Hz, 
1H), 7.68 – 7.58 (m, 2H), 7.54 (dd, J = 8.2, 2.5 Hz, 1H), 7.47 – 7.42 (m, 3H), 7.41 – 7.35 (m, 1H), 
7.24 – 7.16 (m, 1H), 7.12 (dd, J = 8.2, 2.0 Hz, 1H), 6.80 (d, J = 1.9 Hz, 1H), 5.36 (d, J = 11.0 Hz, 1H), 
5.03 – 4.96 (m, 2H), 4.72 – 4.59 (m, 1H), 4.57 (t, J = 8.4 Hz, 1H), 4.43 (s, 1H), 3.87 (d, J = 11.0 Hz, 
1H), 3.76 – 3.54 (m, 19H), 2.97 (d, J = 9.8 Hz, 1H), 2.65 – 2.36 (m, 5H), 2.20 (t, J = 11.6 Hz, 2H), 
2.07 – 1.89 (m, 4H), 1.79 (d, J = 12.9 Hz, 2H), 1.61 – 1.41 (m, 4H), 1.35 – 1.18 (m, 3H), 1.03 (s, 9H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((5-(2-(1-methyl-2,6-dioxopiperidin-
3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)carbamoyl)phenyl)-2''-oxodispiro[cyclohexane-1,2'-
pyrrolidine-3',3''-indoline]-5'-carboxamide (LE-157) 
LE-157 (26 mg, Yield: 98% from MI-1061) was obtained as white powder using the same 
synthetic strategy described for LE-004. 
LC-MS(ESI) m/z (M +H)+: 903.35; calcd for C49H46Cl2FN6O6 (M +H)+ : 903.28; >98% purity. 
1H NMR (400 MHz, Methanol-d4) δ 7.76 – 7.68 (m, 3H), 7.68 – 7.62 (m, 1H), 7.56 (ddd, J = 8.3, 
2.7, 1.3 Hz, 1H), 7.53 – 7.44 (m, 3H), 7.44 – 7.33 (m, 2H), 7.23 – 7.15 (m, 1H), 7.11 (dd, J = 8.2, 
2.0 Hz, 1H), 6.79 (d, J = 1.9 Hz, 1H), 5.32 (d, J = 10.8 Hz, 1H), 5.15 (dt, J = 13.5, 4.7 Hz, 1H), 4.98 
(d, J = 10.8 Hz, 1H), 4.41 – 4.27 (m, 2H), 3.57 (t, J = 6.7 Hz, 2H), 3.09 (d, J = 5.9 Hz, 3H), 2.96 – 
2.89 (m, 2H), 2.58 (t, J = 6.5 Hz, 2H), 2.55 – 2.38 (m, 1H), 2.29 – 2.08 (m, 2H), 2.04 – 1.87 (m, 
5H), 1.78 (d, J = 13.2 Hz, 2H), 1.62 – 1.49 (m, 1H), 1.33 – 1.14 (m, 3H). 
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(3'S,4'R,5'S)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((5-(2-(2,6-dioxopiperidin-3-yl)-1-
oxoisoindolin-4-yl)pent-4-yn-1-yl)carbamoyl)phenyl)-2''-oxodispiro[cyclohexane-1,2'-
pyrrolidine-3',3''-indoline]-5'-carboxamide (LE-154) 
LE-154 (27.9 mg, Yield: 87% from 4-((3'S,4'R,5'S)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-2''-
oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamido)benzoic acid11) was 
obtained as white powder using the same synthetic strategy described for LE-004. 
LC-MS(ESI) m/z (M +H)+: 903.35; calcd for C49H46Cl2FN6O6 (M +H)+ : 903.28; >98% purity. 
1H NMR (400 MHz, Methanol-d4) δ 7.75 – 7.68 (m, 3H), 7.64 (ddd, J = 12.7, 7.6, 1.1 Hz, 1H), 7.56 
(dd, J = 8.2, 2.6 Hz, 1H), 7.52 – 7.46 (m, 2H), 7.46 – 7.42 (m, 1H), 7.41 – 7.31 (m, 2H), 7.19 (tdd, J 
= 8.2, 3.5, 1.1 Hz, 1H), 7.12 (dd, J = 8.2, 2.0 Hz, 1H), 6.80 (d, J = 2.0 Hz, 1H), 5.36 (dd, J = 10.8, 1.4 
Hz, 1H), 5.13 (ddd, J = 13.1, 7.8, 5.1 Hz, 1H), 4.99 (dd, J = 10.9, 1.7 Hz, 1H), 4.41 – 4.31 (m, 2H), 
3.57 (t, J = 6.6 Hz, 2H), 2.98 – 2.84 (m, 2H), 2.84 – 2.70 (m, 1H), 2.62 – 2.43 (m, 3H), 2.29 – 2.11 
(m, 2H), 2.05 – 1.87 (m, 5H), 1.79 (d, J = 13.2 Hz, 2H), 1.62 – 1.48 (m, 1H), 1.25 (t, J = 13.5 Hz, 
2H). 
 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-((1r,4R)-4-
(methylcarbamoyl)cyclohexyl)-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-
carboxamide (HXA-110) 
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The synthetic strategy of the MDM2 inhibitors was previously reported.  
Reaction 1: 
In a roundbottom flask, (E)-6-chloro-3-(3-chloro-2-fluorobenzylidene)indolin-2-one (500 mg, 
1.62 mmol), (5R,6S)-5,6-diphenyl-2-morpholinone (492 mg, 1.94 mmol), and cyclohexanone 
(0.51 mL, 4.9 mmol) were suspended in toluene (10 mL) and heated at reflux for 2 h at 140 °C. 
Then the reaction was cooled to room temperature and the solvent was removed under vacuum. 
The crude product was purified by column chromatography to give 108a as a pale yellow solid.  
Reaction 2: 
Then crude product of 108a was dissolved in 10 mL MeOH and 1 mL conc. sulfuric acid was slowly 
added to the reaction. After 2h, the solvent was slowly removed during 30 min by vacuum and 
the reaction was quenched by adding saturated sodium bicarbonate solution (30 mL) and product 
109a was extracted by DCM (30mL *3). The combined organic solution was washed by brine, 
dried by sodium sulfate and crude 109a was obtained by removing solvent under vacuum.  
Reaction 3: 
Cerium ammonium nitrate (1.83 g, 3.3 mmol) was added to a solution of the resulting 109a in 
MeCN (13 mL) and stirred for 5 min at room temperature, then H2O (13 mL) was added. After 
stirring the reaction for an additional 10 min, it was quenched with saturated sodium 
bicarbonate, brine was added, and the solution was extracted with EtOAc. The EtOAc solution 
was dried over sodium sulfate and concentrated under vacuum to obtain the diastereisomers of 
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products. The crude material was dissolved in a 3:1 mixture of MeOH/H2O that was acidified with 
trifluoroacetic acid and aged for 2 days. Then the product was purified by reverse phase C18 
column to afford 110a.  
Reaction 4: 
110a (450 mg, 0.89 mmol) was dissolved in THF (2.2 mL) and lithium hydroxide monohydrate 
(112 mg, 2.7 mmol) was added followed by water (2.2 mL) and methanol (0.3 mL). After 2 hours, 
water (3.5 mL) was added and the reaction was slowly neutralized with 2M hydrochloric acid and 
the suspension was stirred for 15 min in ice-bath. The resulting precipitate was filtered, washed 
with cold water and then with ether. The solid was then dried in desiccators under vacuum to 
produce the product 111a. 
Reaction 5: 
HATU (100 mg, 0.26 eq.) and N,N-Diisopropylethylamine (0.12 mL, 0.66 mmol) were added to a 
solution of 111a (100 mg, 0.22 mmol) in 3 mL DMF and stirred. After 10 minutes, trans-methyl 4-
aminocyclohexanecarboxylate (52 mg, 0.33 mmol) was added to the reaction. After 30 minutes, 
the solvent was removed and the crude was dissolved in 3:1 methanol/water, acidified with 
trifluoroacetic acid and purified by reverse phase C18 column to afford to give 112a. 
Reaction 6: 
112a (50 mg, 0.085 mmol) was dissolved in THF (1 mL) and lithium hydroxide monohydrate (14 
mg, 0.27 mmol) was added followed by water (1 mL) and methanol (0.15 mL). After 2 hours, the 
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reaction was acidified by trifluoroacetic acid and purified by reverse phase C18 column to afford 
to give product. Then the product (20mg, 0.034 mmol was dissolved in 0.5 mL DMF. HATU (15 
mg, 0.039) and N,N-Diisopropylethylamine (0.026 mL, 0.15 mmol) dissolved in DMF (0.5 mL) was 
added to the reaction After 10 minutes, methylamine hydrochloride (4.5 mL, 0.068 mmol) was 
added to the reaction. After 30 minutes, the solvent was removed and the crude was dissolved 
in 3:1 methanol/water, acidified with trifluoroacetic acid and purified by reverse-phase 
preparative HPLC. The purified fractions were combined, concentrated in vacuo, re-dissolved in 
H2O, frozen and lyophilized to give HXA-110 (14.2 mg, Yield: 69%) as white powder. 
LC-MS(ESI) /z (M +H)+:600.98, calcd for C31H36Cl2FN4O3 (M +H)+ 601.21; >95% purity. 
1H NMR (400 MHz, MeOD) δ 7.64 (t, J = 7.2 Hz, 1H), 7.48 (dd, J = 8.2, 2.0 Hz, 1H), 7.39 (dd, J = 
11.0, 4.2 Hz, 1H), 7.16 (t, J = 8.1 Hz, 1H), 7.10 (dd, J = 8.2, 1.9 Hz, 1H), 6.79 (d, J = 1.8 Hz, 1H), 5.09 
(d, J = 11.1 Hz, 1H), 4.78 (d, J = 11.2 Hz, 1H), 3.64 (dd, J = 13.6, 9.6 Hz, 1H), 2.85 (d, J = 9.5 Hz, 1H), 
2.67 (s, 3H), 2.19 (d, J = 13.7 Hz, 1H), 2.10 – 1.59 (m, 10H), 1.59 – 1.41 (m, 3H), 1.32 – 1.13 (m, 
3H), 0.87 (ddd, J = 25.4, 12.8, 3.4 Hz, 1H). 
(3'R,4'R,5'R)-6''-chloro-4'-(3-chlorophenyl)-N-((1r,4R)-4-(methylcarbamoyl)cyclohexyl)-2''-
oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide (LE-211) 
LE-211 (15.3 mg, Yield: 74%) was obtained using the same synthetic strategy described for HXA-
109. 
LC-MS(ESI) m/z (M +H)+:583.01, calcd for C31H37Cl2N4O3 (M +H)+ 583.22; >95% purity. 
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1H NMR (400 MHz, MeOD) δ 7.56 (d, J = 8.2 Hz, 1H), 7.34 (s, 1H), 7.25 (dt, J = 7.5, 1.9 Hz, 1H), 7.22 
– 7.13 (m, 2H), 7.10 (dd, J = 8.2, 2.0 Hz, 1H), 6.76 (d, J = 1.9 Hz, 1H), 5.13 (d, J = 11.1 Hz, 1H), 4.35 
(d, J = 11.1 Hz, 1H), 3.74 – 3.52 (m, 1H), 2.84 (d, J = 10.9 Hz, 1H), 2.67 (s, 3H), 2.19 (d, J = 12.9 Hz, 
1H), 2.08 – 1.70 (m, 9H), 1.63 (dd, J = 9.1, 3.6 Hz, 1H), 1.58 – 1.39 (m, 3H), 1.29 – 1.12 (m, 3H), 
0.96 – 0.83 (m, 1H). 
(3'R,4'S,5'R)-6''-chloro-4'-(2-fluorophenyl)-N-((1r,4R)-4-(methylcarbamoyl)cyclohexyl)-2''-
oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide (HXA-119) 
HXA-119 (13.6 mg, Yield: 66%) was obtained using the same synthetic strategy described for 
HXA-109. 
LC-MS(ESI) m/z (M +H)+:567.05, calcd for C31H37ClFN4O3 (M +H)+ 567.25; >95% purity. 
1H NMR (400 MHz, MeOD) δ 7.56 (d, J = 8.2 Hz, 1H), 7.20 (td, J = 8.0, 6.2 Hz, 1H), 7.14 – 7.05 (m, 
2H), 7.04 – 6.90 (m, 2H), 6.75 (d, J = 1.9 Hz, 1H), 5.15 (d, J = 11.1 Hz, 1H), 4.37 (d, J = 11.1 Hz, 1H), 
3.74 – 3.51 (m, 1H), 2.85 (d, J = 12.5 Hz, 1H), 2.67 (s, 3H), 2.19 (d, J = 13.0 Hz, 1H), 2.08 – 1.69 (m, 
9H), 1.63 – 1.42 (m, 4H), 1.28 – 1.13 (m, 3H), 0.89 (ddd, J = 25.1, 12.8, 3.6 Hz, 1H). 
(3'R,4'R,5'R)-6''-chloro-N-((1r,4R)-4-(methylcarbamoyl)cyclohexyl)-2''-oxo-4'-
phenyldispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide (LE-217) 
LE-217 (13.2 mg, Yield: 64%) was obtained using the same synthetic strategy described for HXA-
109. 
LC-MS(ESI) m/z (M +H)+:549.01, calcd for C31H38ClN4O3 (M +H)+549.26; >95% purity. 
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1H NMR (400 MHz, MeOD) δ 7.56 (d, J = 8.2 Hz, 1H), 7.31 – 7.14 (m, 5H), 7.09 (dd, J = 8.2, 1.9 Hz, 
1H), 6.72 (d, J = 1.9 Hz, 1H), 5.20 (d, J = 11.2 Hz, 1H), 4.31 (d, J = 11.2 Hz, 1H), 3.61 (tt, J = 11.7, 
3.8 Hz, 1H), 2.85 (d, J = 12.3 Hz, 1H), 2.66 (s, 3H), 2.20 (d, J = 12.3 Hz, 1H), 2.06 – 1.65 (m, 9H), 
1.58 – 1.32 (m, 4H), 1.29 – 1.13 (m, 3H), 0.85 (ddd, J = 25.1, 12.9, 3.8 Hz, 1H). 
(3R,4'R,5'R)-6-chloro-2',2'-dimethyl-N-((1r,4R)-4-(methylcarbamoyl)cyclohexyl)-2-oxo-4'-
phenylspiro[indoline-3,3'-pyrrolidine]-5'-carboxamide (HXA-120) 
HXA-120 (14.1 mg, Yield: 69%) was obtained using the same synthetic strategy described for 
HXA-109. 
LC-MS(ESI) m/z (M +H)+:509.03, calcd for C28H34ClN4O3 (M +H)+ 509.23; >95% purity. 
1H NMR (400 MHz, MeOD) δ 7.58 (d, J = 7.6 Hz, 1H), 7.33 – 7.14 (m, 5H), 7.10 (t, J = 7.6 Hz, 1H), 
6.71 (d, J = 7.8 Hz, 1H), 5.18 (dd, J = 11.2, 3.0 Hz, 1H), 4.37 (d, J = 11.2 Hz, 1H), 3.67 – 3.49 (m, 1H), 
2.66 (s, 3H), 2.06 – 1.90 (m, 4H), 1.76 (dd, J = 40.9, 13.3 Hz, 2H), 1.64 – 1.25 (m, 7H), 1.18 (dd, J = 
25.1, 13.0 Hz, 1H), 0.88 (dd, J = 24.9, 12.3 Hz, 1H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-((1r,4R)-4-((5-(2-(2,6-dioxopiperidin-3-
yl)-1,3-dioxoisoindolin-4-yl)pent-4-yn-1-yl)carbamoyl)cyclohexyl)-2''-oxodispiro[cyclohexane-
1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide (AA-231) 
AA-231 (15.7 mg, Yield: 61%) was obtained using the same synthetic strategy described for LE-
004. 
LC-MS(ESI) m/z (M +H)+:895.00, calcd for C48H50Cl2FN6O6 (M +H)+ 895.31; >95% purity. 
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1H NMR (400 MHz, Methanol-d4) δ 7.74 (dd, J = 7.6, 1.0 Hz, 1H), 7.70 – 7.55 (m, 2H), 7.55 – 7.44 
(m, 2H), 7.39 (ddd, J = 8.5, 7.2, 1.6 Hz, 1H), 7.17 (td, J = 8.0, 1.1 Hz, 1H), 7.10 (ddd, J = 8.2, 2.0, 0.8 
Hz, 1H), 6.79 (d, J = 1.9 Hz, 1H), 5.19 (dd, J = 13.4, 5.2 Hz, 1H), 5.15 – 5.03 (m, 1H), 4.79 (dd, J = 
11.1, 1.6 Hz, 1H), 4.51 (q, J = 17.7 Hz, 2H), 3.69 – 3.54 (m, 1H), 3.42 – 3.32 (m, 2H), 3.01 – 2.74 
(m, 3H), 2.67 – 2.45 (m, 3H), 2.25 – 2.13 (m, 2H), 2.07 – 1.73 (m, 10H), 1.67 – 1.59 (m, 1H), 1.58 
– 1.41 (m, 3H), 1.37 (dd, J = 6.7, 3.6 Hz, 1H), 1.28 – 1.11 (m, 3H), 0.95 – 0.77 (m, 1H). 
(3'R,4'R,5'R)-6''-chloro-4'-(3-chlorophenyl)-N-((1r,4R)-4-((5-(2-(2,6-dioxopiperidin-3-yl)-1,3-
dioxoisoindolin-4-yl)pent-4-yn-1-yl)carbamoyl)cyclohexyl)-2''-oxodispiro[cyclohexane-1,2'-
pyrrolidine-3',3''-indoline]-5'-carboxamide (LE-297) 
LE-297 (11.4 mg, Yield: 45 %) was obtained using the same synthetic strategy described for LE-
004. 
LC-MS(ESI) m/z (M +H)+:876.98, calcd for C48H51Cl2N6O6 (M +H)+ 877.32; >95% purity. 
1H NMR (400 MHz, MeOD) δ 7.74 (dd, J = 7.6, 0.8 Hz, 1H), 7.65 – 7.52 (m, 2H), 7.49 (t, J = 7.6 Hz, 
1H), 7.34 (d, J = 1.6 Hz, 1H), 7.26 (dt, J = 7.4, 1.6 Hz, 1H), 7.22 – 7.14 (m, 2H), 7.11 (dt, J = 8.2, 2.0 
Hz, 1H), 6.76 (d, J = 1.9 Hz, 1H), 5.20 (ddd, J = 13.3, 5.1, 1.4 Hz, 1H), 5.12 (dd, J = 11.1, 1.4 Hz, 1H), 
4.51 (q, J = 17.7 Hz, 2H), 4.37 (dd, J = 11.1, 6.0 Hz, 1H), 3.71 – 3.53 (m, 1H), 3.40 – 3.26 (m, 2H), 
3.00 – 2.74 (m, 3H), 2.65 – 2.46 (m, 3H), 2.31 – 2.13 (m, 2H), 2.13 – 1.64 (m, 11H), 1.64 – 1.39 (m, 
4H), 1.30 – 1.13 (m, 3H), 0.93 – 0.81 (m, 1H). 
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(3'R,4'S,5'R)-6''-chloro-N-((1r,4R)-4-((5-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-
yl)pent-4-yn-1-yl)carbamoyl)cyclohexyl)-4'-(2-fluorophenyl)-2''-oxodispiro[cyclohexane-1,2'-
pyrrolidine-3',3''-indoline]-5'-carboxamide (LE-295) 
LE-295 (13.7 mg, Yield: 55%) was obtained using the same synthetic strategy described for LE-
004. 
LC-MS(ESI) m/z (M +H)+:861.05, calcd for C48H51ClFN6O6 (M +H)+ 861.35; >95% purity. 
1H NMR (400 MHz, MeOD) δ 7.74 (d, J = 7.6 Hz, 1H), 7.70 – 7.52 (m, 2H), 7.48 (t, J = 7.6 Hz, 1H), 
7.20 (dd, J = 14.1, 7.8 Hz, 1H), 7.10 (dd, J = 8.3, 1.8 Hz, 2H), 7.05 – 6.86 (m, 2H), 6.75 (d, J = 1.8 Hz, 
1H), 5.20 (dd, J = 13.0, 4.8 Hz, 1H), 5.14 (dd, J = 11.1, 1.2 Hz, 1H), 4.51 (q, J = 17.7 Hz, 2H), 4.39 
(dd, J = 11.1, 5.6 Hz, 1H), 3.60 (ddd, J = 15.4, 7.8, 3.9 Hz, 1H), 3.43 – 3.23 (m, 2H), 3.02 – 2.72 (m, 
3H), 2.66 – 2.39 (m, 3H), 2.18 (dd, J = 11.2, 3.6 Hz, 2H), 2.09 – 1.65 (m, 11H), 1.63 – 1.36 (m, 4H), 
1.31 – 1.11 (m, 3H), 0.94 – 0.78 (m, 1H). 
(3'R,4'R,5'R)-6''-chloro-N-((1r,4R)-4-((5-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-
yl)pent-4-yn-1-yl)carbamoyl)cyclohexyl)-2''-oxo-4'-phenyldispiro[cyclohexane-1,2'-
pyrrolidine-3',3''-indoline]-5'-carboxamide (LE-298) 
LE-298 (18.3 mg, Yield: 75%) was obtained using the same synthetic strategy described for LE-
004. 
LC-MS(ESI) m/z (M +H)+:843.03, calcd for C48H52ClN6O6 (M +H)+ 843.36; >95% purity. 
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1H NMR (400 MHz, MeOD) δ 7.73 (d, J = 7.6 Hz, 1H), 7.63 – 7.53 (m, 2H), 7.48 (t, J = 7.6 Hz, 1H), 
7.30 – 7.15 (m, 5H), 7.09 (dt, J = 8.2, 1.6 Hz, 1H), 6.72 (d, J = 1.8 Hz, 1H), 5.27 – 5.08 (m, 2H), 4.50 
(q, J = 17.8 Hz, 2H), 4.33 (dd, J = 11.2, 5.3 Hz, 1H), 3.59 (ddd, J = 11.8, 8.0, 4.0 Hz, 1H), 3.40 – 3.22 
(m, 2H), 3.02 – 2.76 (m, 3H), 2.60 (ddt, J = 13.3, 10.0, 5.1 Hz, 1H), 2.50 (t, J = 6.7 Hz, 2H), 2.26 – 
2.11 (m, 2H), 2.05 – 1.65 (m, 11H), 1.61 – 1.35 (m, 4H), 1.29 – 1.10 (m, 3H), 0.92 – 0.72 (m, 1H). 
(3R,4'R,5'R)-6-chloro-N-((1r,4R)-4-((5-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-
yl)pent-4-yn-1-yl)carbamoyl)cyclohexyl)-2',2'-dimethyl-2-oxo-4'-phenylspiro[indoline-3,3'-
pyrrolidine]-5'-carboxamide (LE-296) 
LE-296 (10.0 mg, Yield: 43%) was obtained using the same synthetic strategy described for LE-
004. 
LC-MS(ESI) m/z (M +H)+:803.03, calcd for C45H48ClN6O6 (M +H)+ 803.33; >95% purity. 
1H NMR (400 MHz, MeOD) δ 7.74 (d, J = 7.5 Hz, 1H), 7.68 – 7.54 (m, 2H), 7.48 (t, J = 7.6 Hz, 1H), 
7.37 – 7.14 (m, 5H), 7.14 – 6.98 (m, 1H), 6.73 (d, J = 1.9 Hz, 1H), 5.29 – 5.09 (m, 2H), 4.51 (q, J = 
17.7 Hz, 2H), 4.38 (dd, J = 11.2, 5.3 Hz, 1H), 3.59 (ddd, J = 11.7, 7.5, 3.6 Hz, 1H), 3.39 – 3.25 (m, 
2H), 3.02 – 2.74 (m, 2H), 2.66 – 2.41 (m, 3H), 2.25 – 2.11 (m, 1H), 2.09 – 1.86 (m, 5H), 1.86 – 1.66 
(m, 4H), 1.58 – 1.28 (m, 6H), 1.16 (ddd, J = 25.2, 12.8, 3.5 Hz, 1H), 0.92 – 0.77 (m, 1H). 
 (3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-methyl-2''-oxodispiro[cyclohexane-
1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide (LD-103)  
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LD-103 (15.1 mg, Yield: 74%) was obtained as white powder using the same synthetic strategy 
described for LD-222. 
LC-MS(ESI) m/z (M +H)+:476.32, calcd for C24H25Cl2FN3O2 (M +H)+ 476.13; >95% purity. 
1H NMR (400 MHz, Methanol-d4) δ 7.63 (ddd, J = 8.0, 6.3, 1.6 Hz, 1H), 7.52 (dd, J = 8.2, 2.7 Hz, 
1H), 7.38 (td, J = 7.7, 7.3, 1.6 Hz, 1H), 7.17 (td, J = 8.0, 1.2 Hz, 1H), 7.11 (dd, J = 8.2, 2.0 Hz, 1H), 
6.77 (d, J = 2.0 Hz, 1H), 5.15 (d, J = 10.9 Hz, 1H), 4.83 (d, J = 11.0 Hz, 1H), 2.91 – 2.80 (m, 1H), 
2.80 – 2.67 (m, 3H), 2.17 (dd, J = 14.4, 3.1 Hz, 1H), 2.04 – 1.82 (m, 3H), 1.81 – 1.68 (m, 2H), 1.62 
– 1.41 (m, 1H), 1.28 – 1.14 (m, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(3-(2-(2,6-dioxopiperidin-3-yl)-1-
oxoisoindolin-4-yl)propyl)-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-
carboxamide (LE-010) 
LE-010 (7.8 mg, Yield: 48%) was obtained as white powder using the same synthetic strategy 
described for LD-222. 
LC-MS(ESI) m/z (M +H)+:746.45, calcd for C39H39Cl2FN5O5 (M +H)+ 746.23; >95% purity. 
1H NMR (400 MHz, Methanol-d4) δ 7.73 – 7.58 (m, 2H), 7.50 (dd, J = 8.3, 2.5 Hz, 1H), 7.43 (td, J = 
7.6, 2.1 Hz, 1H), 7.34 (dddd, J = 8.6, 7.3, 5.7, 1.6 Hz, 1H), 7.24 (ddd, J = 7.6, 5.4, 1.0 Hz, 1H), 7.18 
(tt, J = 8.1, 1.2 Hz, 1H), 7.13 – 7.06 (m, 1H), 6.78 (d, J = 1.9 Hz, 1H), 5.26 – 5.11 (m, 2H), 4.82 (d, J 
= 11.2 Hz, 1H), 4.51 – 4.29 (m, 2H), 3.50 – 3.34 (m, 1H), 3.12 – 2.99 (m, 1H), 2.99 – 2.74 (m, 3H), 
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2.57 – 2.36 (m, 3H), 2.27 – 2.09 (m, 2H), 2.01 – 1.83 (m, 3H), 1.82 – 1.64 (m, 4H), 1.50 (dd, J = 
15.3, 11.9 Hz, 1H), 1.21 (td, J = 13.8, 4.0 Hz, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-(2-(2,6-dioxopiperidin-3-yl)-1-
oxoisoindolin-4-yl)butyl)-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-
carboxamide (LE-016) 
LE-016 (10.4 mg, Yield: 63%) was obtained as white powder using the same synthetic strategy 
described for LD-222. 
LC-MS(ESI) m/z (M +H)+:760.51, calcd for C40H41Cl2FN5O5 (M +H)+ 760.25; >95% purity. 
1H NMR (400 MHz, Methanol-d4) δ 7.67 – 7.61 (m, 2H), 7.48 (tt, J = 8.7, 5.4 Hz, 2H), 7.38 – 7.21 
(m, 2H), 7.16 – 7.06 (m, 2H), 6.77 (d, J = 2.0 Hz, 1H), 5.24 – 5.10 (m, 2H), 4.77 (d, J = 11.1 Hz, 
1H), 4.53 – 4.35 (m, 2H), 3.44 – 3.35 (m, 1H), 3.26 – 2.69 (m, 5H), 2.64 – 2.43 (m, 3H), 2.21 – 
2.13 (m, 2H), 1.91 (dd, J = 21.1, 11.4 Hz, 3H), 1.76 (d, J = 13.4 Hz, 2H), 1.58 – 1.35 (m, 5H), 1.24 – 
1.13 (m, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(5-(2-(2,6-dioxopiperidin-3-yl)-1-
oxoisoindolin-4-yl)pentyl)-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-
carboxamide (LD-277) 
LD-277 (7.8 mg, Yield: 48%) was obtained as white powder using the same synthetic strategy 
described for LD-222. 
LC-MS(ESI) m/z (M +H)+:746.45, calcd for C39H39Cl2FN5O5 (M +H)+ 746.23; >95% purity. 
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1H NMR (400 MHz, Methanol-d4) δ 7.65 (dd, J = 7.4, 3.9 Hz, 2H), 7.52 – 7.40 (m, 3H), 7.34 (ddd, J 
= 8.0, 6.1, 2.6 Hz, 1H), 7.15 (t, J = 8.0 Hz, 1H), 7.10 (dt, J = 8.2, 2.4 Hz, 1H), 6.77 (d, J = 2.0 Hz, 
1H), 5.18 (dt, J = 13.3, 5.6 Hz, 1H), 5.07 (d, J = 10.8 Hz, 1H), 4.76 (d, J = 2.4 Hz, 1H), 4.53 – 4.40 
(m, 2H), 3.37 (ddd, J = 13.5, 6.9, 2.5 Hz, 1H), 3.03 (dt, J = 10.1, 7.0 Hz, 2H), 2.91 (dd, J = 13.3, 5.0 
Hz, 1H), 2.84 – 2.76 (m, 1H), 2.73 – 2.64 (m, 1H), 2.63 – 2.46 (m, 3H), 2.39 – 2.33 (m, 1H), 2.23 – 
2.09 (m, 2H), 1.95 – 1.83 (m, 3H), 1.73 (t, J = 11.1 Hz, 2H), 1.56 – 1.29 (m, 5H), 1.17 – 1.09 (m, 
2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(2-(3-(2-(2,6-dioxopiperidin-3-yl)-1-
oxoisoindolin-4-yl)propoxy)ethyl)-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-
5'-carboxamide (LE-344) 
LE-344 (8.2 mg, Yield: 48%) was obtained as white powder using the same synthetic strategy 
described for LD-222. 
LC-MS(ESI) m/z (M +H)+:790.23, calcd for C41H43Cl2FN5O6 (M +H)+ 790.26; >95% purity. 
1H NMR (400 MHz, Methanol-d4) δ 7.69 – 7.60 (m, 2H), 7.53 – 7.44 (m, 2H), 7.41 (dd, J = 7.6, 1.2 
Hz, 1H), 7.27 (dddd, J = 23.7, 8.5, 7.1, 1.5 Hz, 1H), 7.17 – 7.06 (m, 2H), 6.76 (dd, J = 1.9, 0.8 Hz, 
1H), 5.25 – 5.12 (m, 1H), 4.79 (d, J = 11.0 Hz, 1H), 4.55 – 4.35 (m, 2H), 3.58 (dtd, J = 13.9, 6.2, 4.1 
Hz, 1H), 3.38 – 3.09 (m, 5H), 3.02 – 2.85 (m, 2H), 2.84 – 2.76 (m, 2H), 2.63 (td, J = 7.5, 2.3 Hz, 
2H), 2.53 (qd, J = 13.2, 4.6 Hz, 1H), 2.24 – 2.12 (m, 2H), 2.00 – 1.87 (m, 3H), 1.81 – 1.68 (m, 4H), 
1.51 (q, J = 13.8 Hz, 1H), 1.25 – 1.15 (m, 2H). 
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(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(2-(2-(3-(2-(2,6-dioxopiperidin-3-yl)-1-
oxoisoindolin-4-yl)propoxy)ethoxy)ethyl)-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-
indoline]-5'-carboxamide (LD-257) 
LD-257 (7.8 mg, Yield: 48%) was obtained as white powder using the same synthetic strategy 
described for LD-222. 
LC-MS(ESI) m/z (M +H)+:834.35, calcd for C43H47Cl2FN5O7 (M +H)+ 834.28; >95% purity. 
1H NMR (400 MHz, Methanol-d4) δ 7.67 (dd, J = 6.4, 2.3 Hz, 1H), 7.65 – 7.58 (m, 1H), 7.57 – 7.41 
(m, 3H), 7.29 (dd, J = 8.0 Hz, 1H), 7.19 – 7.01 (m, 2H), 6.75 (d, J = 2.0 Hz, 1H), 5.19 (dd, J = 13.3, 
5.2 Hz, 1H), 4.75 (d, J = 10.4 Hz, 1H), 4.56 – 4.37 (m, 2H), 3.66 – 3.31 (m, 12H), 3.00 – 2.86 (m, 
1H), 2.86 – 2.72 (m, 3H), 2.56 – 2.45 (m, 1H), 2.22 – 2.13 (m, 1H), 2.08 – 1.61 (m, 8H), 1.58 – 
1.45 (m, 1H), 1.22 – 1.01 (m, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(2-(2-(2-(3-(2-(2,6-dioxopiperidin-3-yl)-
1-oxoisoindolin-4-yl)propoxy)ethoxy)ethoxy)ethyl)-2''-oxodispiro[cyclohexane-1,2'-
pyrrolidine-3',3''-indoline]-5'-carboxamide (LD-256) 
LD-256 (6.5 mg, Yield: 34%) was obtained as white powder using the same synthetic strategy 
described for LD-222. 
LC-MS(ESI) m/z (M +H)+:878.65, calcd for C45H51Cl2FN5O8 (M +H)+ 878.31; >95% purity. 
1H NMR (400 MHz, Methanol-d4) δ 7.73 – 7.61 (m, 2H), 7.55 – 7.45 (m, 3H), 7.35 (t, J = 7.5 Hz, 
1H), 7.20 – 7.04 (m, 2H), 6.78 (d, J = 1.9 Hz, 1H), 5.21 (dt, J = 13.3, 4.8 Hz, 1H), 4.79 (d, J = 10.7 
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Hz, 1H), 4.60 – 4.40 (m, 2H), 3.74 – 3.38 (m, 13H), 3.33 – 3.18 (m, 2H), 2.95 (ddd, J = 17.6, 13.5, 
5.4 Hz, 1H), 2.88 – 2.77 (m, 3H), 2.75 – 2.61 (m, 1H), 2.61 – 2.45 (m, 1H), 2.25 – 2.16 (m, 1H), 
2.09 (d, J = 13.8 Hz, 1H), 2.02 – 1.67 (m, 7H), 1.55 (q, J = 13.9 Hz, 1H), 1.27 – 1.05 (m, 2H). 
(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(5-(2-(1-methyl-2,6-dioxopiperidin-3-
yl)-1-oxoisoindolin-4-yl)pentyl)-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-
carboxamide (LE-024)  
LE-024 (7.1 mg, Yield: 42%) was obtained as white powder using the same synthetic strategy 
described for LD-222. 
LC-MS(ESI) m/z (M +H)+:788.31, calcd for C42H45Cl2FN5O5 (M +H)+ 788.28; >95% purity. 
(S)-2-((S)-2-((R)-2-isobutyramdo-2-methylpent-4-enamido)-5-(3-((2,2,4,6,7-pentamethyl-2,3-
dihydrobenzofuran-5-yl)sulfonyl)guanidino)pentanamido)butanoic acid (302).  
Fmoc-2-Abu-OH (8.1 mmol, 2.6 g) was loaded on the 2.7 mmol 2-chlorotrityl chloride resin 
(ChemPep) (1.2 mmol/g) overnight in CH2Cl2 and in the presence of DIPEA (8.1 mmol, 1.4 mL). 
Then, the resin was washed with DMF, MeOH, CH2Cl2, respectively, mixed with DIPEA (0.29 mmol, 
0.5 mL) in MeOH:CH2Cl2 (1:5) and was shaken for 30 min to endcap unreacted 2-chlorotrityl group 
on the resin. Next, classical chain elongation was carried out with Fmoc chemistry. The carboxylic 
acid intermediate (26) was cleaved from the resin by treatment with 4 ml of 1% trifluoroacetic 
acid in CH2Cl2 (3×10 min).  The filtrate was evaporated and the remaining crude was purified with 
preparative HPLC using the C18 reverse phase column (Waters, Sunfire™ Prep C18 OBD™, 5µm, 
50×100mm), yielding 0.9 g white powder (70 % yield).  
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MS (ESI): m/z calculated for [M+H]+ 693.37, found 693.42.  
1H NMR (300 MHz, CD3OD) δ: 5.79-5.63 (m, 1H), 5.12-5.03 (m, 2H), 4.45-4.36 (m, 1H), 4.24 (dd, J 
= 5.2, 8.4 Hz, 1H), 3.24-3.15 (m, 2H), 3.00 (s, 2H), 2.79-2.67 (m, 1H), 2.60-2.43 (m, 8H), 2.08 (s, 
3H), 1.99-1.51 (m, 6H), 1.45 (s, 6H), 1.40 (s, 3H), 1.07 (d, J = 6.8 Hz, 6H), 0.97 (t, J = 7.4 Hz, 3H). 
13C NMR (75 MHz, CD3OD) δ : 179.89, 176.19, 175.20, 174.09, 133.74, 126.49, 119.96, 118.86, 
88.10, 60.30, 60.21, 55.49, 54.00, 44.04, 41.91, 36.07, 30.31, 28.89, 25.75, 23.06, 20.17, 19.91, 
19.77, 18.48, 12.71, 11.03. 
(9H-fluoren-9-yl)methyl (R)-2-((2-(allylamino)-2-oxo-1-phenylethyl)amino)-2-oxoacetate 
(303a).  
2.7 mmol (1 g) Fmoc-R-phenylglycine was mixed with allylamine hydrochloride (4.1 mmol, 0.38 
g), EDCI (4.1 mmol, 0.79 g), HOAt (4.1 mmol, 0.55 g), 3 equiv DIPEA (8.1 mmol, 1.4 mL) in 100 mL 
CH2Cl2 and stirred at room temperature for 3h. The reaction mixture was quenched with H2O and 
extracted to CH2Cl2. The organic layer together with a white precipitate was collected and 
concentrated in vacuo. The remaining white solid was washed from CH2Cl2 yielding 0.96 g 
intermediate (303a) as white powder (86 % yield).  
HRMS (ESI): m/z calc. for C26H25N2O3 [M + H]+ 413.1860, found 413.1862.  
1H NMR (300 MHz, CD3CN) δ : 7.85 (d, J = 7.5 Hz, 2H), 7.68 (d, J = 7.0 Hz, 2H), 7.47-7.29 (m, 9H), 
6.83 (brs, 1H),  6.47 (brs, 1H), 5.85-5.71 (m, 1H), 5.16 (d, J = 6.6 Hz, 1H), 5.07-4.96 (m, 2H), 4.35 
(d, J = 6.8 Hz, 2H), 4.24 (t, J = 6.9 Hz, 1H), 3.81-3.74 (m, 2H).  
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13C NMR (75 MHz, CD3CN): δ 170.75, 145.28, 145.18, 142.26, 135.61, 129.81, 129.24, 128.81, 
128.42, 128.24, 126.30, 121.09, 115.87, 67.53, 59.96, 48.18, 42.31.      
(R)-N-((6S,9S,12R)-9-ethyl-1-imino-7,10,13-trioxo-1-(2,2,4,6,7-pentamethyl-2,3-
dihydrobenzofuran-5-sulfonamido)-12-phenyl-2,8,11,14-tetraazaheptadec-16-en-6-yl)-2-
isobutyramido-2-methylpent-4-enamide (304a).  
Intermediate 304a was treated with diethylamine (20 equiv.) in CH3CN for 2h at room 
temperature followed by removal of the solvent and diethylamine in vacuo. The resulting crude 
was further dried under vacuum, then taken into CH2Cl2 and mixed with the corresponding 303a 
(1.5 equiv.), EDCI (1.5 equiv.), HOAt (1.5 equiv.) and diisopropylethylamine (1.5 equiv.). The 
reaction mixture was stirred at room temperature for 2 h, quenched with H2O and extracted to 
CH2Cl2. The organic layers were collected and dried over anhydrous Na2SO4, filtered, evaporated 
and purified over flash chromatography using EtOAc:MeOH (30:1). White solid (72 % yield). 
(304a) as white solid (62 % yield).  
HRMS (ESI): m/z calc. for C44H65N8O8S [M+H]+ 865.4641, found 865.4642.  
1H NMR (300 MHz, CD3OD) δ : 7.45-7.28 (m, 5H), 5.84-5.64 (m, 2H), 5.42 (s, 1H), 5.14-4.99 (m, 
4H), 4.26-4.19 (m, 2H), 3.89-3.69 (m, 2H), 3.15 (t, J = 6.7 Hz, 2H), 2.99 (s, 2H), 2.74-2.65 (m, 1H), 
2.60-2.40 (m, 8H), 2.07 (s, 3H), 1.98-1.48 (m, 6H), 1.45 (s, 6H),  1.37 (s, 3H),  1.13-1.06 (m, 6H), 
0.92 (t, J = 7.4 Hz, 3H). 
 13C NMR (75 MHz, CD3OD): δ 180.33, 176.96, 174.56, 174.22, 172.49, 160.08, 158.33, 139.58, 
138.59, 135.36, 134.61, 134.16, 133.72, 129.93, 129.55, 129.21, 126.22, 119.95, 118.64, 116.31, 
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87.87, 59.99, 59.54, 56.93, 55.03, 44.19, 42.92, 41.24, 36.15, 30.01, 28.91, 25.96, 23.42, 20.43, 
20.03, 19.84, 19.75, 18.57, 12.69, 11.25.  
N-((3R,6S,9S,12R)-6-ethyl-9-(3-guanidinopropyl)-12-methyl-2,5,8,11-tetraoxo-3-phenyl-
1,4,7,10-tetraazacyclohexadecan-12-yl)isobutyramide (MM-401).  
To a solution of intermediate 304a in CH2Cl2, Hoveyda-Grubbs 2nd Generation catalyst (0.5 equiv.) 
was added under N2 atmosphere, and the reaction mixture stirred at 45 oC overnight under N2 
atmosphere. Another portion of the catalyst (0.5 equiv.) was added and stirred further overnight 
under the same conditions before filtering through celite and concentrating in vacuo. The 
remaining crude was purified over flash chromatography using CH2Cl2:MeOH. The cyclic product 
was taken up to MeOH and the double bond was reduced using 10% Pd/C under 1 atm of H2. The 
reaction mixture was filtered through celite and concentrated. The remaining crude was refluxed 
in CH2Cl2: Trifluoroacetic acid:H2O (20:10:0.5) for 2h in order to remove the Pbf group from 
arginine guanidine, and evaporated. The crude product was purified with preparative HPLC using 
the C18 reverse phase column (Waters, Sunfire™ Prep C18 OBD™, 5µm, 50×100mm). The final 
compound then dissolved in CH3CN:H2O (1:1) and lyophilized to obtain white solid (53% yield 
over 3 steps).  
HRMS (ESI+): m/z calculated for C29H47N8O5 [M+H]+ 587.3664, found 587.3664.  
1H NMR (300 MHz, MeOD): δ 7.42-7.30 (m, 5H), 5.25 (s, 1H), 4.30 (dd, J = 4.2, 9.8 Hz, 1H), 4.16 
(dd, J = 6.2, 7.7 Hz, 1H), 3.51-3.42 (m, 1H), 3.19 (t, J = 6.9 Hz, 2H), 3.12-2.99 (m, 1H), 2.59-2.48 
(m, 1H), 1.94-1.26 (m, 15H), 1.15-1.08 (m, 6H), 0.92 (t, J = 7.4 Hz, 3H).  
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13C NMR (75 MHz, MeOD-d4): δ 179.86, 176.83, 174.99, 173.64, 172.97, 158.86, 137.93, 130.06, 
129.69, 129.32, 61.24, 60.70, 56.67, 55.27, 41.91, 40.34, 39.25, 36.12, 29.99, 26.39, 25.94, 22.81, 
21.83, 20.06, 19.91, 10.84. 
N-((3R,6S,9S,12R)-6-ethyl-9-(3-guanidinopropyl)-2,5,8,11-tetraoxo-3-phenyl-1,4,7,10-
tetraazacyclohexadecan-12-yl)isobutyramide CF3COOH salt (LC-058).  
Fmoc-D-Phg-OH (0.5 mmol, 0.17 g) was loaded on the 0.1 mmol 2-chlorotrityl chloride  resin 
(ChemPep) (1 mmol/g) overnight in CH2Cl2 and in the presence of 2,4,6-collidine (3 mmol, 0.4 
mL). Then, the resin was washed with DMF, MeOH, CH2Cl2, respectively, mixed with DIPEA (0.29 
mmol, 0.5 mL) in MeOH:CH2Cl2 (1:5) and was shaken for 30 min to endcap unreacted 2-
chlorotrityl group on the resin. Next, classical chain elongation was carried out with Fmoc 
chemistry. The peptide intermediate (306d) was cleaved from the resin by treatment of 305d 
with 4 ml of 1% trifluoroacetic acid in CH2Cl2 (3×10 min). The filtrate was evaporated and followed 
by treatment with 10% trifluoroacetic acid in CH2Cl2 for 30 min. Then the solvent was evaporated 
and the remaining crude was purified with preparative HPLC using the C18 reverse phase column 
(Waters, Sunfire™ Prep C18 OBD™, 5µm, 50×100mm) to yield 306d. White powder,  
MS (ESI): m/z calculated for C41H63N8O9S [M+H]+ 843.44, found 843.38. 
Intermediate 306d (50 mg, 0.05 mmol) dissolved in 5 mL DMF was slowly added to a solution of 
HATU (38 mg, 0.1 mmol) and DIPEA (0.05 mL, 0.25 mmol) in 5 mL DMF during 30 min. The reaction 
was stirred for another 30 min and then the solvent was evaporated. The remaining crude was 
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purified with preparative HPLC using the C18 reverse phase column (Waters, Sunfire™ Prep C18 
OBD™, 5µm, 50×100mm) to yield 307d. White powder,  
MS (ESI): m/z calculated for C41H61N8O8S [M+H]+ 825.43, found 825.36.  
The cyclic product 307d was then dissolved in trifluoroacetic acid:H2O (95:5) and stirred at room 
temperature for 2h in order to remove the Pbf group from arginine guanidine. Then the solvent 
was evaporated and the crude product was purified with preparative HPLC using the C18 reverse 
phase column (Waters, Sunfire™ Prep C18 OBD™, 5µm, 50×100mm). The final compound LC-058 
then dissolved in CH3CN:H2O (1:1) and lyophilized. White solid (12.7 % yield over 4 steps).  
HRMS (ESI): m/z calculated for C28H45N8O5 [M+H]+ 573.3513, found 573.3507.  
1H NMR (400 MHz, CD3OD) δ 7.50-7.28 (m, 5H), 5.14 (s, 1H), 4.28 (t, J = 6.8 Hz, 1H), 4.13 (dd, J = 
10.4, 5.2 Hz, 1H), 4.08-3.99 (m, 1H), 3.54-3.41 (m, 1H), 3.18 (td, J = 7.1, 2.5 Hz, 2H), 3.04-2.97 (m, 
1H), 2.62-2.51 (m, 1H), 1.94-1.54 (m, 9H), 1.47-1.24 (m, 3H), 1.13 (dd, J = 6.9, 3.3 Hz, 6H), 0.90 (t, 
J = 7.5 Hz, 3H).  
13C NMR (101 MHz, CD3OD) δ 180.51, 175.63, 174.34, 173.64, 172.92, 158.63, 137.30, 129.92, 
129.67, 129.31, 61.54, 57.09, 56.08, 55.83, 41.61, 39.68, 35.72, 32.14, 29.95, 29.24, 26.68, 26.53, 
23.37, 19.93, 19.74, 10.25. 
N-((3R,6S,9S,12R)-6-ethyl-9-(3-guanidinopropyl)-2,5,8,11-tetraoxo-3-phenyl-1,4,7,10-
tetraazacyclopentadecan-12-yl)isobutyramide CF3COOH salt (LC-043-1).  
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A method applied for LC-042-1 was used to make LC-043-1 starting from resin. White solid (21.5 
% yield over 4 steps).  
HRMS (ESI): m/z calculated for C27H43N8O5 [M+H]+ 559.3356, found 559.3351.  
1H NMR (400 MHz, CD3OD) δ 7.47-7.25 (m, 5H), 5.27 (s, 1H), 4.31 (dd, J = 10.5, 5.0 Hz, 1H), 4.20 
(dd, J = 7.9, 6.4 Hz, 1H), 3.96 (dd, J = 9.5, 3.7 Hz, 1H), 3.46-3.37 (m, 1H), 3.24-3.01 (m, 3H), 2.65-
2.49 (m, 1H), 1.93-1.60 (m, 10H), 1.15 (dd, J = 6.9, 5.9 Hz, 6H), 0.93 (t, J = 7.5 Hz, 3H).  
13C NMR (101 MHz, CD3OD) δ 180.68, 175.30, 174.76, 173.75, 172.98, 158.61, 137.32, 129.90, 
129.58, 129.22, 60.94, 56.96, 56.23, 55.33, 41.56, 39.56, 35.76, 29.84, 28.93, 26.58, 26.15, 19.96, 
19.63, 10.67. 
N-((3R,6S,9S,12R)-6-ethyl-9-(3-guanidinopropyl)-2,5,8,11-tetraoxo-3-phenyl-1,4,7,10-
tetraazacyclotetradecan-12-yl)isobutyramide CF3COOH salt (LC-042-1).  
A method applied for LC-058 was used to make LC-042-1 starting from resin. White solid (21.7 % 
yield over 4 steps).  
HRMS (ESI): m/z calculated for C26H41N8O5 [M+H]+ 545.3200, found 545.3197.  
1H NMR (400 MHz, CD3OD) δ 7.44-7.36 (m, 2H), 7.36-7.26 (m, 3H), 5.44 (s, 1H), 4.33-4.21 (m, 2H), 
4.18 (dd, J = 7.7, 6.2 Hz, 1H), 3.68 (dt, J = 14.4, 3.7 Hz, 1H), 3.26-3.10 (m, 2H), 2.88 (dd, J = 14.3, 
11.8 Hz, 1H), 2.65 (hept, J = 6.6 Hz, 1H), 2.55-2.39 (m, 1H), 2.22-2.03 (m, 1H), 1.89-1.59 (m, 6H), 
1.19 (dd, J = 13.8, 6.8 Hz, 6H), 0.94 (t, J = 7.4 Hz, 3H).  
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13C NMR (101 MHz, CD3OD) δ 181.84, 175.27, 175.05, 172.50, 172.27, 158.65, 139.13, 129.49, 
129.39, 128.96, 58.55, 57.07, 55.76, 54.13, 41.74, 36.09, 35.68, 30.21, 28.78, 26.53, 24.52, 20.38, 
19.42, 11.07. 
(R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(dibenzylamino)-2-methylbutanoic acid 
CF3COOH salt (308).  
(R)-2-Fmoc-NH-2-methylpent-4-enoic acid (1 mmol, 350 mg) was dissolved in THF/H2O (2.6 mL/ 
1 mL) in a flask. The hood lights were turned off and the flask was covered by aluminum foil. 
Osmium tetroxide (0.05 mmol in 0.32 mL H2O) was added to the flask. After 5 min, NaIO4 (2.5 
mmol, 535 mg) was added in small portions over a 15 min period. The reaction was kept at room 
temperature for 4 h before it was filtrated and the THF was evaporated off. The residue was 
dissolved in EtOAc and saturated NH4Cl aqueous solution was added. The aqueous phase was 
extracted with EtOAc (2 x 30 mL) and the organic phase was combined, washed with brine, and 
dried over anhydrous Na2SO4. The solution was concentrated in vacuo and the crude product was 
dissolved in 1,2-dichloroethane (3 mL) in  a flask. Then dibenzylamine (1.5 mmol, 0.29 mL) and 
sodium triacetoxyborohydride (3 mmol, 636 mg) were added to the flask. The reaction was 
stirred at room temperature until the starting material disappeared on TLC. The solvent was 
evaporated and the remaining crude was purified with C-18 reverse phase flash column to yield 
308. White solid (75 % yield over 2 steps)  
MS (ESI): m/z calculated for C34H35N2O4 [M+H]+ 535.26, found 535.23.  
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1H NMR (400 MHz, Methanol-d4) δ 7.80 (d, J = 7.6 Hz, 2H), 7.62 (dd, J = 15.7, 7.5 Hz, 2H), 7.48-
7.35 (m, 12H), 7.33-7.25 (m, 2H), 4.43-4.05 (m, 7H), 3.25-3.03 (m, 2H), 2.55 (q, J = 8.3, 6.5 Hz, 
1H), 2.46-2.20 (m, 1H), 1.35 (s, 3H).  
13C NMR (101 MHz, MeOD) δ 176.68, 157.48, 145.26, 145.07, 142.58, 142.56, 132.20, 131.24, 
130.45, 130.44, 128.86, 128.19, 126.29, 126.14, 120.98, 67.91, 58.81, 58.40, 48.28, 31.28, 24.16. 
N-((3R,6S,9S,12R)-6-ethyl-9-(3-guanidinopropyl)-12-methyl-2,5,8,11-tetraoxo-3-phenyl-
1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide CF3COOH salt (LC-081).  
Fmoc-D-Phg-OH (0.5 mmol, 0.17 g) was loaded on the 0.1 mmol 2-chlorotrityl chloride resin 
(ChemPep) (1 mmol/g) overnight in CH2Cl2 and in the presence of 2,4,6-collidine (3 mmol, 0.4 
mL). Then, the resin was washed with DMF, MeOH, CH2Cl2, respectively, mixed with DIPEA (0.29 
mmol, 0.5 mL) in MeOH:CH2Cl2 (1:5) and was shaken for 30 min to endcap unreacted 2-
chlorotrityl group on the resin. Next, classical chain elongation was carried out with Fmoc 
chemistry. The peptide intermediate was cleaved from the resin by treatment of 309a with 4 ml 
of 1% trifluoroacetic acid in CH2Cl2 (3×10 min). The filtrate was evaporated and the residue was 
dissolved in anhydrous ethanol. Pd/C (20 mg) was added to the flask and the reaction was stirred 
at H2 atmosphere for 12h at 50 oC. Then the reaction was filtered, the filtrate was evaporated 
and the remaining crude was purified with preparative HPLC using the C18 reverse phase column 
(Waters, Sunfire™ Prep C18 OBD™, 5µm, 50×100mm) to yield 310a. White powder, 
MS (ESI): m/z calculated for C40H61N8O9S [M+H]+ 829.43, found 829.25. 
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The  method applied for LC-058 was used to make LC-081 starting from 310a. White solid (8.7 % 
yield over 4 steps).  
HRMS (ESI): m/z calculated for C27H43N8O5 [M+H]+ 559.3352, found 559.3351.  
1H NMR (400 MHz, Methanol-d4) δ 7.49-7.37 (m, 2H), 7.37-7.20 (m, 3H), 5.46 (d, J = 9.2 Hz, 1H), 
4.38 (dd, J = 10.5, 3.8 Hz, 1H), 4.24-4.06 (m, 1H), 3.85-3.63 (m, 1H), 3.26-3.16 (m, 2H), 2.76-2.56 
(m, 3H), 2.24-2.07 (m, 1H), 1.92-1.59 (m, 5H), 1.53 (s, 3H), 1.40-1.32 (m, 1H), 1.23 (d, J = 6.9 Hz, 
3H), 1.16 (d, J = 6.7 Hz, 3H), 0.96 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, MeOD) δ 182.07, 177.62, 175.47, 172.28, 172.11, 158.66, 139.36, 129.48, 
129.42, 128.86, 59.98, 58.21, 57.51, 55.53, 41.72, 38.63, 36.40, 35.98, 28.83, 26.67, 24.75, 21.17, 
18.90, 11.06. 
N-((3R,6S,9S,12R)-6-ethyl-9-(3-guanidinopropyl)-12-methyl-2,5,8,11-tetraoxo-3-phenyl-
1,4,7,10-tetraazacyclopentadecan-12-yl)isobutyramide CF3COOH salt (LC-044).  
A method applied for LC-058 was used to make LC-044 starting from resin. White solid (19.4 % 
yield over 4 steps).  
HRMS (ESI): m/z calculated for C28H45N8O5 [M+H]+ 573.3513, found 573.3506.  
1H NMR (400 MHz, CD3OD) δ 7.55-7.23 (m, 5H), 5.35 (s, 1H), 4.40 (dd, J = 10.0, 4.7 Hz, 1H), 4.16 
(dd, J = 8.6, 6.3 Hz, 1H), 3.41-3.33 (m, 1H), 3.24-3.12 (m, 3H), 2.65-2.37 (m, 1H), 2.00-1.48 (m, 
10H), 1.46 (s, 3H), 1.12 (dd, J = 6.8, 2.5 Hz, 6H), 0.94 (t, J = 7.4 Hz, 3H).  
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13C NMR (101 MHz, CD3OD) δ 179.91, 176.79, 174.82, 174.33, 172.75, 158.62, 138.00, 129.82, 
129.37, 128.93, 60.47, 60.37, 56.91, 55.12, 41.74, 40.12, 37.57, 35.81, 28.76, 26.24, 25.14, 23.68, 
21.04, 19.97, 19.36, 11.00. 
N-((3R,6S,9S,12R)-6-ethyl-9-(3-guanidinopropyl)-12-methyl-2,5,8,11-tetraoxo-3-phenyl-
1,4,7,10-tetraazacycloheptadecan-12-yl)isobutyramideCF3COOH salt (HK-06-223C).  
HK-06-223C was prepared as MM-401. White solid (28 % yield over 3 steps).  
HRMS (ESI): m/z calc. for C30H49N8O5 [M+H]+ 601.3820, found601.3827.  
1H NMR (300 MHz, CD3OD) δ: 7.45-7.32 (m, 5H), 5.22 (s, 1H), 4.45-4.31 (m, 2H), 3.28-3.13 (m, 
4H), 2.59-2.49 (m, 1H), 1.97-1.05 (m, 23H), 0.89 (t, J = 7.5 Hz, 3H).  
13C NMR (75 MHz, CD3OD) δ: 179.80, 176.66, 174.54, 173.62, 173.32, 158.81, 137.54, 130.08, 
129.79, 129.44, 61.04, 60.91, 55.74, 54.59, 41.83, 41.69, 39.95, 36.05, 30.64, 29.75, 27.18, 27.10, 
26.14, 25.08, 21.12, 20.33, 19.48, 10.18. 
N-((3R,6S,9S,12R)-6-ethyl-9-(3-guanidinopropyl)-12-methyl-2,5,8,11-tetraoxo-3-phenyl-
1,4,7,10-tetraazacyclooctadecan-12-yl)isobutyramide CF3COOH salt (HK-05-121C).  
HK-05-121C prepared as MM-401 White solid (46 % yield over 3 steps).  
HRMS (ESI): m/z calc. for C31H51N8O5 [M+H]+ 615.3977, found 615.3976.  
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1H NMR (300 MHz, CD3OD) δ: 7.45-7.29 (m, 5H), 5.40 (s, 1H), 4.29-4.19 (m, 2H), 3.59-3.47 (m, 
1H), 3.19 (t, J = 6.7Hz, 2H), 3.09-2.96 (m, 1H), 2.63-2.52 (m, 1H), 2.02-1.59 (m, 8H), 1.58-1.27 (m, 
11H), 1.14 (d, J = 6.5Hz, 3H), 1.12 (d, J = 6.5Hz, 3H), 0.89 (t, J = 7.4 Hz, 3H).  
13C NMR (75 MHz, CD3OD) δ: 180.53, 177.59, 174.48, 173.99, 172.88, 158.86, 138.38, 129.97, 
129.57, 60.67, 59.87, 56.51, 55.22, 42.04, 39.80, 37.53, 36.09, 29.98, 28.42, 28.38, 26.42, 25.37, 
22.72, 22.47, 20.08, 19.94, 10.69. 
N-((3R,6S,9S,12R)-6-ethyl-9-(3-guanidinopropyl)-12-methyl-2,5,8,11-tetraoxo-3-phenyl-
1,4,7,10-tetraazacycloicosan-12-yl)isobutyramide CF3COOH salt (HK-06-229C).  
HK-06-229C was prepared as MM-401. White solid (27 % yield over 3 steps). 
HRMS (ESI): m/z calc. for C33H55N8O5 [M+H]+ 643.4290, found 643.4292.  
1H NMR (300 MHz, CD3OD) δ: 7.41-7.30 (m, 5H), 5.40 (s, 1H), 4.34-4.28 (m, 1H), 4.18 (t, J = 7.1 Hz, 
1H), 3.55-3.44 (m, 1H), 3.17 (t, J = 6.9 Hz, 2H), 3.07-2.95 (m, 1H), 2.61-2.50 (m, 1H), 2.00-1.28 (m, 
23H), 1.16-1.07 (m, 6H), 0.92 (t, J = 7.4 Hz, 3H).  
13C NMR (75 MHz, CD3OD) δ: 180.22, 176.92, 174.53, 174.30, 172.69, 158.81, 138.70, 130.03, 
129.55, 129.39, 60.72, 59.51, 57.11, 54.55, 42.14, 40.03, 38.56, 36.13, 30.28, 29.31, 28.92, 28.63, 
28.04, 26.56, 26.16, 26.10, 23.50, 22.76, 20.05, 10.81. 
N-((3R,6S,9S,12R)-6-ethyl-12-methyl-9-(3-(3-methylguanidino)propyl)-2,5,8,11-tetraoxo-3-
phenyl-1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide CF3COOH salt (LC-089).  
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A method applied for LC-081 was used to make LC-089 starting from resin. White solid (15.4 % 
yield over 4 steps).  
HRMS (ESI): m/z calculated for C28H45N8O5 [M+H]+ 573.3507, found 573.3511.  
1H NMR (400 MHz, Methanol-d4) δ 7.44-7.37 (m, 2H), 7.37-7.26 (m, 3H), 5.48-5.44 (m, 1H), 4.38 
(dd, J = 10.5, 3.7 Hz, 1H), 4.17 (td, J = 7.0, 3.2 Hz, 1H), 3.80-3.72 (m, 1H), 3.28-3.16 (m, 2H), 2.83 
(s, 3H), 2.75-2.57 (m, 3H), 2.25-2.11 (m, 1H), 1.96-1.69 (m, 4H), 1.53 (s, 3H), 1.41-1.32 (m, 1H), 
1.22 (d, J = 6.9 Hz, 3H), 1.16 (d, J = 6.7 Hz, 3H), 0.95 (t, J = 7.4 Hz, 3H).  
13C NMR (101 MHz, MeOD) δ 182.17, 177.63, 175.52, 172.28, 172.10, 158.21, 139.37, 129.49, 
129.41, 128.86, 60.07, 58.20, 57.47, 55.52, 41.75, 38.63, 36.41, 36.02, 28.88, 28.31, 26.64, 24.75, 
21.18, 18.90, 11.06. 
N-((3S,6S,9S,12R)-6-ethyl-12-methyl-9-(3-(3-methylguanidino)propyl)-2,5,8,11-tetraoxo-3-
phenyl-1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide CF3COOH salt (LC-088).  
LC-088 was obtained in the synthesis of LC-089 starting from reisn, as D-α-phenylglycine was 
isomerized to L-α-phenylglycine during the solid phase peptide synthesis. White solid (7 % yield 
over 4 steps).  
HRMS (ESI): m/z calculated for C28H45N8O5 [M+H]+ 573.3507, found 573.3504.  1H NMR (300 MHz, 
Methanol-d4) δ 7.36-7.19 (m, 5H), 5.21 (s, 1H), 4.27 (dd, J = 8.8, 6.3 Hz, 1H), 4.00 (dd, J = 8.5, 6.0 
Hz, 1H), 3.38 (dt, J = 14.6, 3.9 Hz, 1H), 3.28-3.14 (m, 2H), 3.04 (t, J = 13.5 Hz, 1H), 2.84 (s, 3H), 
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2.70- 2.53 (m, 2H), 2.00-1.60 (m, 7H), 1.55 (s, 3H), 1.20 (d, J = 5.5 Hz, 3H), 1.18 (d, J = 5.3 Hz, 3H), 
0.91 (t, J = 7.4 Hz, 3H).  
13C NMR (101 MHz, MeOD) δ 181.09, 177.37, 174.97, 173.54, 171.64, 158.20, 138.80, 129.24, 
128.74, 128.60, 60.17, 59.82, 57.73, 57.65, 41.83, 37.48, 37.15, 36.12, 28.51, 28.30, 26.74, 26.11, 
21.12, 19.18, 10.88. 
N-((3R,6S,9S,12R)-9-(3-guanidinopropyl)-6-isopropyl-12-methyl-2,5,8,11-tetraoxo-3-phenyl-
1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (LC-313) 
LC-313 was synthesized using the procedure applied for LC-081 to yield 11.7 mg, white powder, 
20 % yield over 4 steps. 
LC-MS(ESI) m/z (M +H)+: 573.43; calcd for C28H45N8O5 (M +H)+ : 573.35; >98% purity. 
1H NMR (400 MHz, Methanol-d4) δ 8.53 (s, 1H), 8.23 (d, J = 3.6 Hz, 1H), 7.98 (t, J = 9.7 Hz, 2H), 
7.93 – 7.85 (m, 1H), 7.45 – 7.36 (m, 2H), 7.36 – 7.24 (m, 3H), 5.47 (d, J = 9.0 Hz, 1H), 4.59 (dd, J = 
10.2, 3.9 Hz, 1H), 4.15 (ddd, J = 7.7, 6.3, 3.5 Hz, 1H), 3.75 (td, J = 13.1, 10.9, 3.2 Hz, 1H), 3.28 – 
3.14 (m, 2H), 2.76 – 2.61 (m, 3H), 2.61 – 2.50 (m, 1H), 1.98 – 1.66 (m, 4H), 1.52 (s, 3H), 1.38 – 
1.29 (m, 1H), 1.21 (d, J = 6.9 Hz, 3H), 1.18 (d, J = 6.7 Hz, 3H), 1.03 (d, J = 6.9 Hz, 3H), 0.92 (d, J = 
6.9 Hz, 3H). 
N-((3R,6S,9S,12R)-9-(3-guanidinopropyl)-12-methyl-2,5,8,11-tetraoxo-3-phenyl-6-propyl-
1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (LC-300) 
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LC-300 was synthesized using the procedure applied for LC-081 to yield 19.6 mg, white powder, 
34 % yield over 4 steps. 
LC-MS(ESI) m/z (M +H)+: 573.33; calcd for C28H45N8O5 (M +H)+ : 573.35; >98% purity. 
1H NMR (400 MHz, Methanol-d4) δ 8.64 (s, 1H), 8.38 (d, J = 4.0 Hz, 1H), 8.19 (d, J = 9.5 Hz, 1H), 
8.03 (d, J = 9.2 Hz, 1H), 7.93 – 7.86 (m, 1H), 7.45 – 7.39 (m, 2H), 7.36 – 7.25 (m, 3H), 5.46 (d, J = 
9.2 Hz, 1H), 4.47 (ddd, J = 11.0, 9.5, 3.6 Hz, 1H), 4.15 (ddd, J = 7.5, 6.3, 4.0 Hz, 1H), 3.83 – 3.68 
(m, 1H), 3.30 – 3.15 (m, 2H), 2.75 – 2.57 (m, 3H), 2.18 – 2.05 (m, 1H), 1.91 – 1.65 (m, 5H), 1.53 
(s, 3H), 1.47 – 1.26 (m, 4H), 1.23 (d, J = 6.9 Hz, 3H), 1.16 (d, J = 6.6 Hz, 3H), 0.93 (t, J = 7.3 Hz, 
3H). 
N-((3R,6S,9S,12R)-6-((R)-sec-butyl)-9-(3-guanidinopropyl)-12-methyl-2,5,8,11-tetraoxo-3-
phenyl-1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (LC-314) 
LC-314 was synthesized using the procedure applied for LC-081 to yield 7.8 mg, white powder, 
14 % yield over 4 steps. 
LC-MS(ESI) m/z (M +H)+: 587.44; calcd for C29H47N8O5 (M +H)+ : 587.37; >98% purity. 
1H NMR (400 MHz, Methanol-d4) δ 8.53 (s, 1H), 8.22 (d, J = 3.6 Hz, 1H), 8.01 (d, J = 9.0 Hz, 1H), 
7.92 (t, J = 9.7 Hz, 2H), 7.42 – 7.35 (m, 2H), 7.35 – 7.23 (m, 3H), 5.46 (d, J = 9.0 Hz, 1H), 4.61 (dd, 
J = 10.2, 3.7 Hz, 1H), 4.14 (ddd, J = 7.7, 6.3, 3.5 Hz, 1H), 3.75 (td, J = 9.6, 5.3 Hz, 1H), 3.28 – 3.13 
(m, 2H), 2.77 – 2.57 (m, 3H), 2.36 – 2.23 (m, 1H), 1.94 – 1.58 (m, 5H), 1.52 (s, 3H), 1.36 – 1.25 
(m, 2H), 1.22 (d, J = 6.9 Hz, 3H), 1.18 (d, J = 6.7 Hz, 3H), 0.97 – 0.89 (m, 6H). 
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N-((8S,11R,16R)-8-(3-guanidinopropyl)-11-methyl-7,10,15,18-tetraoxo-16-phenyl-6,9,14,17-
tetraazaspiro[4.13]octadecan-11-yl)isobutyramide (LC-322) 
LC-322 was synthesized using the procedure applied for LC-081 to yield 4.2 mg, white powder, 
7 % yield over 4 steps. 
LC-MS(ESI) m/z (M +H)+: 585.43; calcd for C29H45N8O5 (M +H)+ : 585.35; >98% purity. 
N-((3R,6S,9S,12R)-6-ethyl-9-(3-guanidinopropyl)-3,12-dimethyl-2,5,8,11-tetraoxo-1,4,7,10-
tetraazacyclotetradecan-12-yl)isobutyramide (AK-012)  
AK-012 was synthesized using the procedure applied for LC-081, white powder, 38 % yield over 
4 steps.  
MS (ESI): m/z calculated for C22H41N8O5 [M+H]+ 497.32, found 497.20.  
1H NMR (400 MHz, Methanol-d4) δ 8.50 (s, 1H), 8.24 (d, J = 4 Hz, 1H), 8.15 (d, J = 9.6 Hz, 1H), 7.62-
7.58 (m, 1H), 7.52-7.45 (m, 1H), 4.51-4.38 (m, 2H), 4.12-4.05 (m, 1H), 3.78-3.68 (m, 1H), 3.28-
3.18 (m, 3H), 2.76-2.68 (m, 1H), 2.65-2.50 (m, 2H), 2.22-2.12 (m, 1H), 1.92-1.83 (m, 2H), 1.80-
1.65 (m, 4H), 1.50 (s, 3H), 1.36-1.28 (m, 6H), 1.19 (d, J = 6.8 Hz, 3H), 1.14 (d, J = 6.8 Hz, 3H), 0.94 
(t, J = 7.6 Hz, 3H). 
N-((3R,6S,9S,12R)-6-ethyl-9-(3-guanidinopropyl)-3-isobutyl-12-methyl-2,5,8,11-tetraoxo-
1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (AK-010)  
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AK-010 was synthesized using the procedure applied for LC-081, white powder, 35 % yield over 
4 steps.  
MS (ESI): m/z calculated for C25H47N8O5 [M+H]+ 539.37, found 539.28.  
1H NMR (400 MHz, Methanol-d4) δ 8.52 (s, 1H), 8.27-8.21 (m, 2H), 7.61-7.57 (m, 1H), 7.27 (d, J = 
9.2 Hz, 1H), 4.53-4.38 (m, 2H), 4.16-4.08 (m, 1H), 3.68-3.78 (m, 1H), 3.28-3.18 (m, 3H), 2.72-
2.64 (m, 1H), 2.60-2.51 (m, 2H), 2.22-2.12 (m, 1H), 1.92-1.82 (m, 3H), 1.78-1.68 (m, 3H), 1.65-
1.55 (m, 1H), 1.54-1.42 (m, 5H), 1.38-1.28 (m, 1H), 1.18 (d, J = 7.2 Hz, 3H), 1.16-1.08 (m, 5H), 
0.97-0.90 (m, 9H). 
N-((3R,6S,9S,12R)-3-cyclopentyl-6-ethyl-9-(3-guanidinopropyl)-12-methyl-2,5,8,11-tetraoxo-
1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (AK-020)  
AK-020 was synthesized using the procedure applied for LC-081, white powder, 31 % yield over 
4 steps.  
MS (ESI): m/z calculated for C26H47N8O5 [M+H]+ 551.37, found 551.46.  
1H NMR (400 MHz, Methanol-d4) δ 8.48 (s, 1H), 8.23-8.17 (m, 2H), 7.62-7.59 (m, 1H), 7.35 (d, J = 
10.0 Hz, 1H), 4.55-4.44 (m, 2H), 4.11-4.07 (m, 1H), 3.75-3.71 (m, 1H), 3.28-3.15 (m, 3H), 2.78-
2.48 (m, 4H), 2.28-2.15 (m, 1H), 1.92-1.83 (m, 2H), 1.82-1.62 (m, 6H), 1.58-1.45 (m, 8H), 1.38-
1.35 (m, 2H), 1.34-1.23 (m, 2H), 1.18 (d, J = 6.8 Hz, 3H), 1.13 (d, J = 6.8 Hz, 3H), 0.94 (t, J = 7.6 
Hz, 3H). 
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N-((3R,6S,9S,12R)-3-cyclohexyl-6-ethyl-9-(3-guanidinopropyl)-12-methyl-2,5,8,11-tetraoxo-
1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (AK-011)  
AK-011 was synthesized using the procedure applied for LC-081, white powder, 51 % yield over 
4 steps.  
MS (ESI): m/z calculated for C27H49N8O5 [M+H]+ 565.38, found 565.39.  
1H NMR (400 MHz, Methanol-d4) δ 8.54 (s, 1H), 8.25-8.17 (m, 2H), 7.64-7.58 (m, 1H), 7.28 (d, J = 
9.6 Hz, 1H), 4.53-4.44 (m, 1H), 4.39-4.33 (m, 1H), 4.15-4.08 (m, 1H), 3.82-3.72 (m, 1H), 3.28-
3.15 (m, 3H), 2.70-2.62 (m, 1H), 2.60-2.50 (m, 2H), 2.25-2.15 (m, 2H), 1.90-1.82 (m, 2H), 1.80-
1.60 (m, 9H), 1.48 (s, 3H), 1.35-1.25 (m, 4H), 1.20-1.00 (m, 10H), 0.94 (t, J = 7.2 Hz, 3H). 
N-((3R,6S,9S,12R)-3-(cyclohexylmethyl)-6-ethyl-9-(3-guanidinopropyl)-12-methyl-2,5,8,11-
tetraoxo-1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (LC-261)   
LC-261 was synthesized using the procedure applied for LC-081, white powder, 34 % yield over 
4 steps.  
MS (ESI): m/z calculated for C28H51N8O5 [M+H]+ 579.40, found 579.47.  
1H NMR (400 MHz, Methanol-d4) δ 8.59 (s, 1H), 8.30-8.20 (m, 2H), 7.59 (d, J = 8.4 Hz, 1H), 7.28 
(d, J = 9.6 Hz, 1H), 4.54-4.47 (m, 1H), 4.46-4.39 (m, 1H), 4.14-4.08 (m, 1H), 3.80-3.67 (m, 1H), 
3.30-3.18 (m, 3H), 2.73-2.63 (m, 1H), 2.61-2.50 (m, 2H), 2.23-2.12 (m, 1H), 1.98-1.80 (m, 4H), 
1.79-1.60 (m, 8H), 1.51-1.38 (m, 4H), 1.37-1.15 (m, 9H), 1.12 (d, J = 6.8 Hz, 3H), 1.15-0.85 (m, 
6H). 
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N-((3R,6S,9S,12R)-3-benzyl-6-ethyl-9-(3-guanidinopropyl)-12-methyl-2,5,8,11-tetraoxo-
1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (AK-005)  
AK-005 was synthesized using the procedure applied for LC-081, white powder, 56 % yield over 
4 steps.  
MS (ESI): m/z calculated for C28H45N8O5 [M+H]+ 573.35, found 573.35.  
1H NMR (400 MHz, Methanol-d4) δ 8.52 (s, 1H), 8.22 (d, J = 4.4 Hz, 1H), 8.15 (d, J = 9.6 Hz, 1H), 
7.33 (d, J = 9.6 Hz, 1H), 7.25-7.14 (m, 5H), 4.66-4.59 (m, 1H), 4.24-4.14 (m, 1H), 4.13-4.09 (m, 
1H), 3.82-3.72 (m, 1H), 3.48-3.42 (m, 1H), 3.30-3.15 (m, 1H), 2.75-2.55 (m, 4H), 2.07-1.97 (m, 
1H), 1.90-1.82 (m, 1H), 1.80-1.60 (m, 4H), 1.50 (s, 3H), 1.38-1.28 (m, 1H), 1.18 (d, J = 6.8 Hz, 3H), 
1.11 (d, J = 6.8 Hz, 3H), 0.86 (t, J = 7.6 Hz, 3H). 
N-((3R,6S,9S,12R)-6-ethyl-3-(2-fluorobenzyl)-9-(3-guanidinopropyl)-12-methyl-2,5,8,11-
tetraoxo-1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (AK-021)  
AK-021 was synthesized using the procedure applied for LC-081, white powder, 30 % yield over 
4 steps.  
MS (ESI): m/z calculated for C28H44FN8O5 [M+H]+ 591.34, found 591.47.  
1H NMR (400 MHz, Methanol-d4) δ 8.54 (s, 1H), 8.20 (d, J = 4.4 Hz, 1H), 8.13 (d, J = 9.6 Hz, 1H), 
7.68-7.60 (m, 1H), 7.45-7.40 (m, 1H), 7.27-7.18 (m, 2H), 7.08-6.98 (m, 2H), 4.74-4.67 (m, 1H), 
4.20-4.10 (m, 1H), 3.85-3.75 (m, 1H), 3.65-3.55 (m, 1H), 3.25-3.15 (m, 3H), 2.73-2.58 (m, 4H), 
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2.05-1.95 (m, 1H), 1.88-1.80 (m, 2H), 1.78-1.68 (m, 2H), 1.65-1.55 (m, 2H), 1.49 (s, 3H), 1.40-
1.28 (m, 4H), 1.18 (d, J = 6.8 Hz, 3H), 1.11 (d, J = 6.8 Hz, 3H), 0.86 (t, J = 7.6 Hz, 3H). 
N-((3R,6S,9S,12R)-6-ethyl-3-(3-fluorobenzyl)-9-(3-guanidinopropyl)-12-methyl-2,5,8,11-
tetraoxo-1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (AK-022)  
AK-022 was synthesized using the procedure applied for LC-081, white powder, 31 % yield over 
4 steps.  
MS (ESI): m/z calculated for C28H44FN8O5 [M+H]+ 591.34, found 591.45.  
1H NMR (400 MHz, Methanol-d4) δ 8.54 (s, 1H), 8.21 (d, J = 4.0 Hz, 1H), 8.11 (d, J = 9.6 Hz, 1H), 
7.65-7.58 (m, 1H), 7.35 (d, J = 9.6 Hz, 1H), 7.30-7.20 (m, 1H), 7.03-6.95 (m, 2H), 6.94-6.86 (m, 
1H), 4.69-4.62 (m, 1H), 4.28-4.20 (m, 1H), 4.13-4.07 (m, 1H), 3.82-3.72 (m, 1H), 3.47-3.40 (m, 
1H), 3.30-3.20 (m, 2H), 2.80-2.72 (m, 1H), 2.70-2.50 (m, 3H), 2.10-2.00 (m, 1H), 1.95-1.80 (m, 
3H), 1.79-1.60 (m, 4H), 1.48 (s, 3H), 1.40-1.28 (m, 3H), 1.18 (d, J = 6.8 Hz, 3H), 1.11 (d, J = 6.8 Hz, 
3H), 0.88 (t, J = 7.6 Hz, 3H). 
N-((3R,6S,9S,12R)-6-ethyl-3-(4-fluorobenzyl)-9-(3-guanidinopropyl)-12-methyl-2,5,8,11-
tetraoxo-1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (AK-036)  
AK-036 was synthesized using the procedure applied for LC-081, white powder, 27 % yield over 
4 steps.  
MS (ESI): m/z calculated for C28H44FN8O5 [M+H]+ 591.34, found 591.43.  
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1H NMR (400 MHz, Methanol-d4) δ 8.55 (s, 1H), 8.23 (d, J = 4.4 Hz, 1H), 8.10 (d, J = 9.6 Hz, 1H), 
7.65-7.60 (m, 1H), 7.34 (d, J = 9.6 Hz, 1H), 7.21-7.16 (m, 2H), 7.00-6.90 (m, 2H), 4.65-4.57 (m, 
1H), 4.30-4.20 (m, 1H), 4.12-4.06 (m, 1H), 3.83-3.73 (m, 1H), 3.43-3.36 (m, 1H), 3.30-3.15 (m, 
3H), 2.80-2.72 (m, 1H), 2.71-2.50 (m, 3H), 2.10-2.00 (m, 1H), 1.90-1.80 (m, 2H), 1.79-1.60 (m, 
4H), 1.48 (s, 3H), 1.35-1.27 (m, 1H), 1.17 (d, J = 6.8 Hz, 3H), 1.11 (d, J = 6.8 Hz, 3H), 0.88 (t, J = 
7.2 Hz, 3H).  
N-((3R,6S,9S,12R)-6-ethyl-9-(3-guanidinopropyl)-12-methyl-3-(naphthalen-1-ylmethyl)-
2,5,8,11-tetraoxo-1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (AK-033)  
AK-033 was synthesized using the procedure applied for LC-081, white powder, 15 % yield over 
4 steps.  
MS (ESI): m/z calculated for C32H47N8O5 [M+H]+ 623.37, found 623.48.  
1H NMR (400 MHz, Methanol-d4) δ 8.54 (s, 1H), 8.23-8.18 (m, 1H), 8.12 (d, J = 10.0 Hz, 1H), 7.85-
7.73 (m, 3H), 7.70-7.63 (m, 2H), 7.47-7.35 (m, 4H), 4.78-4.70 (m, 1H), 4.23-4.16 (m, 1H), 4.15-
4.07 (m, 1H), 3.85-3.75 (m, 1H), 3.65-3.58 (m, 1H), 3.30-3.20 (m, 2H), 2.95-2.85 (m, 1H), 2.70-
2.52 (m, 3H), 2.00-1.93 (m, 1H), 1.88-1.81 (m, 2H), 1.78-1.65 (m, 2H), 1.64-1.55 (m, 1H), 1.48 (s, 
3H), 1.40-1.30 (m, 1H), 1.18 (d, J = 6.8 Hz, 3H), 1.11 (d, J = 6.8 Hz, 3H), 0.83 (t, J = 7.6 Hz, 3H). 
N-((3R,6S,9S,12R)-6-ethyl-9-(3-guanidinopropyl)-3,12-dimethyl-2,5,8,11-tetraoxo-3-phenyl-
1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (LC-294)  
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LC-294 was synthesized using the procedure applied for LC-081 to yield 2.5 mg, white powder, 
5 % yield over 4 steps. 
LC-MS(ESI) m/z (M +H)+: 573.32; calcd for C28H45N8O5 (M +H)+ : 573.35; >98% purity. 
N-((3R,6S,9S,12R)-6-ethyl-3-(2-fluorophenyl)-9-(3-guanidinopropyl)-12-methyl-2,5,8,11-
tetraoxo-1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (LC-334) 
LC-334 was synthesized using the procedure applied for LC-081 to yield 10.5 mg, white powder, 
18 % yield over 4 steps. 
LC-MS(ESI) m/z (M +H)+: 577.39; calcd for C27H42FN8O5 (M +H)+ : 577.33; >98% purity. 
1H NMR (400 MHz, Methanol-d4) δ 8.62 (s, 1H), 8.35 (d, J = 3.9 Hz, 1H), 8.18 (d, J = 9.5 Hz, 1H), 
8.07 (d, J = 9.2 Hz, 1H), 7.89 – 7.73 (m, 1H), 7.43 (td, J = 7.5, 1.7 Hz, 1H), 7.36 – 7.26 (m, 1H), 
7.14 (td, J = 7.6, 1.2 Hz, 1H), 7.08 (ddd, J = 9.6, 8.3, 1.2 Hz, 1H), 5.84 (d, J = 9.2 Hz, 1H), 4.41 (td, J 
= 10.1, 3.7 Hz, 1H), 4.15 (td, J = 7.5, 7.0, 3.9 Hz, 1H), 3.87 – 3.65 (m, 1H), 3.22 (ddt, J = 13.6, 
11.4, 7.1 Hz, 2H), 2.79 – 2.50 (m, 3H), 2.19 (m, J = 14.8, 7.5, 3.8 Hz, 1H), 1.93 – 1.67 (m, 5H), 
1.52 (s, 3H), 1.36 – 1.28 (m, 1H), 1.22 (d, J = 6.9 Hz, 3H), 1.16 (d, J = 6.6 Hz, 3H), 0.96 (t, J = 7.4 
Hz, 3H). 
N-((3R,6S,9S,12R)-6-ethyl-3-(3-fluorophenyl)-9-(3-guanidinopropyl)-12-methyl-2,5,8,11-
tetraoxo-1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (LC-321) 
LC-321 was synthesized using the procedure applied for LC-081 to yield 8.0 mg, white powder, 
14 % yield over 4 steps. 
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LC-MS(ESI) m/z (M +H)+: 577.34; calcd for C27H42FN8O5 (M +H)+ : 577.33; >98% purity. 
1H NMR (400 MHz, Methanol-d4) δ 8.64 (s, 1H), 8.38 (d, J = 3.9 Hz, 1H), 8.16 (d, J = 9.5 Hz, 1H), 
8.06 (d, J = 9.2 Hz, 1H), 7.86 (dd, J = 9.9, 2.9 Hz, 1H), 7.34 (td, J = 8.0, 5.9 Hz, 1H), 7.21 (dt, J = 
7.7, 1.2 Hz, 1H), 7.17 (dt, J = 9.8, 2.1 Hz, 1H), 7.11 – 6.91 (m, 1H), 5.49 (d, J = 9.2 Hz, 1H), 4.39 
(td, J = 10.1, 3.6 Hz, 1H), 4.17 (td, J = 7.5, 7.0, 3.9 Hz, 1H), 3.85 – 3.64 (m, 1H), 3.28 – 3.15 (m, 
2H), 2.76 – 2.55 (m, 3H), 2.19 (ddd, J = 14.2, 7.4, 3.7 Hz, 1H), 1.87 – 1.66 (m, 5H), 1.53 (s, 3H), 
1.37 (dd, J = 6.7, 3.7 Hz, 1H), 1.22 (d, J = 6.9 Hz, 3H), 1.16 (d, J = 6.6 Hz, 3H), 0.96 (t, J = 7.4 Hz, 
3H). 
N-((3R,6S,9S,12R)-6-ethyl-3-(4-fluorophenyl)-9-(3-guanidinopropyl)-12-methyl-2,5,8,11-
tetraoxo-1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (AK-035-2)  
AK-035-2 was synthesized using the procedure applied for LC-081 to yield 8.0 mg, white 
powder, 10 % yield over 4 steps.  
MS (ESI): m/z calculated for C27H42FN8O5 [M+H]+ 577.33, found 577.34.  
1H NMR (400 MHz, Methanol-d4) δ 8.61 (s, 1H), 8.35-8.30 (m, 1H), 8.16 (d, J = 9.6 Hz, 1H), 8.02 
(d, J = 9.2 Hz, 1H), 7.90-7.82 (m, 1H), 7.44-7.39 (m, 2H), 7.07-7.02 (m, 2H), 5.47 (d, J = 8.8 Hz, 
1H), 4.44-4.35 (m, 1H), 4.20-4.10 (m, 1H), 3.80-3.72 (m, 1H), 3.30-3.17 (m, 3H), 2.80-2.60 (m, 
3H), 2.24-2.12 (m, 1H), 1.92-1.68 (m, 6H), 1.53 (s, 3H), 1.38-1.32 (m, 1H), 1.22 (d, J = 6.8 Hz, 3H), 
1.20-1.10 (m, 4H), 0.96 (t, J = 7.6 Hz, 3H). 
214 
 
N-((3R,6S,9S,12R)-3-(2-chlorophenyl)-6-ethyl-9-(3-guanidinopropyl)-12-methyl-2,5,8,11-
tetraoxo-1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (AK-057)  
AK-057 was synthesized using the procedure applied for LC-081 to yield 8.0 mg, white powder, 
26 % yield over 4 steps.  
MS (ESI): m/z calculated for C27H42ClN8O5 [M+H]+ 593.30, found 593.29.  
1H NMR (400 MHz, Methanol-d4) δ 8.40 (s, 2H), 8.24 (d, J = 5.2 Hz, 1H), 7.99 (d, J = 9.2 Hz, 1H), 
7.90-7.85 (m, 1H), 7.55-7.45 (m, 1H), 7.35-7.25 (m, 3H), 7.20-7.24 (m, 1H), 5.25-5.23 (m, 1H), 
4.35-4.25 (m, 1H), 4.10-3.99 (m, 1H), 3.40-3.05 (m, 3H), 2.70-2.55 (m, 3H), 2.05-1.60 (m, 8H), 
1.25-1.15 (m, 6H), 0.86 (t, J = 7.6 Hz, 3H). 
N-((6S,9S,12R)-3-(3-chlorophenyl)-6-ethyl-9-(3-guanidinopropyl)-12-methyl-2,5,8,11-tetraoxo-
1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (AK-058)  
AK-058 was synthesized using the procedure applied for LC-081 to yield 8.0 mg, white powder, 
15 % yield over 4 steps.  
MS (ESI): m/z calculated for C27H42ClN8O5 [M+H]+ 593.30, found 593.29.  
1H NMR (400 MHz, Methanol-d4) δ 8.60 (s, 1H), 8.31 (d, J = 4.0 Hz, 1H), 8.21 (d, J = 9.2 Hz, 1H), 
8.10 (d, J = 8.8 Hz, 1H), 7.80-7.70 (m, 1H), 7.51-7.48 (m, 1H), 7.42-7.41 (m, 1H), 7.32-7.28 (m, 
2H), 6.05(d, J = 9.2 Hz, 1H), 4.43-4.39 (m, 1H), 4.19-4.18 (m, 1H), 3.85-3.70 (m, 1H), 3.33-3.25 
(m, 2H), 2.78-2.62 (m, 3H), 2.28-2.15 (m, 1H), 1.90-1.70 (m, 5H), 1.54 (s, 3H), 1.40-1.32 (m, 1H), 
1.25 (d, J = 6.8 Hz, 3H), 1.20 (d, J = 6.8 Hz, 3H), 0.97 (t, J = 7.2 Hz, 3H).  
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N-((3R,6S,9S,12R)-3-(4-chlorophenyl)-6-ethyl-9-(3-guanidinopropyl)-12-methyl-2,5,8,11-
tetraoxo-1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (AK-059)  
AK-059 was synthesized using the procedure applied for LC-081 to yield 8.0 mg, white powder, 
20 % yield over 4 steps.  
MS (ESI): m/z calculated for C27H42ClN8O5 [M+H]+ 593.30, found 593.29.  
1H NMR (400 MHz, Methanol-d4) δ 8.40-8.39 (m, 2H), 8.23-8.21 (d, J = 6 Hz, 1H), 8.00 (d, J = 9.2 
Hz, 1H), 7.87-7.85 (m, 1H), 7.51-7.49 (m, 1H), 7.33 (d, J = 8.4 Hz, 2H), 7.26 (d, J = 8.4 Hz, 2H), 
5.24 (s, 1H), 4.32-4.27 (m, 1H), 4.04-4.03 (m, 1H), 3.35-3.20 (m, 2H), 3.18-3.08 (m, 1H), 2.70-
2.55 (m, 1H), 2.00-1.60 (m, 8H), 1.56 (s, 3H), 1.25-1.15 (m, 6H), 1.05 (t, J = 7.2 Hz, 3H).  
N-((3R,6S,9S,12R)-6-ethyl-9-(3-guanidinopropyl)-3-(2-methoxyphenyl)-12-methyl-2,5,8,11-
tetraoxo-1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (AK-042)  
AK-042 was synthesized using the procedure applied for LC-081 to yield 8.0 mg, white powder, 
25% yield over 4 steps.  
MS (ESI): m/z calculated for C28H45N8O6 [M+H]+ 589.35, found 589.25.  
1H NMR (400 MHz, Methanol-d4) δ 8.51 (s, 1H), 8.32 (d, J = 9.6 Hz, 1H), 8.19 (d, J = 4 Hz, 1H), 
7.89 (d, J = 9.2 Hz), 7.32-7.22 (m, 2H), 7.00-6.89 (m, 2H), 5.76 (d, J = 9.2 Hz, 1H), 4.45-4.35 (m, 
1H), 4.25-4.15 (m, 1H), 3.85 (s, 3H), 3.82-3.72 (m, 1H), 3.40-3.15 (m, 3H), 2.75-2.60 (m, 2H), 
2.20-2.15 (m, 1H), 1.80-1.70 (m, 4H), 1.79-1.60 (m, 4H), 1.53 (s, 3H), 1.38-1.32 (m, 1H), 1.22 (d, J 
= 6.8 Hz, 3H), 1.20-1.10 (m, 4H), 0.96 (t, J = 7.6 Hz, 3H).  
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N-((3R,6S,9S,12R)-6-ethyl-9-(3-guanidinopropyl)-3-(3-methoxyphenyl)-12-methyl-2,5,8,11-
tetraoxo-1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (LC-345) 
LC-345 was synthesized using the procedure applied for LC-202 from LC-343 to yield 2.3 mg, 
white powder, 42 % yield. 
LC-MS(ESI) m/z (M +H)+: 589.36; calcd for C28H45N8O6 (M +H)+ : 589.35; >98% purity. 
1H NMR (400 MHz, Methanol-d4) δ 8.59 (s, 1H), 8.32 (d, J = 4.1 Hz, 1H), 8.19 (d, J = 9.5 Hz, 1H), 
7.96 (d, J = 9.2 Hz, 1H), 7.87 (d, J = 9.2 Hz, 1H), 7.22 (t, J = 7.9 Hz, 1H), 7.08 – 7.01 (m, 1H), 6.97 
(dt, J = 7.6, 1.2 Hz, 1H), 6.89 – 6.77 (m, 1H), 5.42 (d, J = 9.1 Hz, 1H), 4.38 (td, J = 10.1, 3.8 Hz, 
1H), 4.16 (td, J = 7.5, 7.1, 4.1 Hz, 1H), 3.91 – 3.65 (m, 4H), 3.29 – 3.15 (m, 2H), 2.78 – 2.54 (m, 
3H), 2.18 (ddd, J = 14.1, 7.4, 3.9 Hz, 1H), 1.94 – 1.62 (m, 5H), 1.53 (s, 3H), 1.41 – 1.34 (m, 1H), 
1.28 – 1.20 (m, 3H), 1.16 (d, J = 6.7 Hz, 3H), 0.95 (t, J = 7.4 Hz, 3H). 
N-((3R,6S,9S,12R)-6-ethyl-9-(3-guanidinopropyl)-3-(4-methoxyphenyl)-12-methyl-2,5,8,11-
tetraoxo-1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (LC-339) 
LC-339 was synthesized using the procedure applied for LC-081 to yield 6.0 mg, white powder, 
10 % yield over 4 steps. 
LC-MS(ESI) m/z (M +H)+: 589.38; calcd for C28H45N8O6 (M +H)+ : 589.35; >98% purity. 
1H NMR (400 MHz, Methanol-d4) δ 8.59 (s, 1H), 8.32 (d, J = 4.1 Hz, 1H), 8.20 (d, J = 9.5 Hz, 1H), 
7.92 (d, J = 9.2 Hz, 1H), 7.85 (d, J = 9.2 Hz, 1H), 7.39 – 7.25 (m, 2H), 6.94 – 6.83 (m, 2H), 5.41 (d, J 
= 9.2 Hz, 1H), 4.37 (td, J = 10.1, 3.8 Hz, 1H), 4.15 (td, J = 7.5, 7.0, 4.0 Hz, 1H), 3.91 – 3.61 (m, 4H), 
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3.28 – 3.12 (m, 2H), 2.74 – 2.52 (m, 3H), 2.26 – 2.11 (m, 1H), 1.96 – 1.69 (m, 5H), 1.52 (s, 3H), 
1.40 – 1.31 (m, 1H), 1.22 (d, J = 6.9 Hz, 3H), 1.16 (d, J = 6.6 Hz, 3H), 0.95 (t, J = 7.4 Hz, 3H). 
N-((3R,6S,9S,12R)-6-ethyl-9-(3-guanidinopropyl)-12-methyl-3-(naphthalen-1-yl)-2,5,8,11-
tetraoxo-1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (LC-324) 
LC-324 was synthesized using the procedure applied for LC-081 to yield 3.3 mg, white powder, 
6 % yield over 4 steps. 
LC-MS(ESI) m/z (M +H)+: 609.35; calcd for C31H45N8O5 (M +H)+ : 609.35; >98% purity. 
N-((3R,6S,9S,12R)-6-ethyl-9-(3-guanidinopropyl)-12-methyl-3-(naphthalen-2-yl)-2,5,8,11-
tetraoxo-1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (LC-326) 
LC-326 was synthesized using the procedure applied for LC-081 to yield 9 mg, white powder, 
15 % yield over 4 steps. 
LC-MS(ESI) m/z (M +H)+: 609.42; calcd for C31H45N8O5 (M +H)+ : 609.35; >98% purity. 
1H NMR (400 MHz, Methanol-d4) δ 8.63 (s, 1H), 8.37 (d, J = 4.0 Hz, 1H), 8.22 (d, J = 9.5 Hz, 1H), 
8.13 (d, J = 9.2 Hz, 1H), 7.94 (d, J = 8.5 Hz, 1H), 7.89 – 7.78 (m, 4H), 7.58 (dd, J = 8.5, 1.8 Hz, 1H), 
7.52 – 7.38 (m, 2H), 5.66 (d, J = 9.1 Hz, 1H), 4.40 (td, J = 10.1, 3.7 Hz, 1H), 4.19 (td, J = 7.1, 4.0 
Hz, 1H), 3.88 – 3.73 (m, 1H), 3.28 – 3.11 (m, 2H), 2.79 – 2.55 (m, 3H), 2.28 – 2.10 (m, 1H), 1.92 – 
1.68 (m, 5H), 1.55 (s, 3H), 1.43 – 1.34 (m, 1H), 1.24 (d, J = 6.9 Hz, 3H), 1.18 (d, J = 6.7 Hz, 3H), 
0.97 (t, J = 7.4 Hz, 3H). 
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N-((3R,6S,9S,12R)-6-ethyl-12-methyl-2,5,8,11-tetraoxo-9-phenethyl-3-phenyl-1,4,7,10-
tetraazacyclotetradecan-12-yl)isobutyramide (LC-186-2) 
LC-186-2 was synthesized using the procedure applied for LC-081 to yield 3.9 mg, white 
powder, 7 % yield over 3 steps. 
LC-MS(ESI) m/z (M +H)+: 564.39; calcd for C31H42N5O5 (M +H)+ : 564.32; >98% purity. 
1H NMR (400 MHz, Methanol-d4) δ 8.56 (s, 1H), 8.31 (d, J = 4.3 Hz, 1H), 8.21 (d, J = 9.5 Hz, 1H), 
7.99 (d, J = 9.2 Hz, 1H), 7.88 (d, J = 9.2 Hz, 1H), 7.53 – 7.38 (m, 2H), 7.38 – 7.25 (m, 5H), 7.25 – 
7.08 (m, 3H), 5.46 (d, J = 9.2 Hz, 1H), 4.39 (td, J = 10.1, 3.8 Hz, 1H), 4.10 (ddd, J = 8.1, 5.6, 4.2 Hz, 
1H), 3.84 – 3.68 (m, 1H), 2.86 – 2.56 (m, 5H), 2.24 – 2.01 (m, 3H), 1.86 – 1.71 (m, 1H), 1.55 (s, 
3H), 1.42 – 1.32 (m, 1H), 1.23 (d, J = 6.9 Hz, 3H), 1.17 (d, J = 6.6 Hz, 3H), 0.97 (t, J = 7.4 Hz, 3H). 
N-((3R,6S,9S,12R)-6-ethyl-12-methyl-2,5,8,11-tetraoxo-3-phenyl-9-(3-phenylpropyl)-1,4,7,10-
tetraazacyclotetradecan-12-yl)isobutyramide (LC-183-2) 
LC-183-2 was synthesized using the procedure applied for LC-081 to yield 3.9 mg, white 
powder, 7 % yield over 3 steps. 
LC-MS(ESI) m/z (M +H)+: 578.43; calcd for C32H44N5O5 (M +H)+ : 578.33; >98% purity. 
1H NMR (400 MHz, Methanol-d4) δ 8.53 (s, 1H), 8.20 (d, J = 3.9 Hz, 1H), 8.11 (d, J = 9.5 Hz, 1H), 
8.02 (d, J = 9.2 Hz, 1H), 7.87 (d, J = 9.4 Hz, 1H), 7.46 – 7.37 (m, 2H), 7.37 – 7.21 (m, 5H), 7.21 – 
7.06 (m, 3H), 5.45 (d, J = 9.2 Hz, 1H), 4.36 (td, J = 10.1, 3.7 Hz, 1H), 4.19 – 4.05 (m, 1H), 3.84 – 
3.68 (m, 1H), 2.76 – 2.49 (m, 5H), 2.16 (ddd, J = 14.2, 7.4, 3.8 Hz, 1H), 1.90 – 1.67 (m, 5H), 1.51 
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(s, 3H), 1.37 – 1.32 (m, 1H), 1.20 (d, J = 6.9 Hz, 3H), 1.12 (d, J = 6.7 Hz, 3H), 0.91 (t, J = 7.4 Hz, 
3H). 
N-((3R,6S,9S,12R)-6-ethyl-12-methyl-2,5,8,11-tetraoxo-3-phenyl-9-(3-ureidopropyl)-1,4,7,10-
tetraazacyclotetradecan-12-yl)isobutyramide (LC-187-2) 
LC-187-2 was synthesized using the procedure applied for LC-081 to yield 3.2 mg, white 
powder, 6 % yield over 3 steps. 
LC-MS(ESI) m/z (M +H)+: 560.26; calcd for C27H42N7O6 (M +H)+ : 560.32; >98% purity. 
1H NMR (400 MHz, Methanol-d4) δ 8.57 (s, 1H), 8.48 (s, 1H), 8.18 (d, J = 9.5 Hz, 1H), 8.04 (d, J = 
9.2 Hz, 1H), 7.52 – 7.40 (m, 2H), 7.40 – 7.15 (m, 4H), 5.46 (d, J = 9.3 Hz, 1H), 4.39 (td, J = 10.1, 
3.7 Hz, 1H), 4.14 (td, J = 6.5, 3.6 Hz, 1H), 3.83 – 3.71 (m, 1H), 3.17 (q, J = 6.6 Hz, 2H), 2.77 – 2.60 
(m, 3H), 2.19 (ddt, J = 14.9, 11.3, 7.2 Hz, 1H), 1.93 – 1.77 (m, 3H), 1.67 – 1.59 (m, 2H), 1.54 (s, 
3H), 1.39 – 1.33 (m, 1H), 1.22 (d, J = 6.9 Hz, 3H), 1.16 (d, J = 6.7 Hz, 3H), 0.96 (t, J = 7.4 Hz, 3H) 
N-((3R,6S,9S,12R)-9-(4-(dimethylamino)butyl)-6-ethyl-12-methyl-2,5,8,11-tetraoxo-3-phenyl-
1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (LC-169) 
LC-169 was synthesized using the procedure applied for LC-164 from LC-167 to yield 3.9 mg, 
white powder, 32 % yield.  
LC-MS(ESI) m/z (M +H)+: 559.45; calcd for C29H47N6O5 (M +H)+ : 559.36; >98% purity. 
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1H NMR (400 MHz, Methanol-d4) δ 8.60 (s, 1H), 8.32 (d, J = 4.1 Hz, 1H), 8.18 (d, J = 9.5 Hz, 1H), 
8.00 (d, J = 9.2 Hz, 1H), 7.87 (d, J = 9.3 Hz, 1H), 7.58 – 7.39 (m, 2H), 7.39 – 7.16 (m, 3H), 5.46 (d, J 
= 9.2 Hz, 1H), 4.37 (td, J = 10.1, 3.8 Hz, 1H), 4.14 (td, J = 7.5, 7.0, 4.0 Hz, 1H), 3.82 – 3.69 (m, 1H), 
3.12 (dd, J = 9.2, 6.9 Hz, 2H), 2.88 (s, 6H), 2.75 – 2.57 (m, 3H), 2.17 (dtd, J = 14.8, 7.4, 3.9 Hz, 
1H), 1.95 – 1.83 (m, 2H), 1.83 – 1.67 (m, 3H), 1.61 – 1.41 (m, 5H), 1.40 – 1.32 (m, 1H), 1.23 (d, J 
= 6.9 Hz, 3H), 1.16 (d, J = 6.7 Hz, 3H), 0.95 (t, J = 7.4 Hz, 3H). 
N-((3R,6S,9S,12R)-6-ethyl-12-methyl-9-(2-((1-methylpiperidin-4-yl)amino)ethyl)-2,5,8,11-
tetraoxo-3-phenyl-1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (LC-174) 
LC-174 was synthesized using the procedure applied for LC-164 from LC-172 to yield 3.8 mg, 
white powder, 65 % yield. 
LC-MS(ESI) m/z (M +2H)2+: 300.93; calcd for C31H51N7O5 (M +2H)2+ : 300.70; >98% purity. 
1H NMR (400 MHz, Methanol-d4) δ 8.64 (s, 1H), 7.96 (d, J = 9.2 Hz, 1H), 7.94 – 7.83 (m, 1H), 7.47 
– 7.38 (m, 2H), 7.38 – 7.21 (m, 3H), 5.47 (d, J = 9.2 Hz, 1H), 4.40 (dd, J = 10.5, 3.9 Hz, 1H), 4.30 
(t, J = 7.5 Hz, 1H), 3.77 (t, J = 10.1 Hz, 1H), 3.64 (d, J = 12.5 Hz, 2H), 3.53 – 3.40 (m, 1H), 3.39 – 
3.30 (m, 1H), 3.29 – 3.21 (m, 1H), 3.20 – 3.00 (m, 2H), 2.89 (s, 3H), 2.77 – 2.56 (m, 3H), 2.49 – 
2.32 (m, 2H), 2.32 – 2.08 (m, 3H), 2.08 – 1.87 (m, 2H), 1.81 (ddd, J = 14.2, 10.5, 7.3 Hz, 1H), 1.54 
(s, 3H), 1.40 – 1.31 (m, 1H), 1.22 (d, J = 6.9 Hz, 3H), 1.15 (d, J = 6.6 Hz, 3H), 0.95 (t, J = 7.4 Hz, 
3H). 
N-((3R,6S,9S,12R)-6-ethyl-12-methyl-9-(3-((1-methylpiperidin-4-yl)amino)propyl)-2,5,8,11-
tetraoxo-3-phenyl-1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (LC-164) 
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LC-162 (18 mg, 0.035 mmol) was dissolved in DCE (2 mL). N-methyl-4-piperidone (6.5 uL, 
0.5mmol) and NaBH(OAc)3 (30 mg, 0.14 mmol) were added to the reaction. The reaction was 
stirred at room temperature for 4 hr and then quenched with saturated ammonium chloride 
solution (10 mL). The product was extracted with ethyl acetate (3* 10mL) and the combined 
organic solution was dried and concentrated under vacuum. The residue was purified with 
preparative HPLC using the C18 reverse phase column (Waters, Sunfire™ Prep C18 OBD™, 5µm, 
50×100mm), yielding LC-164 (10.7 mg, white powder, 50 % yield).  
LC-MS(ESI) m/z (M +H)+: 614.53; calcd for C32H52N7O5 (M +H)+ : 614.40; >98% purity. 
1H NMR (400 MHz, Methanol-d4) δ 8.61 (s, 1H), 8.43 (d, J = 4.1 Hz, 1H), 8.21 (d, J = 9.5 Hz, 1H), 
7.99 (d, J = 9.1 Hz, 1H), 7.89 (dd, J = 9.4, 2.6 Hz, 1H), 7.45 – 7.37 (m, 2H), 7.37 – 7.24 (m, 3H), 
5.46 (d, J = 9.2 Hz, 1H), 4.38 (td, J = 10.1, 3.8 Hz, 1H), 4.15 (dd, J = 7.6, 4.1 Hz, 1H), 3.79 – 3.71 
(m, 1H), 3.65 (d, J = 12.6 Hz, 2H), 3.48 – 3.38 (m, 1H), 3.17 – 3.08 (m, 3H), 2.88 (s, 3H), 2.74 – 
2.61 (m, 3H), 2.38 (d, J = 13.5 Hz, 2H), 2.18 (ddd, J = 14.2, 7.4, 3.9 Hz, 1H), 1.95 – 1.75 (m, 6H), 
1.53 (s, 3H), 1.43 – 1.24 (m, 2H), 1.22 (d, J = 6.9 Hz, 3H), 1.15 (d, J = 6.6 Hz, 3H), 0.95 (t, J = 7.4 
Hz, 3H). 
N-((3R,6S,9S,12R)-9-(3-((4,5-dihydro-1H-imidazol-2-yl)amino)propyl)-6-ethyl-12-methyl-
2,5,8,11-tetraoxo-3-phenyl-1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (LC-210) 
LC-210 was synthesized using the procedure applied for LC-202 from LC-162 to yield 1.4 mg, 
white powder, 24 % yield.  
LC-MS(ESI) m/z (M +H)+: 583.31; calcd for C29H43N8O5 (M +H)+ : 583.34; >98% purity. 
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1H NMR (400 MHz, Methanol-d4) δ 8.80 (d, J = 6.7 Hz, 1H), 8.63 (d, J = 10.6 Hz, 1H), 8.33 (d, J = 
4.0 Hz, 1H), 8.19 (d, J = 9.4 Hz, 1H), 7.99 (d, J = 9.1 Hz, 1H), 7.86 (d, J = 9.1 Hz, 1H), 7.52 – 7.23 
(m, 5H), 6.89 – 6.82 (m, 1H), 5.45 (s, 1H), 4.38 (td, J = 10.0, 3.9 Hz, 1H), 4.22 – 4.12 (m, 1H), 3.96 
– 3.88 (m, 1H), 3.80 – 3.56 (m, 2H), 2.76 – 2.51 (m, 3H), 2.23 – 2.14 (m, 1H), 1.99 – 1.67 (m, 5H), 
1.53 (s, 3H), 1.40 – 1.31 (m, 2H), 1.22 (d, J = 6.9 Hz, 3H), 1.15 (d, J = 6.6 Hz, 3H), 0.93 (t, J = 7.4 
Hz, 3H). 
N-((3R,6S,9S,12R)-6-ethyl-12-methyl-2,5,8,11-tetraoxo-3-phenyl-9-(3-(pyridin-2-
ylamino)propyl)-1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (LC-182) 
LC-162 (5mg, 0.01 mmol) was dissolved in 2-fluoropyridine (0.2 mL). The reaction was heated to 
120 oC for 4 hr under microwave. Then the reaction was cooled to room temperature and the 
residue was purified with preparative HPLC using the C18 reverse phase column (Waters, 
Sunfire™ Prep C18 OBD™, 5µm, 50×100mm), yielding LC-182 (2.6 mg, , white powder, 45 % 
yield).  
LC-MS(ESI) m/z (M +H)+: 594.34; calcd for C31H44N7O5 (M +H)+ : 594.34; >98% purity. 
1H NMR (400 MHz, Methanol-d4) δ 8.61 (s, 1H), 8.37 (d, J = 4.0 Hz, 1H), 8.23 (d, J = 9.5 Hz, 1H), 
7.99 (d, J = 9.2 Hz, 1H), 7.95 – 7.78 (m, 3H), 7.47 – 7.38 (m, 2H), 7.37 – 7.23 (m, 3H), 7.05 (d, J = 
9.1 Hz, 1H), 6.89 (t, J = 6.7 Hz, 1H), 5.47 (d, J = 9.2 Hz, 1H), 4.39 (td, J = 10.0, 3.7 Hz, 1H), 4.27 – 
4.15 (m, 1H), 3.76 (t, J = 11.2 Hz, 1H), 3.52 – 3.38 (m, 2H), 2.78 – 2.57 (m, 3H), 2.18 (ddd, J = 
14.2, 7.5, 4.0 Hz, 1H), 1.99 – 1.72 (m, 5H), 1.53 (s, 3H), 1.40 – 1.29 (m, 2H), 1.22 (d, J = 6.8 Hz, 
3H), 1.16 (d, J = 6.5 Hz, 3H), 0.93 (t, J = 7.4 Hz, 3H). 
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N-((3R,6S,9S,12R)-6-ethyl-12-methyl-2,5,8,11-tetraoxo-3-phenyl-9-(3-(pyrimidin-2-
ylamino)propyl)-1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (LC-227) 
LC-227 was synthesized using the procedure applied for LC-202 from LC-162 to yield 2.3 mg, 
white powder, 69 % yield.  
LC-MS(ESI) m/z (M +H)+: 595.43; calcd for C30H43N8O5 (M +H)+ : 595.34; >98% purity. 
1H NMR (400 MHz, Methanol-d4) δ 8.60 (s, 1H), 8.42 (d, J = 5.1 Hz, 2H), 8.31 (d, J = 4.0 Hz, 1H), 
8.17 (d, J = 9.6 Hz, 1H), 8.02 (d, J = 9.2 Hz, 1H), 7.87 (d, J = 9.3 Hz, 1H), 7.50 – 7.22 (m, 5H), 6.79 
(t, J = 5.1 Hz, 1H), 5.46 (d, J = 9.2 Hz, 1H), 4.38 (td, J = 10.1, 3.7 Hz, 1H), 4.23 – 4.13 (m, 1H), 3.82 
– 3.71 (m, 1H), 3.48 (td, J = 7.0, 2.7 Hz, 2H), 2.75 – 2.56 (m, 3H), 2.22 – 2.11 (m, 1H), 1.96 – 1.86 
(m, 2H), 1.86 – 1.71 (m, 3H), 1.53 (s, 3H), 1.36 – 1.28 (m, 2H), 1.21 (d, J = 6.9 Hz, 3H), 1.12 (d, J = 
6.7 Hz, 3H), 0.93 (t, J = 7.4 Hz, 3H). 
N-((3R,6S,9S,12R)-9-(3-((4,5-dihydro-1H-imidazol-2-yl)amino)propyl)-6-ethyl-12-methyl-
2,5,8,11-tetraoxo-3-phenyl-1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (LC-202) 
LC-162 (5mg, 0.01 mmol) was dissolved in Ethanol (0.2 mL) and DIEA (0.05 mL). 2-Methylthio-2-
imidazoline hydroiodide (25mg, 0.1 mmol) was added to the reaction. The reaction was heated 
to 120 oC for 4 hr under microwave under there is no starting materials left checked by UPLC. 
Then the reaction was cooled to room temperature and the residue was purified with 
preparative HPLC using the C18 reverse phase column (Waters, Sunfire™ Prep C18 OBD™, 5µm, 
50×100mm), yielding LC-202 (3.1 mg, , white powder, 53 % yield).  
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LC-MS(ESI) m/z (M +H)+: 585.47; calcd for C29H45N8O5 (M +H)+ : 585.35; >98% purity. 
1H NMR (400 MHz, Methanol-d4) δ 8.60 (s, 1H), 8.33 (d, J = 4.1 Hz, 1H), 8.20 (d, J = 9.6 Hz, 1H), 
7.99 (d, J = 9.2 Hz, 1H), 7.87 (d, J = 9.3 Hz, 1H), 7.44 – 7.38 (m, 2H), 7.36 – 7.25 (m, 3H), 5.46 (d, J 
= 9.2 Hz, 1H), 4.38 (td, J = 10.1, 3.8 Hz, 1H), 4.15 (td, J = 7.0, 4.1 Hz, 1H), 3.81 – 3.73 (m, 1H), 
3.70 (s, 4H), 3.29 – 3.22 (m, 2H), 2.76 – 2.62 (m, 3H), 2.18 (ddt, J = 15.0, 7.5, 3.7 Hz, 1H), 1.92 – 
1.71 (m, 5H), 1.53 (s, 3H), 1.40 – 1.30 (m, 2H), 1.23 (d, J = 6.9 Hz, 3H), 1.16 (d, J = 6.6 Hz, 3H), 
0.95 (t, J = 7.4 Hz, 3H). 
N-((3R,6S,9S,12R)-6-ethyl-12-methyl-2,5,8,11-tetraoxo-3-phenyl-9-(3-((1,4,5,6-
tetrahydropyrimidin-2-yl)amino)propyl)-1,4,7,10-tetraazacyclotetradecan-12-
yl)isobutyramide (LC-337) 
LC-337 was synthesized using the procedure applied for LC-202 from LC-162 to yield 7.2 mg, 
white powder, 65 % yield.  
LC-MS(ESI) m/z (M +H)+: 599.46; calcd for C30H47N8O5 (M +H)+ : 599.37; >98% purity. 
1H NMR (400 MHz, Methanol-d4) δ 8.60 (s, 1H), 8.33 (d, J = 4.1 Hz, 1H), 8.20 (d, J = 9.5 Hz, 1H), 
7.99 (d, J = 9.2 Hz, 1H), 7.93 – 7.82 (m, 1H), 7.48 – 7.37 (m, 2H), 7.37 – 7.23 (m, 3H), 5.46 (d, J = 
9.1 Hz, 1H), 4.38 (td, J = 10.1, 3.8 Hz, 1H), 4.15 (td, J = 7.1, 4.0 Hz, 1H), 3.81 – 3.71 (m, 1H), 3.38 
– 3.32 (m, 4H), 3.26 – 3.08 (m, 2H), 2.76 – 2.57 (m, 3H), 2.26 – 2.10 (m, 1H), 1.98 – 1.90 (m, 2H), 
1.90 – 1.65 (m, 5H), 1.53 (s, 3H), 1.42 – 1.32 (m, 1H), 1.22 (d, J = 6.9 Hz, 3H), 1.16 (d, J = 6.6 Hz, 
3H), 0.95 (t, J = 7.4 Hz, 3H). 
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N-((3R,6S,9S,12R)-9-(3-(3-acetylguanidino)propyl)-6-ethyl-12-methyl-2,5,8,11-tetraoxo-3-
phenyl-1,4,7,10-tetraazacyclotetradecan-12-yl)isobutyramide (LC-315) 
LC-315 was synthesized using the procedure applied for LC-202 from LC-162 to yield 3.4 mg, 
white powder, 61 % yield.  
LC-MS(ESI) m/z (M +H)+: 601.44; calcd for C29H44N8O6 (M +H)+ : 600.34; >98% purity. 
1H NMR (400 MHz, Methanol-d4) δ 8.60 (s, 1H), 8.33 (d, J = 4.0 Hz, 1H), 8.21 (d, J = 9.5 Hz, 1H), 
7.99 (d, J = 9.2 Hz, 1H), 7.87 (d, J = 9.2 Hz, 1H), 7.49 – 7.37 (m, 2H), 7.37 – 7.20 (m, 3H), 5.46 (d, J 
= 9.2 Hz, 1H), 4.39 (td, J = 10.1, 3.8 Hz, 1H), 4.22 – 4.14 (m, 1H), 3.82 – 3.71 (m, 1H), 3.46 – 3.34 
(m, 2H), 2.75 – 2.58 (m, 3H), 2.25 – 2.08 (m, 4H), 1.97 – 1.73 (m, 5H), 1.53 (s, 3H), 1.40 – 1.33 
(m, 1H), 1.22 (d, J = 6.9 Hz, 3H), 1.16 (d, J = 6.7 Hz, 3H), 0.95 (t, J = 7.4 Hz, 3H). 
N-((3R,6S,9S,12R)-6-ethyl-12-methyl-3-(naphthalen-2-yl)-2,5,8,11-tetraoxo-9-(3-((1,4,5,6-
tetrahydropyrimidin-2-yl)amino)propyl)-1,4,7,10-tetraazacyclotetradecan-12-
yl)isobutyramide (LC-395) 
LC-395 was synthesized using the procedure applied for LC-202 from LC-162 to yield 3.9 mg, 
white powder, 68 % yield. 
LC-MS(ESI) m/z (M +H)+: 649.45; calcd for C34H49N8O5 (M +H)+ : 649.38; >98% purity. 
1H NMR (400 MHz, Methanol-d4) δ 8.64 (s, 1H), 8.38 (d, J = 4.1 Hz, 1H), 8.22 (d, J = 9.5 Hz, 1H), 
8.12 (d, J = 9.1 Hz, 1H), 7.93 (d, J = 8.8 Hz, 1H), 7.89 – 7.77 (m, 4H), 7.58 (dd, J = 8.5, 1.7 Hz, 1H), 
7.51 – 7.44 (m, 2H), 5.65 (d, J = 9.1 Hz, 1H), 4.40 (td, J = 10.1, 3.7 Hz, 1H), 4.19 (td, J = 7.0, 3.9 
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Hz, 1H), 3.80 (t, J = 11.2 Hz, 1H), 3.37 – 3.32 (m, 4H), 3.26 – 3.10 (m, 2H), 2.78 – 2.59 (m, 3H), 
2.27 – 2.17 (m, 1H), 1.97 – 1.65 (m, 7H), 1.55 (s, 3H), 1.40 – 1.34 (m, 1H), 1.24 (d, J = 6.9 Hz, 3H), 
1.17 (d, J = 6.6 Hz, 3H), 0.96 (t, J = 7.5 Hz, 3H). 
Cell Growth Inhibition, Apoptosis Analysis, and Western Blotting Assay 
The human acute leukemia RS4;11 cell line (CRL-1873) was purchased from the American 
Type Culture Collection. In all experiments, RS4;11 human leukemia cells were used within three 
months of thawing fresh vials. RS4;11 cells were cultured in RPMI 1640 media supplemented with 
10% FBS and 1% penicillin–streptomycin at 37 °C in a humidified atmosphere containing 5% CO2 
in air. 
In cell growth experiments, cells were seeded in 96-well cell culture plates at a density of 
10000−20000 cells/well in 100 μL of culture medium. Each compound tested was serially diluted 
in the appropriate medium, and 100 μL of the diluted solution containing the tested compound 
was added to the appropriate wells of the cell plate. After addition of the tested compound, the 
cells were incubated for 4 days at 37 °C in an atmosphere of 5% CO2. Cell growth was evaluated 
by a lactate dehydrogenase-based WST-8 assay (Dojindo Molecular Technologies) using a Tecan 
Infinite M1000 multimode microplate reader (Tecan, Morrisville, NC). The WST-8 reagent was 
added to the plate, incubated for at least 1 h, and read at 450 nm. The readings were normalized 
to the DMSO-treated cells, and the IC50 was calculated by nonlinear regression analysis using 
GraphPad Prism 6 software. 
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To assess the effect of long-term treatment of compound LC-089 on leukemia cells, 
MOLM-13 and MV4;11 cell lines were plated at a density of 5x104cell/ml (2 ml total) in 24-well 
plates, and treated with the relevant concentrations On day 4, cell viability for each treatment 
was measured using the WST-8 cell count kit. Then 10% of viable cells from each well were 
transferred to freshly prepared medium containing corresponding concentrations of compound 
LC-089 and cultured for additional 3 days. On day 7, cell viability for each treatment was 
determined. 
For Western blot analysis, 2 × 106 cells/well were treated with compounds at the 
indicated concentrations for various times. Cells were collected and lysed in RIPA buffer 
containing protease inhibitors. An amount of 20 μg of lysate was run in each lane of a PAGE–SDS 
and blotted into PVDF membranes. Antibodies for immunoblotting were MDM2 (SMP14) and 
p53 (DO-1) purchased from Santa Cruz. 
Efficacy and Pharmacodynamics Studies in the RS4;11 Xenograft Model in Mice 
All animal experiments were done under the guidelines of the University of Michigan 
Committee for Use and Care of Animals and using an approved animal protocol (PRO00005315, 
PI, Shaomeng Wang). 
To develop xenograft tumors, 5 × 106 RS4;11 cells with 50% Matrigel were injected 
subcutaneously on the dorsal side of severe combined immunodeficient (SCID) mice, obtained 
from Charles River, one tumor per mouse. When tumors reached ∼100 mm3, mice were 
randomly assigned to treatment and vehicle control groups. Animals were monitored daily for 
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any signs of toxicity and weighed 2–3 times per week during the treatment and weighed at least 
weekly after the treatment ended. Tumor size was measured 2–3 times per week by electronic 
calipers during the treatment period and at least weekly after the treatment was ended. Tumor 
volume was calculated as V = LW2/2, where L is the length and W is the width of the tumor. 
For pharmacodynamic analysis, resected RS4;11 xenograft tumor tissues were ground 
into powder in liquid nitrogen and lysed in lysis buffer (1% CHAPS, 150 mM NaCl, 20 mM Tris-HCl, 
1 mM. EDTA, 1 mM EGTA, and COMPLETE proteinase inhibitor (Roche)). Whole tumor lysates 
were separated on 4–20% Novex gels. The separated proteins were transferred to a 
polyvinylidene difluoride membrane for immunoblotting. The following antibodies were used: 
antibodies for MDM2(SMP14), p53 (DO-1), GAPDH (FL-335) from Santa Cruz Biotechnology; p21 
(12D1), PARP (46D11), and caspase-3 (8G10) from Cell Signaling Technology. The secondary 
antibody used was horseradish peroxidase conjugated goat anti-rabbit (Thermo Scientific). The 
BIO-RAD Clarity Western Enhanced Chemiluminescence Substrates and HyBlot 
Chemiluminescence film were used for signal development and detection using a SRX-101A 
tabletop processor (Konica Minolta). 
Determination of Drug Concentrations in Plasma and RS4;11 Tumor Tissue 
Pharmacokinetics of compound 23 was determined in female SCID C.B-17 mice bearing 
RS4;11 tumors following a single intravenous dose of 5 mg/kg. LE-102 was dissolved in the vehicle 
containing 20% (v/v) polyethylene glycol 400, 6% (v/v) Cremophor EL and 74% (v/v) PBS (20% 
PCP). Mice were sacrificed at 1, 2, 4, 8, 24 and 48 h after drug treatment and at 6 h after vehicle 
treatment, followed by collection of blood samples (300 μL) and tumor samples. Blood samples 
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were centrifuged at 15 000 rpm for 10 min, then the supernatant plasma was saved for analysis. 
Isolated tumor samples were immediately frozen and ground with a mortar and pestle in liquid 
nitrogen. All plasma and tumor samples were stored at −80 °C prior to analysis. 
Plasma and tumor concentrations of LE-102 were determined by a LC–MS/MS method 
developed and validated for this study. The LC–MS/MS method, consisting of a Shimadzu HPLC 
system and chromatographic separation of tested compound, was achieved using a Waters 
XBridge-C18 column (5 cm × 2.1 mm, 3.5 μm). An AB Sciex QTrap 5500 mass spectrometer 
equipped with an electrospray ionization source (Applied Biosystems, Toronto, Canada) in the 
positive-ion multiple reaction monitoring (MRM) mode was used for detection. The mobile 
phases were 0.1% formic acid in purified water (A) and 0.1% formic acid in acetonitrile (B). The 
gradient (B) was held at 10% (0–0.3 min), increased to 95% at 0.7 min, then held at isocratic 95% 
B for 2.3 min and then immediately stepped back down to 10% for 2 min re-equilibration. The 
flow rate was set at 0.4 mL/min. 
Competitive Binding Experiments to WDR5 Protein  
The binding affinities of these synthesized compounds were tested using a fluorescence 
polarization (FP) based competitive binding assay described earlier.111 Briefly, to a 5 µl solution 
of the tested compound in DMSO, 120 µl of pre-incubated complex solution (N-terminal His-
tagged WDR5 protein (residues 24-334), named WDR5Δ23, and 5-FAM labeled tracer) in assay 
buffer (0.1M Phosphate, 25mM KCl, 0.01% Triton, pH 6.5) was added, giving final concentrations 
of WDR523 and the tracer to be 4 nM and 0.6 nM, respectively. The plates were incubated at 
room temperature on a shaker for 3h, and then the mP values were measured using the Tecan 
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Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, NC). Ki values were calculated 
using the equation described previously.111, 137 
In vitro cell-free MLL HMT functional assay  
 The recombinant MLL complex containing human MLL (MLL1) protein (3735 - 3973) with 
N-terminal GST tag and MW= 53.7 kDa; full length human WDR5 with N-terminal 6×His tag and 
MW= 35 kDa; full length human ASH2L with N-terminal 6×His tag and MW= 61 kDa; full length 
human RbBP5 with N-terminal 6×His-tag and MW= 60 kDa, and full length human DPY30 with N-
terminal 6×His-tag and MW=12 kDa, and recombinant nucleosomes were obtained from 
Activmotif (Carlsbad, CA). Anti-Histone H3 Lysine 4 (H3K4me1-2) AlphaLISA acceptor beads, 
AlphaScreen Streptavidin donor beads and biotinylated anti-H3 (C-terminus) antibody were 
obtained from PerkinElmer Life Sciences (Waltham, MA). 2.5 µl of compound serial dilutions in 
assay buffer with 4% DMSO and 5 µl of the pentameric MLL complex solution were added into a 
white low volume 384 well microtiter plate which was incubated for 30 minutes with gentle 
shaking at room temperature, followed by adding 2.5 µL of SAM/Nucleosome mixture. The 
methylation reaction was performed in 50 mM Tris, pH 8.5 with 1 mM DTT and 0.01% Tween-20 
added right before the assay. Final concentrations of MLL complex, SAM, and nucleosomes were 
5 nM, 200 nM, and 3 nM, respectively. Final DMSO in the reaction mixture was 1%. The reaction 
was allowed to perform for 120 minutes in dark with gentle shaking at room temperature. 
Concentrations of reaction components and times were adjusted accordingly for assay 
development experiments. 5 µL of high salt stopping solution (50 mM Tris, pH 7.4 with 1 M NaCl, 
0.1% Tween-20, and 0.3% poly-L-Lysine) was added to stop the methylation reactions for 15 
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minutes. 5 µl of 5x acceptor beads/biotinylated anti-H3 antibody mixture in detection buffer (50 
mM Tris, pH 7.4 with 0.3 M NaCl, 0.1% Tween-20, and 0.001% poly-L-Lysine) was added, followed 
by 1 hour incubation at room temperature to allow full interaction between antibodies and 
methylated nucleosomes. Add 5 µl of 5x streptavidin donor beads in detection and incubate 30 
minutes. 
Plates were read on a BMG CLARIOstar microplate reader with an excitation wavelength 
of 680 nm and emission wavelength of 615 nm. IC50 values of compounds were obtained by fitting 
the fluorescence intensities detected at 615 nm vs compound concentrations in a sigmoidal dose-
response curve (variable slope) with a non-linear regression, using Graphpad Prism 6.0 software 
(Graphpad Software, San Diego, CA). 
Computational Docking  
Docking studies were performed using our previously reported structure of WDR5 in 
complex with MM-101 (PDB ID: 4GM3) with the GOLD26-27 program (version 5.2) with the Arg 
moiety of compound MM-101 serving as a scaffold for constrained docking. For each genetic 
algorithm (GA) run, a maximum number of 200,000 operations were performed on a population 
of five islands of 100 individuals. Operator weights for cross-over, mutation, and migration were 
set to 95, 95, and 10, respectively. The docking simulations were terminated after 10 runs for 
each ligand, using the Goldscore fitness function to evaluate the docked conformations. The top 
10 conformations were saved for analysis of the predicted docking modes. 
NONMEM code for population PK study 
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$PROBLEM 5-COMPARTMENT ORAL MPA;  
$DATA ../MPA_MPAG_AcMPAG_Feng.csv IGNORE=C 
$INPUT C ID TIME AMT ADDL II CONC XDV DV=LNDV MDV CMT NDOS AGE WT SEX ALT AST 
CREA TBIL HB 
$SUBROUTINES ADVAN5 TRANS1 
$MODEL 
    NCOMPARTMENTS=5 
    COMP=(1)    ;DOSE 
    COMP=(2)    ;CENTRAL COMPARTMENT FOR Parent 
    COMP=(3)    ;CENTRAL COMPARTMENT FOR MPAG 
    COMP=(4)    ;CENTRAL COMPARTMENT FOR AcMPAG 
    COMP=(5)    ;PERIPH COMPARTMENT FOR Parent 
 
$PK 
MU_1 = THETA(1) 
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MU_2 = THETA(2) 
MU_3 = THETA(3)      
MU_4 = THETA(4) 
MU_5 = THETA(5) 
MU_6 = THETA(6) 
MU_7 = THETA(7) 
MU_8 = THETA(8) 
MU_9 = THETA(9) 
MU_10 = THETA(10) 
MU_11 = THETA(11) 
 
CLM1  = EXP(MU_1+ETA(1))     ;CLM=CL_MPAG, LN(CLM)=MU_1+ETA(1) 
V3   = EXP(MU_2+ETA(2))     ;V3 for MPAG 
CL1  = EXP(MU_3+ETA(3))     ;CL1 for MPA 
V2   = EXP(MU_4+ETA(4))     ;V2 for CENTRAL Parent 
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V5   = EXP(MU_5+ETA(5))     ;V5 for PERIPH Parent 
Q    = EXP(MU_6+ETA(6)) 
K12  = EXP(MU_7+ETA(7))     ;MPA absorption RATE CONSTANT 
K31  = EXP(MU_8+ETA(8))     ;EHR 
CLM2  = EXP(MU_9+ETA(9))     ;CLM2=CL_AcMPAG,  
V4   = EXP(MU_10+ETA(10))     ;V4 for AcMPAG 
K41  = EXP(MU_11+ETA(11))     ;EHR of AcMPAG 
FM1   = 0.9 
FM2   = 0.1 
 
K20=CL1*(1-FM1-FM2)/V2 
K23=CL1*FM1/V2 
K24=CL1*FM2/V2 
K30=CLM1/V3 
K40=CLM2/V4 
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K25=Q/V2 
K52=Q/V5 
 
S2 = V2/1000 ;Scaling factor 
S3 = V3/1000 ;Scaling factor 
S4 = V4/1000 ;Scaling factor 
 
$ERROR (OBSERVATION ONLY)  
;OBSERVATION ONLY: do not estimate EPSs for missing DVs 
IPRED=LOG(F) 
QSF=0 
QK=0 
IF (CMT.EQ.4) QK=1 
IF (CMT.EQ.3) QSF=1 
Y=LOG(F)+((1-QSF)*(1-QK)*ERR(1)+QSF*(1-QK)*ERR(2)+QK*(1-QSF)*ERR(3)) 
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$THETA   
(0,0.19)        ;1 CLM1 of MPAG 
$THETA  (0,2.97)        ;2 V3 for MPAG CENTRAL COMP 
$THETA  (0,2.93)        ;3 CL1 
$THETA  (0,4.23)        ;4 V2 for MPA CENTRAL COMP 
$THETA  (0,7.68)        ;5 V4 for MPA Periph COMP 
$THETA  (0,3.35)        ;6 Q 
$THETA  (-5,-0.095)     ;7 KA 
$THETA  (-20,-10.7)     ;8 K31 
$THETA  (0,1.69)        ;9 CLM2 of AcMPAG 
$THETA  (0,4.46)        ;10 V5 for AcMPAG 
$THETA  (-30,-3.74)     ;11 K41 
 
$OMEGA 
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0.5          ;1.CLM1_MPAG 
2.27         ;2.V3 
0.25         ;3.CL1 
0.76         ;4.V2 
3.38         ;5.V4 
0.79         ;6.Q 
0.00001 FIX  ;7.KA(K12) 
0.00001 FIX  ;8.K31 
0.39         ;9.CLM2_AcMPAG 
0.79         ;10.V5 
0.00001 FIX  ;11.K41 
 
$SIGMA 
0.5 
0.2 
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0.4 
;$EST METHOD=ITS INTER NITER=100 PRINT=10 NOABORT NOPRIOR=1 MCETA=10 NOCOV=0 
$EST METHOD=SAEM EONLY=0 INTER CTYPE=3 NBURN=15000 NITER=1000 PRINT=500 DF=0 
IACCEPT=0.4 NOCOV=0 
$EST METHOD=IMP EONLY=1 NITER=5 ISAMPLE=1000 PRINT=1 DF=4 IACCEPT=1.0 MAPITER=0 
NOCOV=0 
$COVARIANCE MATRIX=R PRINT=E COMPRESS UNCONDITIONAL 
$TABLE ID TIME AMT DV IPRED K12 CL1 CLM1 CLM2 V2 V3 V4 V5 K31 K41 WT CWRES CMT 
CIWRES  
NOPRINT ONEHEADER FILE=run8.fit 
$TABLE ID ETAS(1:LAST)  
NOPRINT ONEHEADER FILE=run8.eta 
  
239 
 
 
References 
1. Wade, M.; Li, Y. C.; Wahl, G. M., MDM2, MDMX and p53 in oncogenesis and cancer 
therapy. Nat Rev Cancer 2013, 13 (2), 83-96. 
2. Brown, C. J.; Lain, S.; Verma, C. S.; Fersht, A. R.; Lane, D. P., Awakening guardian angels: 
drugging the p53 pathway. Nat Rev Cancer 2009, 9 (12), 862-73. 
3. Stiewe, T., The p53 family in differentiation and tumorigenesis. Nat Rev Cancer 2007, 7 
(3), 165-8. 
4. Hainaut, P.; Hollstein, M., p53 and human cancer: the first ten thousand mutations. Adv 
Cancer Res 2000, 77, 81-137. 
5. Momand, J.; Zambetti, G. P.; Olson, D. C.; George, D.; Levine, A. J., The mdm-2 oncogene 
product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 
1992, 69 (7), 1237-45. 
6. Freedman, D. A.; Wu, L.; Levine, A. J., Functions of the MDM2 oncoprotein. Cell Mol Life 
Sci 1999, 55 (1), 96-107. 
7. Wu, X.; Bayle, J. H.; Olson, D.; Levine, A. J., The p53-mdm-2 autoregulatory feedback 
loop. Genes Dev 1993, 7 (7A), 1126-32. 
8. Juven-Gershon, T.; Oren, M., Mdm2: the ups and downs. Mol Med 1999, 5 (2), 71-83. 
9. Ding, Q.; Zhang, Z.; Liu, J. J.; Jiang, N.; Zhang, J.; Ross, T. M.; Chu, X. J.; Bartkovitz, D.; 
Podlaski, F.; Janson, C.; Tovar, C.; Filipovic, Z. M.; Higgins, B.; Glenn, K.; Packman, K.; Vassilev, L. 
240 
 
T.; Graves, B., Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical 
development. J Med Chem 2013, 56 (14), 5979-83. 
10. Holzer, P.; Masuya, K.; Furet, P.; Kallen, J.; Valat-Stachyra, T.; Ferretti, S.; Berghausen, J.; 
Bouisset-Leonard, M.; Buschmann, N.; Pissot-Soldermann, C.; Rynn, C.; Ruetz, S.; Stutz, S.; 
Chene, P.; Jeay, S.; Gessier, F., Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): 
A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt 
Tumors. J Med Chem 2015, 58 (16), 6348-58. 
11. Aguilar, A.; Lu, J.; Liu, L.; Du, D.; Bernard, D.; McEachern, D.; Przybranowski, S.; Li, X.; 
Luo, R.; Wen, B.; Sun, D.; Wang, H.; Wen, J.; Wang, G.; Zhai, Y.; Guo, M.; Yang, D.; Wang, S., 
Discovery of 4-((3'R,4'S,5'R)-6''-Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2''-
oxodispiro[ cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamido)bicyclo[2.2.2]octane -
1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 
(MDM2) Inhibitor in Clinical Development. J Med Chem 2017, 60 (7), 2819-2839. 
12. Li, Z. H., Discovery of AMG 232, an inhibitor of the MDM2-p53 interaction: From lead to 
a clinical candidate. Cancer Research 2014, 74 (19). 
13. Vu, B.; Wovkulich, P.; Pizzolato, G.; Lovey, A.; Ding, Q.; Jiang, N.; Liu, J. J.; Zhao, C.; 
Glenn, K.; Wen, Y.; Tovar, C.; Packman, K.; Vassilev, L.; Graves, B., Discovery of RG7112: A Small-
Molecule MDM2 Inhibitor in Clinical Development. Acs Med Chem Lett 2013, 4 (5), 466-9. 
14. Wang, S.; Sun, W.; Zhao, Y.; McEachern, D.; Meaux, I.; Barriere, C.; Stuckey, J. A.; 
Meagher, J. L.; Bai, L.; Liu, L.; Hoffman-Luca, C. G.; Lu, J.; Shangary, S.; Yu, S.; Bernard, D.; 
Aguilar, A.; Dos-Santos, O.; Besret, L.; Guerif, S.; Pannier, P.; Gorge-Bernat, D.; Debussche, L., 
241 
 
SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and 
durable tumor regression. Cancer Res 2014, 74 (20), 5855-65. 
15. Lai, A. C.; Crews, C. M., Induced protein degradation: an emerging drug discovery 
paradigm. Nat Rev Drug Discov 2017, 16 (2), 101-114. 
16. Crews, C. M.; Georg, G.; Wang, S., Inducing Protein Degradation as a Therapeutic 
Strategy. J Med Chem 2016, 59 (11), 5129-30. 
17. Neklesa, T. K.; Winkler, J. D.; Crews, C. M., Targeted protein degradation by PROTACs. 
Pharmacol Ther 2017, 174, 138-144. 
18. Lu, J.; Qian, Y.; Altieri, M.; Dong, H.; Wang, J.; Raina, K.; Hines, J.; Winkler, J. D.; Crew, A. 
P.; Coleman, K.; Crews, C. M., Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target 
BRD4. Chem Biol 2015, 22 (6), 755-63. 
19. Winter, G. E.; Buckley, D. L.; Paulk, J.; Roberts, J. M.; Souza, A.; Dhe-Paganon, S.; 
Bradner, J. E., DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target 
protein degradation. Science 2015, 348 (6241), 1376-81. 
20. Raina, K.; Lu, J.; Qian, Y.; Altieri, M.; Gordon, D.; Rossi, A. M.; Wang, J.; Chen, X.; Dong, 
H.; Siu, K.; Winkler, J. D.; Crew, A. P.; Crews, C. M.; Coleman, K. G., PROTAC-induced BET protein 
degradation as a therapy for castration-resistant prostate cancer. Proc Natl Acad Sci U S A 2016, 
113 (26), 7124-9. 
21. Neklesa, T. K.; Jin, M. Z.; Crew, A. P.; Rossi, A. K.; Willard, R. R.; Dong, H. Q.; Siu, K.; 
Wang, J.; Gordon, D. A.; Chen, X.; Ferraro, C.; Crews, C. M.; Coleman, K.; Winkler, J. D., ARV-330: 
Androgen receptor PROTAC degrader for prostate cancer. J Clin Oncol 2016, 34 (2). 
242 
 
22. Lai, A. C.; Toure, M.; Hellerschmied, D.; Salami, J.; Jaime-Figueroa, S.; Ko, E.; Hines, J.; 
Crews, C. M., Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem 
Int Ed Engl 2016, 55 (2), 807-10. 
23. Demizu, Y.; Shibata, N.; Hattori, T.; Ohoka, N.; Motoi, H.; Misawa, T.; Shoda, T.; Naito, 
M.; Kurihara, M., Development of BCR-ABL degradation inducers via the conjugation of an 
imatinib derivative and a cIAP1 ligand. Bioorg Med Chem Lett 2016, 26 (20), 4865-4869. 
24. Bondeson, D. P.; Mares, A.; Smith, I. E.; Ko, E.; Campos, S.; Miah, A. H.; Mulholland, K. E.; 
Routly, N.; Buckley, D. L.; Gustafson, J. L.; Zinn, N.; Grandi, P.; Shimamura, S.; Bergamini, G.; 
Faelth-Savitski, M.; Bantscheff, M.; Cox, C.; Gordon, D. A.; Willard, R. R.; Flanagan, J. J.; Casillas, 
L. N.; Votta, B. J.; den Besten, W.; Famm, K.; Kruidenier, L.; Carter, P. S.; Harling, J. D.; Churcher, 
I.; Crews, C. M., Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol 
2015, 11 (8), 611-7. 
25. Aguilar, A.; Sun, W.; Liu, L.; Lu, J.; McEachern, D.; Bernard, D.; Deschamps, J. R.; Wang, 
S., Design of chemically stable, potent, and efficacious MDM2 inhibitors that exploit the retro-
mannich ring-opening-cyclization reaction mechanism in spiro-oxindoles. J Med Chem 2014, 57 
(24), 10486-98. 
26. Toledo, F.; Wahl, G. M., Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. 
Nat Rev Cancer 2006, 6 (12), 909-23. 
27. Vousden, K. H.; Lu, X., Live or let die: the cell's response to p53. Nat Rev Cancer 2002, 2 
(8), 594-604. 
28. Feki, A.; Irminger-Finger, I., Mutational spectrum of p53 mutations in primary breast and 
ovarian tumors. Crit Rev Oncol Hematol 2004, 52 (2), 103-16. 
243 
 
29. Oliner, J. D.; Saiki, A. Y.; Caenepeel, S., The Role of MDM2 Amplification and 
Overexpression in Tumorigenesis. Cold Spring Harb Perspect Med 2016, 6 (6). 
30. Momand, J.; Jung, D.; Wilczynski, S.; Niland, J., The MDM2 gene amplification database. 
Nucleic Acids Res 1998, 26 (15), 3453-9. 
31. Wang, S.; Zhao, Y.; Aguilar, A.; Bernard, D.; Yang, C. Y., Targeting the MDM2-p53 
Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges. Cold Spring Harb 
Perspect Med 2017, 7 (5). 
32. Momand, J.; Wu, H. H.; Dasgupta, G., MDM2--master regulator of the p53 tumor 
suppressor protein. Gene 2000, 242 (1-2), 15-29. 
33. Kussie, P. H.; Gorina, S.; Marechal, V.; Elenbaas, B.; Moreau, J.; Levine, A. J.; Pavletich, N. 
P., Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation 
domain. Science 1996, 274 (5289), 948-53. 
34. Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; 
Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E. A., In vivo activation of the p53 pathway 
by small-molecule antagonists of MDM2. Science 2004, 303 (5659), 844-8. 
35. Zhao, Y. J.; Liu, L.; Sun, W.; Lu, J. F.; McEachern, D.; Li, X. Q.; Yu, S. H.; Bernard, D.; 
Ochsenbein, P.; Ferey, V.; Carry, J. C.; Deschamps, J. R.; Sun, D. X.; Wang, S. M., Diastereomeric 
Spirooxindoles as Highly Potent and Efficacious MDM2 Inhibitors. Journal of the American 
Chemical Society 2013, 135 (19), 7223-7234. 
36. Arnhold, V.; Schmelz, K.; Proba, J.; Winkler, A.; Wunschel, J.; Toedling, J.; Deubzer, H. E.; 
Kunkele, A.; Eggert, A.; Schulte, J. H.; Hundsdoerfer, P., Reactivating TP53 signaling by the novel 
244 
 
MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma. Oncotarget 
2018, 9 (2), 2304-2319. 
37. Salami, J.; Crews, C. M., Waste disposal-An attractive strategy for cancer therapy. 
Science 2017, 355 (6330), 1163-1167. 
38. Wells, J. A.; McClendon, C. L., Reaching for high-hanging fruit in drug discovery at 
protein-protein interfaces. Nature 2007, 450 (7172), 1001-9. 
39. Sakamoto, K. M.; Kim, K. B.; Kumagai, A.; Mercurio, F.; Crews, C. M.; Deshaies, R. J., 
Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for 
ubiquitination and degradation. Proc Natl Acad Sci U S A 2001, 98 (15), 8554-9. 
40. Sakamoto, K. M.; Kim, K. B.; Verma, R.; Ransick, A.; Stein, B.; Crews, C. M.; Deshaies, R. 
J., Development of Protacs to target cancer-promoting proteins for ubiquitination and 
degradation. Mol Cell Proteomics 2003, 2 (12), 1350-8. 
41. Schneekloth, J. S., Jr.; Fonseca, F. N.; Koldobskiy, M.; Mandal, A.; Deshaies, R.; 
Sakamoto, K.; Crews, C. M., Chemical genetic control of protein levels: selective in vivo targeted 
degradation. J Am Chem Soc 2004, 126 (12), 3748-54. 
42. Hines, J.; Gough, J. D.; Corson, T. W.; Crews, C. M., Posttranslational protein knockdown 
coupled to receptor tyrosine kinase activation with phosphoPROTACs. Proc Natl Acad Sci U S A 
2013, 110 (22), 8942-7. 
43. Raina, K.; Crews, C. M., Targeted protein knockdown using small molecule degraders. 
Curr Opin Chem Biol 2017, 39, 46-53. 
245 
 
44. Schneekloth, A. R.; Pucheault, M.; Tae, H. S.; Crews, C. M., Targeted intracellular protein 
degradation induced by a small molecule: En route to chemical proteomics. Bioorg Med Chem 
Lett 2008, 18 (22), 5904-8. 
45. Naito, M.; Ohoka, N.; Shibata, N.; Hattori, T., Degradation of oncogenic proteins by 
SNIPER compounds. Cancer Sci 2018, 109, 562-562. 
46. Itoh, Y.; Ishikawa, M.; Naito, M.; Hashimoto, Y., Protein knockdown using methyl 
bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated 
degradation of cellular retinoic acid-binding proteins. J Am Chem Soc 2010, 132 (16), 5820-6. 
47. Itoh, Y.; Ishikawa, M.; Kitaguchi, R.; Okuhira, K.; Naito, M.; Hashimoto, Y., Double protein 
knockdown of cIAP1 and CRABP-II using a hybrid molecule consisting of ATRA and IAPs 
antagonist. Bioorg Med Chem Lett 2012, 22 (13), 4453-7. 
48. Okuhira, K.; Demizu, Y.; Hattori, T.; Ohoka, N.; Shibata, N.; Nishimaki-Mogami, T.; Okuda, 
H.; Kurihara, M.; Naito, M., Development of hybrid small molecules that induce degradation of 
estrogen receptor-alpha and necrotic cell death in breast cancer cells. Cancer Sci 2013, 104 (11), 
1492-8. 
49. Ito, T.; Ando, H.; Suzuki, T.; Ogura, T.; Hotta, K.; Imamura, Y.; Yamaguchi, Y.; Handa, H., 
Identification of a primary target of thalidomide teratogenicity. Science 2010, 327 (5971), 1345-
50. 
50. Zhou, B.; Hu, J.; Xu, F.; Chen, Z.; Bai, L.; Fernandez-Salas, E.; Lin, M.; Liu, L.; Yang, C. Y.; 
Zhao, Y.; McEachern, D.; Przybranowski, S.; Wen, B.; Sun, D.; Wang, S., Discovery of a Small-
Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular 
Potencies and Capable of Achieving Tumor Regression. J Med Chem 2018, 61 (2), 462-481. 
246 
 
51. Remillard, D.; Buckley, D. L.; Paulk, J.; Brien, G. L.; Sonnett, M.; Seo, H. S.; Dastjerdi, S.; 
Wuhr, M.; Dhe-Paganon, S.; Armstrong, S. A.; Bradner, J. E., Degradation of the BAF Complex 
Factor BRD9 by Heterobifunctional Ligands. Angew Chem Int Ed Engl 2017, 56 (21), 5738-5743. 
52. Martin, L. J.; Koegl, M.; Bader, G.; Cockcroft, X. L.; Fedorov, O.; Fiegen, D.; Gerstberger, 
T.; Hofmann, M. H.; Hohmann, A. F.; Kessler, D.; Knapp, S.; Knesl, P.; Kornigg, S.; Muller, S.; Nar, 
H.; Rogers, C.; Rumpel, K.; Schaaf, O.; Steurer, S.; Tallant, C.; Vakoc, C. R.; Zeeb, M.; Zoephel, A.; 
Pearson, M.; Boehmelt, G.; McConnell, D., Structure-Based Design of an in Vivo Active Selective 
BRD9 Inhibitor. J Med Chem 2016, 59 (10), 4462-75. 
53. Robb, C. M.; Contreras, J. I.; Kour, S.; Taylor, M. A.; Abid, M.; Sonawane, Y. A.; Zahid, M.; 
Murry, D. J.; Natarajan, A.; Rana, S., Chemically induced degradation of CDK9 by a proteolysis 
targeting chimera (PROTAC). Chem Commun (Camb) 2017, 53 (54), 7577-7580. 
54. Buckley, D. L.; Van Molle, I.; Gareiss, P. C.; Tae, H. S.; Michel, J.; Noblin, D. J.; Jorgensen, 
W. L.; Ciulli, A.; Crews, C. M., Targeting the von Hippel-Lindau E3 ubiquitin ligase using small 
molecules to disrupt the VHL/HIF-1alpha interaction. J Am Chem Soc 2012, 134 (10), 4465-8. 
55. Frost, J.; Galdeano, C.; Soares, P.; Gadd, M. S.; Grzes, K. M.; Ellis, L.; Epemolu, O.; 
Shimamura, S.; Bantscheff, M.; Grandi, P.; Read, K. D.; Cantrell, D. A.; Rocha, S.; Ciulli, A., Potent 
and selective chemical probe of hypoxic signalling downstream of HIF-alpha hydroxylation via 
VHL inhibition. Nat Commun 2016, 7, 13312. 
56. Buckley, D. L.; Gustafson, J. L.; Van Molle, I.; Roth, A. G.; Tae, H. S.; Gareiss, P. C.; 
Jorgensen, W. L.; Ciulli, A.; Crews, C. M., Small-molecule inhibitors of the interaction between 
the E3 ligase VHL and HIF1alpha. Angew Chem Int Ed Engl 2012, 51 (46), 11463-7. 
247 
 
57. Zengerle, M.; Chan, K. H.; Ciulli, A., Selective Small Molecule Induced Degradation of the 
BET Bromodomain Protein BRD4. Acs Chem Biol 2015, 10 (8), 1770-7. 
58. Zhang, Z.; Ding, Q.; Liu, J. J.; Zhang, J.; Jiang, N.; Chu, X. J.; Bartkovitz, D.; Luk, K. C.; 
Janson, C.; Tovar, C.; Filipovic, Z. M.; Higgins, B.; Glenn, K.; Packman, K.; Vassilev, L. T.; Graves, 
B., Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer 
therapy. Bioorgan Med Chem 2014, 22 (15), 4001-9. 
59. Huggins, D. J.; Sherman, W.; Tidor, B., Rational approaches to improving selectivity in 
drug design. J Med Chem 2012, 55 (4), 1424-44. 
60. Fischer, E. S.; Bohm, K.; Lydeard, J. R.; Yang, H.; Stadler, M. B.; Cavadini, S.; Nagel, J.; 
Serluca, F.; Acker, V.; Lingaraju, G. M.; Tichkule, R. B.; Schebesta, M.; Forrester, W. C.; Schirle, 
M.; Hassiepen, U.; Ottl, J.; Hild, M.; Beckwith, R. E.; Harper, J. W.; Jenkins, J. L.; Thoma, N. H., 
Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 2014, 512 
(7512), 49-53. 
61. Mori, T.; Ito, T.; Liu, S.; Ando, H.; Sakamoto, S.; Yamaguchi, Y.; Tokunaga, E.; Shibata, N.; 
Handa, H.; Hakoshima, T., Structural basis of thalidomide enantiomer binding to cereblon. Sci 
Rep 2018, 8 (1), 1294. 
62. Ottis, P.; Crews, C. M., Proteolysis-Targeting Chimeras: Induced Protein Degradation as a 
Therapeutic Strategy. Acs Chem Biol 2017, 12 (4), 892-898. 
63. Lu, G.; Middleton, R. E.; Sun, H.; Naniong, M.; Ott, C. J.; Mitsiades, C. S.; Wong, K. K.; 
Bradner, J. E.; Kaelin, W. G., Jr., The myeloma drug lenalidomide promotes the cereblon-
dependent destruction of Ikaros proteins. Science 2014, 343 (6168), 305-9. 
248 
 
64. Richardson, P. G.; Xie, W.; Jagannath, S.; Jakubowiak, A.; Lonial, S.; Raje, N. S.; Alsina, M.; 
Ghobrial, I. M.; Schlossman, R. L.; Munshi, N. C.; Mazumder, A.; Vesole, D. H.; Kaufman, J. L.; 
Colson, K.; McKenney, M.; Lunde, L. E.; Feather, J.; Maglio, M. E.; Warren, D.; Francis, D.; 
Hideshima, T.; Knight, R.; Esseltine, D. L.; Mitsiades, C. S.; Weller, E.; Anderson, K. C., A phase 2 
trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and 
relapsed/refractory myeloma. Blood 2014, 123 (10), 1461-9. 
65. Walczak, M. J.; Petzold, G.; Thoma, N. H., Targeted protein degradation: You can glue it 
too! Nat Chem Biol 2017, 13 (5), 452-453. 
66. Huang, X.; Dixit, V. M., Drugging the undruggables: exploring the ubiquitin system for 
drug development. Cell Res 2016, 26 (4), 484-98. 
67. Kronke, J.; Udeshi, N. D.; Narla, A.; Grauman, P.; Hurst, S. N.; McConkey, M.; Svinkina, T.; 
Heckl, D.; Comer, E.; Li, X.; Ciarlo, C.; Hartman, E.; Munshi, N.; Schenone, M.; Schreiber, S. L.; 
Carr, S. A.; Ebert, B. L., Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple 
myeloma cells. Science 2014, 343 (6168), 301-5. 
68. Matyskiela, M. E.; Lu, G.; Ito, T.; Pagarigan, B.; Lu, C. C.; Miller, K.; Fang, W.; Wang, N. Y.; 
Nguyen, D.; Houston, J.; Carmel, G.; Tran, T.; Riley, M.; Nosaka, L.; Lander, G. C.; Gaidarova, S.; 
Xu, S.; Ruchelman, A. L.; Handa, H.; Carmichael, J.; Daniel, T. O.; Cathers, B. E.; Lopez-Girona, A.; 
Chamberlain, P. P., A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin 
ligase. Nature 2016, 535 (7611), 252-7. 
69. Cesa, L. C.; Mapp, A. K.; Gestwicki, J. E., Direct and Propagated Effects of Small 
Molecules on Protein-Protein Interaction Networks. Front Bioeng Biotechnol 2015, 3, 119. 
249 
 
70. Choi, J.; Chen, J.; Schreiber, S. L.; Clardy, J., Structure of the FKBP12-rapamycin complex 
interacting with the binding domain of human FRAP. Science 1996, 273 (5272), 239-42. 
71. Griffith, J. P.; Kim, J. L.; Kim, E. E.; Sintchak, M. D.; Thomson, J. A.; Fitzgibbon, M. J.; 
Fleming, M. A.; Caron, P. R.; Hsiao, K.; Navia, M. A., X-ray structure of calcineurin inhibited by 
the immunophilin-immunosuppressant FKBP12-FK506 complex. Cell 1995, 82 (3), 507-22. 
72. Ribrag, V.; Damien, S.; Gharibo, M.; Gironella, M.; Santoro, A.; Rasco, D. W.; Edenfield, 
W.; Wei, X.; James, A.; Hagner, P.; Gandhi, A. K.; Chopra, R.; DiMartino, J. F.; Pourdehnad, M.; 
Stoppa, A. M., CC-122 Degrades the Lymphoid Transcription Factor Aiolos (IKZF3) By 
Modulating Cereblon and Shows Clinical Activity in a Phase Ib Study of Subjects with Relapsed 
or Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma. Blood 2014, 124 (21). 
73. Matyskiela, M. E.; Zhang, W.; Man, H. W.; Muller, G.; Khambatta, G.; Baculi, F.; Hickman, 
M.; LeBrun, L.; Pagarigan, B.; Carmel, G.; Lu, C. C.; Lu, G.; Riley, M.; Satoh, Y.; Schafer, P.; Daniel, 
T. O.; Carmichael, J.; Cathers, B. E.; Chamberlain, P. P., A Cereblon Modulator (CC-220) with 
Improved Degradation of Ikaros and Aiolos. J Med Chem 2018, 61 (2), 535-542. 
74. Hansen, J. D.; Condroski, K.; Correa, M.; Muller, G.; Man, H. W.; Ruchelman, A.; Zhang, 
W.; Vocanson, F.; Crea, T.; Liu, W.; Lu, G.; Baculi, F.; LeBrun, L.; Mahmoudi, A.; Carmel, G.; 
Hickman, M.; Lu, C. C., Protein Degradation via CRL4(CRBN) Ubiquitin Ligase: Discovery and 
Structure-Activity Relationships of Novel Glutarimide Analogs That Promote Degradation of 
Aiolos and/or GSPT1. J Med Chem 2018, 61 (2), 492-503. 
75. Ishoey, M.; Chorn, S.; Singh, N.; Jaeger, M. G.; Brand, M.; Paulk, J.; Bauer, S.; Erb, M. A.; 
Parapatics, K.; Muller, A. C.; Bennett, K. L.; Ecker, G. F.; Bradner, J. E.; Winter, G. E., Translation 
250 
 
Termination Factor GSPT1 Is a Phenotypically Relevant Off-Target of Heterobifunctional 
Phthalimide Degraders. Acs Chemical Biology 2018, 13 (3), 553-560. 
76. Han, T.; Goralski, M.; Gaskill, N.; Capota, E.; Kim, J.; Ting, T. C.; Xie, Y.; Williams, N. S.; 
Nijhawan, D., Anticancer sulfonamides target splicing by inducing RBM39 degradation via 
recruitment to DCAF15. Science 2017, 356 (6336). 
77. Uehara, T.; Minoshima, Y.; Sagane, K.; Sugi, N. H.; Mitsuhashi, K. O.; Yamamoto, N.; 
Kamiyama, H.; Takahashi, K.; Kotake, Y.; Uesugi, M.; Yokoi, A.; Inoue, A.; Yoshida, T.; Mabuchi, 
M.; Tanaka, A.; Owa, T., Selective degradation of splicing factor CAPERalpha by anticancer 
sulfonamides. Nat Chem Biol 2017, 13 (6), 675-680. 
78. Delker, C.; Raschke, A.; Quint, M., Auxin dynamics: the dazzling complexity of a small 
molecule's message. Planta 2008, 227 (5), 929-41. 
79. Sheard, L. B.; Tan, X.; Mao, H.; Withers, J.; Ben-Nissan, G.; Hinds, T. R.; Kobayashi, Y.; 
Hsu, F. F.; Sharon, M.; Browse, J.; He, S. Y.; Rizo, J.; Howe, G. A.; Zheng, N., Jasmonate 
perception by inositol-phosphate-potentiated COI1-JAZ co-receptor. Nature 2010, 468 (7322), 
400-5. 
80. Che, Y. G., A. M.; Shanmugasundaram, V. Noe, M. C., Inducing Protein-Protein 
interactions with Molecular Glues. Bioorg Med Chem Lett 2018. 
81. Inder, K. L. L., D.; Zheng, Y. Z.; Parton, R. G.; Foster, L. J.; Hill, M. M., Normalization of 
protein at diJerent stages in SILAC subcellular proteomics affects functional analysis. J. Integr. 
Omics 2012, 2 (2), 114-122. 
251 
 
82. Chen, D.; Shah, A.; Nguyen, H.; Loo, D.; Inder, K. L.; Hill, M. M., Online quantitative 
proteomics p-value calculator for permutation-based statistical testing of peptide ratios. J 
Proteome Res 2014, 13 (9), 4184-91. 
83. Hess, J. L., MLL: a histone methyltransferase disrupted in leukemia. Trends Mol Med 
2004, 10 (10), 500-7. 
84. Jude, C. D.; Climer, L.; Xu, D.; Artinger, E.; Fisher, J. K.; Ernst, P., Unique and independent 
roles for MLL in adult hematopoietic stem cells and progenitors. Cell Stem Cell 2007, 1 (3), 324-
37. 
85. Meyer, C.; Hofmann, J.; Burmeister, T.; Groger, D.; Park, T. S.; Emerenciano, M.; Pombo 
de Oliveira, M.; Renneville, A.; Villarese, P.; Macintyre, E.; Cave, H.; Clappier, E.; Mass-Malo, K.; 
Zuna, J.; Trka, J.; De Braekeleer, E.; De Braekeleer, M.; Oh, S. H.; Tsaur, G.; Fechina, L.; van der 
Velden, V. H.; van Dongen, J. J.; Delabesse, E.; Binato, R.; Silva, M. L.; Kustanovich, A.; 
Aleinikova, O.; Harris, M. H.; Lund-Aho, T.; Juvonen, V.; Heidenreich, O.; Vormoor, J.; Choi, W. 
W.; Jarosova, M.; Kolenova, A.; Bueno, C.; Menendez, P.; Wehner, S.; Eckert, C.; Talmant, P.; 
Tondeur, S.; Lippert, E.; Launay, E.; Henry, C.; Ballerini, P.; Lapillone, H.; Callanan, M. B.; 
Cayuela, J. M.; Herbaux, C.; Cazzaniga, G.; Kakadiya, P. M.; Bohlander, S.; Ahlmann, M.; Choi, J. 
R.; Gameiro, P.; Lee, D. S.; Krauter, J.; Cornillet-Lefebvre, P.; Te Kronnie, G.; Schafer, B. W.; 
Kubetzko, S.; Alonso, C. N.; zur Stadt, U.; Sutton, R.; Venn, N. C.; Izraeli, S.; Trakhtenbrot, L.; 
Madsen, H. O.; Archer, P.; Hancock, J.; Cerveira, N.; Teixeira, M. R.; Lo Nigro, L.; Moricke, A.; 
Stanulla, M.; Schrappe, M.; Sedek, L.; Szczepanski, T.; Zwaan, C. M.; Coenen, E. A.; van den 
Heuvel-Eibrink, M. M.; Strehl, S.; Dworzak, M.; Panzer-Grumayer, R.; Dingermann, T.; Klingebiel, 
252 
 
T.; Marschalek, R., The MLL recombinome of acute leukemias in 2013. Leukemia 2013, 27 (11), 
2165-76. 
86. Borkhardt, A.; Wuchter, C.; Viehmann, S.; Pils, S.; Teigler-Schlegel, A.; Stanulla, M.; 
Zimmermann, M.; Ludwig, W. D.; Janka-Schaub, G.; Schrappe, M.; Harbott, J., Infant acute 
lymphoblastic leukemia - combined cytogenetic, immunophenotypical and molecular analysis 
of 77 cases. Leukemia 2002, 16 (9), 1685-90. 
87. Felix, C. A.; Lange, B. J.; Chessells, J. M., Pediatric Acute Lymphoblastic Leukemia: 
Challenges and Controversies in 2000. Hematology Am Soc Hematol Educ Program 2000, 285-
302. 
88. Krivtsov, A. V.; Armstrong, S. A., MLL translocations, histone modifications and 
leukaemia stem-cell development. Nat Rev Cancer 2007, 7 (11), 823-33. 
89. Thiel, A. T.; Blessington, P.; Zou, T.; Feather, D.; Wu, X.; Yan, J.; Zhang, H.; Liu, Z.; Ernst, 
P.; Koretzky, G. A.; Hua, X., MLL-AF9-induced leukemogenesis requires coexpression of the wild-
type Mll allele. Cancer Cell 2010, 17 (2), 148-59. 
90. Milne, T. A.; Kim, J.; Wang, G. G.; Stadler, S. C.; Basrur, V.; Whitcomb, S. J.; Wang, Z.; 
Ruthenburg, A. J.; Elenitoba-Johnson, K. S.; Roeder, R. G.; Allis, C. D., Multiple interactions 
recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. Mol Cell 2010, 
38 (6), 853-63. 
91. Grebien, F.; Vedadi, M.; Getlik, M.; Giambruno, R.; Grover, A.; Avellino, R.; Skucha, A.; 
Vittori, S.; Kuznetsova, E.; Smil, D.; Barsyte-Lovejoy, D.; Li, F.; Poda, G.; Schapira, M.; Wu, H.; 
Dong, A.; Senisterra, G.; Stukalov, A.; Huber, K. V. M.; Schonegger, A.; Marcellus, R.; Bilban, M.; 
Bock, C.; Brown, P. J.; Zuber, J.; Bennett, K. L.; Al-Awar, R.; Delwel, R.; Nerlov, C.; Arrowsmith, C. 
253 
 
H.; Superti-Furga, G., Pharmacological targeting of the Wdr5-MLL interaction in C/EBPalpha N-
terminal leukemia. Nat Chem Biol 2015, 11 (8), 571-578. 
92. Karatas, H.; Townsend, E. C.; Cao, F.; Chen, Y.; Bernard, D.; Liu, L.; Lei, M.; Dou, Y.; Wang, 
S., High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein 
interaction. J Am Chem Soc 2013, 135 (2), 669-82. 
93. Dou, Y.; Milne, T. A.; Ruthenburg, A. J.; Lee, S.; Lee, J. W.; Verdine, G. L.; Allis, C. D.; 
Roeder, R. G., Regulation of MLL1 H3K4 methyltransferase activity by its core components. Nat 
Struct Mol Biol 2006, 13 (8), 713-9. 
94. Tkachuk, D. C.; Kohler, S.; Cleary, M. L., Involvement of a homolog of Drosophila 
trithorax by 11q23 chromosomal translocations in acute leukemias. Cell 1992, 71 (4), 691-700. 
95. Zieminvanderpoel, S.; Mccabe, N. R.; Gill, H. J.; Espinosa, R.; Patel, Y.; Harden, A.; 
Rubinelli, P.; Smith, S. D.; Lebeau, M. M.; Rowley, J. D.; Diaz, M. O., Identification of a Gene, Mll, 
That Spans the Breakpoint in 11q23 Translocations Associated with Human Leukemias. P Natl 
Acad Sci USA 1991, 88 (23), 10735-10739. 
96. Slany, R. K.; Zeisig, B. B.; Milne, T.; Martin, M. E.; Borkhardt, A.; Chanda, S.; Hess, J. L.; 
Garcia, M., Hoxa9 and Meis1 are key targets for MLL-ENL mediated cellular immortalization. 
Blood 2003, 102 (11), 170a-170a. 
97. Krivtsov, A. V.; Twomey, D.; Feng, Z.; Stubbs, M. C.; Wang, Y.; Faber, J.; Levine, J. E.; 
Wang, J.; Hahn, W. C.; Gilliland, D. G.; Golub, T. R.; Armstrong, S. A., Transformation from 
committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006, 442 (7104), 
818-22. 
254 
 
98. Ballabio, E.; Milne, T. A., Molecular and Epigenetic Mechanisms of MLL in Human 
Leukemogenesis. Cancers (Basel) 2012, 4 (3), 904-44. 
99. Chen, C. W.; Armstrong, S. A., Targeting DOT1L and HOX gene expression in MLL-
rearranged leukemia and beyond. Exp Hematol 2015, 43 (8), 673-84. 
100. Lim, D. A.; Huang, Y. C.; Swigut, T.; Mirick, A. L.; Garcia-Verdugo, J. M.; Wysocka, J.; 
Ernst, P.; Alvarez-Buylla, A., Chromatin remodelling factor Mll1 is essential for neurogenesis 
from postnatal neural stem cells. Nature 2009, 458 (7237), 529-33. 
101. Gan, T.; Jude, C. D.; Zaffuto, K.; Ernst, P., Developmentally induced Mll1 loss reveals 
defects in postnatal haematopoiesis. Leukemia 2010, 24 (10), 1732-41. 
102. Marschalek, R., Mixed lineage leukemia: roles in human malignancies and potential 
therapy. Febs J 2010, 277 (8), 1822-31. 
103. Milne, T. A.; Hughes, C. M.; Lloyd, R.; Yang, Z.; Rozenblatt-Rosen, O.; Dou, Y.; Schnepp, R. 
W.; Krankel, C.; Livolsi, V. A.; Gibbs, D.; Hua, X.; Roeder, R. G.; Meyerson, M.; Hess, J. L., Menin 
and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl 
Acad Sci U S A 2005, 102 (3), 749-54. 
104. Xia, Z. B.; Popovic, R.; Chen, J.; Theisler, C.; Stuart, T.; Santillan, D. A.; Erfurth, F.; Diaz, M. 
O.; Zeleznik-Le, N. J., The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase 
inhibitor CDKN1B (p27kip1) expression. Proc Natl Acad Sci U S A 2005, 102 (39), 14028-33. 
105. Yokoyama, A.; Somervaille, T. C.; Smith, K. S.; Rozenblatt-Rosen, O.; Meyerson, M.; 
Cleary, M. L., The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-
associated leukemogenesis. Cell 2005, 123 (2), 207-18. 
255 
 
106. Caslini, C.; Yang, Z.; El-Osta, M.; Milne, T. A.; Slany, R. K.; Hess, J. L., Interaction of MLL 
amino terminal sequences with menin is required for transformation. Cancer Res 2007, 67 (15), 
7275-83. 
107. Southall, S. M.; Wong, P. S.; Odho, Z.; Roe, S. M.; Wilson, J. R., Structural basis for the 
requirement of additional factors for MLL1 SET domain activity and recognition of epigenetic 
marks. Mol Cell 2009, 33 (2), 181-91. 
108. Wysocka, J.; Swigut, T.; Milne, T. A.; Dou, Y.; Zhang, X.; Burlingame, A. L.; Roeder, R. G.; 
Brivanlou, A. H.; Allis, C. D., WDR5 associates with histone H3 methylated at K4 and is essential 
for H3 K4 methylation and vertebrate development. Cell 2005, 121 (6), 859-72. 
109. Dharmarajan, V.; Lee, J. H.; Patel, A.; Skalnik, D. G.; Cosgrove, M. S., Structural basis for 
WDR5 interaction (Win) motif recognition in human SET1 family histone methyltransferases. J 
Biol Chem 2012, 287 (33), 27275-89. 
110. Alicea-Velazquez, N. L.; Shinsky, S. A.; Loh, D. M.; Lee, J. H.; Skalnik, D. G.; Cosgrove, M. 
S., Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed 
Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A 
Methyltransferase Complexes. J Biol Chem 2016, 291 (43), 22357-22372. 
111. Karatas, H.; Townsend, E. C.; Bernard, D.; Dou, Y.; Wang, S., Analysis of the binding of 
mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the 
design of inhibitors of the MLL1-WDR5 interaction. J Med Chem 2010, 53 (14), 5179-85. 
112. Cao, F.; Townsend, E. C.; Karatas, H.; Xu, J.; Li, L.; Lee, S.; Liu, L.; Chen, Y.; Ouillette, P.; 
Zhu, J.; Hess, J. L.; Atadja, P.; Lei, M.; Qin, Z. S.; Malek, S.; Wang, S.; Dou, Y., Targeting MLL1 
H3K4 methyltransferase activity in mixed-lineage leukemia. Mol Cell 2014, 53 (2), 247-61. 
256 
 
113. Karatas, H.; Li, Y.; Liu, L.; Ji, J.; Lee, S.; Chen, Y.; Yang, J.; Huang, L.; Bernard, D.; Xu, J.; 
Townsend, E. C.; Cao, F.; Ran, X.; Li, X.; Wen, B.; Sun, D.; Stuckey, J. A.; Lei, M.; Dou, Y.; Wang, S., 
Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting 
the WD Repeat Domain 5 Protein (WDR5)-Mixed Lineage Leukemia (MLL) Protein-Protein 
Interaction. J Med Chem 2017, 60 (12), 4818-4839. 
114. Senisterra, G.; Wu, H.; Allali-Hassani, A.; Wasney, G. A.; Barsyte-Lovejoy, D.; Dombrovski, 
L.; Dong, A.; Nguyen, K. T.; Smil, D.; Bolshan, Y.; Hajian, T.; He, H.; Seitova, A.; Chau, I.; Li, F.; 
Poda, G.; Couture, J. F.; Brown, P. J.; Al-Awar, R.; Schapira, M.; Arrowsmith, C. H.; Vedadi, M., 
Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5. The 
Biochemical journal 2013, 449 (1), 151-9. 
115. Bolshan, Y.; Getlik, M.; Kuznetsova, E.; Wasney, G. A.; Hajian, T.; Poda, G.; Nguyen, K. T.; 
Wu, H.; Dombrovski, L.; Dong, A.; Senisterra, G.; Schapira, M.; Arrowsmith, C. H.; Brown, P. J.; 
Al-Awar, R.; Vedadi, M.; Smil, D., Synthesis, Optimization, and Evaluation of Novel Small 
Molecules as Antagonists of WDR5-MLL Interaction. Acs Med Chem Lett 2013, 4 (3), 353-7. 
116. Getlik, M.; Smil, D.; Zepeda-Velazquez, C.; Bolshan, Y.; Poda, G.; Wu, H.; Dong, A.; 
Kuznetsova, E.; Marcellus, R.; Senisterra, G.; Dombrovski, L.; Hajian, T.; Kiyota, T.; Schapira, M.; 
Arrowsmith, C. H.; Brown, P. J.; Vedadi, M.; Al-Awar, R., Structure-Based Optimization of a Small 
Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and 
Mixed-Lineage Leukemia 1 (MLL1). J Med Chem 2016, 59 (6), 2478-96. 
117. Li, D. D.; Wang, Z. H.; Chen, W. L.; Xie, Y. Y.; You, Q. D.; Guo, X. K., Structure-based 
design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage 
leukemia 1 (MLL1)-WDR5 interaction. Bioorgan Med Chem 2016, 24 (22), 6109-6118. 
257 
 
118. Li, D. D.; Chen, W. L.; Xu, X. L.; Jiang, F.; Wang, L.; Xie, Y. Y.; Zhang, X. J.; Guo, X. K.; You, 
Q. D.; Sun, H. P., Structure-based design and synthesis of small molecular inhibitors disturbing 
the interaction of MLL1-WDR5. Eur J Med Chem 2016, 118, 1-8. 
119. Li, D. D.; Chen, W. L.; Wang, Z. H.; Xie, Y. Y.; Xu, X. L.; Jiang, Z. Y.; Zhang, X. J.; You, Q. D.; 
Guo, X. K., High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 
interaction inhibit MLL1 complex H3K4 methyltransferase activity. Eur J Med Chem 2016, 124, 
480-489. 
120. Song, J. J.; Kingston, R. E., WDR5 interacts with mixed lineage leukemia (MLL) protein via 
the histone H3-binding pocket. J Biol Chem 2008, 283 (50), 35258-64. 
121. Staatz, C. E.; Tett, S. E., Clinical pharmacokinetics and pharmacodynamics of 
mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007, 46 (1), 13-58. 
122. Staatz, C. E.; Tett, S. E., Pharmacology and toxicology of mycophenolate in organ 
transplant recipients: an update. Arch Toxicol 2014, 88 (7), 1351-89. 
123. Sherwin, C. M.; Fukuda, T.; Brunner, H. I.; Goebel, J.; Vinks, A. A., The evolution of 
population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic 
acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet 2011, 50 (1), 
1-24. 
124. Kiang, T. K. L.; Ensom, M. H. H., Population Pharmacokinetics of Mycophenolic Acid: An 
Update. Clin Pharmacokinet 2018, 57 (5), 547-558. 
125. Allison, A. C.; Kowalski, W. J.; Muller, C. D.; Eugui, E. M., Mechanisms of action of 
mycophenolic acid. Ann N Y Acad Sci 1993, 696, 63-87. 
258 
 
126. Allison, A. C.; Eugui, E. M., Mechanisms of action of mycophenolate mofetil in 
preventing acute and chronic allograft rejection. Transplantation 2005, 80 (2 Suppl), S181-90. 
127. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and 
corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative 
Study Group. Lancet 1995, 345 (8961), 1321-5. 
128. Zegarska, J.; Hryniewiecka, E.; Zochowska, D.; Tszyrsznic, W.; Jazwiec, R.; Borowiec, A.; 
Pawlowska, E.; Dadlez, M.; Paczek, L., Mycophenolic Acid Metabolites Acyl-Glucuronide and 
Glucoside Affect the Occurrence of Infectious Complications and Bone Marrow Dysfunction in 
Liver Transplant Recipients. Ann Transplant 2015, 20, 483-92. 
129. Langers, P.; Press, R. R.; Inderson, A.; Cremers, S. C.; den Hartigh, J.; Baranski, A. G.; van 
Hoek, B., Limited sampling model for advanced mycophenolic acid therapeutic drug monitoring 
after liver transplantation. Ther Drug Monit 2014, 36 (2), 141-7. 
130. Barau, C.; Furlan, V.; Debray, D.; Taburet, A. M.; Barrail-Tran, A., Population 
pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in 
liver transplant children. Br J Clin Pharmacol 2012, 74 (3), 515-24. 
131. Wang, X. X.; Liu, W.; Zheng, T.; Park, J. M.; Smith, D. E.; Feng, M. R., Population 
pharmacokinetics of mycophenolic acid and its glucuronide metabolite in lung transplant 
recipients with and without cystic fibrosis. Xenobiotica 2017, 47 (8), 697-704. 
132. Wang, X. X.; Feng, M. R.; Nguyen, H.; Smith, D. E.; Cibrik, D. M.; Park, J. M., Population 
pharmacokinetics of mycophenolic acid in lung transplant recipients with and without cystic 
fibrosis. Eur J Clin Pharmacol 2015, 71 (6), 673-679. 
259 
 
133. Yoshimura, K.; Yano, I.; Yamamoto, T.; Kawanishi, M.; Isomoto, Y.; Yonezawa, A.; Kondo, 
T.; Takaori-Kondo, A.; Matsubara, K., Population pharmacokinetics and pharmacodynamics of 
mycophenolic acid using the prospective data in patients undergoing hematopoietic stem cell 
transplantation. Bone Marrow Transplant 2018, 53 (1), 44-51. 
134. Hwang, S.; Song, G. W.; Jung, D. H.; Park, G. C.; Ahn, C. S.; Moon, D. B.; Ha, T. Y.; Kim, K. 
H.; Lee, S. G., Intra-individual variability of mycophenolic acid concentration according to renal 
function in liver transplant recipients receiving mycophenolate monotherapy. Ann 
Hepatobiliary Pancreat Surg 2017, 21 (1), 11-16. 
135. Lecker, S. H.; Goldberg, A. L.; Mitch, W. E., Protein degradation by the ubiquitin-
proteasome pathway in normal and disease states. J Am Soc Nephrol 2006, 17 (7), 1807-19. 
136. Stockwell, B., Outsmarting Cancer. A biologist talks about what makes disease-causing 
proteins so difficult to target with drugs. Sci Am 2011, 305 (4), 20. 
137. Nikolovska-Coleska, Z.; Wang, R.; Fang, X.; Pan, H.; Tomita, Y.; Li, P.; Roller, P. P.; 
Krajewski, K.; Saito, N. G.; Stuckey, J. A.; Wang, S., Development and optimization of a binding 
assay for the XIAP BIR3 domain using fluorescence polarization. Anal Biochem 2004, 332 (2), 
261-73. 
 
 
